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Abstract 
Background 
Depression is a major health problem worldwide and the majority of patients 
presenting with depressive symptoms are managed in primary care. Current 
approaches for assessing depressive symptoms in primary care are not accurate 
in predicting future clinical outcomes, which may potentially lead to over or 
under treatment. The Allostatic Load (AL) theory suggests that by measuring 
multi-system biomarker levels as a proxy of measuring multi-system physiological 
dysregulation, it is possible to identify individuals at risk of having adverse 
health outcomes at a prodromal stage. Allostatic Index (AI) score, calculated by 
applying statistical formulations to different multi-system biomarkers, have 
been associated with depressive symptoms.  
 
Aims and Objectives 
To test the hypothesis, that a combination of allostatic load (AL) biomarkers will 
form a predictive algorithm in defining clinically meaningful outcomes in a 
population of patients presenting with depressive symptoms. 
The key objectives were:  
1. To explore the relationship between various allostatic load biomarkers and 
prevalence of depressive symptoms in patients, especially in patients diagnosed 
with three common cardiometabolic diseases (Coronary Heart Disease (CHD), 
Diabetes and Stroke).  
2 To explore whether allostatic load biomarkers predict clinical outcomes in 
patients with depressive symptoms, especially in patients with three common 
cardiometabolic diseases (CHD, Diabetes and Stroke).  
3 To develop a predictive tool to identify individuals with depressive symptoms 
at highest risk of adverse clinical outcomes. 
 
Methods 
Datasets used: ‘DepChron’ was a dataset of 35,537 patients with existing 
cardiometabolic disease collected as a part of routine clinical practice. ‘Psobid’ 
was a research data source containing health related information from 666 
participants recruited from the general population. The clinical outcomes for 
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both datasets were studied using electronic data linkage to hospital and 
mortality health records, undertaken by Information Services Division, Scotland. 
 
Cross-sectional associations between allostatic load biomarkers calculated at 
baseline, with clinical severity of depression assessed by a symptom score, were 
assessed using logistic and linear regression models in both datasets. Cox’s 
proportional hazards survival analysis models were used to assess the 
relationship of allostatic load biomarkers at baseline and the risk of adverse 
physical health outcomes at follow-up, in patients with depressive symptoms. 
The possibility of interaction between depressive symptoms and allostatic load 
biomarkers in risk prediction of adverse clinical outcomes was studied using the 
analysis of variance (ANOVA) test. Finally, the value of constructing a risk 
scoring scale using patient demographics and allostatic load biomarkers for 
predicting adverse outcomes in depressed patients was investigated using 
clinical risk prediction modelling and Area Under Curve (AUC) statistics.  
 
Key Results  
 
Literature Review Findings 
The literature review showed that twelve blood based peripheral biomarkers 
were statistically significant in predicting six different clinical outcomes in 
participants with depressive symptoms. Outcomes related to both mental health 
(depressive symptoms) and physical health were statistically associated with 
pre-treatment levels of peripheral biomarkers; however only two studies 
investigated outcomes related to physical health. 
 
Cross-sectional Analysis Findings 
In DepChron, dysregulation of individual allostatic biomarkers (mainly 
cardiometabolic) were found to have a non-linear association with increased 
probability of co-morbid depressive symptoms (as assessed by Hospital Anxiety 
and Depression Score HADS-D≥8). A composite AI score constructed using five 
biomarkers did not lead to any improvement in the observed strength of the 
association. In Psobid, BMI was found to have a significant cross-sectional 
association with the probability of depressive symptoms (assessed by General 
Health Questionnaire GHQ-28≥5). BMI, triglycerides, highly sensitive C - reactive 
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protein (CRP) and High Density Lipoprotein-HDL cholesterol were found to have a 
significant cross-sectional relationship with the continuous measure of GHQ-28. 
A composite AI score constructed using 12 biomarkers did not show a significant 
association with depressive symptoms among Psobid participants. 
Longitudinal Analysis Findings 
In DepChron, three clinical outcomes were studied over four years: all-cause 
death, all-cause hospital admissions and composite major adverse cardiovascular 
outcome-MACE (cardiovascular death or admission due to MI/stroke/HF). 
Presence of depressive symptoms and composite AI score calculated using mainly 
peripheral cardiometabolic biomarkers was found to have a significant 
association with all three clinical outcomes over the following four years in 
DepChron patients. There was no evidence of an interaction between AI score 
and presence of depressive symptoms in risk prediction of any of the three 
clinical outcomes. There was a statistically significant interaction noted 
between SBP and depressive symptoms in risk prediction of major adverse 
cardiovascular outcome, and also between HbA1c and depressive symptoms in 
risk prediction of all-cause mortality for patients with diabetes. In Psobid, 
depressive symptoms (assessed by GHQ-28≥5) did not have a statistically 
significant association with any of the four outcomes under study at seven years: 
all cause death, all cause hospital admission, MACE and incidence of new cancer. 
A composite AI score at baseline had a significant association with the risk of 
MACE at seven years, after adjusting for confounders. A continuous measure of 
IL-6 observed at baseline had a significant association with the risk of three 
clinical outcomes- all-cause mortality, all-cause hospital admissions and major 
adverse cardiovascular event. Raised total cholesterol at baseline was associated 
with lower risk of all-cause death at seven years while raised waist hip ratio-
WHR at baseline was associated with higher risk of MACE at seven years among 
Psobid participants. There was no significant interaction between depressive 
symptoms and peripheral biomarkers (individual or combined) in risk prediction 
of any of the four clinical outcomes under consideration.  
 
Risk Scoring System Development 
In the DepChron cohort, a scoring system was constructed based on eight 
baseline demographic and clinical variables to predict the risk of MACE over four 
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years. The AUC value for the risk scoring system was modest at 56.7% (95% CI 
55.6 to 57.5%). In Psobid, it was not possible to perform this analysis due to the 
low event rate observed for the clinical outcomes. 
Conclusion 
Individual peripheral biomarkers were found to have a cross-sectional association 
with depressive symptoms both in patients with cardiometabolic disease and 
middle-aged participants recruited from the general population. AI score 
calculated with different statistical formulations was of no greater benefit in 
predicting concurrent depressive symptoms or clinical outcomes at follow-up, 
over and above its individual constituent biomarkers, in either patient cohort. 
SBP had a significant interaction with depressive symptoms in predicting 
cardiovascular events in patients with cardiometabolic disease; HbA1c had a 
significant interaction with depressive symptoms in predicting all-cause 
mortality in patients with diabetes. Peripheral biomarkers may have a role in 
predicting clinical outcomes in patients with depressive symptoms, especially for 
those with existing cardiometabolic disease, and this merits further 
investigation.  
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Chapter 1 Thesis Overview- Aims, Research 
Questions and Outline of Chapters 
1.1 Chapter Summary 
This chapter provides a general overview of the thesis, explaining the context 
and why this subject was chosen.  The overall hypothesis underpinning this 
thesis and its main objectives are described. A brief outline of the datasets 
analysed for this thesis is provided and followed by details of the research 
questions and an outline of the chapters.  
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1.2 Depressive Symptoms in Primary Care - Current 
Challenges 
This section provides background information about the prevalence estimates of 
depressive symptoms in primary care, economic costs, and the likely outcomes 
for patients presenting with depressive symptoms in primary care. The 
challenges of assessing and managing depressive symptoms in primary care are 
summarised, thereby setting the context of this thesis.  
The prevalence estimate for depressive symptoms is approximately 10%, with 
some significant variations observed across different geographical locations. The 
estimates from studies, mainly from North America and Europe, have suggested 
prevalence rates of 5-10% in primary care (1). In a large international study 
involving 15 different cities across the world, Sartorius and Üstün reported a 
prevalence of 10.4% of depressive symptoms, but there were significant 
geographical variations (2). The prevalence rate varied from 29.5% in Santiago, 
Chile to 2.6% observed in Nagasaki, Japan (2). A study involving five different 
European countries and more than 8,000 patients reported an overall prevalence 
of 8.56% in the general population, with higher prevalence reported among 
women and in urban populations (3). While, a study across six different countries 
in Europe reported a prevalence estimate of 4 to 18% for major depressive 
disorder (MDD) in primary care (4). Similar rates (major depression 4.5% and mild 
depression 13.3%) have been observed in primary care centres in post-conflict 
areas of northern Sri Lanka (5). The prevalence of depressive symptoms in 
patients attending primary care has been usually recorded to be higher than that 
observed in the general population (6,7).  
There is a significant economic burden associated with depressive symptoms as a 
health problem. Ferrari et al concluded that depressive disorders (MDD and 
dysthymia) were the leading cause of disability adjusted life years and the 
second leading cause of years lived with disability globally, in the global burden 
of disease survey in 2010 (8). Meanwhile, a review in Nature, in a special edition 
on this topic, suggested that depression accounts for the biggest share of the 
world’s burden of disease measured by years lost to disability (see Figure 
1-1)(9). The estimated annual health and social care costs (including loss of 
output) from mental illness was £105.2 billion  in England and £8.6  billion  in 
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Scotland, with most of the available evidence of economic burden related to 
depression (10).  
Figure 1-1 Top ten causes of disability globally (9)  
 
Reproduced with permission from Nature Publishing Group 
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The likely trajectory and outcome for depressive symptoms in primary care has 
been studied extensively, with some conflicting results. A systematic review  in 
2007 found 8 studies investigating recovery for primary care MDD patients and 
reported recovery rates varying from 32% to 71%, and only one study reporting 
follow-up longer than 12 months (11). More recently, a study  in the Netherlands 
reported a 43% recovery rate at 39 months for 174 MDD patients in primary care 
(12). The same study reported that 17% of patients had a chronic and 40% had a 
fluctuating course of illness. In a Finnish study involving 79 MDD patients, it was 
found that roughly 25% had achieved full remission, roughly 25% had persistent 
symptoms and the remaining 49% had a recurring course of illness at 18 months 
follow-up (13). A review on prognosis of depression in older patients reported a 
short term(<1 year) persistence rate of 22.7 to 51.3% (14).  In summary, 
depressive symptoms are common in primary care, associated with significant 
economic costs with some patients experiencing a full recovery (perhaps less 
than 50%), while the rest may experience a chronic or a relapsing and remitting 
course.  
In my experience as a general practitioner (GP), one of the biggest challenges 
for a primary care physician in managing patients presenting with depressive 
symptoms is difficulty in accurate risk stratification owing to heterogeneity in 
presentation. The two widely used diagnostic criteria for MDD, proposed by the 
World Health Organisation’s (WHO) International Classification of Diseases (ICD-
10)(15) and American Psychological Association’s (APA) Diagnostic and Statistics 
Manual-V (DSM-V)(16), have some important differences. In addition, not all 
patients with depressive symptoms in primary care will meet the diagnostic 
criteria for MDD and many may have minor or subthreshold depressive 
symptoms. But there is a significant amount of heterogeneity in defining minor 
and subthreshold depressive symptoms as well (17). The accuracy of primary 
care physicians in diagnosing and risk stratifying depressive symptoms has been 
reported to be less than 50%, when compared to a gold standard diagnostic 
interview for MDD (18,19). A gold standard diagnostic interview is not feasible in 
a primary care consultation due to time constraints and lack of training; hence 
various depression symptom questionnaire tools have been proposed and 
validated against the gold standard (20). However, it remains unclear if regular 
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symptom monitoring and structured assessment of depressive symptoms using a 
validated symptom questionnaire by a primary care physician has any benefit on 
outcomes, with evidence in favour (21) and against it (22), although higher 
patient confidence has been reported with the use of such an approach (23). 
Thus, primary care physicians face difficulties in accurate risk stratification of 
depressive symptoms and it remains unclear if the use of a structured and 
validated symptom questionnaire is the correct approach to yield better clinical 
outcomes.  
The difficulties in risk stratification of depressive symptoms are compounded in 
patients with cardiometabolic disease, due to the increase in prevalence of 
depressive symptoms, overlap with physical symptoms, and increase in 
cardiovascular mortality observed with co-occurrence (24). It has been proposed 
that there are common biological alterations observed with depressive symptoms 
and cardiometabolic diseases which might mediate the link between the two 
conditions (25). It remains unclear if the observed relationship between 
depressive symptoms and various biological alterations (especially in patients 
with cardiometabolic disease) can be translated in to clinical application by 
using peripheral biomarkers in risk assessment of depressive symptoms in 
primary care.  
The allostatic load (AL) framework has been put forward as the “price” an 
individual’s body has to pay to maintain internal stability, in response to stress 
(26,27). The AL theory suggests that by measuring multi-system biomarker levels 
as a proxy of measuring multi-system physiological dysregulation, it is possible to 
identify individuals at risk of having adverse health outcomes at a prodromal 
stage (27). Allostatic Index (AI) score, calculated by applying statistical 
formulations to different multi-system biomarkers, has been linked with various 
adverse physical and mental health outcomes, including depressive symptoms 
(28). 
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1.3 Project Hypothesis 
In this thesis, the hypothesis that a combination of allostatic load (AL) 
biomarkers will form a predictive algorithm in defining clinically meaningful 
outcomes in a population of patients presenting with depressive symptoms is 
tested.  
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1.4 Objectives 
The three main objectives are: 
1 To explore the relationship between various allostatic load biomarkers and 
prevalence of depressive symptoms in patients, especially in patients diagnosed 
with three common cardiometabolic diseases (Coronary Heart Disease (CHD), 
Diabetes and Stroke).  
2 To explore whether allostatic load biomarkers predict clinical outcomes in 
patients with depressive symptoms, especially in patients with three common 
cardiometabolic diseases (CHD, Diabetes and Stroke).  
3 To develop a predictive tool to identify individuals with depressive symptoms 
at highest risk of adverse clinical outcomes.  
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1.5 Datasets 
Two datasets were used to explore the hypothesis and to meet the 
aforementioned research objectives. The first dataset DepChron (‘Depression in 
Chronic Disease’ dataset) comes from the West of Scotland, with a sample size 
of more than 125,000 patients with a diagnosed cardiometabolic disease. This 
dataset uses information collected in 2008-09 as part of routine clinical practice 
within a chronic disease management programme called ‘Local Enhanced 
Services’(LES) in primary care aimed at patients with three cardiometabolic 
conditions (CHD, diabetes and stroke). LES are contractual arrangements at a 
local health board level with general practices where incentivisation is offered 
to primary care practitioners to complete certain indicators of chronic disease 
management.  However, there are no penalties for non-adherence. In the areas 
under investigation in our study, general practices were paid under the LES 
scheme to carry out a comprehensive annual health assessment, which included 
depression screening, for patients with the three common conditions described 
above. The annual health assessment was usually carried out by a practice nurse 
and lasted approximately one hour.  The protocol for health assessment was 
specific for each of the three diseases but included monitoring of blood pressure 
(BP), total cholesterol, body mass index (BMI) and in those with diabetes, 
HbA1c. The large sample size and data collected from real life clinical practice 
are major strengths of this dataset.  
The second dataset, Psobid (‘Psychological, social and biological determinants 
of ill health’ dataset) has 666 patients recruited in 2006-07 from the general 
population in Glasgow, with patients recruited from the most affluent and the 
most deprived areas based on Scottish Index of Multiple Deprivation(SIMD) (29).  
Participants aged 35-64 years were invited for two health visits during 
recruitment and a variety of information ranging from demographics, lifestyle 
information, medical history, clinical examination, blood tests and brain imaging 
was collected during these visits. The Psobid dataset has participants with and 
without a diagnosis of a cardiometabolic condition. The details of information 
available on behavioural measures for participants and the availability of a wide 
variety of blood based biomarker results are the key strengths of this dataset. 
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Data on clinical outcomes for the two cohorts were obtained through the use of 
data linkage facilities provided by Information Services Division, Scotland. The 
follow-up data on adverse clinical outcomes such as hospitalization, 
cardiovascular events and mortality were available over a period of four years 
for DepChron and seven years for Psobid. 
The two datasets were employed in this thesis for three different reasons. 
Firstly, the two datasets offered distinct advantages with larger sample size in 
DepChron dataset and better availability of biomarker data in Psobid dataset. 
Secondly, DepChron was a primary care cohort with existing cardiometabolic 
disease while Psobid was a younger cohort recruited from general population 
with relatively better health status. It was hypothesized that the relationship 
between peripheral biomarkers, depressive symptoms and adverse health 
outcomes may vary significantly based on underlying health status. Finally, 
performing the analysis in two datasets had the potential of offering external 
validity.  
 
 
 
 
 
 
 
 
 
 
Chapter 1  29 
1.6 Research Questions 
Below are outlined the five research questions to be addressed in this 
thesis by undertaking analysis of the two datasets, DepChron and Psobid. 
1. Research Question 1 (RQ1):  
What is the association, if any, between a composite Allostatic Index (AI) 
score calculated using available allostatic load biomarkers and depressive 
symptoms?   
2. Research Question 2 (RQ2): 
What is the association, if any, between individual allostatic load 
biomarkers and depressive symptoms and how does it compare with the 
relationship between composite AI score and depressive symptoms? 
3. Research Question 3 (RQ3):  
What is the association, if any, between a composite AI score at baseline 
and the risk of future adverse health outcomes such as vascular events, 
hospitalisation and mortality in patients with depressive symptoms?  
4. Research Question 4 (RQ4):  
What is the association, if any, between individual allostatic load 
biomarkers at baseline and the risk of future adverse health outcomes, 
such as vascular events, hospitalisation and mortality in patients with 
depressive symptoms and how does it compare with the relationship 
between composite AI score at baseline and risk of adverse outcomes? 
5.  Research Question 5 (RQ5):  
What is the accuracy of a risk scoring system developed using patient 
demographics, allostatic load biomarker values and severity of depressive 
symptoms, in predicting adverse health outcomes in patients with 
depressive symptoms?    
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1.7 Outline of Chapters 
1. Chapter 2 provides a background of the existing literature on the role of 
peripheral biomarkers in the prediction of clinical outcomes for patients 
presenting with depressive symptoms.  
2. Chapter 3 summarises the current evidence base in the area of depressive 
symptoms co-morbid with cardiometabolic disease. The prevalence 
estimates, suggested methods of management, reported clinical outcomes 
and proposed underlying mechanisms for the relationship between 
depression and cardiometabolic disease are reviewed.  
3. Chapter 4 discusses the allostatic load theory, its relationship with 
depressive symptoms and other health related outcomes, and the various 
statistical methods used to calculate the AI score.  The characteristics of 
the two population cohorts-DepChron and Psobid are described in detail.  
4. Chapter 5 provides the findings of cross-sectional analysis in the DepChron 
dataset to address research questions 1 and 2 (RQ 1 and 2). 
5. Chapter 6 provides the findings of cross-sectional analysis in the Psobid 
dataset to address research question 1 and 2 (RQ1 and 2).  
6. Chapter 7 describes the findings of longitudinal analysis after following up 
the cohort in the DepChron dataset for a period of four years to address 
research questions 3 and 4 (RQ 3 and 4).  
7. Chapter 8 describes the findings of longitudinal analysis after following up 
the cohort in the Psobid dataset for a period of seven years to address 
research questions 3 and 4 (RQ 3 and4).  
8. Chapter 9 presents the findings of risk scoring system development for 
predicting adverse clinical outcomes in patients in both datasets with 
depressive symptoms to address research question 5 (RQ5). The 
presentation of the findings of the analysis were evaluated against the 
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TRIPOD statement (Transparent reporting of a multivariable prediction 
model for individual prognosis or diagnosis) check list (30).   
9. Chapter 10 summarises the findings of this overall programme of work, 
compares it with the existing literature, and discusses strengths and 
limitations as well as potential implications of the findings including 
directions for future research in this area.   
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Chapter 2 Potential Role of Peripheral Biomarkers 
in Depression Risk Assessment – A Background 
2.1 Chapter Summary 
In this chapter, there are five parts including the introduction section. In the 
introduction section, the heterogeneity of depressive symptoms, the health 
related hazards associated with subthreshold depressive symptoms and problems 
in management of depressive symptoms in primary care (owing to drawbacks of 
currently available diagnostic classification systems) are discussed. This is 
followed by a brief overview of the proposed mechanisms of pathogenesis of 
depressive symptoms, the association of depressive symptoms with peripheral 
biomarkers and the aim of this background chapter. The first section is followed 
by a methods section describing the literature search and review methodology. 
The next two sections describe the results from the literature review and 
discussion of the findings, respectively. Finally, the last part describes the 
findings after updating the literature search and review.  
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2.2 Introduction 
2.2.1 Heterogeneity in depressive symptoms 
Depressive disorders are heterogeneous with a spectrum ranging from minor/sub 
threshold depression to MDD (31). The methods currently available for risk 
assessment and stratification of symptom severity for patients presenting with 
depressive symptoms rely predominantly on counting the absolute number of 
depressive symptoms present and there are two problems associated with this 
approach. Firstly, there is no universally accepted standardised definition of 
MDD or subthreshold depression. The DSM-IV’s diagnosis of a MDD requires the 
presence of at least 5 out of 9 symptoms of depression with significant 
impairment or distress, while those presenting with at least 2 but fewer than 5 
symptoms and no previous history of MDD are stratified as sub threshold or minor 
depression (32).  However, the category of sub threshold depression has been 
removed from the recently published DSM-V (16).  In contrast,  the ICD-10 
stratifies depressive symptoms on the basis of the number of depressive 
symptoms present into mild (4 out of 10), moderate (5 or 6 out of 10) and severe 
(7 or more out of 10) depressive symptoms (15). The problem of lack of 
consensus in definition also extends to subthreshold depression, with lots of 
variations in how it is defined based on symptom count and duration (17). 
Secondly, this approach has also been questioned as it ignores the complexity 
and diversity observed with different presentations of depressive symptoms (33).   
2.2.2 Are all types of depressive symptoms hazardous? 
The global burden of disease survey in 2010 attributed significant disability 
adjusted life years and years lived with disability to subthreshold depression, 
although these effects were much more significant with MDD (8).  Subthreshold 
depression has been associated with severe deficits in psychological well-being, 
quality of life, and increased mortality (34–36). In addition, subthreshold 
depression has also been found to have low spontaneous remission rate and 
higher risk of converting into MDD, especially in older adults where it is more 
prevalent (37,38).  
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2.2.3 Management of depressive symptoms- usefulness of 
currently available diagnostic classification 
The majority of patients reporting depressive symptoms are managed in primary 
care (20,39). The following section examines the utility of the currently 
available diagnostic classification against two criteria- ease of use in primary 
care and deciding appropriate management. The methods of classifying 
depressive symptoms based on current diagnostic classification systems can be 
broadly categorized into two main types- ‘gold standard’ diagnostic interviews 
and psychometric depression symptom questionnaire tools. Diagnostic interviews 
are not practical to implement in primary care, especially in the U.K. where 
average consultation duration is 10 minutes and often involves dealing with 
multiple health problems (40). On the other hand, GPs have often found the use 
of psychometric tools ‘not consultation friendly’, while some GPs have 
questioned the validity of using these tools (23,41). Furthermore, if GPs do not 
use either of the above two methods, their diagnostic accuracy has been 
reported to be about 50% compared to a gold standard diagnostic interview, 
based on a meta-analysis of 41 studies involving more than 50,000 patients (19).  
 
The uncertainty in stratifying depression severity based on symptom count 
affects subsequent management. A review of treatment guidelines for 
depression across North America and Europe revealed that “mild MDD and sub 
threshold depression has the most variance in recommendations”; with 
suggested approaches ranging from watchful waiting to active treatment with 
antidepressants (42).  In the last decade, three separate meta-analyses reported 
that the efficacy of antidepressants is related to the initial severity of 
depression and they may not be effective in the treatment of mild depression 
(43–45). However, this view has been challenged recently with emerging 
evidence suggesting that the efficacy of antidepressants in depression may not 
be related to its initial severity (46,47), and that efficacy is not limited to MDD 
only and may extend to the whole spectrum of depressive symptoms (48). 
Similarly, psychological therapies have also been found to be effective in the 
management of mild depression and prevention of MDD (49).  
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In summary, there are significant health hazards associated with minor 
depression. The diagnostic tools available to primary care physicians for 
differentiating minor depression and MDD are either impractical or unpopular 
among primary care physicians. Most importantly, the two different 
management approaches used for depressive symptoms (antidepressants and 
psychological therapies) have similar efficacy for both mild depression and MDD. 
Thus, the risk stratification of depressive symptoms needs a new approach and 
cannot merely rely on counting the number of depressive symptoms alone. The 
focus of the stratification of depressive symptoms should be based on the risk of 
adverse clinical outcomes (both related to depressive symptoms and physical 
health). In this context, the advances made so far in the study of pathogenesis 
of depressive symptoms may have a role.  
 
2.2.4 Pathogenesis of depressive symptoms- an overview 
The etiopathogenesis of depression has been extensively studied over the last 
five decades with various explanatory mechanisms involving different 
physiological systems, suggesting heterogeneity (50). The ‘monoamine 
hypothesis of depression’ was proposed in the 1960s with early work showing 
increased levels of plasma tryptophan (a serotonin precursor) in patients with 
major depression (51). Failure to suppress cortisol in response to dexamethasone 
in patients with depression was the initial finding which supported the role of 
the hypothalamic-pituitary-adrenal (HPA) axis hyperactivity in the 
pathophysiology of depression (52). The ‘cytokine hypothesis’ suggests that 
depression is triggered, in part, via inflammatory processes in response to 
various internal and external stressors, following  some seminal work in the early 
1990s (53). The ‘neurogenesis hypothesis’ of depression proposes that depression 
is  characterized  by neurodegeneration and impaired neurogenesis in the brain, 
in particular the hippocampus region (54). It is likely that several hypotheses 
may overlap here. Mössner et al have summarized various pathological 
mechanisms which could form the basis of depressive symptoms and proposed 
that there could be a role to play for biomarkers in management of depressive 
symptoms (55) (see Figure 2-1).  
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Figure 2-1 Various pathological mechanisms associated with depressive symptoms   
 
Proposed by Mössner and colleagues(55). Reproduced with permission from Taylor and Francis.  
 
2.2.5 Biomarkers of depression 
A biomarker can be defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacologic responses to a therapeutic intervention (Biomarkers Definitions 
Working Group, 2001). The research into pathogenesis of depression has led to 
an extensive evidence base supporting a cross-sectional relationship between 
depressive symptoms and a number of different biomarkers pertaining to some 
of the physiological systems described above, but their role, if any,  in 
predicting clinical outcomes in depressive symptoms remains unclear due to lack 
of a sufficient number of longitudinal studies (56) (57). Peripheral biomarkers 
(blood based) are relatively non-invasive (other than the need for a blood 
sample) and easy to measure; hence they have a greater potential for 
translational application into routine clinical practice, when compared to 
imaging, genetic and CNS biomarkers. Peripheral biomarkers such as those 
related to the HPA axis, inflammatory and monoamine systems may have a role 
in the diagnosis  of depression by identifying a ‘biological sub-type’  of 
depressive symptoms, and more importantly in prognostication of depressive 
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symptoms by predicting  treatment response, which in turn could help in 
severity stratification and management (58–60). 
 
2.2.6 Aim of the literature review 
The aim of the literature search and review was to examine the current 
evidence base exploring the potential role of peripheral biomarkers measured at 
baseline as a risk assessment tool in predicting future outcomes in patients with 
depressive symptoms.
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2.3 Methods  
Two electronic databases (Ovid Medline and Embase) for studies published 
between 1946 and Jan 2013 using the MESH terms “Biological markers” AND 
“Depression” were searched.  All original and review studies using peripheral 
biomarkers at baseline as a risk assessment tool for predicting future outcomes 
in patients with depressive symptoms were included. If a meta-analysis was 
included in the review, findings from that meta-analysis were considered for the 
review, and not the findings of the primary studies included in that meta-
analysis. Clinical outcomes pertaining to both mental health (e.g. depressive 
symptoms) and physical health (e.g. cardiovascular events) were included. Only 
studies published in English language were considered for inclusion. Studies 
related to animal, imaging biomarkers, cerebrospinal fluid biomarkers, and 
mood disorders other than depression were excluded.  Studies which 
investigated the role of depressive symptoms and peripheral biomarkers 
independently in predicting adverse physical outcomes but did not examine the 
interaction between depressive symptoms and peripheral biomarkers, or in other 
words did not perform a sub-group analysis in patients with depressive 
symptoms, were excluded.  Studies that investigated changes in peripheral 
biomarker levels following treatment for depressive symptoms were excluded as 
the aim of this review was to focus on the use of peripheral biomarkers at 
baseline or pre-treatment as a predictive tool of clinical outcome (both mental 
and physical), rather than a change in biomarker level itself. The search strategy 
returned 1096 studies from the two databases after excluding duplicates (see 
Figure 2-2 for details).  
 
Title, abstract and full text screening followed by reference and citation 
searching and data extraction were carried out independently by two 
researchers (myself and Dr Gary McLean). Data extraction comprised of study 
sample size and country, type of study and setting, details of how a depressive 
disorder was diagnosed and treated, follow-up duration, biomarkers assessed, 
clinical outcomes studied and potential bias in the results.  The description of 
methodology used by included studies for biomarker measurement and the 
source of peripheral biomarker (i.e. serum or plasma or whole blood) was also 
reviewed in data extraction.   
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Figure 2-2 Flow chart for the review on the role of peripheral biomarkers predicting 
outcomes in patients with depressive symptoms (61) 
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2.4 Results 
2.4.1 Included studies and their characteristics 
There was extensive evidence (109 studies) exploring and supporting the cross-
sectional relationship between depression and different peripheral biomarkers. 
However, only a minority of studies (n=14) investigated the use of peripheral 
biomarkers to predict future outcomes in patients with depressive symptoms. 
Fourteen papers were included for data extraction; which consisted of eight 
prospective cohort studies (62–69), three case-control studies (70–72), two 
randomized controlled trials (73,74) and one meta-analysis (75).  Full details of 
included studies are summarized in Table 2-1.  
 
Sample sizes ranged from 8 to 986 with sample sizes of fewer than 50 
participants in 6 studies (62,64,65,68,70,71), while three studies had a sample 
size of 25 or fewer (62,68,70). Follow-up duration ranged from 4 weeks to 18 
years with the follow-up duration being less than 6 months in 8 studies 
(62,64,68–70,72–74), while only five studies followed their subjects for more 
than 12 months (63,65–67,71). Six studies each used a diagnostic interview 
technique (64,66,68,70–72), and a depression rating scale (62,63,67,69,73,74); 
while diagnostic method for depressive disorder was not specified in one of the 
included studies (65). The nature of the treatment was specified in nine studies 
(62,64,68–70,72–75); the relationship between outcome and baseline depression 
severity was only taken into account in five studies (64,66,68,70,71). The 
included meta-analysis had a variable sample size and follow-up duration 
depending on the different research questions considered by the study, while 
the diagnostic methods used were heterogeneous including various symptoms 
scores and interview techniques (75). The meta-analysis was published in 1993 
and none of the original studies included in the meta-analysis were included in 
this review. 
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Table 2-1 Summary of studies included in the review(61).  
Study and Country Type of Study and 
Setting 
Sample Size at 
follow-up 
Depression Diagnosis Criteria Treatment Offered Follow-up 
Duration 
Alvarez et al (1999); 
France 
Cohort; Psychiatry 
inpatients 
N=8 MADRS ≥ 20 Fluoxetine 20 mg 28 days 
Arolt et al (2003); 
Germany 
Case-control; Psychiatry 
inpatients 
N=25 (MDD), N=25 
(healthy controls) 
Composite International 
Diagnostic Interview  for DSM-
IV criteria for MDD 
Different groups of 
anti-depressants 
28 days 
Baldwin et al (2006);  
UK 
Case-control; 
Community 
N=28 (MDD), N=35 
(healthy controls) 
SCID  for MDD Not specified 3.1 years 
Baune et al (2012); 
Australia 
Cohort; Community N=73 GDS ≥6 Not specified 23.39 months 
(average) 
Duval et al. (1996); 
France 
Cohort study; Psychiatry 
Inpatients  
N=30 Unstructured interview for 
DSM-IV for MDD 
1.Amitriptyline 
(n=13) 
2.Fluoxetine (n=9) 
3.Toloxatone (n=8)  
1 month 
Jang et al (2008); South 
Korea 
Case-control; Psychiatry 
Outpatients 
N= 59 (MDD), N=34 
(healthy controls) 
SCID for MDD Different groups of 
anti-depressants 
6 weeks 
Johnston et al (1999); 
UK 
Cohort; Psychiatry 
Outpatients & Inpatients 
N=34 SCID for MDD Not specified 8 years (average)  
Jokinen et al (2009); 
Sweeden 
Cohort; Psychiatry 
Inpatients 
N=346 
 
DSM- IV criteria for all mood 
disorders, diagnostic method 
unspecified 
Not specified 18 years 
(average) 
Kin et al (1997); Multi-
centre 
RCT with 3 arms; not 
specified 
N=70 randomized 
into 3 arms 
HDRS ≥ 18 3 arms: 1. 
Nortriptyline 75 mg 
2.Moclobemide 400 
mg 
3. Placebo 
7 weeks 
Ladwig et al (2005); 
Germany 
Cohort; Community N=975  (only males) von Zerssen affective 
symptom check list with a 
score ≥11 
Not specified 7.7 years 
(average) 
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Lanquillon et al. (2000); 
Germany 
Cohort; Psychiatry 
Inpatients 
N=24 SCID for MDD Amitriptyline in 
increasing dose 
6 weeks 
Perez et al. (1998); 
Spain 
Cohort; Psychiatry 
Inpatients 
N=83 HDRS ≥ 17 Different groups of 
anti-depressants 
6 weeks 
Raison et al. (2013); US RCT with 2 arms; 
Community 
N=60 randomized 
into two arms 
Treatment resistance 
Depression diagnosed using 
Massachusetts 
General Hospital Staging 
method for treatment 
resistance ≥ 2 
2 arms: 
1.Infliximab 
infusions ×3 
2. Placebo 
12 weeks 
Ribeiro et al. (1993); US Meta-analysis with 3 
different research 
questions (RQ1-3) 
RQ-1 
N=127 
Heterogeneous, including 
different symptoms scores and 
interview techniques 
Various Not specified 
RQ-2 
N=412 
Heterogeneous, including 
different symptoms scores and 
interview techniques 
Various 1-7 weeks 
RQ-3 
N=411 
Heterogeneous, including 
different symptoms scores and 
interview techniques 
Various 1-60 months 
Legend: MADRS: Montgomery Asperg Depression Rating Scale, HDRS: Hamilton Depression Rating Scale, DSM-IV: Diagnostic and Statistical Manual IV, 
MDD: Major Depressive Disorder, SCID: Structured Diagnostic Interview for DSM-IV, GDS: Geriatric Depression Scale, RCT: Randomized Controlled 
Trial, 5-HIAA: 5-Hydroxyindoleacetic acid, RQ: Research Question. 
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2.4.2 Biomarkers studied and method of collection 
The included studies assessed 36 different peripheral biomarkers at baseline as a 
predictor of clinical outcomes. These biomarkers were measured in serum or 
plasma and could be broadly classified as pertaining to inflammatory (n=14), 
neurotransmitter metabolism (n=9), neuroendocrine (n=8), metabolic (n=4) and 
neurotrophic (n=1) systems.  The peripheral biomarkers and clinical outcomes 
considered by the included studies are summarized in Figure 2-3. All included 
studies assessed statistical significance based on the criteria of having a p-value 
less than 0.05. Twelve biomarkers were found to be statistically significant in 
predicting outcomes (summarised in Figure 2-3), while 24 biomarkers were found 
to have no association with the clinical outcomes studied. Inflammatory 
(63,67,68,71,74) and neuroendocrine (64–66,73,75) biomarkers were each 
assessed in five of the included studies, followed by neurotransmitter 
biomarkers in three studies (62,66,69), neurotrophic biomarkers in two studies 
(70,72), while metabolic biomarkers were assessed in only one study (71).  
 
The source of peripheral biomarker measurement was plasma in half of the 
included studies (n=7) (64–66,69,70,73,74); serum in two studies (63,67,72); 
whole blood (68) and mixed (both serum and plasma) (62) in one study each; and 
not reported in two of the included studies (71,75). Four of the included studies 
did not describe the procedures of measuring peripheral biomarker in detail 
(64,65,71,75). Four of the included studies describe the anticoagulant used for 
collecting plasma samples, with ethylenediaminetetraacetic acid (EDTA) used by 
two studies (69,74); and heparin (70) and sodium citrate (62) used by one study 
each. 
 
2.4.3 Types of clinical outcomes studied 
The majority of included studies (n=12) considered outcomes pertaining to 
mental health or depressive symptoms (62–64,66,68–75), with only two studies 
assessing physical health outcomes (65,67) (see Table 2-2).   The commonest 
outcome was author defined positive treatment response to anti-depressants 
with improvement in depressive symptoms (e.g. 50% reduction in depression 
rating scale Hamilton Depression Rating Scale (HDRS) from baseline)  being 
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considered by nine included studies (62,64,68–70,72–75). This was followed by 
other mental health outcomes such as pre-defined criteria for poor outcome of 
depressive symptoms (n=3)(66,71,75), for example Lee and Murray operational 
criteria for outcome in depression. Remission of depression symptoms was used 
in three studies(63,64,74), for example HDRS <8 at follow-up.  
 
Physical health outcomes measured were: cardiovascular deaths-two studies 
(65,67), myocardial infarction (67) and death due to natural causes (65) by one 
study each. Biomarkers were shown to be statistically significant in predicting all 
of the six outcomes considered, including mental and physical outcomes. Figure 
2-3 summarizes the six different mental and physical health outcomes studied, 
the number of studies which examined each outcome, the 12 peripheral 
biomarkers which were noted to be statistically significant in predicting each 
outcome and the direction of the relationship between the biomarker and the 
outcome.  
 
2.4.4 Statistical methods used and their limitations 
There were some limitations of the statistical methods used in the included 
studies. The Area Under Curve (AUC) statistic was presented only by one study, 
with AUC statistic for Dexamethasone suppression test (DST) reported as 0.65 for 
predicting increased incidence of cardiovascular deaths, only for the male subset 
(n=126/382) of their sample (65). DST was found to have a significant impact in 
predicting three different outcomes in two different studies; which included 
adverse outcomes such as increased incidence of all-cause mortality and 
cardiovascular deaths (65), and the favourable outcome of positive treatment 
response (as measured by 50% reduction in HDRS) to anti-depressants (73). In the 
included meta-analysis, there was no evidence of an association between DST at 
baseline and a 50% improvement in HDRS in the group taking anti-depressants, 
though there was evidence of an association between baseline DST and a 50% 
improvement in HDRS in the group taking placebo (75). Elevated levels of serum 
S100B was the only biomarker which was found to have a statistically significant 
association with the same clinical outcome (positive treatment response to anti-
depressants) in more than one included study (70,72).  
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Figure 2-3 Different outcomes in depression and their statistically significant predictors: 
findings from review(61) 
 
Legend: The figure describes the various mental and physical health outcomes considered by included 
studies and the number of studies which examined each outcome. The figure includes only those peripheral 
biomarkers which were found to have a statistically significant impact in predicting each outcome and the 
direction of the relationship. DST: Dexamethasone Suppression Test, CRP: C Reactive Protein, IL: Interleukin, 
5HT: 5 Hydroxytryptamine, TSH: Thyroid Stimulating Hormone, ↑: higher, ↓: lower. * The study did not 
specify the source of the biomarker studied (i.e. serum or plasma).
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Table 2-2 Summary of peripheral biomarkers and clinical outcomes considered by included studies    
Study and Country Source of Biomarker (Serum/Plasma/whole blood), Biomarkers Assessed (and type of biomarker) 
* implies statistically significant (p-value<0.05) 
Outcomes studied 
Alvarez et al 
(1999); France 
a. Serum 5 plasma fluoxetine (Neurotransmitter metabolism) 
b. Plasma norfluoxetine (Neurotransmitter metabolism) 
c. Plasma fluoxetine plus norfluoxetine (Neurotransmitter metabolism)  
d. Plasma 5 HT (Neurotransmitter metabolism) 
e. Serum 5HT (Neurotransmitter metabolism) 
Treatment Response defined as 50% 
reduction in MADRS scores from baseline 
Arolt et al (2003); 
Germany 
a. Plasma S100 B protein* (Neurotrophic) Treatment Response defined as 50% 
reduction in HDRS from baseline 
Baldwin et al 
(2006);  UK 
a. HDL cholesterol* (Metabolic) 
b. LDL cholesterol  (Metabolic) 
c. BMI (Metabolic) 
d. ESR (Inflammatory) 
e. Pre-prandial glucose (Metabolic) 
Source: Serum/Plasma/Whole blood was not specified 
Poor Outcome of depression based on 
author described criteria assessed by SCID 
Baune et al 
(2012); Australia 
a. Serum IL1β (Inflammatory) 
b. Serum IL6 (Inflammatory) 
c. Serum IL8 * (Inflammatory) 
d. Serum IL10 (Inflammatory) 
e. Serum IL 12p70 * (Inflammatory) 
f. sVCAM-1  (Inflammatory) 
g. Serum PAI-1  (Inflammatory) 
h. SAA (Inflammatory) 
i. Serum TNF-α (Inflammatory) 
j. Serum CRP  (Inflammatory) 
Remission of depression symptoms defined 
as GDS <6 
Duval et al. 
(1996); France 
a. Plasma TSH (Neuroendocrine) 
b. Plasma Free T3 (Neuroendocrine) 
c. Plasma Free T4 (Neuroendocrine) 
d. Plasma TSH  response to Protirelin stimulation* ( for outcomes 1 and 2) (Neuroendocrine) 
e. Plasma Free T3 response to Protirelin stimulation (Neuroendocrine) 
f. Plasma Free T4 response to Protirelin stimulation (Neuroendocrine) 
1. Remission of depression symptoms 
defined as HDRS<8 
 2. “Partial Response” (treatment 
response) defined as HDRS 8-15  
Jang et al (2008); 
South Korea 
a. Serum S100B protein * (Neurotrophic) Treatment Response defined as 50% 
reduction in HDRS from baseline 
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Johnston et al 
(1999); UK 
a. Plasma Norepinephrine* (Neuroendocrine) 
b. Plasma Cortisol (Neuroendocrine) 
Poor Outcome defined by Depression 
Outcome Scale & Lee and Murray criteria  
Jokinen et al 
(2009); Sweeden 
a. Plasma Cortisol* (for outcomes 1 and 2) (Neuroendocrine) 
b. Plasma Dexamethasone non-suppression* (for outcomes 1 and 2) (Neuroendocrine) 
1.Death due to natural causes 
2.Cardiovascular deaths 
Kin et al (1997); 
Multi-centre 
a. Plasma Dexamethasone non-suppression* (only in Nortriptyline arm) (Neuroendocrine) Treatment Response defined as 50% 
reduction in HDRS from baseline 
Ladwig et al 
(2005); Germany 
a. Serum Highly sensitive CRP high risk group > 3 mg/ml* (Inflammatory) 1.Myocardial Infarction 
2.Sudden cardiac death 
Lanquillon et al. 
(2000); Germany 
a. Whole blood Lymphocyte count (Inflammatory) 
b. Whole blood Monocyte count (Inflammatory) 
c. Whole blood Ratio lymphocyte/monocyte* (Inflammatory) 
d. Whole blood CRP (Inflammatory) 
e. Whole blood ESR (Inflammatory) 
f. Whole blood IL-6 * (Inflammatory) 
g. Whole blood TNF-alpha (Inflammatory) 
Treatment Response defined as 50% 
reduction in HDRS and MADRS from  
baseline 
Perez et al. 
(1998); Spain 
a. Plasma 5HIAA (Neurotransmitter) 
b. Plasma Total Tryptophan (Neurotransmitter) 
c. Plasma 5 HT (Neurotransmitter) 
d. Platelet 5 HT with high concentration 800 ng/109 platelets* (stronger relationship in SSRI 
sub-group) 
(Neurotransmitter) 
Treatment Response defined as 50% 
reduction in HDRS from baseline 
Raison et al. 
(2013); US 
a. Plasma Highly sensitive CRP high risk group > 5 mg/ml (Inflammatory) 1.Treatment Response defined as 50% 
reduction in HDRS from baseline 
2. Remission of depression symptoms 
defined as HDRS<8 
Ribeiro et al. 
(1993); US 
a. Dexamethasone non-suppression* (for RQ2 only) 
 
Source: Serum/Plasma/Whole blood was not specified for the included studies 
1.(RQ1) “Treatment Response” 
 
2.(RQ2) Response to Placebo 
 
3. Long term outcome of depression based 
on predefined author criteria 
 
Legend: 5HT: 5 Hydroxytryptamine, HDL: High Density Lipoprotein, LDL: Low Density Lipoprotein, ESR: Erythrocyte Sedimentation Rate, BMI: Body Mass Index, IL: 
Interleukin, sVCAM-1: Serum Vascular Cell Adhesion Molecule -1, PAI-1: Plasminogen Activator Inhibitor-1, SAA: Serum Amyloid A, TNF-α: Tumour Necrotic Factor-
alpha, CRP: C Reactive Protein, TSH: Thyroid Stimulating Hormone, RQ: Research Question. 
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2.4.5 Patient demographics and attrition rate 
Description of patient demographics, co-morbid conditions and attrition at 
follow-up for the 14 included studies is provided in Table 2-3.  Details of the age 
of participants were not described by three studies (63,73,75); while information 
on gender distribution was missing from five studies (63,70,71,73,75). The socio-
economic status of participants was very poorly described with only two studies 
(67,75) characterizing it and only one study (67) including socio-economic status 
in their statistical analysis. Patients with pre-existing chronic disease were 
excluded by the majority of the included studies (n=8)(64–70,72) and chronic 
disease status was not considered or described by four of the included studies 
(62,71,73,75). Of the two studies which explicitly included patients with co-
existing chronic disease (63,74), only one study accounted for the number of co-
morbidities in their statistical analysis (74). The reported participant attrition 
rate at follow-up varied from 0 to 44%; with two included studies not specifying 
the details of attrition (63,75).  
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Table 2-3 Patient population and attrition rates for the included studies  
Study  Mean Age in years (Standard Deviation, if 
available) and  
Sex F=Females M=Males 
Co-morbid Medical Conditions Participant numbers 
Number of participants at baseline (B) and follow-
up(FU); attrition in percentage 
Alvarez et al (1999) 45 (13.8)  
6F, 2M 
Not described 10 B 
8 FU 20% attrition 
Arolt et al (2003) 46.4 (9.8)  
Not described 
Patients with co-morbid conditions 
excluded from study 
25 B 
25 FU No attrition 
Baldwin et al (2006) 73.9  
Not described 
Not described 50 B 
28 FU 44% attrition 
Baune et al (2012) Not described Presence/absence of a list of medical 
conditions noted and entered into 
statistical analysis 
73 B 
Sample size at follow-up not specified 
Duval et al (1996) 39.8 (12.9); 
19M, 11F 
Patients with co-morbid conditions 
excluded from study 
30 B 
30 FU No attrition 
Jang et al (2008) 60.3; 
43F, 16M 
Patients with co-morbid conditions 
excluded from study 
59 B 
59 FU No attrition 
Johnston et al (1999) 47; 
24F, 10M 
Patients with co-morbid conditions 
excluded from study 
47 B 
34 FU 27.6% attrition 
Jokinen et al (2009) 52 (16.4); 
256F, 126M 
Patients with co-morbid conditions 
excluded from study 
382 B 
346 FU 9.4% attrition 
Kin et al (1997) Not described Not described 95 B 
70 FU 26.3% attrition 
Ladwig et al (2005) 57.75 (7.8); 
975M 
Patients with co-morbid conditions 
excluded from study 
986 B 
975 FU 1.1% attrition 
Lanquillon et al (2000) 53.5; 
15F, 9M 
Patients with co-morbid conditions 
excluded from study 
35 B 
24 FU 30.5% attrition 
 Perez et al. (1998) M 45 (2.9), F 44.9 (2.0); 
59F, 24M 
Patients with co-morbid conditions 
excluded from study 
89 B 
83 FU 6.7% attrition 
Raison et al. (2013) 42.5 (8.2) placebo group,     44.3 (9.4) 
intervention group; 
40F, 20M 
Notable exclusions- previous history of 
cancer, history of unstable 
cardiovascular, endocrinologic, 
hematologic, 
hepatic, renal, or neurologic disease 
(determined by 
Physical examination and laboratory 
testing). 
Number of co-morbid medical conditions 
noted and entered into statistical analysis 
60 B 
60 FU No attrition 
Ribeiro et al. (1993) Not described Not described Not described 
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2.5 Discussion 
2.5.1 Summary of Findings 
This review shows that blood based peripheral biomarkers were statistically 
significant in predicting six different clinical outcomes in participants with 
depressive symptoms. Outcomes related to both mental health (depressive 
symptoms) and physical health were statistically associated with pre-treatment 
levels of peripheral biomarkers; however only two studies investigated outcomes 
related to physical health. Twelve different biomarkers related to five different 
biological systems (inflammatory, neuroendocrine, neurotransmitter 
metabolism, neurotrophic and metabolic) were found to have a statistically 
significant association with clinical outcomes in patients with depressive 
symptoms, while 24 biomarkers were found to have no association with clinical 
outcomes studied. Despite extensive research on the biomarkers of 
etiopathogenesis of depressive symptoms, there is limited published research 
exploring its translational application in clinical practice. Furthermore, the 
research is of generally limited quality and lacks clinical utility.  
 
2.5.2 Limitations of the included studies 
The included studies have several methodological problems. The study sample 
size was small and follow-up duration was short in the majority of included 
studies.  In addition, most studies used questionnaire scores that relied on 
symptom counts for diagnosing depression at baseline, while the gold standard 
interview technique for depression diagnosis was used by only a minority. There 
was lot of heterogeneity in the included study in terms of methods used for 
assessing depression, the follow-up duration and antidepressants offered for 
study participants. Baseline severity of depressive symptoms assessed using 
symptom count is associated with higher rate of relapse in patients with 
depressive symptoms (76), but accounting for the baseline severity of depressive 
symptoms was only undertaken by a minority of studies. There is a strong 
evidence base suggesting that depression is two to three time more prevalent in 
patients with co-existing chronic disease as compared to the general population 
(77–79), but the effect of co-morbidity on clinical outcomes was examined by 
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only one study and most studies excluded patients with existing co-morbidities. 
The information on socio-economic status was either missing or was not 
accounted for as a confounder in statistical modelling for the majority of the 
studies.  
 
Importantly, the clinical implications of the observed statistical relationships in 
the included studies were not well explained. The area under receiver operating 
characteristic (ROC) curve (80), which is regarded as one of the standard 
methods for evaluating clinical discriminating power of a biomarker in predicting 
clinical outcomes, was reported by only one study.  The utility of statistical 
models associating biomarkers with physical outcomes in the included study was 
not compared against robustly validated and routinely used risk scores, for 
example the Framingham score for cardiovascular events (81). Finally, some of 
the biomarkers included in this review are complicated to measure and likely to 
be expensive, making them impractical for use in routine clinical practice. The 
source and method of measurement for biomarkers in the included studies were 
heterogeneous and this may have an influence on assay levels of the biomarkers 
measured (82–84). The cost implications of doing these tests were not 
considered in detail in the included studies and this is likely to be a relevant 
factor when considering their potential use in routine clinical practice.  
 
In summary, there is some evidence that peripheral biomarkers may have a role 
in stratifying depression severity by means of predicting various physical and 
mental health outcomes in depression but further and more robust research 
needs to be done in this area to address the shortcomings of the available 
evidence. 
 
2.5.3 Outcomes based approach in depression severity 
stratification 
The use of prediction rules and biomarkers to inform clinical decision making is 
not a novel concept. It has been used in making management decisions in a wide 
variety of clinical scenarios such as patients presenting with high cholesterol, 
atrial fibrillation, chest pain, ankle injury and intensive care (85). In psychiatry, 
this principle has been proposed for predicting inpatient violence (86). 
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Depression contributes to disease burden not only owing to a reduction in quality 
of life and functional productivity, but also due to the increased risk of adverse 
physical outcomes such as hospitalisation and mortality (8). There is strong 
evidence showing an association of depressive symptoms (MDD and mild 
depression) with increased risk of adverse physical outcomes such as all-cause 
mortality, cardiovascular disease, hypertension, stroke, diabetes, Alzeimer’s 
disease, obesity and cancer (69).  Physical adverse outcomes associated with 
depression contribute to a significant amount of morbidity and mortality (8,87). 
Consequently, it is imperative that the risk of adverse physical outcomes 
associated with depression should be considered while taking decisions regarding 
depression severity stratification and subsequent management. Crucially, the 
clinical utility of biomarkers in predicting physical outcomes in depression, if 
any, should be compared and validated against some of the established and 
available risk scoring systems (for example the Framingham score for 
cardiovascular events (81)) for physical outcomes.  
 
2.5.4 Role of peripheral biomarkers in identifying depression 
subtypes 
The use of peripheral biomarkers in identifying different subtypes of depression 
has been explored by other studies in the literature. A meta-analysis reviewing 
the association between HPA axis hyperactivity (Dexamethasone non-
suppression) and depression suggested a dose-response relationship, with 
patients with mild depression showing higher HPA hyperactivity compared to 
controls but lower than that of patients with MDD (88). Peripheral inflammatory 
markers such as Tumour necrotic factor (TNF)-α and IL (Interleukin)-6, serum 
neopterin) have been shown to have an association with melancholic subtypes of 
MDD (89,90).  A review of metabolic and neuroendocrine biomarkers BMI, waist-
hip ratio (WHR), fasting glucose, serum adrenocorticotropic hormone (ACTH) in 
pre-menopausal women with MDD supported their role in identifying three 
different subtypes of MDD- melancholic, atypical and undifferentiated (91).  This 
suggests that peripheral biomarkers may have a useful role in addressing some of 
the challenges posed by heterogeneity of depression, with a particular 
biomarker likely to have a more useful role in a specific subtype of depression. 
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However, before any decisions are made, much better high quality research is 
needed.  
 
2.5.5 Novel Biomarkers in Depression 
In recent years, novel techniques in proteomics, metabolomics, genetics and 
epigenetics have led to several new biomarkers being proposed as markers for 
assessing depressive symptoms depression. Proteomic techniques have been used 
to identify nine differentiating proteins belonging to lipid metabolism and the 
immune system from treatment naïve patients with depression, when compared 
against healthy controls (92).  Similarly, metabolomic techniques such as nuclear 
magnetic response (NMR) based analysis of both urine and plasma have been 
utilized to identify differentiating proteins related to lipid metabolism and 
neurotransmitter system with good accuracy in treatment naïve patients with 
depression, when compared to healthy controls (93,94). Thus, novel techniques 
may help us identify peripheral biomarkers associated with depressive 
symptoms, and in turn they may have a role in prognostication of depressive 
symptoms.  
 
The role of brain-derived neurotrophic gene polymorphisms, glucocorticoid 
receptor polymorphism and serotonin gene receptor have been studied in the 
diagnosis and prognostication of depression with some encouraging results(95–
97). Although the findings from genome wide association studies (GWAS) to date 
in depression have failed to make a major breakthrough, they may have a 
potential role in stratification of depression and further research is ongoing 
(98,99). Thus, these emerging techniques and biomarkers may have a role in 
diagnosis, identifying specific subtypes of depression and prognostication in 
depression (100).  
 
2.5.6 Limitations of review 
The review described above has a number of limitations.  The search strategy 
was limited to studies published in the English language due to resource 
constraints. A variety of other biomarkers such as genetic, imaging and CSF 
biomarkers may have a role in depression stratification by predicting clinical 
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outcomes(100). However, this review considered only peripheral or blood-based 
biomarkers used in current clinical practice due to their comparative non-
invasive nature and ease of measurement, as the aim was to identify biomarkers 
that might be feasible for use in routine clinical practice.  The uncertainty 
surrounding  management decisions in patients with depression in current 
practice is a particular issue at the time of initial presentation(42). Hence, this 
review was focussed on addressing the issue of the use of peripheral biomarkers 
at baseline or pre-treatment as a predictive tool of clinical outcome (both 
mental and physical) and not on assessing changes in a peripheral biomarker 
level following treatment for depression.  
 
2.5.7 Future research 
There is a need for further research in this area, involving large scale studies 
with longer duration of follow-up, better characterization of patient populations 
and inclusion of patients with chronic diseases. An ‘ideal’ scientific process for a 
biomarker evaluation in clinical risk discrimination has been highlighted in other 
fields such as cardiovascular disease, and a similar approach can be adopted for 
biomarkers of depression (101). Further high quality epidemiological studies that 
minimize potential bias and evaluate clinical utility are urgently needed. Future 
studies need to incorporate other physical health outcomes such as rate of 
cardiovascular events, incidence of cancer and all-cause mortality associated 
with depression and compare validity against established benchmarks, along 
with mental health outcomes related to depression symptoms. There is some 
early evidence to suggest that an index comprising multiple biomarkers may 
exhibit a stronger relationship with depressive symptoms, especially in elderly 
populations, when compared with examination of individual biomarkers in 
isolation (102). The role of multiple biomarkers in risk assessment and predicting 
outcomes in patients with depression needs to be explored and compared 
against the role of individual biomarkers and is discussed further in Chapter 4.  
 
2.5.8  Conclusion 
Pre-treatment levels of 12 different blood based peripheral biomarkers related 
to five different biological pathways were found to have a statistically 
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significant relationship with outcomes in patients with depression. Six different 
outcomes in depression were predicted using these biomarkers, pertaining to 
both physical and mental health, but the clinical implications remain unclear. It 
appears likely that peripheral biomarkers may have an important role in helping 
clinicians to stratify depression severity and to predict clinical outcomes.  
However, the available evidence has multiple methodological limitations which 
must be overcome to make any real clinical headway; in particular, interaction 
between these biomarkers, depressive symptoms and co-morbid physical 
conditions needs to be explored further. This literature review was revisited 
prior to thesis submission to ensure the latest findings could be incorporated in 
this thesis.  The following section looks at whether the any further publications 
have added to the current state of knowledge. 
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2.6 Literature Search Update 
The literature search was updated to include recently published studies. Two 
electronic databases (Ovid Medline and Embase) for papers published between 
Jan 2013 and Jan 2016 using the MESH terms “Biological markers” AND 
“Depression” were searched. The inclusion and exclusion criteria were the same 
as those described in detail in the methods section, earlier in the chapter. The 
search results included 186 papers after removing duplicates. Out of these, 143 
papers were removed at title screening stage and 29 papers were removed at 
abstract screening stage.  In total, 14 papers were included for full paper 
screening and only 2 papers met the inclusion criteria. The findings of these 2 
studies are discussed below. 
The first included study was a secondary data analysis published in the Journal 
of Clinical Psychiatry by Papakostas et al. in 2014 (103). The analysis was based 
on a sample of 75 patients (originally recruited for a RCT in the US) reported to 
have SSRI resistant MDD (DSM-IV criteria), with 61 patients completing the 
follow-up of 60 days. The outcome variable was treatment response to L-
Methylfolate 15 mg administered daily, as measured by pooled mean change in 
HDRS-28 between baseline and at 60 days follow-up. Four biomarker values and 
16 genetic marker values at baseline were found to have a statistically 
significant association with better treatment response to L-Methylfolate at 60 
days. The pooled mean change in HDRS was significantly greater in sub-groups of 
participants with BMI≥30 (vs. BMI<30), hsCRP≥2.25 mg/L sample median value (vs 
hsCRP level <2.25), S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) 
ratio <2.71 (vs. SAM/SAH ratio ≥2.71) and 4-hydroxy-2-nonenal (4-HNE) ≥3.28 
ug/ml sample median value (vs. 4-HNE <3.28). SAM/SAH is related to 
methylation metabolism, while 4-HNE is a metabolite of lipid peroxidation. The 
main drawbacks of this study were: small sample size, relatively short follow-up 
and not using complete remission of depressive symptoms as an outcome 
variable.  
The second included study was a meta-analysis published in the European 
Neuropsychopharmacology in 2015 (104).  The meta-analysis investigated the 
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association between baseline inflammatory biomarker values at baseline (IL-6, 
TNF-alpha, CRP and a composite measure of inflammation) and treatment 
response in patients with major depression. The authors of this meta-analysis 
calculated a composite measure of ‘inflammation’ calculated by applying a 
statistical formula to a variety of inflammatory biomarker values available in 
their included studies, based on the consideration that all selected inflammatory 
biomarkers would measure the same latent construct i.e. ‘inflammation’. The 
details on the statistical formula used for calculating the composite measure of 
inflammation was not published. Elevated baseline ‘inflammation’ calculated 
using a composite measure was not found to have a statistically significant 
association with treatment response in patients with major depression (number 
of included studies=13, total number of participants not reported). Similarly, 
baseline IL-6 values (number of included studies=5, total number of participants 
not reported), baseline TNF-alpha values (number of included studies=5, total 
number of participants not reported) and baseline CRP values (number of 
included studies=4, total number of participants not reported) were not found to 
have a statistically significant association with treatment response in patients 
with major depression. The authors concluded that baseline inflammatory 
markers did not have a significant relationship in predicting treatment response 
in major depression. However, this meta-analysis had major drawbacks such as: 
the duration of follow-up in the included studies and the diagnostic criteria or 
the instrument used for assessing major depression in the included studies were 
not reported. The original studies included in this meta-analysis were not 
included in the search strategy employed by the review; this is a limitation of 
the search strategy employed for the literature review.  
Both of these newly included studies did not report information on co-morbidity 
or socio-economic status of their participants (103,104). Additionally, both these 
studies did not consider physical clinical outcomes and did not use ROC or cost 
effectiveness analysis. These limitations are consistent with the limitations 
observed in the majority of included studies from the original review.  
The influence of co-morbid depressive symptoms on prevalence and clinical 
outcomes in cardiometabolic diseases has been studied extensively, and is 
discussed in the next chapter- Chapter 3. 
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Chapter 3 Background Information on Depression 
in Patients with Cardiometabolic Disease 
3.1 Chapter Summary 
In this chapter, the following issues are addressed: 1) the reported prevalence 
estimates for depression in patients with cardiometabolic disease and its 
associated complications; 2) the current evidence base for assessment methods 
for depression and for the use of pharmacological and psychological therapies in 
the management of depression in cardiometabolic disease; and 3) the suggested 
underlying mechanistic pathways for depression comorbid with cardiometabolic 
disease.  
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3.2 Introduction 
Depression is up to two to three times more common in patients with 
cardiometabolic disease as compared to the general population, with prevalence 
estimates of depression from 15-25% in patients with cardiometabolic diseases 
such as CHD, diabetes and previous stroke (105–107).  Depression, comorbid with 
these cardiometabolic diseases, has detrimental effects on mortality, clinical 
outcomes, and functional outcomes such as the ability to carry out activities of 
daily living (108–111).  
The utility of different management approaches have been investigated for 
patients with depression in cardiometabolic disease. Depression screening has 
been recommended by some for patients with cardiometabolic disease in view of  
the high prevalence of depression (112,113); however there is lack of evidence 
to date that routine depression screening on its own, for patients with 
cardiometabolic disease, leads to any improvement in depressive symptoms or 
long term cardiovascular outcomes (114,115). Current evidence shows that the 
use of antidepressants, psychological therapies and disease management 
programmes for the management of depression in patients with cardiometabolic 
disease is associated with short term improvement in depressive symptoms but 
not associated with improvement in cardiovascular outcomes (116–119).  
The exact pathophysiological mechanism explaining the relationship between 
depression and cardiometabolic diseases remains unclear. Various theories have 
been hypothesised to explain the association between depression and adverse 
outcomes in these diseases, for example, increased platelet activation (120), 
low heart rate variability (121), higher levels of chronic inflammation (122) and 
insulin resistance (123).  This remains an area of ongoing research.  
  
60 
3.3 Prevalence of Depression in Patients with 
Cardiometabolic Disease and Associated 
Complications 
This section is divided into four parts. The prevalence of depression and 
associated complications for each of the three cardiometabolic diseases is 
presented individually in the first three parts; followed by a summary section 
and a summary table (see Table 3-1) with quality appraisal of evidence using in 
the final part.  
3.3.1 Prevalence of Depression in Patients with Coronary Heart 
Disease and Associated Complications 
Over the last three decades, there have been various studies which have 
reported an increase in prevalence of depression in patients with CHD (124). The 
majority of these studies have investigated the prevalence of depressive 
symptoms in relation to the event of an acute myocardial infarction (MI) (125). 
Thombs and colleagues published a systematic review of 24 studies and 14,326 
patients reporting the prevalence of depressive symptoms hospitalized with 
acute MI (125). The prevalence estimates varied between 16 to 45% for 8 studies 
which used a structured clinical interview for diagnosing depression; and 10 to 
47% for 17 studies which used a validated questionnaire for diagnosing 
depression. The weighted prevalence was 20.5% (N=10,785; confidence interval 
[CI] 19.8% to 21.3%) for studies using a structured interview (125). In addition, 
this review found that the increase in prevalence of depressive symptoms 
persisted for up to 12 months following an acute MI. The review noted 
heterogeneity in study size, timing (in relation to the event of MI) and diagnostic 
method of depression assessment, and the criteria for symptom duration among 
the included studies (125).  The ‘Heart and Soul’ study reported a prevalence of 
19.6% for depressive symptoms in 1017 patients with stable CHD (105). To 
summarise, approximately 1 in 5 patients, but possibly as few as 1 in 10 or as 
many as 1 in 2, with stable CHD or after surviving an acute MI, may suffer from 
depressive symptoms (105,125).  
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The increase in risk of mortality and future cardiac events with depression in 
patients with CHD has been widely reported. Some of the early work in this area 
was done by Frasure-Smith and colleagues in the early 1990s (126). They 
followed a group of 222 patients following an acute MI to report that patients 
who developed depressive symptoms after MI were more likely to die at 6 
months of follow-up. There have been several published meta-analyses since the 
turn of the century that have reported an increase in rate of cardiac events and 
all cause deaths in patients with depressive symptoms after MI or with CHD 
(110,127,128). Barth and colleagues reported in a meta-analysis of 20 studies 
that the risk of death in patients with depressive symptoms and CHD was 
approximately 1.5 to 3.5 times higher than the risk of death in patients with CHD 
and no depressive symptoms (Odds Ratio [OR], 2.24; 95%  CI 1.37–3.60) (127). In 
the largest meta-analysis to date based on 16,889 MI patients, Meijer and 
colleagues report that post-MI depression within 2 years of MI was associated 
with an increased risk of all-cause mortality (OR, 2.25; 95% CI 1.73–2.93), 
cardiac mortality (OR, 2.71; 95% CI 1.68–4.36) and further cardiac events (OR, 
1.59; 95% CI 1.37–1.85) (110).  The same group of authors (Meijer and 
colleagues) performed another meta-analysis in 2013 which involved time to 
event survival analysis on 10,175 MI patients from 16 studies. They reported a 
Hazard Ratio (HR) of 1.32 (95% CI 1.26-1.38) for all-cause mortality and HR of 
1.19 (95% CI 1.14-1.24) for cardiovascular events in post MI patients with 
depression as compared to those without depression (129). Similarly, in the 
‘Heart and Soul’ study of 1017 patients with stable CHD, after adjustment for 
comorbid conditions and disease severity, depressive symptoms were associated 
with a 31% higher rate of cardiovascular events (HR 1.31; 95% CI 1.00-1.71) at 
the end of 4 years (105). In addition to that, depression has been also reported 
as an important contributory factor in functional impairment in patients with 
CHD (130,131). There is substantial evidence to suggest that patients with CHD 
and depressive symptoms are more likely to have poor clinical outcomes, which 
has led to the American Heart Association identifying depression as a risk factor 
for poor prognosis in patients who have experienced an acute coronary syndrome 
(ACS) (109). 
The influence of timing of onset of depressive symptoms, in relation to the onset 
of a cardiac event, and in terms of first ever versus recurrent depressive 
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episode, on the risk of cardiovascular events has also been studied. A systematic 
review published in 2011 found that only six studies had investigated these 
questions (132). The review concluded that there is some evidence to suggest 
that ACS patients with first and new onset depression are at higher risk of worse 
prognosis, but that the existing evidence was inconsistent and there were some 
methodological limitations in the included studies (for e.g. small number of 
patients with follow-up data in some of the included studies) (132).  
3.3.2 Prevalence of Depression in Patients with Diabetes and 
Associated Complications 
The prevalence of depression in patients with diabetes has been extensively 
studied over the last 30 years. An early meta-analysis of 42 studies published in 
2001 by Lustman and colleagues reported that the odds of depression in the 
diabetic group were twice that of the non-diabetic comparison group (OR 2.0, 
95% CI 1.8-2.2) (133). This review did not differentiate between patients with 
Type 1 and Type 2 diabetes. In the past few years, research has been carried out 
to differentiate the prevalence estimates of depression between the two types 
of diabetes. A systematic review published in 2006 reported depression 
prevalence of 12% for Type 1 diabetes as compared to 3.2% for control subjects 
(134). The review did not report any odds ratio for comparison, which is a major 
limitation (134).  Another review published in the same year for Type 2 diabetes 
reported a prevalence estimate of 17.6% vs. 9.8% in the control group (OR 1.6, 
95% CI 1.2-2.0)  (107). More recently, a review conducted by Roy and his 
colleagues in 2012 reported a prevalence rate of 12% (range 5.8-43.3%) for Type 
1 vs. 3.2% (range 2.7-11.4%) in the control group; and 19.1% (range 6.5-33%) for 
Type 2 diabetes vs. 10.7% (range 3.8-19.4%) in the control group (135). Again, 
this systematic review did not report a pooled odds ratio of included studies for 
comparison of prevalence rates of depression between patients with diabetes 
and the control group (135), which is a major limitation. Thus, there is evidence 
from multiple systematic reviews to suggest  that the prevalence of depressive 
symptoms in patients with diabetes, (both types 1 and 2) is two to three times 
more as compared to those without diabetes (107,133–135).  
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Several studies have investigated the association of depression co-morbid with 
diabetes and its potential impact on complications related to diabetes. A meta-
analysis done by Lustman and his colleagues of 24 studies of patients with types 
1 and 2 diabetes showed that depression was associated with hyperglycaemia in 
diabetes patients (136). The review found that the effect size of this association 
was similar for type 1 and 2 diabetes but stronger when depression was 
diagnosed with a diagnostic interview as compared to a self-reported depression 
symptoms questionnaire (136). The same group of authors reported an 
association between co-morbid depression with diabetes and a variety of 
diabetes complications such as diabetic retinopathy, nephropathy, neuropathy, 
macrovascular complications, and sexual dysfunction (137). These findings were 
based on a meta-analysis of 27 studies with more than 5000 patients with 
diabetes and reported a consistent and moderate effect size of association 
(overall effect size Pearson correlation co-efficient r = 0.25, 95% CI 0.22-0.28) 
for both types of diabetes (137). Additionally, there is evidence from a review of 
47 studies to suggest that  depression comorbid with diabetes is associated with 
increased risk of treatment non-adherence and lack of self-care (Pearson co-
efficient r = 0.21, 95% CI 0.17-0.25) (138). A large cohort of more than 10,000 
patients in the USA with diabetes was followed up for a period of 8 years in 
another study; and they reported a higher risk of all-cause mortality and CHD 
related deaths in patients with depression and diabetes as compared to those 
with diabetes alone (139). A meta-analysis of 42,363 patients with diabetes from 
10 studies reported a higher risk of mortality (pooled HR=1.50, 95% CI 1.35-1.66) 
with co-morbid depressive symptoms (111). Thus, there is consistent evidence to 
show that depression comorbid with diabetes is associated with increased risk of 
poor glycaemic control, treatment non-adherence and diabetes related 
complications and mortality.  
3.3.3 Prevalence of Post Stroke Depression and Associated 
Complications 
Depressive disorders are very common among patients who have survived an 
episode of stroke. Some of the early work in this area was done by Robinson and 
colleagues, who proposed three distinct types of mood disorders in stroke 
survivors in 1986 (140). The first type of patients were the ones who met the 
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criteria for a Major Depressive Disorder, the second group of patients reported 
symptoms consistent with dysthymia (a mild but chronic form of depression) 
while the third group of patients presented with a sense of indifference and 
apathy in their mood (140). The early reported prevalence rates for post stroke 
depression ranged from 23% to 79%, depending on the clinical setting and 
instrument chosen to assess depressive symptoms (141). A meta-analysis 
published in 2005 reported a pooled estimate of 33% (95% CI, 29 to 36%) for 
depression prevalence in patients with previous stroke (142). These findings 
were based on a meta-analysis of 51 studies involving patients with stroke in 
hospital, rehabilitation units and the community (142). A review published in 
2010 reported an overall prevalence rate of 21.7% (range 6% to 40%) for post 
stroke major depression and 19.5% (range 8% to 44%) for post stroke minor 
depression (143). A multi-national study of 220 stroke patients observed that the 
prevalence of depression remained as high as 33% for up to a period of 5 years 
after an episode of stroke (144). The chronic nature of depressive symptoms 
could be due to realization among stroke survivors that their disability is unlikely 
to recover. In summary, one in three patients is at risk of developing depressive 
symptoms for up to a period of 5 years after an acute stroke.  
Post stroke depression has been associated with various adverse clinical 
outcomes. A review assessing post stroke mortality reported increased odds (OR 
1.22, 95% CI 1.02 to 1.47) for a period of 2 to 5 years among patients with 
depressive symptoms based on findings from 13 studies including 59,598 patients 
with stroke (108).  The reported confidence intervals for the pooled effect size 
are considerably wider and only marginally statistically significant as the lower 
confidence interval is very close to 1.0. The review also concluded that the risk 
of mortality after stroke was not significantly different among depressed 
individuals in the long term follow-up (>5 years) when compared to those with 
stroke and without depression, however the studies with long term follow-up 
had small sample size (108). A multi-centre study in China with 1 year follow-up 
results for 1713 patients with stroke observed a 49% (OR = 1.49, 95%CI: 1.03–
2.15) higher odds of recurrent stroke in patients with post stroke depression as 
compared to patients without it (145). A prospective study in Spain found an 
association between post stroke depression and cognitive decline at 2 years of 
follow-up (146). A review reported an association between post stroke 
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depression and poor functional outcomes and recovery based on 26 included 
studies; however the review did not report any overall effect sizes and there was 
a lot of heterogeneity among included studies  (106). Thus, there is some 
evidence that prevalence of depressive symptoms is associated with a higher risk 
of functional decline and mortality in stroke survivors.   
3.3.4 Summary 
In this section, a summary of some of the key systematic reviews or meta-
analyses for prevalence and associated complications of depressive symptoms in 
CHD, diabetes and stroke is presented in a table (see Table 3-1). The search 
strategy was comprehensive for all of these studies and they used multiple 
databases. Among the reviews on prevalence rates, the majority of the included 
studies on post MI (125) and post stroke (143) depression were cohort studies. 
Hence, it was not possible to compare depression prevalence in the study 
population with a control group, as reported in the review by Roy and colleagues 
for patients with diabetes (135). Only one review (out of six reviews) used 
statistical measures for investigating heterogeneity and publication bias. The 
meta-analysis by Park and colleagues on patients with diabetes found that there 
was little evidence of heterogeneity (Cochran Q=13.52, p-value=0.20) and no 
significant publication bias (Egger's regression intercept=0.98, p-value=0.23) 
(111). The meta-analysis by Bartoli and colleagues on patients with stroke did 
not report if they had done any adjustments for the effects of potential 
confounders on their results (108). Overall, these studies used appropriate 
methodology and their results were based on a large number of primary studies 
involving large samples of patients. The AMSTAR tool (A Measurement Tool to 
Assess Systematic Reviews) was used for quality appraisal (147). The AMSTAR is a 
validated tool which gives a score out of 11, based on 11 pre-defined criteria to 
assess methodological quality of systematic reviews 
(http://amstar.ca/Amstar_Checklist.php). The total AMSTAR score for each 
systematic review is presented in the table while the details on each individual 
item of the scoring are presented in the appendix (Appendix 6). 
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Table 3-1 Overview of key studies on prevalence of depression and associated complications in patients with cardiometabolic disease 
Lead 
author; 
year of 
Publica
tion 
Journal Subject Study 
desig
n 
Numb
er of 
includ
ed 
studie
s 
Patients 
included 
in the 
analysis 
Key Findings AMSTAR 
score 
(out of 
11) 
Thombs 
et al; 
2006 
Journal of 
General 
Internal 
Medicine 
Prevalence 
of depression 
post MI 
Syste
matic 
Revie
w 
24 N=14,326 1. Prevalence estimate varied with different diagnostic 
techniques for depression. 
2. N=8 studies using a diagnostic interview method: prevalence 
ranged from 16 to 45%; weighted prevalence was 19.8% 
(CI=19.1% to 20.6%) 
3. N=17 studies using a validated questionnaire: prevalence 
ranged from 10 to 47%; weighted prevalence varied with 
different questionnaires. 
8/11 
Roy et 
al; 2012 
Journal of 
Affective 
Disorder 
Prevalence 
of depression 
in diabetes 
against 
control 
Syste
matic 
Revie
w 
21 N=170,571 1. Prevalence of depression in Type 1 Diabetes= 12% (range 
5.8%-43.3%) against control= 3.2% (range 2.7%-11.4%) 
2. Prevalence of depression in Type 2 Diabetes= 19.1% (range 
6.5%-33%) against control=10.7% (range 3.8%-19.4%) 
7/11 
Robinso
n  et al; 
Canadian 
Journal of 
Psychiatr
Prevalence 
of depression 
Syste
matic 
Revie
43 N=7,068 1. Prevalence rate of 21.7% (range 6% to 40%) for post stroke 
major depression 
2. Prevalence rate of 19.5% (range 8% to 44%)for post stroke 
minor depression 
5/11 
67 
2010 y post stroke w 
Meijer 
et al; 
2013 
The 
British 
Journal of 
Psychiatr
y 
Depression 
after MI and 
association 
with 
outcomes 
Meta-
analys
is 
16 N=10,175 1. Hazard Ratio for depression for all-cause mortality in MI 
patients=1.32 (95% CI=1.21-1.38). Adjusted for: diabetes, 
smoking, BMI, LV function, age, sex. 
2. Hazard Ratio for depression for cardiovascular events in MI 
patients=1.19 (95% CI 1.14-1.24). Adjusted for: same as above 
10/11 
Park et 
al; 2013 
General 
Hospital 
Psychiatr
y 
Depression 
co-morbid 
with diabetes 
and 
outcomes 
Meta-
analys
is 
10 N=42,363 1. Hazard Ratio for depression for all-cause mortality in patients 
with diabetes= 1.50 (95% CI 1.35-1.66). Adjusted for age, sex, 
smoking, physical activity and Charlson comorbidity score. 
10/11 
Bartoli 
et al; 
2013 
Stroke 
Research 
and 
Treatmen
t 
Depression 
after stroke 
and 
outcomes 
Meta-
analys
is 
13 N=59,598 1. Odds Ratio for depression for all-cause mortality in patients 
post stroke=1.22 (95% CI 1.02-1.47). Adjusting confounders 
not stated. 
2. Hazard Ratio analysis performed only in 4 studies with N=2075 
patients.  
3. Hazard Ratio for depression for all-cause mortality in patients 
post stroke=1.50 (95% CI 1.02-2.26). Adjusting confounders 
not stated. 
9/11 
Legend: MI=Myocardial Infarction; CI=Confidence Intervals; LV=Left Ventricle; BMI=body mass index ; AMSTAR= A Measurement Tool to Assess 
Systematic Reviews (see Appendix 6 for details of the performance of each review on individual items on the score) 
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3.4 Assessment and Management of Depression in 
Patients with Cardiometabolic Disease 
This section is divided into two parts. The first part provides an overview on 
suggested benefits of screening, if any, and discusses various assessment 
methods of depressive symptoms in patients with cardiometabolic disease; while 
the second part provides an overview of different management approaches for 
depression and their effectiveness.  
3.4.1 Assessment of Depression in Patients with Cardiometabolic 
Disease 
The role of depression screening in patients with cardiometabolic disease has 
been controversial. Due to the high prevalence of depression in patients with 
CHD and its associated complications, the American Heart Association (AHA) 
recommended depression screening for patients with CHD in their guidelines 
published in 2008 (112). However, two systematic reviews published 
subsequently have failed to show any benefit of depression screening in terms of 
improving outcomes in patients with cardiometabolic disease (114,115).  In spite 
of  extensive search strategies, these two systematic reviews did not find a 
single trial evaluating the efficacy of depression screening as a standalone 
intervention, in patients with CHD, stroke or diabetes (114,115). Most of the 
evidence in this area has come from trials evaluating the benefits of depression 
screening as a part of a wider intervention, which also involved management of 
depressive symptoms (114,115).  These studies have not found any evidence of 
improvements in mortality or cardiovascular outcomes with comprehensive 
interventions involving depression screening and its management in patients with 
cardiometabolic disease (114,115).  
In the UK, NICE (National Institute for Health and Care Excellence) recommends 
that depression screening or ‘case finding’ in patients with chronic disease 
should only be targeted towards those who are believed to be ‘high risk’ (148). 
The UK Quality and Outcomes Framework (QOF) offered financial incentives to 
primary care practitioners for routine depression screening for all patients with 
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CHD and diabetes, between 2006 and 2013 (149). These financial incentives have 
been withdrawn from the QOF programme since 2013/14 (150).  In the UK, NICE 
has recommended using a short 2 question item scale such as PHQ-2 as a 
depression screening instrument for ‘high risk’ patients with chronic disease 
followed by a detailed depression assessment if the short item scale is found to 
be positive (148). However, the definition of ‘high risk’ patients has not been 
clearly stated in this guideline (148). Similarly in the USA, a working group from 
the National Heart, Lung and Blood Institute (NHLBI) has recommended a two-
step algorithm using PHQ-2 for depression screening in CHD, followed by PHQ-9 
for positive cases (151). However, the potential role of universal depression 
screening for patients with CHD, as a standalone intervention without any 
specific depression management interventions, in improving cardiovascular 
outcomes remains unclear.  
A number of self-reported depression symptom scores have been used as 
screening tools in patients with CHD. A systematic review found 13 studies on 
diagnostic accuracy of depression symptom scores compared against one of the 
gold standard methods (such as diagnostic interview) for diagnosing depression 
(114). Different screening instruments assessed in this review were the Hospital 
Anxiety and Depression Scale-Depressive subscale (HADS-D) (152), PHQ-9 
(Patient Health Questionnaire-9) (153),  PHQ-2 (Patient Health Quesionnaire-2) 
(154), Beck Depression Inventory (BDI) (155), Beck Depression Inventory-II (BDI-
II) (156), the Centre for Epidemiological Study Depression Scale (CES-D) (157), 
Geriatric Depression Scale (GDS) (158) and GDS-15 (159). The review did not find 
any one particular symptom score performing convincingly better over the 
others, and reported a lack of consistency in results on accuracy from multiple 
sites.  
A variety of symptom scores have been used for diagnosing and screening for 
depression in patients with diabetes. A systematic review found only 16 studies 
(7%) evaluating diagnostic accuracy of depression symptom scores out of 235 
studies of patients with diabetes (160).  BDI- I & II (155,156) and CES-D (157) 
were by far the two most widely used symptom scores for studying depression in 
patients with diabetes (160). The review concluded that most of the depression 
screening tools with available validity results (BDI I and II, CES-D, HADS-D, PHQ-
9, Zung’s self-rating depression scale (SDS) (161) and World Health Organization 
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(WHO)-5 (162)) had very high negative predictive value but low positive 
predictive value with varying prevalence rates (160). The review also did not 
recommend any one particular depression symptom score as having clear 
superiority over others for use in diabetes patients (160).  
The use of various depression symptom scores has been assessed in detecting 
post stroke depression. The Post Stroke Depression Rating Scale (PSDS) was 
developed specifically for assessing depressive symptoms in stroke patients 
(163), however it has not been widely used compared to some of the 
aforementioned instruments. The Stroke Aphasic Depression Questionnaire 
(SADQ) has been developed for assessing depressive symptoms in stroke patients 
with aphasia and found to have good reliability and validity (164). Similar to CHD 
and diabetes patients, a review on diagnostic accuracy of depression symptom 
scores for post stroke depression did not find any supremacy of one particular 
symptom score. The review concluded that CES-D, HDRS and PHQ-9 were the 
“most promising options” (165).  
In summary, various depression symptom scores have been used for measuring 
depression in patients with cardiometabolic diseases.  There is no single 
depression symptom score which has significantly better diagnostic accuracy. An 
overview of the three systematic reviews in this area is presented in Table 3-2. 
Again, the AMSTAR tool was used for quality appraisal giving a score out of 11, 
based on 11 pre-defined criteria to assess methodological quality of systematic 
reviews (147). The total AMSTAR score for each systematic review is presented 
in the table which shows that the reviews were of high quality, while the details 
on each individual item of the scoring are presented in the appendix (Appendix 
6).   
Another important issue is the ease of use of such symptom scores in routine 
clinical practice.  Barriers to utilisation in primary care include: time constraints 
and GP’s perceived doubts about their value and effectiveness which have been 
discussed  in Chapter 2 (40) (23,41). These practical problems may affect use of 
depression symptom scores for assessing depressive symptoms in patients with 
cardiometabolic disease in primary care. 
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Table 3-2 Overview of studies evaluating diagnostic accuracy of depression symptom scores in patients with cardiometabolic disease 
Lead 
author; 
year of 
Publication 
Journal  Subject Study 
design 
Num
ber 
of 
inclu
ded 
studi
es 
Number of 
patients 
included in 
analysis 
Key Findings AMSTAR score 
(out of 11) 
Thombs et 
al; 2013 
Plos One Accuracy (sensitivity and 
specificity) of various 
depression symptom scores in 
measuring depression for post 
MI and CHD patients 
Syste
matic 
Revie
w 
N=15 N-5917 1. Best reported sensitivity: BDI 
and GDS (100% each) 
2. Best reported specificity: 
PHQ-9 
10/11 
Roy et al; 
2012 
Diabetic 
Medicine 
Accuracy (sensitivity and 
specificity) of various 
depression symptom scores in 
measuring depression in 
patients with diabetes 
Syste
matic 
Revie
w 
N=16 N=8297 1. Best reported sensitivity: 
Zung’s rating scale and WHO-5 
(100% each) 
2. Best reported specificity: GDS 
(92.3%) 
      9/11 
Meader et Journal of 
Neurology, 
Accuracy (sensitivity and 
specificity) of various 
Meta-
analys
N=24 N=2097 1. Best reported sensitivity: BDI 
(86%) and PHQ-9 (86%) 
2. Best reported specificity: CES-
     9/11 
72 
al; 2014 Neurosurgery 
& Psychiatry 
depression symptom scores in 
measuring post stroke 
depression 
is D (88%) 
Legend: BDI=Beck’s Depression Inventory; GDS=Geriatric Depression Scale; PHQ=Patient Health Questionnaire; WHO=World Health Organization; CES-D: Centre for Epidemiological 
Studies Depression Scale. AMSTAR= A Measurement Tool to Assess Systematic Reviews (see Appendix 6 for details of the performance of each review on individual items on the 
score) 
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3.4.2 Management of depression in patients with cardiometabolic 
disease 
Current management approaches for depression in cardiometabolic disease can 
be divided into three categories: psychological therapies; antidepressants; and 
use of disease management programmes (for e.g. collaborative care) which 
usually combines the preceding two. The following section provides a summary 
of the evidence and an overview of some of the key meta-analyses published in 
this area in a table (see Table 3-3) at the end of this section.   
3.4.2.1 CHD Patients 
There have been two systematic reviews and meta-analyses on different 
interventions for management of depression co-morbid with CHD. A Cochrane 
review on patients with depression with CHD concluded that psychological 
interventions may have a small but clinically meaningful benefit in short term 
improvement of depressive symptoms (117). The review found that seven trials 
investigated the role of psychological therapies in treatment of post CHD 
depression, but only one trial looked at long term follow-up (>6 months) and 
remission rates (166). Only one trial (ENRICHD) reported on the rate of cardiac 
events and deaths in patients with post CHD depression and found no difference 
between the cognitive behavioural therapy (CBT) group and the usual care group 
(167). This trial did not find any beneficial effects on mortality rates, or rates of 
cardiac events and cardiovascular hospitalizations. Overall, results of this review 
provide some evidence of a small beneficial effect of psychological interventions 
compared to usual care on depression symptoms and remission rate in the short 
term, but no evidence of a beneficial effect on cardiac-related mortality or 
morbidity.  
The Cochrane review also analysed the role of pharmacological interventions in 
the treatment of depression in patients with CHD and found eight trials with 
1098 patients in total (117). Baumeister and colleagues conducted a meta-
analysis based on the three trials and 707 patients using selective serotonin 
reuptake inhibitors (SSRI) (117).  The meta-analysis showed improvement in 
depressive symptoms, remission and hospitalization rates in the short term (less 
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than 6 months follow-up) favouring antidepressants against placebo (168–170).  
There were no studies investigating the long term benefits on remission rates or 
improvement of depressive symptoms. The review also found five other trials 
investigating the role of pharmacological therapies in the short term but 
concluded that these trials did not report enough information to allow 
calculation of effect sizes (117). The review concluded that there was not 
enough evidence to support any beneficial effect of pharmacological 
interventions on reducing all-cause mortality or future cardiovascular events 
(117).  
A systematic review by Tully et al. published in 2015 concluded that 
collaborative care (an intervention consisting of a multi-disciplinary disease 
management programme which includes a structured and regular patient follow-
up) led to improvements in depressive symptoms but no improvements in 
cardiovascular events (171). This review performed a literature search until April 
2014 and found 6 RCTs (total n=1284, 655 patients in intervention group) (171). 
The review reported that collaborative depression care led to a significant 
reduction in MACE in the short term (RR 0.54; CI 0.31 to 0.95), however the 
difference was not sustained in the longer term. Subsequent to the publication 
of this review, Coventry and colleagues published the results of their RCT  of 
collaborative care interventions involving just under 200 patients with diabetes 
and cardiovascular disease (172). This RCT showed that the patients in the 
intervention arm had improvements in  depressive and anxiety symptoms at 12 
months but no improvement in quality of life or disease specific indicators (such 
as angina symptom score; they did not study cardiovascular outcomes (172).  
3.4.2.2 Diabetes Patients 
A Cochrane review by Baumeister and colleagues reviewed the role of 
psychological interventions in the treatment of depression in patients with 
diabetes in 2012 (116). The meta-analysis showed that treatment of depressive 
symptoms with psychological interventions (eight trials; 1122 patients) was 
associated with an improvement in depressive symptoms and remission rates in 
the short to medium term (less than 6 months) for patients with diabetes (116). 
The review found that long term effects (more than 6 months) of psychosocial 
interventions were investigated by only one study. A RCT of 361 patients in the 
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Netherlands showed that a self-management psychological intervention was 
associated with improvements in depression symptoms at 9 months of follow-up 
in diabetes patients (173). The Cochrane review concluded that the evidence on 
improvements in glycaemic control, medication adherence, quality of life and 
health care related costs was inconclusive for supporting the use of 
psychological interventions in the treatment of depression in diabetes patients. 
Moreover, the review did not find any studies which investigated the benefits of 
psychological interventions on reducing the rate of diabetes related 
complications or mortality. In summary, there is evidence to suggest benefits in 
improving depression related outcomes in the short to medium term but lack of 
data on improvements in diabetes related or other health outcomes.  
The Cochrane review also summarised the role of pharmacological interventions  
(eight trials; 377 patients) in the treatment of depression for diabetes patients 
and found very similar results (116). Pharmacological interventions were shown 
to improve depression symptoms and remission rates in the short to medium 
term (less than 6 months) in patients with diabetes, but there were no studies 
investigating long term outcomes (116). Contrary to psychological interventions, 
treatment with antidepressants was associated with improvements in glycaemic 
control in the short term (116). The review did not find conclusive evidence on 
benefits in health related quality of life, medication adherence or health care 
related costs in diabetes patients (116). Again, there were no trials looking at 
benefits on diabetes related complications or mortality rates (116).  
The authors concluded that both pharmacological and psychological 
interventions were associated with improvements in depression symptoms and 
remission rates. However, outcomes such as medication adherence, health 
related costs and quality of life, diabetes related complications and mortality 
rates have not been sufficiently studied (116). 
A meta-analysis published in 2014 found seven RCTs (with 1895 patients) 
examining the benefits of collaborative care on patients with diabetes and co-
morbid depression (174). The review found that collaborative care led to 
improvements in depressive symptoms and HbA1c levels at medium to long term 
follow-up (12 to 52 weeks); the benefits on cardiovascular events were not 
investigated in the review (174).  
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3.4.2.3   Stroke Patients 
Due to the very high prevalence of depressive symptoms in stroke patients, 
researchers have tested the benefits of using psychological interventions in 
prevention as well as treatment of depressive symptoms. In 2008, Hackett and 
colleagues published two Cochrane reviews that assessed the benefits of 
psychological interventions in both prevention (175) and treatment of depressive 
symptoms (176), for patients with stroke. The review for prevention of 
depressive symptoms found four trials using different psychological interventions 
involving 902 stroke patients and concluded that these interventions had a small 
but significant effect in preventing depressive symptoms in stroke patients 
(175).  However, the review for treatment of depressive symptoms using 
psychological interventions found no benefit in improvement of depressive 
symptoms,  on the basis of three trials and 445 stroke patients (175). Neither of 
these reviews identified any evidence of benefits of psychological interventions 
in stroke recovery or improving functional outcome (175,176).  
The two Cochrane systematic reviews described above also investigated the 
benefits of using pharmacological interventions in the prevention and treatment 
of depressive symptoms for stroke survivors (175,176). The Cochrane review on 
pharmacological interventions in prevention of depressive symptoms did not find 
any significant benefit in preventing depressive symptoms in the intervention 
arm based on results from 11 studies involving 591 patients (175). The review on 
treatment found 13 trials using 12 different antidepressants and involved 1121 
stroke patients (176). The pooled effect for the odds of remission of depressive 
symptoms at the end of 12 to 26 weeks of follow-up was lower in the control 
group as compared to the intervention group: OR of 0.47 (95% CI 0.22 to 0.98) 
(176). Similar to the results with psychological interventions, pharmacological 
interventions were not shown to have any evidence of beneficial effects in 
activities of daily living or cognitive function in stroke patients in either review 
(175,176). Another Cochrane review investigated the benefits of SSRI for various 
different outcomes in patients with post stroke depression, and included 52 
trials with 4059 participants (177). The meta-analysis found evidence of 
improvements in depressive symptoms (Standardized mean difference SMD=        
-1.91 (95% CI -2.34 to -1.48) and neurological deficit (SMD= -1.00 (95% CI -1.26 to 
-0.75) but no evidence of improvement in survival in the intervention group who 
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received SSRI; and there was high heterogeneity reported among included trials 
(177). There are some emerging concerns about using antidepressants in stroke 
survivors. A cohort study of 16770 stroke survivors in Taiwan reported an 
increase risk of stroke recurrence over 10 years associated with use of 
antidepressants (HR 1.42; 95% CI 1.24-1.62) (178).  
A trial in the USA involving 92 patients with previous stroke found an 
improvement in  depressive symptoms at 12 months of follow-up in the 
intervention group, who had an 8 week intervention involving a combination of 
antidepressants and a brief behavioural intervention (OR for remission in 
intervention group= 2.7 (95% CI 1.1 to 6.6) (179). Another approach for 
management of post stroke depressive symptoms could be exercise therapy. A 
meta-analysis of 13 studies and 1022 patients with post stroke depression found 
a reduction in depressive symptoms at short term follow-up (<6 months) with 
exercise therapy (SMD = -0.13 (95% CI -0.26 to -0.01) (180). However, the 
improvement in depressive symptoms was not sustained in the long (12 months 
or more) (180).  
3.4.2.4 Summary 
In patients with CHD, there is evidence that psychological, pharmacological and 
collaborative care interventions can have benefits in the short and medium term 
(up to 6 months), in terms of reduction in depressive symptoms. There is no 
evidence to show long term improvements in depressive symptoms or reductions 
in adverse cardiovascular outcomes. In patients with diabetes, there is evidence 
of benefit, in terms of reducing depressive symptoms and improving HbA1c 
control with pharmacotherapy and collaborative care but no benefits on 
reducing cardiovascular outcomes. In patients with stroke, pharmacotherapy has 
proven beneficial in terms of improving depressive symptoms and neurological 
deficits, but there is no evidence of positive effects on survival. Exercise therapy 
has also been associated with improvement in post stroke depressive symptoms 
in the short term but not on health care outcomes. Overall, there is lack of 
evidence on improvements in quality of life or physical health outcomes with any 
of the interventions across the three disease groups. Please see Table 3-3 for an 
overview of key studies. Again, the AMSTAR tool was used for quality appraisal 
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giving a score out of 11, while the details on each individual item of the scoring 
are presented in the appendix (Appendix 6) (147). 
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Table 3-3 Overview of studies evaluating different management strategies for depressive symptoms in patients with Cardiometabolic Disease  
Lead 
author; 
year 
Journal  Subject Number of 
included studies 
Number of patients 
included in analysis 
Key Findings AMSTAR Score 
(out of 11) 
Baumei
ster; 
2011 
Cochra
ne  
Psychological and 
pharmacological 
interventions in 
CHD with 
depression 
Psychological 
interventions n=7 
Pharmacological 
interventions  
n=8 
n=2858 
(psychological) 
N=1098 
(pharmacological) 
1. Psychological interventions: SMD 
improvement at short term (12 weeks): -
0.81 (95% CI-1.26 to -0.36) ; SMD 
improvement at medium term (6 months): 
-0.19 (95% CI -0.28 to -0.10) 
2. Pharmacological interventions: SMD 
improvement at short term (12 weeks): -
0.24 (95% CI -0.38 to -0.09); Odds of 
remission (12 weeks): OR 1.93 (95% CI 1.14 
to 3.25 
3. Lack of evidence on long term outcomes, 
improvement in cardiovascular outcomes 
11/11 
Tully; 
2015 
BMJ 
Open 
Collaborative Care 
in CHD with 
depression 
n=6 n=1284 1. SMD improvement at 12 weeks: -0.31 (95% 
CI -0.43 to -0.19) 
2. No sustained reduction in cardiovascular 
outcomes 
11/11 
Baumei
ster; 
2012 
Cochra
ne  
Psychological and 
pharmacological 
interventions in 
Diabetes with 
depression 
Psychological 
interventions n=8 
Pharmacological 
interventions 
n=1122 
(psychological) 
n=377 
(pharmacological) 
1. Psychological interventions: SMD 
improvement at medium term (6 months): 
-0.42(95% CI -0.70 to -0.14); Odds of 
remission at medium term (6 months): OR 
2.49 (95% 1.44 to 4.32); no improvements 
in HbA1c 
2. Pharmacological interventions: SMD 
improvement at short term (12 weeks): -
0.61 (95%CI -0.94 to -0.27); Odds of 
11/11 
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n=8 
 
remission at short term (12 weeks): OR 
2.50 (95% CI 1.21 to 5.15); HbA1c 
improvement at short term (12 weeks): 
weighted mean difference -0.4% (95% CI -
0.6 to -0.1) 
3. Lack of evidence on improvement in 
quality of life, medication adherence and 
cardiovascular outcomes 
Atlanti
s; 2014 
BMJ 
Open 
Collaborative  Care 
in Depression with 
diabetes 
n=7 n=1895 1. SMD improvement at 12 to 52 weeks: -0.32 
(95% CI -0.53 to -0.11) 
2. HbA1c improvement at 12 to 52 weeks: 
weighted mean difference         -0.33% 
(95% CI -0.66 to -0.0) 
8/11 
Mead; 
2012 
Cochra
ne  
SSRI for Stroke 
Recovery 
n=52 n=4059 1. SMD improvements in depressive 
symptoms: -1.91 (95% CI -2.34 to -1.48)  
2. SMD improvement in neurological deficit: -
1.00 (95% CI -1.26 to -0.75) 
3. No evidence of improvement in survival  
4. There was with high heterogeneity 
reported among included trials 
10/11 
Eng; 
2014 
Clinical 
Rehabil
itation 
Exercise therapy 
for post stroke 
depression 
n=13 n=1022 1. SMD improvement in depressive symptoms 
at <6 months: = -0.13 (95% CI -0.26 to -
0.01)   
2. No improvement in depressive symptoms 
at longer follow-up 
10/11 
Cochrane= Cochrane Database of Systematic Reviews; SMD= Standardized mean difference; CI= Confidence intervals; SSRI=Selective Serotonin Reuptake Inhibitors; AMSTAR= A 
Measurement Tool to Assess Systematic Reviews (see Appendix 6 for details of the performance of each review on individual items on the score) 
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3.5 Proposed Underlying Mechanisms for Depression 
Co-morbid with Cardiometabolic Disease 
3.5.1 Depression and CHD 
There is substantial evidence from various epidemiological studies that presence 
of depression is an independent risk factor in development of CHD (181,182), 
and it has been proposed that the relationship between depression and CHD is 
bidirectional in nature (183).  Many researchers have tried to explain why 
depression is associated with worse outcomes among patients with CHD, and 
different mechanistic models have been hypothesized (25,184). The mechanistic 
model which has been most studied is that the adverse effects of depression on 
cardiovascular outcomes in patients with CHD are mediated through a 
combination of different biological and behavioural factors. The leading 
candidates for common causal biological factors are increased platelet 
activation (120), low heart rate variability (121) and higher levels of chronic 
inflammation (122). The common behavioural factors which may contribute to 
adverse outcomes in CHD patients with depression are increased smoking, 
reduced physical activity and reduced adherence to medications (105,185). The 
alternative explanation proposed is that those with the most severe CHD are 
more likely to get depressive symptoms and subsequently more likely to have 
worst outcomes, hence depression is an epiphenomenon or a non-causal variable 
risk factor in patients with CHD (186,187). Finally, common genetic factors have 
been hypothesized as a mechanism to explain the relationship between 
depression and CHD but the evidence remains inconclusive (188).  
3.5.2 Depression and Diabetes 
Several possible pathophysiological mechanisms have been proposed to explain 
the relationship between depression and diabetes (189). Mcintyre and colleagues 
reported that depression and type 2 diabetes share disturbances in metabolic 
networks such as glucose-insulin homeostasis, immune-inflammatory processes 
and glucocorticoid signalling and hence labelled depression as a 
“neuropsychiatric syndrome” or “metabolic syndrome type II” (190). Based on 
evidence from animal studies, Wang and colleagues proposed a model that 
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suggests diabetes impairs hippocampal function via advanced glycation, which in 
turn impairs hippocampal neurogenesis and contributes to diabetes related 
depression (191). Another study suggested a lack of brain derived neurotropic 
factor in the brain as a common pathological factor in depression comorbid with 
diabetes (192). However, equally, as mentioned in relation to CHD in the 
preceding section it has been suggested that  depression may simply be 
associated with poor self-care and treatment adherence in diabetic patients; 
which in turn might explain the relationship between depression and increased 
risk of diabetes related complications (138).  
3.5.3 Depression and Stroke 
Researchers studying the relationship between depression and stroke have 
suggested that biological and psychosocial factors are contributory to this 
relationship  (193). The “vascular depression” hypothesis suggests that post 
stroke depression was caused by silent cerebral infarcts (194). In addition to 
that, brain imaging studies have shown a possible role of ischaemic lesions of 
striato-frontal circuits in post stroke depression (195). On the other hand, the 
positive association between the degree of disability in stroke and the degree of 
depressive symptoms have supported the idea that  psychosocial factors link 
depression and stroke (195,196). A meta-analysis of four studies and 260 stroke 
patients identified 5-HTTLPR genotype as a risk factor for the development of 
post stroke depression (197). There is a lack of evidence to support the 
superiority of one of these mechanisms over the other and the most likely 
explanation is that, for most stroke patients experiencing depressive symptoms, 
there is overlap and interplay across various biological, psychosocial and genetic 
factors (193,198). 
3.5.4 Summary 
It is most likely that a combination of biological, behavioural and genetic factors 
may contribute towards the observed relationship between depression and 
cardiometabolic disease. The available evidence currently appears inconclusive 
for a definitive explanation. The list of potential mechanisms discussed above is 
not exhaustive and it is not the focus of research in this thesis. Importantly, 
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there has not been significant translational application of the evidence from 
mechanistic studies in clinical practice. Certain biomarkers of some of the 
common biological pathways may have a role to play in assessing and managing 
depressive symptoms in patients with cardiometabolic disease. For example, two 
studies included in the review in Chapter 2 found that plasma cortisol and highly 
sensitive CRP levels at baseline were predictors of which patients with 
depressive symptoms were likely to experience cardiovascular outcomes (65,67). 
Unfortunately, these studies specifically excluded patients with existing 
cardiometabolic disease. There is a need to evaluate the benefits of using 
peripheral biomarkers in assessing and managing depressive symptoms in 
patients with cardiometabolic disease.   
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3.6 Conclusion 
Depression is a common co-morbid condition in patients with cardiometabolic 
diseases such as CHD, diabetes and stroke, with higher prevalence rates than the 
general population. Depression co-morbid with these diseases is associated with 
increased risk of cardiovascular complications in CHD patients, diabetes related 
complications in diabetes patients, reduced functional recovery in stroke 
patients and increased mortality in all three conditions. There is some evidence 
to show that treatment with psychological and pharmacological interventions 
leads to short term improvement in depressive symptoms in patients with CHD, 
diabetes and stroke. However, there is no strong evidence of these interventions 
reducing cardiovascular complications, diabetes related complications, 
functional recovery and mortality. Various bio psychosocial and genetic theories 
have been hypothesized to explain the relationship between depression and 
cardiometabolic diseases and most likely multiple mechanisms are responsible 
with considerable overlap; the available evidence is inconclusive and there is 
lack of evidence about its potential clinical applicability.   
In this thesis, the underlying hypothesis is that patients with cardiometabolic 
disease and co-morbid depression with abnormal values of certain cardiovascular 
biomarkers may be at higher risk of adverse cardiovascular outcomes as 
compared to those with normal cardiovascular biomarker values. This hypothesis 
is explored in the DepChron dataset, where all patients had existing 
cardiometabolic disease. In the next chapter, the allostatic load theory is 
discussed in detail and the two datasets and methods used for AI score 
calculation are described.  
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Chapter 4 Methods- Allostatic Load Theory, 
Allostatic Index Score and Description of Datasets 
4.1 Chapter Summary 
In this chapter, six issues are addressed: 1)  the allostatic load (AL) model, 
which proposes that multi-system physiological dysregulation induced by stress 
can contribute to various disease trajectories;  2) the statistical methods 
proposed in the literature, as a means of calculating a composite allostatic index 
score, using multi-system markers of allostatic load; 3)  findings from studies 
which examine the relationships between markers of allostatic load and 
depressive symptoms; 4)  the methods of data collection, depression assessment 
and participant characteristics of the two cohorts used in my study, DepChron 
and Psobid;  5) the different biomarkers available for allostatic index score 
calculation in DepChron and Psobid; & 6) the different methods of AI score 
calculation used in the study are described. The potential strengths and 
weaknesses of each dataset for the purpose of this study are also discussed. The 
next section of this chapter provides a summary and appraisal of the first three 
issues in the list above and sets the context of the study and selection of 
datasets. The third section of this chapter describes the datasets, while the 
fourth section describes the AI score calculation in the two datasets. The 
chapter concludes with a summary section of all of the issues described above.  
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4.2 Allostatic Load Theory, Allostatic Index Score 
Calculation and Relationship between Allostatic Load 
and Depression 
4.2.1 Allostatic Load Theory 
4.2.1.1 Definitions 
Allostasis: Allostasis refers to the process whereby an organism maintains 
physiological stability by changing parameters of its internal milieu and matching 
them appropriately to environmental demands (26).  
Allostatic Load: AL represents the “wear and tear” the body experiences when 
repeated allostatic responses are activated during stressful situations (199).  
The potential effect of stress on the human body has been a subject of medical 
research for many decades. In 1936, Hans Selye proposed that the physiological 
systems activated by stress may have a role, not only in protecting and 
restoring, but also in damaging the body (200). Selye suggested that the long 
term effects of stress can lead to enlargement of the adrenal gland, atrophy of 
the thymus, spleen and other lymphoid tissue, and gastric ulcerations (200). 
Sterling and Eyer discussed the multi-system physiological changes in response to 
arousal which are directed towards maintaining body stability and referred to 
them as “Allostasis”.  In 1993, McEwen and Stellar, proposed the formulation of 
AL to study the relationship between stress and processes leading to disease. 
The concept has evolved significantly with widely reported associations in 
population studies between AL and various diseases (28). In this section, there is 
a description of the physiological changes which constitute the AL.  
4.2.1.2 Allostatic Load Conditions 
Acute (major life events) and chronic (everyday minor) stress can have long-term 
physiological effects. There are two important factors which contribute to an 
individual’s response to stressful stimuli-an individual’s perception of stressful 
stimuli and an individual’s state of physical health (see Figure 4-1), which in turn 
are influenced by multiple factors. An individual’s perception of threat is 
instrumental in defining their behavioural response such as fighting or fleeing.  
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For example, the HPA (hypothalamic-pituatary-adrenal) axis measured by 
salivary cortisol was increased in most individuals when they were subjected to 
the stress of speaking or doing complex arithmetic in front of an audience (201). 
However, in some participants described as “low responders”, salivary cortisol 
levels were unaltered after repeated stimuli; while others continued to have 
high salivary cortisol (“high responders”) (201). Cardiovascular (CV) responses to 
stress obtained in a laboratory setting are, in real life, not only replicated but 
also often larger (202). Real life CV responses to stress can also be related to 
subjective ratings of stress and emotions (202). An individual’s response to stress 
is influenced by genetic factors, lifestyle and behavioural choices. For instance, 
male adolescents with CYP17A1 gene loci were found to have increased blood 
pressure reactivity to mental stress(203).  
Figure 4-1 Physiological Response to Stress and Allostatic Load (204) 
 
Reproduced with permission, Copyright Massachusetts Medical Society.  
McEwen proposed that the body’s response to a challenging situation usually 
involves two steps (204). The first step is turning on an allostatic response, while 
the second is switching it off when the challenging situation has resolved. The 
allostatic response is usually mediated through the sympathetic nervous system 
and HPA axis, and involves increase in the levels of catecholamines and cortisol. 
When the challenging or stressful situation is resolved, these systems are 
deactivated and catecholamines and cortisol levels return to normal. McEwen 
proposed that there are three types of AL based on the variations of allostatic 
response to four different situations (see Figure 4-2). The first condition is due 
to repeated exposure to a stressful stimulus, with appropriate “allostatic” 
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response and similarly appropriate “switching off” and “normal adaptation” with 
reduced scale of responses. In the second condition, there is lack of adaptation 
to stressful stimuli and hence it leads to prolonged exposure to stress hormones 
as described earlier. In the third type, there is failure to shut off allostatic 
response after stressful stimuli, which again leads to prolonged exposure to 
stress hormones. Finally, in the fourth condition and the last type of AL variant, 
there is inadequate allostatic response to stressful stimuli. As a result of this, 
another physiological system such as the inflammatory response is activated. 
Figure 4-2 Three types of Allostatic Load (AL) in four conditions (204) 
  
Reproduced with permission, Copyright Massachusetts Medical Society 
4.2.1.3 Primary and Secondary Allostatic Load Markers 
Chronic over activation of stress mediators and subsequent physiological 
response in allostatic load conditions can lead to damage to various organ 
systems in the body (204). Stress mediators in AL have been divided into primary 
and secondary mediators.  The primary mediators of AL operate in a non-linear 
fashion, which means that each mediator has the ability to regulate the activity 
of the other mediators and reciprocally get regulated by other mediators as well 
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(205). At first, in response to stress, there is activation of the sympathetic-
adrenal-medullary (SAM) activation, which leads to release of catecholamines 
such as epinephrine and norepinephrine. The other major group of “stress 
hormones” are glucocorticoids (antagonized by dehydroepiandrosterone-DHEA), 
which are released from the HPA axis. Catecholamines and glucocorticoids can 
influence the production of both pro and anti-inflammatory cytokines in a non-
linear fashion (see Figure 4-3). The parasympathetic system also plays an 
important role in this network of allostatic mediators. It generally opposes the 
sympathetic system and it also has anti-inflammatory effect. Over time, 
compensatory mechanisms to over and under production of primary mediators 
such as catecholamines, glucocorticoids and cytokines, leads to increase in 
secondary mediators of AL or secondary outcomes.  
Figure 4-3 Non-linear network of primary mediators of Allostatic Load in stress response 
(205) 
 
Copyright : © 2006 LLS 
The activation of secondary mediators is often referred as the “prodromal” stage 
(28). The secondary mediators of AL are mainly divided into metabolic, 
cardiorespiratory and anthropometric systems. In this stage, the levels of 
secondary mediators or markers are at a sub-clinical stage; physicians routinely 
measure some of the secondary markers but clinical attention is only prompted 
when a marker reaches clinically significant levels. Examples of metabolic 
mediators are blood levels of: HDL cholesterol; low density lipoprotein-LDL 
cholesterol; triglycerides; creatinine; and glucose. Examples of cardiorespiratory 
markers are: systolic blood pressure; diastolic blood pressure; heart rate; and 
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peak expiratory flow.  While examples of anthropometric markers are body mass 
index and waist hip ratio. The primary and secondary mediators of AL and their 
particular role are summarized in Table 4-1, adapted from a systematic review 
by Juster et al (28). The final stage of AL progression is the allostatic overload 
stage, where individuals experiencing chronic AL develop various health related 
diseases or tertiary outcomes. The AL models suggests that by measuring the 
levels of primary and secondary allostatic mediators, individuals at risk of 
developing tertiary outcomes can be identified earlier than they would by 
routine clinical measures (206). This has led to interest in developing methods 
for measuring AL, known as the allostatic index score. 
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Table 4-1 Primary and secondary mediators of allostatic load, overview of their function and measurement.  
NEUROENDOCRINE 
(PRIMARY) 
Cortisol Glucocorticoid produced by the adrenal glands. Functions include role in fat metabolism, 
immunosuppression, regulating heart rate and blood pressure, regulation of limbic and prefrontal 
regions of brain.  
 Dehydroepidrosterone-
DHEA 
Androgen produced by the adrenal glands. Functions include role in regulation of HPA-axis, 
inflammatory cytokines, lipid metabolism and reduction of oxidative stress. 
 Epinephrine Catecholamine produced by the adrenal glands and the brain, part of the “fight-or-flight” 
response, it increases heart rate and glucose levels. 
 Norepinephrine Catecholamine produced by the brain, part of the “fight-or-flight” response, it increases blood 
pressure and modulates brain activities. 
 Dopamine Catecholamine produced primarily in the brain and adrenal glands, it’s a neurotransmitter 
involved in many neurological activities and also increases blood pressure and heart rate. 
 Aldosterone Minerocorticoid produced by the adrenal glands, functions include role in electrolyte and water 
balance and reduces blood pressure.  
INFLAMMATORY 
(PRIMARY) 
Interleukin-6 Cytokine produced by macrophages and T-cells, functions include major role in pro and anti-
inflammatory responses.   
 Tumour Necrosis 
Factor-Alpha 
Cytokine produced by macrophages, functions include role in systemic inflammation by evoking 
mediators of acute phase reactions and role in tumour apoptosis. 
 C-Reactive Protein Protein synthesized in the liver, functions include role in acute phase reactions and promotes 
inflammation. 
 Insulin Like Growth 
Factor-1 
Polypeptide protein hormone produced primarily in the liver and pancreas, functions include cell 
growth stimulation and inhibition of cell apoptosis.  
 Fibrinogen Protein that synthesizes into fibrin in the liver, functions include role in blood clotting.  
METABOLIC 
(SECONDARY) 
High Density 
Lipoprotein 
Cholesterol 
Lipoprotein synthesized in the liver, commonly referred to as “good cholesterol”, as its’ high 
protein/low cholesterol form is more easily removed by blood in the liver and excreted in bile. 
 Low Density 
Lipoprotein 
Cholesterol 
Lipoprotein synthesized in the liver, commonly referred to as “bad cholesterol”, as its’ low 
protein/high cholesterol form is more likely to be deposited in the walls of blood vessels and 
contribute to atherosclerosis. 
 Triglycerides Glyceride formed from glycerol and three chains of fatty acids, it is an important source of 
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energy and a transporter of dietary fat. 
 Glycosylated 
Haemoglobin 
Haemoglobin used to index the average glucose concentration over weeks and months.  
 Glucose Monosaccharide synthesized in the liver and kidneys, functions as the main source of energy. 
 Insulin Protein hormone produced in the pancreas, functions include lowering glucose levels and 
promoting energy storage.  
 Albumin Protein produced by the liver, role in the maintenance of blood volume  
 Creatinine Nitrogenous waste product of muscle creatine phosphate that is filtered and excreted by the 
liver, it’s a marker of glomerular filtration rate and renal function. 
 Homocysteine Amino acid biosynthesized from methionine, functions include role in remethylation and 
transsulfuration pathways that are in part dependent on nutritional intake of folic acid and 
vitamin B12.  
CARDIOVASCULAR AND 
RESPIRATORY 
(SECONDARY) 
Systolic Blood Pressure Measured using a sphygmomanometer, represents the maximal force exerted by blood against 
the blood vessel walls when the left ventricle is contracting during systole. 
 Diastolic Blood 
Pressure 
Measured using a sphygmomanometer, represents the minimal force exerted by blood against the 
blood vessel walls when the left ventricle is relaxed during diastole. 
 Peak Exploratory Flow Measured using a peak flow meter, represents the maximum speed of expiration and the degree 
of obstruction of airflow through the bronchi. 
 Heart Rate/Pulse Measured at sites where arterial pulsation can be felt represents the number of heart beats 
within a period of time. 
ANTHROPOMETRIC 
(SECONDARY) 
Waist Hip Ratio Measure of waist circumference and hip circumference using measuring tape values that are than 
calculated into a ratio by dividing waist by hip. Higher levels represent greater adipose fat 
distribution.  
 Body Mass Index Measure of weight and height that is then calculated into an index by dividing weight by height. 
Represents a proxy measure of an individual's relative body fat percentage.  
Table has been adapted from Juster et al. systematic review (28) 
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4.2.2 Allostatic Load Measurement, Allostatic Index Score 
Calculation and Health Implications 
In this section, the methods of measuring AL, the Allostatic Index (AI) score and 
the relationship between AI score and different health consequences are 
summarized. The early work in AL measurement was done through the MacArthur 
Studies of Successful Ageing, which was a cohort of more than 1000 men and 
women, aged between 70 and 79 years recruited from communities in the North 
East of the United States of America (207). One of the first proposed methods of 
measuring AI score was based on a count based formulation consisting of 10 
biomarkers-12 hour urinary cortisol, epinephrine and norepinephrine output, 
serum dehydroepiandrosterone-sulphate (DHEA-S), total cholesterol to HDL 
cholesterol ratio, HDL cholesterol, plasma glycosylated haemoglobin (HbA1c), 
systolic blood pressure, diastolic blood pressure and waist hip ratio (208).  The 
biomarker values which fell into the high risk category of 75th percentile in 
relation to the sample’s distribution in the cohort were given a score of “1” and 
the remaining values were given a score of “0”. The two markers, DHEA-S and 
HDL cholesterol, were given a score of “1” if their value was in the lower 25th 
percentile. This was added up over the 10 biomarkers to give an AI score of 1-10. 
In the early work on this cohort, higher AI score was found to be a predictor of 
decline in cognitive and physical functioning and increase in cardiovascular risk 
over 3 years, independent of social and demographic factors (208). 
Subsequently, the association between higher AI score and these health related 
outcomes was also seen at 7 years of follow-up (27).  
The health implications of AI score have been studied in other cohorts and in 
other countries apart from the USA.  For example, the relationship between AI 
score and health outcomes was studied in Taiwan, using the Social Environment 
and Biomarkers of Ageing Study (SEBAS) cohort (209). The SEBAS study included 
more than 1000 men and women recruited form urban areas in Taiwan and aged 
54-70 years. In this study, the AI score was calculated using 16 biomarkers and 
the cut-offs used were two tailed. A score of “1” was assigned if the biomarker 
value was in the higher than 90th percentile or lower than 10th percentile of the 
biomarker distribution in the cohort (209). In this group of participants, higher AI 
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score was associated with higher risk of 3 year mortality (209). The authors of 
this study did not explain the reasons for using cut-offs at both the low and high 
extremes or in other words measuring deviation in biomarker values in both 
directions of the sample mean. One of the possible explanations could be that 
the two tailed methods were designed to identify “inadequate physiological 
response”, which is also a type of allostatic state (see Figure 4-2). If we measure 
deviation in biomarker values less than the sample mean, we are able to identify 
individuals who may have an “inadequate physiological response”.   
Seplaki and colleagues compared the count based formulation with a z-score 
technique of AI score calculation in the SEBAS cohort (210). The z-score 
technique involved calculating AI score as the sum of the standardized distances 
of a biomarker value from its respective mean value for the sample. The 
rationale of using the z-score technique was to use the whole distribution of a 
biomarker in calculating AI score and subsequently studying its relationship with 
adverse health outcomes. The study found a positive association between high AI 
score and health related outcomes such as physical mobility, self-rated health 
and cognitive function;  but there was no difference in the observed relationship 
with AI score calculated with a count based formulation or a z-score technique 
(210). In Japanese earthquake survivors, researchers calculated AI score using a 
subset of AL biomarkers and three  more (D-dimer, von Willebrand factor, and 
tissue-type plasminogen activator antigen), and found an association between 
high AI score and higher rates  of myocardial infarction and stroke (211). The 
published evidence on relationship between AI score and health related tertiary 
outcomes has been summarized in two systematic reviews, which shows an 
association of AI score with a wide variety of health outcomes such as mortality, 
cognitive and functional decline, depressive symptoms and cardiovascular 
outcomes (28,212).  
Various novel statistical techniques have been employed in AI score calculations, 
which are summarized in Table 4-2. In 2002, Karlamangla and colleagues used 
canonical correlations to show an association between higher AI score and 7 year 
functional and cognitive decline using the MacArthur Studies of Successful Ageing 
cohort (213). In this method, to assess the individual contribution of every single 
biomarker (allostatic load component) to the association between allostatic load 
and outcomes, the analysis was repeated on 200 bootstrap samples obtained 
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from the complete study sample. Allostatic load biomarkers and outcomes that 
made the least contribution were identified as the ones with the most variable 
canonical weights, and were dropped, one at a time, in a stepwise backward 
elimination process. Based on this method, the authors found certain biomarkers 
contributed more towards predicting physical decline (such as epinephrine, 
waist hip ratio and cortisol) while others contributed more to predicting 
cognitive decline (epinephrine, diastolic blood pressure and HbA1c) (213).  
Gruenewald and colleagues used non-parametric regression techniques such as 
recursive partitioning to study the relationship between individual allostatic load 
biomarkers and gender in predicting 12 year mortality using the MacArthur 
Studies of Successful Ageing Cohort (214). They found that extreme values of 
neuroendocrine and immune biomarkers were associated with risk of death in 
males and systolic blood pressure was associated with risk of death in females 
(214). Using the same cohort, changes in AI score over 2.5 years was used to 
predict mortality at 4.5 years (215). Participants whose AI score increased over 
2.5 years were found to have increased risk of mortality compared to those 
whose AI score reduced over follow-up (215).  The different statistical 
techniques used for calculation of AI score have been reviewed by Juster and his 
colleagues and summarized in the table below, which is adapted from their 
systematic review (28).
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Table 4-2 Different statistical techniques and algorithms for allostatic index score calculation.  
Formulation  Description 
Group allostatic load index Count based formulation which represents the number of biomarkers falling within a high risk percentile (i.e., upper 
or lower 25th percentile or upper or lower 10th percentile) based on the sample's distribution of biomarker values. As 
each biomarker is dichotomized as 0 or 1 depending on cut-offs, each biomarker is allotted an equal weight in the 
index.  
Norm allostatic load index 
(based on clinical cut-offs) 
Count based formulation which represents the number of biomarkers falling within a high risk percentile (i.e., upper 
or lower 25th percentile) based on a population's distribution of normative biomarker values used in clinical practice.  
z-Score allostatic load index Summary measure representing the sum of an individual's obtained z-scores for each biomarker based on the sample's 
distribution of biomarker values. This standardized formulation allows the weight of each biomarker to be different 
depending on its deviation from the sample's mean. 
Difference allostatic load 
score 
Difference between two time-points for a single biomarker or an index measure of multiple biomarkers. For example, 
an index measure of pro-coagulation responses using several homeostatic biomarkers or two measures of cortisol 
before and after exposure to an acute stressor. 
Dynamic allostatic load 
score 
Repeated measures analysis or change scores between three or more time-points for single or multiple biomarkers.  
Bootstrapping Resampling technique used to make inferences about population parameters by generating multiple repetitive 
computations that estimate the shape of a statistic's sampling distribution. 
Canonical correlation Multiple correlational analyses that measure the association between two sets of latent variables representing an 
independent set and a dependent set. It has been used to determine the best linear combinations of weighted 
allostatic load biomarkers at baseline that are maximally correlated to tertiary outcomes like mortality at follow-up. 
Recursive partitioning Multivariate reduction technique that generates categories aimed at precisely classifying participants based on several 
dichotomous dependent variables. It has been used to classify participants into outcome risk categories by first 
identifying the biological markers and cut-points that best differentiate across participants. These have been used to 
define allostatic load categories (e.g., high, intermediate, low) and tertiary outcomes (e.g., mortality). 
Table has been adapted from Juster et al. systematic review (28) 
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4.2.3 Allostatic Load Markers and Depression 
The relationship between allostatic load biomarkers and depressive symptoms 
has been the subject of research in a number of studies. In 2004, Seplaki and 
colleagues used the SEBAS cohort from Taiwan to show a significant cross 
sectional association between some allostatic load biomarkers such as IGF-1 
(Insulin-like growth factor), total Cholesterol and triglycerides with depressive 
symptoms (216). Later on, Goldman and colleagues did a longitudinal analysis 
using the same cohort and found a significant association between composite AI 
score at baseline and depressive symptoms at 3 years of follow-up (209). Juster 
and his colleagues found a significant association between depressive symptoms 
and AI score in cross-sectional analysis but did not find an association between 
AI score at baseline and development of depressive symptoms at 3 and 6 years of 
follow-up (217). In another study, the same author and his colleagues found no 
cross-sectional association between AI score and depressive symptoms in 30 
healthy workers in Canada (218). Finally in 125 elderly US residents, AI score was 
found to have a significant cross-sectional association with affective and somatic 
type of depressive symptoms, as well as with overall depressive symptoms (219).  
These study characteristics are summarized in Table 4-3. 
In the next section, some of the criticisms faced by the allostatic load theory 
and its potential clinical application are discussed. 
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Table 4-3 Summary of studies investigating relationship between allostatic load biomarkers and depressive symptoms 
Lead Author;  
Study Design 
Method of Depression 
Assessment 
Sample Size;  
Age; 
Country 
Allostatic Load Biomarkers 
Seplaki (216) 
Cross-sectional  
 
 
CES-D 
(Centre for Epidemiological 
Studies- Depression Scale) 
N=820;    
>54 years 
Taiwan 
Cortisol, Dopamine, Epinephrine, Norepinephrine, DHEA-S 
(dehydroepiandrosterone sulfate),  IL-6 (Interleukin), IGF- 
1 (Insulin-like Growth Factor, HbA1c (Glycosylated 
Hemoglobin), Glucose,  TC (Total Cholesterol), HDL (High 
Density Lipoprotein) Cholesterol: TC Ratio, Triglycerides, SBP 
(Systolic Blood Pressure), DBP (Diastolic Blood Pressure), WHR 
(Waist Hip Ratio), BMI (Body Mass Index) 
Goldman (209)  
Longitudinal 
CES-D N=820 
>54 years 
Taiwan 
Same as above 
Juster (217) 
Cross-sectional and 
Longitudinal 
GDS (Geriatric Depression 
Scale) 
N=58  
Age: 52-80 
US 
 
Cortisol, TC, HDL Cholesterol, Triglycerides, Glucose, SBP, DBP 
Juster (218) 
Cross-sectional 
BDI (Beck Depression 
Inventory) 
N=30  
Age:27-65 
Canada 
Diurnal Cortisol, CRP (C-Reactive Protein), Albumin, Insulin, 
Glucose, HDL Cholesterol, TC, SBP, DBP, HR (Heart Rate), 
WHR, fibrinogen, amylase, HbA1c 
Kabrosly (219) 
Cross-sectional 
 
CES-D N=125 
Age: 67-94 
US 
Diurnal Cortisol, IGF1, IL-6, WHR, HR, SBP, DBP 
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4.2.4 Critique of Allostatic Load Theory 
Allostatic load theory has come under criticism from some reviewers involved in 
stress related research. Day suggested that the concepts of allostatic load and 
allostatic load mechanisms were simply “rebranding” of the homeostatic 
mechanisms concept, and not entirely useful (220). He also suggested that 
future research should focus on defining and differentiating between a 
“homeostatic response” (usually selective, specific and minor) and a “stress 
response” (usually non-selective and involving multi-system) (220). On the other 
hand, Chaney argued that the concept of allostatic load ignores the 
neurobiological responses involved with providing resilience to psychological 
stress in general and to specific forms of psychopathology (221) and that an 
understanding of psychobiological responses which maintain neural systems in 
the face of a stressful challenge may be better able to provide the 
understanding of why some individuals are able to cope with extreme stress with 
minimal consequences (221).  
Most of the research to date on the association of allostatic load biomarkers and 
tertiary health outcomes has primarily been conducted using two major cohorts 
(28,212). These datasets are the MacArthur Studies of Successful Ageing (n=1189, 
Age Range=70-79, USA) and the SEBAS cohort (n=820, Age Range=54-90, Taiwan) 
(28). Hence, there are questions around the reproducibility of these findings, 
and their applicability in different age groups and different populations.  
Another issue is that the allostatic load concepts suggests that measuring multi-
system dysregulation by the means of biomarkers has clinical utility in predicting 
various tertiary health related outcomes. However, various studies discussed 
above have suggested that certain biomarkers may have better predictive utility 
than a composite score in predicting specific tertiary outcomes (213,214,216); 
for example predictive utility of systolic blood pressure in predicting all-cause 
mortality (214). This leads to the question: why use multiple markers if a single 
marker is equally good or better in predicting a specific clinical outcome? 
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So it would appear that further research is needed to establish the clinical 
implications of the findings so far from the allostatic load literature. If 
measuring a composite AI score using multiple biomarkers is found to have 
clinical usefulness in predicting health outcomes at a prodromal or 
asymptomatic stage, it has to be targeted at individuals who are at highest risk 
of having these outcomes. It is neither productive nor feasible to measure a 
battery of biomarkers on the general population and it would be a difficult task 
to integrate this into routine clinical practice. 
4.2.5 Study hypothesis and selection of datasets 
The existing knowledge of relationship between AL biomarkers and depressive 
symptoms, albeit with its various limitations, led to the development of my 
hypothesis that a combination of AL biomarkers will form a predictive algorithm 
in defining clinically meaningful outcomes in a population of patients with 
depressive symptoms. The objectives of this thesis are to investigate the cross-
sectional association of AL biomarkers and depressive symptoms and association 
of AL biomarkers with clinical outcomes in those with depressive symptoms. 
Clinical outcomes pertaining to physical health are of special interest as the 
review findings (chapter 2) suggested a lack of research in this area. To test the 
hypothesis, two different datasets- DepChron and Psobid are used, which are 
described in detail in sections below. Any dataset has its own strengths and 
limitations and this was certainly true of DepChron and Psobid. Consequently, 
three other research data sources were considered and it was not feasible to use 
them for this study due to different reasons. The datasets considered were: UK 
Biobank (http://www.ukbiobank.ac.uk), Twenty-07 
(http://2007study.sphsu.mrc.ac.uk/) and Generation Scotland 
(http://www.generationscotland.org). UK Biobank did not have any of the blood 
results available for research purposes when this study started. Twenty 07 and 
Generation Scotland did not have information on clinical outcomes available at 
the start of this study.  
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4.3 Description of Datasets-DepChron and Psobid 
4.3.1 Data Collection in DepChron 
DepChron is a dataset with 125,143 participants with at least one of the three 
cardiometabolic diseases-Coronary Heart Disease (CHD), Diabetes, and previous 
Stroke over the period of 2008-2010. The participants in the DepChron dataset 
come from the West of Scotland, with a population of circa 1.8 million served by 
two different health boards.  The local health boards oversaw a programme of 
incentivised depression screening in chronic disease as part of a wider chronic 
disease management programme of LES.  The Quality & Outcomes Framework 
(QOF) is part of the UK wide, pay for performance, General Medical Services 
contract for family practitioners (222). LES are contractual arrangements at a 
local health board level with general practices designed to augment the basic 
QOF specification by incentivising additional indicators that are deemed to be 
particularly important by a given area and there are no penalties for non-
adherence. General practices were paid under the LES scheme to carry out a 
comprehensive annual health assessment for patients with three common 
chronic diseases, CHD, diabetes and stroke, including depression screening. 
Besides depression screening, the annual health assessment also included 
assessment and management of other health related behaviours such as smoking 
status, alcohol consumption, diet and activity levels. The annual health 
assessment was usually carried out by a practice nurse and lasted for 
approximately one hour. The remuneration offered varied according to disease 
area with £31 each for patients with diabetes, £26 each for patients with 
previous stroke and £23 each for patients with CHD. The remuneration was 
dependent on the level of coverage of indicators achieved in the health 
assessment, with full payment offered for >90% coverage, 3/4 payment for 75-
90% coverage and half payment for 60-75% coverage. 
The permission to access the data was given by the data guardian, NHS Greater 
Glasgow and Clyde Keep Well Enhanced Services Data Group.  Approval was also 
obtained from the NHS Practice Advisory Committee (PAC) (reference PAC 
85/12) and the NHS Research Ethics Committee (NRES) (reference 12/LO/1622) 
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for electronic data linkage to study the outcomes data for the DepChron patients 
(see Appendix 4).  
In 2008-9, the period in which data collection took place, the comprehensive 
annual health assessment was offered to all patients on the practice register 
with one of the three aforementioned chronic diseases and was usually carried 
out by practice nurses. The results of the assessment were entered into the 
template with “Read codes” assigned to each data entry. Read codes are the 
coded thesaurus of clinical terms, by which clinicians in the UK record patient 
findings and procedures (223). The assessment included detailed history taking, 
various physical examinations and blood tests, and recording of certain drugs 
prescribed including antidepressants, anti-psychotics and cardiovascular drugs.  
4.3.2 Assessment of Depression Status in DepChron 
The health assessment included screening patients for depression using the 
depressive subscale of the Hospital Anxiety and Depression Score (HADS-D (152).  
Analysis was restricted to adults aged from 18 to 90 and health assessments 
recorded between 01/04/2008 to 31/03/2009. The rationale for the restriction 
in age range was to exclude young adolescents and extremely frail elderly 
patients who may have specific physical and mental health problems which may 
not be generalizable to all patients with chronic cardiometabolic disease. 
Patients who were noted to be under treatment for depression were exempt 
from depression screening and should not have been included in the dataset, but 
there was evidence that some had been. Based on the information available it 
was not possible to explicitly differentiate which of the patients in the dataset 
were being newly prescribed antidepressants from those who were under 
existing treatment for depression (and who should have been exempt from 
screening, but may nonetheless have been screened and included in the 
dataset).  However based on the situational knowledge of primary care practice 
in Scotland, that the average prescription duration is not usually longer than 90 
days, patients who were first prescribed antidepressants more than 90 days after 
the start of the observation period, they were labelled as ‘likely’ to be newly 
started on antidepressants without undergoing depression screening.  Patients 
were labelled as ‘under treatment’ for depression and exempt from depression 
screening if: (a) they were noted to be on antidepressants based on their 
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prescription record with no record of depression screening during the 12 month 
observation period (01/04/2008 to 31/03/2009); or (b) the first prescription for 
antidepressants was issued in the first 3 months of the observation period.  
The depressive subscale of HADS (HADS-D), which has a potential total score of 
21, was used as the depression screening tool. The threshold of HADS ≥8 was 
used as a cut-off for  a ‘positive screening result’  as there is evidence to suggest 
that this offers an optimal balance of sensitivity and specificity (224,225) and 
such an approach has been endorsed by national guidelines (148). All patients 
who underwent depression screening were checked for a new prescription of 
antidepressants in the six months after the date of assessment. No reliable 
information was available on the number of patients who were referred for 
psychological therapies following their depression screening. Information on 
history of previous episodes of depression or history of antidepressants 
prescribed in the past, prior to the observation period was not available.  
4.3.3 Participant Characteristics in DepChron 
Socioeconomic status was recorded in patient notes in the form of the Scottish 
Index of Multiple Deprivations (SIMD) score, which identifies small area 
concentration of multiple deprivations across all of Scotland in a consistent way.  
The SIMD score can be divided into quintiles with lower quintiles representing 
the most deprived areas. The socioeconomic status in DepChron was divided into 
SIMD quintile, quintiles from 1-5 representing the most deprived areas; quintiles 
6-10 representing affluent population (29). A total of 125,143 patients were 
listed as having CHD, diabetes or stroke in the year 2008-09. Figure 4-4 shows 
the distribution of patients across the three diseases and their respective 
proportional combinations. 
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Figure 4-4 Distribution of patients across three diseases for the year 2008-09 in 
DepChron (226) 
 
 
Of the total sample, 10,670 (8.5%) patients were under treatment for 
depression, having received their first antidepressant prescription of the within 
the first 3 months observation period, and were thus assumed exempt from 
screening. The remaining 114,473 (91.5% of total sample size) patients were 
eligible for depression screening.   However, depression screening was only 
undertaken in 35,537 (31.1% of those eligible) and 78,936 (68.9%) were not 
screened. Figure 4-5 shows the distribution of patients according to their 
depression status.   
 
Table 4-4 compares the demographic characteristics of the subset of the 
population who underwent depression screening with the whole participant 
population. The continuous variables are compared using mean and standard 
deviation, while the categorical variables are presented using counts and 
percentages. The table shows that the distribution of variables between these 
populations was very similar.  
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Table 4-4 Comparison of demographic characteristics between total population (n=125143) 
with the subset which underwent depression screening (n=35537) in DepChron (227) 
Mean (SD) are presented for continuous variables and count (%) for categorical. 
              Total  
        Population 
n=125143 
Screened 
Population 
n=35537 
Age (years)  
missing 
67.6 (13.6) 
42 
         69.0 (11.9) 
11 
Sex Female 
Male 
missing 
57566 (46.0%) 
67507 (53.9%) 
70 
14861 (41.8%) 
20658 (58.1%) 
18 
Socio-
economic 
status 
Deprived (SIMD 1-5) 
Affluent (SIMD 6-10) 
missing 
82267 (67.4%) 
39680 (33.5%) 
3196 
22726 (65.3%) 
12079 (34.7%) 
732 
Comorbid 
Condition 
One 
Two 
Three 
missing 
101219 (80.8%) 
21666 (17.3%) 
2258 (1.8%) 
0 
27356 (76.9%) 
7410 (20.8%) 
771 (2.1%) 
0 
 
 
Figure 4-5 Flow chart showing the outcome of depression screening in DepChron (226) 
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4.3.4 Data Collection in Psobid 
The psychological, social, and biological determinants of ill health (Psobid) study 
is an existing research data source with 666 participants recruited in 2006-07 by 
the Glasgow Centre for Population Health (GCPH). The methods for recruitment 
and data collection have been described in detail in the literature (228–230). 
The recruitment of participants was based on SIMD (29) which has been 
described previously. The least and most deprived areas in the Greater Glasgow 
and Clyde health area were identified using the SIMD score. Five general 
practices each with the highest percentage of patients aged 35-64 years living in 
the most deprived and affluent areas as classed by SIMD were approached, and 
all agreed to participate in the recruitment process. A target population of 
21,672 people from the lists of these 10 practices was identified. A sampling 
frame of 3600 participants from the least and most deprived areas was 
constructed from general practice lists and, therefore, included individuals 
regardless of whether they actually visited their general practitioner. The most 
deprived group had poor response rates and hence required oversampling. From 
the sampling frame of 3600 subjects a total of 2,712 invitations were issued to 
recruit a cohort of 700 (25.8%) participants. Out of the 2,712 invitations sent, 
812 (29.9%) people declined to participate and 1,200 (44.3%) did not respond 
(see Figure 4-6). Data collection was completed in April 2007 and data quality 
was tested over the summer of 2007. Of the 700 subjects who participated in the 
study only 34 (4.9%) did not complete both visits, which led to a sample size of 
666 participants. 
The permission to access the Psobid participants’ data was obtained from the 
GCPH. GCPH did have an existing ethical approval in place from the NHS 
Research Ethics Committee (reference number 05/S0705/40) (see appendix 5) 
which was applicable to this study. In addition, an approval was obtained from 
the NHS PAC for electronic data linkage and study of outcomes for Psobid 
participants (reference number PAC86/12) (see Appendix 5).   
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 Figure 4-6 Patient recruitment in Psobid 
 
Figure adapted from Velupillai et al. (224) 
 
4.3.5 Assessment of Depression Status in Psobid 
Participants were screened for the presence of psychological symptoms using the 
General Health Questionnaire (GHQ-28) questionnaire score which has 4 sub-
scales: somatic symptoms, anxiety and insomnia, social dysfunction and severe 
depression (231). A cut-off score of GHQ-28≥5 was used as this cut-off has been 
endorsed by national guidelines to be consistent with major depressive disorder 
(148).  
4.3.6 Participant Characteristics in Psobid 
The sampling procedure in Psobid was stratified to achieve an approximately 
equal distribution across age bands (35-44, 45-54 and 55-64 years), sex and 
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socio-economic status. The target population was identified from two different 
socioeconomic groups in the general population, affluent (least deprived) and 
most deprived. The least deprived group had the top 20% SIMD score while the 
most deprived group had the bottom 5% SIMD scores.  Table 4-5 shows the 
demographic characteristics of participants in Psobid, divided into the most 
deprived and least deprived socio-economic groups. The occupation status was 
classified using the Registrar General Social Class Classification on the basis of 
current job, or if not currently working, on the basis of participants’ last paid 
job. Only those participants who had never been in paid employment were 
classed as “unemployed”. The classification categories were: I-professional 
occupations; II-managerial and technical occupations; II-manual and non-manual 
skilled occupations; IV-partly skilled occupations; V-unskilled occupations. 
Table 4-5 Comparison of Demographics between the least deprived and most deprived 
participant groups in Psobid (232) 
Mean (SD) are presented for continuous variables and count (%) for categorical. 
  Least Deprived 
Group (n=342) 
Most Deprived 
Group (n=324) 
Age (years)  51.8 (8.0) 51.5 (8.5) 
Sex Female 
Male 
171 (50.0%) 
171 (50.0%) 
168 (51.9%) 
156 (48.1%) 
Household Income  £41,699 (£11,921) £16,461 (£10,056) 
Education (total 
years) 
 16.1 (3.6) 11.8 (2.5) 
Residential Status Owner 
Tenant 
334 (97.7%) 
8 (2.3%) 
97 (29.9%) 
227 (70.1%) 
Occupation Status  I and II 
III 
IV and V 
Unemployed 
Undetermined 
251 (73.4%) 
77 (22.5%) 
12 (3.5%) 
1 (0.3%) 
1 (0.3%) 
62 (19.1%) 
139 (42.9%) 
105 (32.4%) 
2 (0.6%) 
16 (5.0%) 
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4.4 Allostatic Load Biomarkers and AI score calculation 
in DepChron and Psobid 
In this section, the biomarkers used to calculate AI score in the two datasets- 
DepChron and Psobid are summarized. In addition, the different statistical 
methods used for AI score calculation for both datasets are also described. 
Finally, the distinct advantages and drawbacks of using these two data resources 
for the purpose of AI score calculation are also discussed. 
4.4.1 AL Biomarkers in DepChron and Psobid 
As previously discussed, there were 35,537 patients within the DepChron dataset 
with recorded HADS-D results (see Figure 4-5). The available AL biomarkers in 
DepChron and their respective AL biomarker category as suggested by the review 
by Juster et al (28) are listed below:  
1. Systolic Blood Pressure (Cardiovascular) 
2. Diastolic Blood Pressure (Cardiovascular) 
3. Body Mass Index (Anthropometric) 
4. Total Cholesterol (Metabolic) 
5. Glycosylated Haemoglobin-HbA1c (Metabolic) (only in a subset of patients 
with diabetes) 
Systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements 
were recorded in mm Hg and body mass index (BMI) in kg/m2 determined from 
height and weight measurements. A blood sample was collected by the practice 
nurse at the time of assessment; the result for total cholesterol was reported in 
mmol/l and HbA1c was reported in Diabetes Control and Complications Trial 
(DCCT) units. HbA1c was available only in the subset of dataset for patients with 
Diabetes (n=18,453).  
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The Psobid dataset had a greater number of biomarkers available for AI score 
calculation for its participants. The AL biomarkers and their respective AL 
biomarker category are listed below:  
1. Systolic Blood Pressure (Cardiovascular) 
2. Diastolic Blood Pressure (Cardiovascular) 
3. Body Mass Index (Anthropometric) 
4. Waist Hip Ratio (Anthropometric) 
5. Total Cholesterol (Metabolic) 
6. HDL Cholesterol (Metabolic) 
7. Serum Triglycerides (Metabolic) 
8. Fasting blood glucose (Metabolic) 
9. Serum Creatinine (Metabolic) 
10. Fibrinogen (Inflammatory) 
11. Interleukin-6 (Inflammatory) 
12. Highly sensitive CRP (Inflammatory) 
The biomarker measurement for participants took place over two visits 
conducted between December 2005 and May 2007, which has been described in 
detail elsewhere (228). In visit one, a research nurse measured systolic and 
diastolic blood pressure in mm Hg; body mass index in kg/m2, and waist hip 
ratio. A fasting blood sample was collected during visit two by the research 
nurse. Serum triglycerides, fasting blood glucose, total cholesterol and HDL 
cholesterol were measured in mmol/l. CRP was measured in mg/dl, Interleukin-6 
in pg/ml and Fibrinogen was measured in g/l. Creatinine was recorded in 
umol/l. 
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4.4.2 Comparison of AL Biomarkers in DepChron and Psobid 
There were key differences between DepChron and Psobid with respect to 
availability of biomarkers and patient and participant characteristics. In 
DepChron, only four biomarkers were available for AI score calculation, while 
the subset of the population with Diabetes had an additional biomarker 
available. The available biomarkers in DepChron were mainly secondary markers 
of AL. In contrast, Psobid had 12 biomarkers available for AI score calculation. 
This facilitated a more comprehensive AI score calculation with both primary 
and secondary markers of AL available in the Psobid dataset.  
DepChron had distinct advantages which included the large sample size, 
comprising mainly older patients, which resembled the age distribution of the 
majority of the cohorts previously used in the study of AI score and relationship 
with tertiary outcomes. On the other hand, Psobid had a much smaller sample 
with a mixture of middle aged and older participants. Moreover, DepChron 
patients were recruited from primary care with existing cardiometabolic 
disease, while Psobid participants were recruited from the general population, 
with only a subset of them suffering from any chronic disease. Thus, there were 
some important differences in the two datasets in relation to their method of 
data collection, age distribution and health status which contributed to the 
strengths and limitations of the study findings. The strengths and limitations of 
each dataset are discussed in more detail, along with the results in Chapters 5 
and 6.  
4.4.3 AI score Methods in DepChron and Psobid 
Table 4-2 provides a summary of some of AI score calculation methods reported 
in the literature. These methods can be broadly divided into count based 
formulations or summary measures and those methods needing complex 
statistical calculations such as canonical correlations and recursive partitioning 
(see Table 4-2). A third type of method is those which require more than one 
measurement of AL biomarkers; this approach was not feasible for either of the 
two datasets available.  
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Four different methods for AI score calculation which included count based and 
summary formulations were used in this thesis.  The four methods used were:  
1. The clinical cut-off method- (Method 1- count based formulation) 
2. The sample distribution cut-offs (25th and 75th percentile) method- 
(Method 2- count based formulation) 
3. The sample distribution cut-offs (10th and 90th percentile) method – 
(Method 3- count based formulation) 
4. The z-score method-(Method 4- summary measure) 
There are various reasons for choosing these particular methods of AI score 
calculation. Firstly,  count based formulation or z-score methods were the most 
widely used AI score calculation methods, based on the findings of three 
systematic reviews on allostatic load studies (28,233,234).  Secondly, few 
studies which compared different methods of AI score calculation have generally 
found that the choice of method was less important than utilizing the whole 
distribution of AL biomarkers, as far as the value of AI score in predicting 
adverse health outcomes is concerned (210,213,214,216,233). Finally, these 
methods were relatively straightforward to compute and hence they had more 
potential to be implemented in routine clinical practice in future.  
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4.5 Conclusion 
The AL framework has been put forward as the “price” an individual’s body has 
to pay to maintain internal stability, in response to stress. The AL theory 
suggests that by measuring multi-system biomarker levels as a proxy of 
measuring multi-system physiological dysregulation, it is possible to identify 
individuals at risk of having adverse health outcomes at a prodromal or 
asymptomatic stage. Various statistical formulations have been proposed for 
calculating a comprehensive AI score using multiple biomarkers representing 
different physiological systems. The two datasets used in this thesis, with 
different age groups, sample sizes, health status of participants and sets of 
biomarkers, have been described. The AL biomarkers and methods used for AI 
score calculation in the respective datasets have also been outlined. The next 
five chapters present the results from analysis of these data sets.  The next 
chapter, Chapter 5, describes the cross-sectional relationship between AL 
biomarkers and depressive symptoms in DepChron patients.
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Chapter 5 Cross Sectional Analysis in DepChron 
Dataset 
5.1  Chapter Summary 
This chapter provides the results of investigations of the cross-sectional 
relationship between depressive symptoms and allostatic load biomarkers in 
patients with existing cardiometabolic disease (DepChron cohort). The objective 
of this analysis is to explore the aetiology of depressive symptoms in 
cardiometabolic disease, without attributing any causation due to the cross-
sectional nature of the analysis. This addresses research questions 1 and 2 using 
the DepChron dataset. These research questions are:  
Research Question 1 (RQ1):  
What is the association, if any, between a composite Allostatic Index (AI) score 
calculated using available allostatic load biomarkers and depressive symptoms in 
patients with existing cardiometabolic disease (DepChron cohort)?   
2. Research Question 2 (RQ2): 
What is the association, if any, between individual allostatic load biomarkers 
and depressive symptoms and how does it compare with the relationship 
between the composite AI score and depressive symptoms in patients with 
existing cardiometabolic disease (DepChron cohort)? 
This  chapter has four sections: the first addresses the statistical methods used 
for this analysis; the second provides findings concerning the cross-sectional 
relationship between a composite AI score and depressive symptoms (assessed by 
HADS-D) (152) in DepChron; the third examines the relationship between 
individual AL biomarkers in DepChron and depressive symptoms is and compares 
the relationship of a composite AI score versus individual constituent biomarkers 
with depressive symptoms; finally, the various strengths and limitations of the 
analyses, comparison of findings with the existing literature and the potential 
implications  are discussed in the final section. 
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5.2 Methods 
5.2.1 AI Score Calculation and Depression Screening in 
DepChron 
All statistical analyses undertaken using R statistical software version 3.2.0 
(235).   
The following five biomarkers were used for AI score calculation:  
1. Systolic Blood Pressure- SBP (Cardiovascular) 
2. Diastolic Blood Pressure-DBP (Cardiovascular) 
3. Body Mass Index-BMI (Anthropometric) 
4. Total Cholesterol (Metabolic) 
5. Glycosylated Haemoglobin-HbA1c (Metabolic)-only available in subset of 
patients with diabetes 
The values for individual biomarkers were restricted to a clinically plausible 
range based on both clinical judgement and the findings of general population 
studies. SBP measurements were restricted to a range between 90 to 240 mm Hg 
and DBP to a range between 50 to 130 mm Hg (236,237). Similarly, BMI was 
restricted to a range between 15 to 55 (238), total cholesterol to 2-10 (239) and 
HbA1C to 3-18% (240). All observations with missing values were excluded from 
analysis.  
Four different count based formulations for AI score calculation were used in the 
analyses and the reasons for choosing these methods are discussed in Chapter 4, 
section 4.4. The methodology employed for the four AI score methods was 
consistent with those used by previous studies and reported in the three 
systematic reviews on allostatic load studies (28,233,234).   
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 These methods were:  
1. Clinical cut-off method- Method 1: Each biomarker was assigned a score of 
0 or 1 based on their value being below or above the clinical cut-off value 
respectively. The AI score was computed by adding the score for each 
constituent biomarker. For SBP and DBP, a clinical cut-off of 140 and 90 
mm Hg was used respectively (241–244). BP was classified into five 
different categories based on clinical judgement to improve 
interpretability of results. The cut-offs used for BMI and total cholesterol 
levels were 30 kg/m2 and 5 mmol/l respectively (244) (245). Finally, the 
clinical cut-off for HbA1c was 7 DCCT(246).  
 
2. Sample distribution cut-offs (25th and 75th percentile)- Method 2: This 
method was also based on a similar count based formula; however it used 
cut-offs both below and above the mean instead of using single clinically 
relevant cut-off used in method 1. The cut-offs were defined on the basis 
of an observation value below the 25th percentile or above the 75th 
percentile of the sample distribution. Similarly to method 1, a score of 0 
or 1 was assigned based on the distribution of the observation value in 
relation to the cut-offs. The AI score was derived by adding the score for 
each constituent biomarker.  
3. Sample distribution cut-offs (10th and 90th percentile) - Method 3: This 
method was the same as method 2, except that the 10th and 90th 
percentiles were used as cut-offs for this method.  
4. Z-score method- Method 4: This method was based on a continuous 
distribution of a biomarker rather than categorical. Each biomarker was 
assigned a score, which was based on the absolute amount of deviation of 
the observation value from their respective sample mean. The z-score 
calculations were standardized so that a score of 1 corresponded to a 
difference between the observation value and its respective mean of one 
standard deviation (SD).  The z-score was a positive value regardless of 
whether the value was below or above the mean, thereby giving the same 
weight to a very low value as a very high one. The allostatic index score 
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was calculated by adding the absolute z-score values for each constituent 
biomarker.  
The depressive subscale of HADS (HADS-D), which gives a total potential score of 
21, was used as a screening tool within the DepChron dataset. The threshold of 
HADS ≥8 was used as a cut-off for  a ‘positive screening result’  as there is 
evidence to suggest that this offers an optimal balance of sensitivity and 
specificity (224,225) and such an approach has been endorsed by national 
guidelines (148). All patients who underwent depression screening were checked 
for a new prescription of antidepressants in the six months after the date of 
initial assessment. No reliable information was available on the number of 
patients who were referred for psychological therapies following their 
depression screening.  Information on history of previous episodes of depression 
or history of antidepressants prescribed in the past, prior to the observation 
period was not available. 
5.2.2 Statistical Modelling - Logistic Regression 
Several logistic regression models were used with HADS-D≥8 as the outcome 
variable (20,152) and AI score as a predictor variable. The utility of the AI score 
calculated using the four different methods outlined above was compared, both 
in univariable and multivariable analysis. Age (as a continuous variable), and sex 
(as a categorical variable) were added to the regression models as potential 
confounders.  Socio-economic status, divided into affluent (Scottish Index of 
Multiple Deprivation (SIMD)(29) scores 1-5) and deprived (SIMD 6-10), and 
number of conditions 1-3 out of diabetes, stroke and coronary heart disease 
(CHD) were also added as potential confounders. The cross-sectional association 
of the four different AI scores with depressive symptoms (HADS-D≥8) was 
analysed, after adjusting for the various potential confounders mentioned 
above.  
In the next part of the analysis, the cross-sectional relationships between 
individual biomarkers and raised HADS-D were analysed using logistic regression 
models, including the aforementioned potential confounders. The quadratic 
terms for each individual biomarker were entered into regression models to 
allow for a non-linear relationship. The turning point for each individual 
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biomarker with a significant non-linear relationship was calculated using the 
formula (nadir/min = −b/2a or peak/max=b/-2a) where “a” represents the 
coefficient of the quadratic term and “b” represents the coefficient of the 
linear term. The turning point will be a “nadir” in the event of a “U-shaped” 
non-linear relationship, while the turning point will be a “zenith” in the event of 
a “bell-shaped” non-linear relationship. The strengths of these relationships 
were evaluated in univariable and multivariable analyses adjusting for the same 
potentially confounding factors age, sex, socio-economic status and number of 
conditions. 
The entire analysis was first performed for the whole sample (N=35,537) and 
then repeated for the subset of patients with diabetes (N=18,453). In patients 
with diabetes, HbA1c was utilized for AI score calculation and the association 
between raised HADS-D and HbA1c was analysed, in addition to the other four 
biomarkers.  
The results of each regression model were presented as odds ratios (OR) with 
95% confidence intervals (CI) and corresponding p-values, for AI scores and 
individual biomarkers. Different logistic regression models used were compared 
by using the Hosmer and Lemeshow's R2 measure (247) and Akaike information 
criterion (AIC) (248). Hosmer and Lemeshow’s R2 is a measure of how well a 
given regression model fits the data; a better value usually implies a better fit of 
the model to the data(247). AIC is a measure of the relative quality of how well 
a given regression model fits the data; a lower value implies a better fit (248). 
In the next step, model diagnostics was performed for a selected few models by 
checking for the presence of multicollinearity using the parameter variance 
inflation factor (VIF <10). Presence of multicollinearity implies that two or more 
predictor variables in a model are highly correlated to each other. A logistic 
regression model assumes that there is no multicollinearity among its predictor 
variables.  
To visualise the results of regression models, predicted probability graphs were 
constructed for a raised HADS-D (≥8) against corresponding values for the 
individual biomarkers and the AI score that was shown to have the best fit and 
predictability out of the four methods in regression modelling. A new data set 
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was constructed using all possible combinations of the potential confounders: 
age (18 to 90 in increments of 10), gender, socio-economic status (deprived and 
affluent) and number of co-morbid conditions (1-3). In the new data set, a 
predicted value was calculated for the probability of a raised HADS-D based on a 
range of values of significant predictors and the values of the potential 
confounders using their respective logistic regression modelling results. Finally, 
six different predicted probability charts were created for the probability of 
raised HADS-D against the best AI score and each of the five individual 
biomarkers.  
5.2.3 Sensitivity Analyses 
For a sensitivity analysis, interactions of the six predictors (best AI score and five 
individual biomarkers) with age, gender, number of comorbid condition and 
deprivation status were tested for each of the corresponding logistic regression 
models to check for potential effect modification. If any predictor was found to 
have a significant interaction with a confounder, the results of the interaction 
were visualised using the predicted probability charts.  
In a subsequent sensitivity analysis, multivariable linear regression models were 
constructed using the HADS-D as a continuous variable. As HADS-D was not 
normally distributed, it was transformed using the square root transformation. 
Similarly, the best AI score and the five individual biomarkers were used as 
predictor variables in six different regression models. Age, sex, socio-economic 
status and number of comorbid conditions were added to all models as potential 
confounding factors. The quadratic terms for AI score and individual biomarker 
were added to regression models to allow for a non-linear relationship. Similarly, 
the turning point was calculated for each of the nine predictors using the 
formula explained above, in the event of a significant non-linear relationship. 
The results of linear regression were presented using standardized regression 
coefficients for predictors with 95% CI and p-values, adjusted R2 values, AIC 
values. For individual biomarkers, regression estimates for their respective 
quadratic terms with CI were also presented, in the event of a significant non-
linear relationship. 
120 
5.2.4 Individual Biomarkers vs. Multiple Biomarkers  
In this part of analysis, DepChron patients were divided into eight categories 
based on their individual biomarker values after excluding missing values and 
values outside a clinically plausible range as explained earlier. The reference 
category was the group of patients with all four individual biomarkers (only SBP, 
only DBP, only BMI or only total cholesterol) within 1 standard deviation (SD) of 
the sample mean. The next four categories were the group of patients with only 
one of the four biomarker values outside 1 SD of the sample mean (only SBP, 
only DBP, only BMI and Only total cholesterol). The next two categories were the 
group of patients with at least two and three biomarkers respectively outside 1 
standard deviation of the sample mean. Finally, the last category was the group 
of patients with all four biomarker values outside their respective 1 standard 
deviation ranges. The absolute number and percentage of patients in each of the 
eight categories with raised HADS-D (≥8) were compared. The entire analysis as 
described above was repeated for two standard deviation biomarker values 
instead of one standard deviation. Results were visualised with the help of 
frequency tables and bar charts.  
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5.3 Results  
5.3.1 Results of Depression Screening, Biomarker and AI score 
distribution in DepChron 
DepChron is a routinely collected data set with a suboptimal completion rate of 
a range of variables. A total of 125,143 patients were listed as having CHD, 
diabetes or stroke in the year 2008-09. Of the total sample, 10,670 (8.5%) 
patients were considered under treatment for depression, having received their 
first antidepressant prescription within the first 3 months of the observation 
period, and were thus exempt from screening. HADS-D results were recorded for 
35,537 (31.1%) of those who were eligible for screening. In the remainder of the 
patients (n=78,936, 68.9% of eligible) depression screening was not recorded. 
Figure 5-1 shows the results of depression screening using HADS-D in the study 
population (n=35,537).  
Figure 5-1 Results of Depression Screening in DepChron(226) 
 
 
7,080 (19.9%) patients had a positive HADS-D result (HADS-D≥8) on depression 
screening in 2008-09, while nearly 4 in 5 who were screened (28,457) had 
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negative results. The majority of patients (4,155/7,080; 58.6%) with a positive 
result had a HADS-D score of 8-10 which is suggestive of mild depressive 
symptoms (152).  
Table 5-1 describes the distribution of the five biomarkers measured in 
DepChron, their missing values, and the different cut-offs used for various AI 
score calculations. Most of the biomarkers had significant numbers of missing 
values. All missing values were excluded from the entire analysis. The clinical 
cut-off value was equal to the value of the 75th percentile for SBP, less than the 
value of the 75th percentile for BMI and more than the value of the 75th 
percentile for the rest of the three biomarkers. Except for DBP, the value of 
clinical cut-off was lower than the 90th percentile for all biomarkers.  
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Table 5-1 Distribution of Allostatic Biomarkers in DepChron (N=35,537).  
   Method 1 AI 
score 
calculation 
(clinical cut-
off) 
Method 2 AI score 
calculation (25th/75th 
percentile) 
Method 3 AI score 
calculation (10th/90th 
percentile) 
Method 4 AI 
calculation 
(z-score 
method) 
Biomarker Range 
 
Missing 
Values 
Clinical cut-
offs 
25th 
percentile 
75th 
percentile 
10th 
percentile 
90th 
percentile 
Mean 
(Standard 
Deviation) 
Systolic Blood 
Pressure in mm 
Hg 
90 to 
240 
32139 
 
140 120 140 110 155 133 (17.5) 
Diastolic Blood 
Pressure in mm 
Hg 
50 to 
130 
 32139 90 69 80 60 88 74·5 (10.3) 
Body Mass Index 
in kg/m2 
15 to 
55 
30139 30 24.92 34.03 22.43 36.51 28·9 (6.0) 
Total Cholesterol 
in mg/dl 
2 to 
10 
 31311 5 3.6 4.8 3.1 5.6 4·3  (1.0) 
HbA1c in DCCT 
N=18,453 
3 to 
18 
15678 7 6.4 8.2 5.9 9.9 7·5  (1.6) 
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A small number of observations for each biomarker were excluded from the 
analysis as the observed values were outside the predetermined clinically 
plausible range: SBP 110 observations (SBP >240=0; SBP <90=110), DBP 167 
observations (DBP >130=2, DBP < 50=165), BMI 97 observations (BMI>55=68; 
BMI<15=29) and total cholesterol 67 observations (total cholesterol >10=17; total 
cholesterol <2=50). Only 2 patients (HbA1c>18=0; HbA1c<3=2) had HbA1c 
observations outside the predetermined clinically plausible range. 
Table 5-2 compares AI scores calculated using methods 1-4 described above, in 
the study population N=35,537 using four biomarkers (SBP, DBP, BMI and total 
cholesterol). The AI scores calculated by methods 1, 2 and 3 had big standard 
deviations relative to their mean value; the standard deviation calculated using 
method 3 AI score was larger than the mean. The range of AI score for the first 
three methods was 0 to 4, while the range was much larger for the method 4 AI 
score calculation. For method 1, the mean was less than 1 and the 75th 
percentile value was 1. This implies that most of the patients had on average 
only 1 individual biomarker value higher than the respective clinical cut-off 
value. The distribution of AI score with method 3 was very similar to method 1 
with values of mean, median and 75th percentile not greater than 1.  
Table 5-3 compares the AI score calculated with five biomarkers (above four plus 
HbA1c) in the sub-group of patients with diabetes (N=18,453) using the four 
different methods. Similar to the trend observed in the whole sample, patients 
with diabetes were found to have large standard deviations relative to the 
sample mean for AI scores calculated by methods 1 to 3. The range of AI score 
calculated using method 4 was much wider compared to methods 1 to 3, as 
observed in the whole sample.  
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Table 5-2 Distribution of AI score in the DepChron dataset (N=35,537) with four different statistical methods 
N=35,537. Missing values and exclusions=10,162. Available N= 25,401 
Biomarkers used for AI score calculation: Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass Index, Total Cholesterol  
 AI score- Method 1-
clinical cut-off 
(Range 0-4) 
AI score-Method 2- 
25th/75th percentile 
(Range 0-4) 
AI score-Method 3- 
10th/90th percentile 
(Range 0-4) 
AI score – Method 4- z 
score method 
(Range 0.2-12.4) 
Mean 0.85 1.82 0.65 3.09 
Standard Deviation 0.86 1.06 0.79 1.40 
Median 1 2 0 2.86 
25%- 75% 0-1 1-3 0-1 2.07-3.85 
 
Table 5-3 Distribution of AI score in N=18,453 subset of DepChron patients with Diabetes using four different statistical methods 
N=18,453 patients with Diabetes. Missing values and exclusions=7561. Available N=10,892 
Biomarkers used: Systolic Blood Pressure, Diastolic Blood Pressure, Total Cholesterol, Body Mass Index and HbA1c 
 AI score- Method 1 
(Range 0-5) 
AI score-Method 2 
(Range 0-5) 
AI score-Method 3 
(Range 0-5) 
AI score – Method 4 
(Range 0.5-12.93) 
Mean 1.54 2.34 0.87 3.85 
Standard Deviation 1.07 1.18 0.91 1.60 
Median 1 2 1 3.59 
25%- 75% 1-2 2-3 0-1 2.70-4.69 
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5.3.2 Results of Logistic Regression Modelling  
5.3.2.1 AI score as a predictor variable 
AI scores calculated with all of the four methods described above were found to 
have a significant cross-sectional association with the probability of having a 
positive depression screening result (HADS-D≥8) in the univariable analysis. Table 
5-4 compares the odds ratios with 95% confidence intervals from the logistic 
regressions of AI score on the odds of a positive depression screening result, 
along with Hosmer and Lemeshow’s measure R2 and AIC for the four different AI 
score methods. The AIC was the lowest and the Hosmer and Lemeshow’s 
measure R2 was the highest for method 4- this implies a better fit of model with 
method 4 AI score; however the difference between the four methods was not 
large. 
The association between AI score and probability of positive HADS-D screening 
result remain unchanged after adjusting for various confounding factors such as 
age, sex, socio-economic status and number of co-morbid conditions (see Table 
5-4). The effect sizes for AI scores for all four methods were reduced after 
adjusting for confounders but remained statistically significant predictors of 
raised HADS-D in all multivariable analysis models. The quadratic term for AI 
score was entered into multivariable regression models and it did not have a 
significant p-value; hence the association between AI score and raised HADS-D 
was linear in nature.  
The odds ratio was biggest for the AI score calculated by method 2 (18% increase 
in odds, 95% CI 3 to 22%) with the provision that it was not comparable to 
method 4 (11%, 95% CI 9 to 13%). This implies that with each unit increase in AI 
score, the odds of raised HADS-D were increased by 18% if we use method 3 and 
11% if we use method 4. The result of method 4 (z-score) is of greater clinical 
significance as the distribution of AI score is much wider with method 4 (range 
for AI score method 4= 0.2-12.4); while only a small number of patients (3515 
patients) had AI score values >1 with method 3.  So if we use method 3 AI score 
as compared to method 4 AI score, the significant relationship between AL 
biomarkers and depressive symptoms will be investigated for a much smaller 
proportion of DepChron patient. 
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Table 5-4 Logistic regression with AI score as a predictor and depressive symptoms (HADS-D≥8) as outcome variable.  
N=35,537. Missing values and exclusions=10,690. Available N= 25,401. HADS-D= Hospital Anxiety and Depression Scale-Depressive 
Subscale. AI=Allostatic Index.  Biomarkers used for AI score calculation: Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass 
Index, Total Cholesterol 
 AI score- Method 1-
clinical cut-off    
N=25,375 
(Range 0-4) 
AI score-Method 2- 
25th/75th percentile 
N=25,375 
(Range 0-4) 
AI score-Method 3- 
10th/90th percentile 
N=25,375 
(Range 0-4) 
AI score – Method 4- 
z score method 
N=25,375 
(Range 0.2-12.4)  
                                                                        Univariable Analysis 
AI score-Odds Ratio 1.15 1.13 1.23 1.15 
95% Confidence Intervals  1.11-1.19 1.09-1.16 1.18-1.27  1.12-1.17 
p-value p<0.001 p<0.001 p<0.001 p<0.001 
Hosmer and Lemeshow’s measure R2 0.002 0.002 0.004 0.006 
Akaike Information Criteria 25250 25249 25201 25149 
Multivariable Analysis. Adjusted for confounder-age, sex, socio-economic status and number of co-morbid conditions 
AI score- Odds Ratio 1.07 1.10 1.18 1.11 
95% Confidence Intervals 1.03-1.11 1.06-1.13 1.03-1.22 1.09-1.13 
p-value p<0.001 p<0.001 p<0.001 p<0.001 
Hosmer and Lemeshow’s measure R 0.032 0.033 0.035 0.036 
Akaike Information Criteria 23948 23922 23891 23867 
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Moreover, the AIC was smallest for method 4 while the Hosmer and Lemeshow’s 
measure R2 was largest for method 4 in multivariable analysis as well; although 
the difference between the four methods was not large. This implies that 
method 4 provided a better fit and representation of the data in both 
univariable and multivariable analyses for logistic regression models using the 
whole sample. Hence, method 4 AI score was used for predicted probability 
charts and sensitivity analyses. Model assumptions were checked for the 
multivariable model using method 4 AI score. The model assumption for logistic 
regression model- of multicollinearity using the parameter variance inflation 
factor (VIF <10) was held. This implies that the predictor variables used in the 
model were not highly correlated.  
 
 
 
 
 
 
 
 
 
 
Key Findings (AI score as predictor variable):  
 AI score, calculated using SBP, DBP, BMI and total cholesterol and by 
applying four different statistical formulations, was found to have a 
statistically significant linear association with the presence of 
depressive symptoms as assessed by HADS-D≥8 (OR 1.15). The 
association persisted after adjusting for the effect of potential 
confounders.  
 The model containing AI score calculated by method 4, the z-score 
method, had the best AIC and Hosmer and Lemeshow’s measure R2 
values which implied best fit to the available model.   
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5.3.2.2 Individual Biomarkers as Predictor Variables 
Each of the individual five biomarkers had statistically significant cross-sectional 
associations with the odds of having a positive HADS-D result. Each biomarker 
was found to have a non-linear association with the probability of HADS-D ≥8. 
Hence, a quadratic term for each biomarker was added to the respective logistic 
regression models. The results of univariable analyses with individual biomarkers 
are presented in Table 5-5.  
The non-linear relationship between all individual biomarkers and HADS-D≥8 
remained significant after adjusting for age, sex, socio-economic status and 
number of co-morbid conditions in multivariable analysis (see Table 5-5). The 
AIC was lowest and Hosmer and Lemeshow’s measure R2 was lowest for the 
model with BMI, which implies best fit of that model to the data. The observed 
nadirs (the value with lowest odds of having concurrent depressive symptoms) 
for all biomarkers (except SBP) for having a raised HADS-D were increased in 
value after adjusting for confounding factors. The nadirs for DBP and total 
cholesterol (74 and 3.6) were below their respective clinical cut-off values (90 
and 5); BMI’s nadir of 30.5 was very close to its clinical cut-off of 30 and the 
value of observed nadir of 148 was higher for SBP than its clinical  cut-off of 140.
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Table 5-5 Logistic Regression using individual biomarkers as predictors and depressive symptoms (HADS-D≥8) as outcome variable. 
N=35,537. Missing values and exclusions=10,690. Available N= 25,401. HADS-D= Hospital Anxiety and Depression Scale-Depressive 
Subscale. 
 Systolic Blood Pressure 
N=25,375 Range: 90 to 240 
Diastolic Blood Pressure 
N=25,375 Range: 50 to 130 
Total Cholesterol                
N=25,375 Range: 15 to 55 
Body Mass Index     
N=25,375  Range: 2 to 10 
                                                                        Univariable Analysis 
Odds Ratio (OR) with 95% 
Confidence Intervals (CI); p-
value 
0.95 (0.93-0.96); p<0.001 0.95 (0.92-0.98); p<0.001 0.79 (0.67-0.92); p=0.003 0.88 (0.85-0.91); p<0.001 
OR for quadratic term with 
95% CI; p-value 
1.00016 (1.0001-1.0002); 
p<0.001 
1.0003 (1.00016-1.00053); 
p<0.001 
1.035 (1.018-1.051); 
p<0.001 
1.0023 (1.0017-1.0029); 
p<0.001 
Hosmer and Lemeshow’s 
measure R2 
0.001 0.001 0.002 0.005 
Akaike Information Criteria 25271 25294 25253 25169 
Nadir 149 68 3.3 26.5 
Multivariable Analysis. Adjusted for confounder-age, sex, socio-economic status and number of co-morbid conditions 
Odds Ratio (OR) with 95% 
Confidence Intervals (CI); p-
value 
0.95 (0.94-0.97); p<0.001 0.96 (0.93-0.99); p<0.001 0.80 (0.68-0.95); p=0.01 0.86 (0.83-0.89); p<0.001 
Hosmer and Lemeshow’s 
measure R2 
0.033 0.032 0.033 0.035 
Akaike Information Criteria 23933 23957 23928 23897 
Nadir 148 74 3.6 30.5 
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Overall, the model parameters AIC and Hosmer and Lemeshow’s measure R2 for 
BMI (the strongest individual biomarker predictor) and AI score calculated by 
method 4 were very similar in values (see Table 5-4 and Table 5-5). Model 
assumption of multicollinearity was checked for the multivariable model using 
the four individual biomarkers. The model assumption of multicollinearity using 
the parameter variance inflation factor (VIF <10) were satisfactory for all of the 
four regression models which implies that the predictor variables in these 
models were not highly correlated.  
 
 
 
 
 
 
 
 
 
 
 
Key Findings (Individual biomarkers as predictor variables):  
 Individual biomarkers (SBP, DBP, BMI and total cholesterol) were found to 
have a “U-shaped” non-linear association with the probability of concurrent 
depressive symptoms (as assessed by HADS-D≥8), after adjusting for the 
effects of age, sex, socio-economic status and number of cardiometabolic 
conditions.  
 The observed “nadir” or the values with the lowest probability of 
concurrent depressive symptoms were 148 for SBP, 74 for DBP, 3.6 for total 
cholesterol and 30.5 for BMI. The probability of having HADS-D positive was 
higher with biomarker values lower or higher than their respective nadir 
values.  
 The strength of association between peripheral biomarkers and depressive 
symptoms was very similar to the observed associations between AI score 
and depressive symptoms. 
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5.3.2.3 Results in Subset of Patients with Diabetes using Logistic 
Regression 
In univariable analyses of the subset of patients with diabetes, AI score 
calculated by all four methods were found to have a statistically significant 
association with raised HADS-D (≥8) (see Table 5-6). 
In multivariable analysis after adjusting for various confounders, all AI scores 
were found to have a statistically significant relationship in predicting raised 
HADS-D. The effect sizes observed in multivariable analysis for the diabetes 
subset was very similar to the ones observed for the whole sample (see Table 5-4 
and Table 5-6). For instance, with each unit increase in AI score calculated by 
method 4, the odds of raised HADS-D were raised by 11% (95% CI 8% to 15%) in 
the diabetes subset. This effect size was same as the one observed for method 4 
AI score in the whole data. The z-score method (method 4) performed 
consistently better in all analyses judging by the model parameters (lower AIC 
and higher Hosmer and Lemeshow’s measure R2 value). The quadratic term for AI 
score was again found to have no significant effect on raised HADS-D in the 
subset of patients with diabetes. 
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Table 5-6 Logistic Regression in Diabetes subset using AI score as predictor variable and depressive symptoms (HADS-D≥8) as outcome variable.  
N=18,453 patients with Diabetes. Missing values and exclusions=7561. Available N=10,892. Biomarkers used for AI score calculation: Systolic Blood 
Pressure, Diastolic Blood Pressure, Body Mass Index, Total Cholesterol and HbA1c. HADS-D= Hospital Anxiety and Depression Scale-Depressive 
Subscale 
                                                                        Univariable Analysis 
 AI score- Method 1-
clinical cut-off    
N=10,629 (Range 0-5) 
AI score-Method 2- 
25th/75th percentile 
N=10,629 (Range 0-5) 
AI score-Method 3- 
10th/90th percentile 
N=10,629 (Range 0-5) 
AI score – Method 4- z 
score method N=10,629 
(Range 0.5-12.93) 
AI score – Odds Ratio with 95% Confidence 
Intervals; p-value 
1.12 (1.07-1.17); 
p<0.001 
1.16 (1.12-1.21); 
p<0.001 
1.21 (1.15-1.28; p<0.001 1.14 (1.11-1.18); 
p<0.001 
Hosmer and Lemeshow’s measure R2 0.002 0.005 0.005 0.008 
Akaike Information Criteria 10794 10767 10763 10731 
Multivariable Analysis. Adjusted for confounder-age, sex, socio-economic status and number of co-morbid conditions 
AI score – Odds Ratio (OR) with 95% 
Confidence Intervals (CI); p-value 
1.09 (1.04-1.14); 
p<0.001   
1.13 (1.08-1.18); 
p<0.001 
1.17 (1.11-1.23); p<0.001 1.11 (1.08-1.15); 
p<0.001 
Hosmer and Lemeshow’s measure R2 0.036 0.038 0.038 0.040 
Akaike Information Criteria 10172 10151 10151 10130 
 
Table 5-7 Logistic Regression in Diabetes subset using HbA1c as predictor variable and depressive symptoms (HADS-D≥8) as outcome variable. 
 HbA1c-univariable analysis 
N=10,892                  (Range 3-18) 
HbA1c-multivariable analysis  
N=10,629  Range (3-18)  
 Confounders- age, sex, socio-economic status and 
number of co-morbid conditions.     
OR with 95% CI; p-value 0.80 (0.67-0.97); p=0.02 0.81 (0.67-0.98); p=0.03 
OR for quadratic term with 95% CI; p-value 1.016 (1.006-1.027); p=0.001 1.014 (1.004-1.025); p=0.006 
Hosmer and Lemeshow’s measure R2 0.003 0.036 
Akaike Information Criteria 10786 10169 
Nadir 6.47 7.04 
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In the analysis using HbA1c alone as a predictor variable, HbA1c was found to 
have a non-linear association with the probability of positive depression 
screening result. Hence, a quadratic term for HbA1c was added to univariable 
and multivariable analyses and found to have a statistically significant 
association with the probability of raised HADS-D in logistic regression. The 
observed nadir for HbA1c in multivariable analysis was 7.04 DCCT which is very 
close to the clinical cut-off value of 7 (see Table 5-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Findings (Diabetes subset):  
 The observed trend in results from the whole sample was unchanged 
for the diabetes subset.  
 AI score (OR 1.14) , calculated using four biomarkers in the main 
analysis + HbA1c  and by applying four different statistical 
formulations, was found to have a statistically significant linear 
association with the presence of depressive symptoms as assessed by 
HADS-D≥8.  
 HbA1c was found to have a non-linear “U shaped” association with the 
possibility of having concurrent depressive symptoms (HADS-D≥8), 
with the observed nadir value at 7.04 DCCT. 
 
135 
5.3.2.4 Predicted Probability Charts 
Figure 5-2 Predicted Probability of raised HADS-D (≥8) against AI score (z-score 
method)shows the predicted probability of raised HADS-D against AI score 
(method 4; z-score) with 95% CI, based on the logistic regression model reported 
above. The probability of raised HADS-D has a linear relationship with AI score 
and ranged from approximately 25% to 45%.  
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Figure 5-2 Predicted Probability of raised HADS-D (≥8) against AI score (z-score method) 
 
Figure 5-3 to Figure 5-6 are predicted probability charts (with 95% CI) for 
individual biomarkers- SBP, DBP, total cholesterol and BMI which were 
constructed using the logistic regression models for the whole sample. These 
charts demonstrate the non-linear relationship between each biomarker and 
probability of raised HADS-D. The chart for SBP is “U-shaped” while the charts 
for other biomarkers are “J-shaped”.   
 
 
 
 
 
 
 
 
137 
Figure 5-3 Predicted Probability of raised HADS-D (≥8) against Systolic Blood Pressure 
 
  
 
Figure 5-4 Predicted Probability of raised HADS-D (≥8) against Diastolic Blood Pressure 
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Figure 5-5 Predicted Probability of raised HADS-D (≥8) against Total Cholesterol. 
 
 
 
Figure 5-6 Predicted Probability of raised HADS-D (≥8) against Body Mass Index. 
 
Using the subset of patients with diabetes, a predicted probability chart was 
constructed for raised HADS-D against HbA1c based on the results of 
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multivariable logistic regression model. Figure 5-7 demonstrates a “J-shaped” 
relationship between HbA1c and concurrent depressive symptoms.  
Figure 5-7 Predicted Probability of raised HADS-D (≥8) against HbA1c for patients with 
Diabetes. 
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5.3.3 Sensitivity Analysis 
5.3.3.1 Results of Interaction Analysis 
In the multivariable analysis for the whole sample, AI score (method 4-z-score) 
was found to have a statistically significant interaction with age (p=0.01), but 
no significant interactions with sex (p=0.61), socio-economic status (p=0.051) 
and number of co-morbid conditions (p=0.65). Patients in the younger age group 
(18-64) had a larger increase in probability of a raised HADS-D with a rise in AI 
score as compared to those in the older age group (65-90). These results are 
visualised using the predicted probability chart in Figure 5-8.  
Figure 5-8 Predicted Probability of raised HADS-D (≥8) against AI score (z-score method) for 
the two different age groups.  
 
In the interaction analyses for individual biomarkers, none of the individual 
biomarkers were found to have a significant interaction with any of the 
confounding factors. In the multivariable analysis for the whole sample:  
 SBP did not have a significant interaction with age (p=0.96), sex (p=0.18), 
socio-economic status (p=0.10) or number of co-morbid conditions 
(p=0.94).  
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 DBP did not have a significant interaction with age (p=0.87), sex (p=0.12), 
socio-economic status (p=0.88) or number of co-morbid conditions 
(p=0.98). 
 Total cholesterol did not have a significant interaction with age (p=0.86), 
sex (p=0.84), socio-economic status (p=0.38) or number of co-morbid 
conditions (p=0.89).  
 BMI did not have a significant interaction with age (p=0.87), sex (p=0.51), 
socio-economic status (p=0.41) or number of co-morbid conditions 
(p=0.27). 
Finally, in the multivariable analysis for the subset of patients with diabetes, 
HbA1c did not have a significant interaction with age (p=0.14), sex (p=0.16), 
socio-economic status (p=0.29) or number of co-morbid conditions (p=0.32).   
5.3.3.2 Results of Linear Regression Modelling 
A similar trend in relationship was observed between AI score and individual 
biomarkers and HADS-D in multivariable linear regression models using HADS-D as 
a continuous outcome variable. AI score (method 4; z-score) was found to have a 
positive linear relationship with HADS-D; standardized regression coefficient was 
0.051 for AI score. All individual biomarkers were found to have a non-linear 
relationship. The strengths of relationship and the model parameters were very 
similar between composite AI score and individual biomarkers (see Table 5-8).  
The values of nadirs for the four biomarkers (SBP, DBP, total cholesterol and 
HbA1c) observed in linear relationship were similar to the ones observed in 
logistic regression models (compare Table 5-5 &Table 5-7 with Table 5-8). 
However, for BMI the observed nadir was approximately 20% higher with linear 
regression at 36.2 as compared to the nadir value of 30.3 observed with logistic 
regression.  
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Key Findings (Sensitivity Analysis):  
 AI score (calculated by z-score method in the whole sample and by 
using SBP, DBP, BMI and total cholesterol) was found to have a 
statistically significant interaction with age categories in predicting 
probability of concurrent depressive symptoms (HADS-D≥8).  
 The increase in probability of having HADS-D≥8 with increase in AI 
score was significantly higher in the younger and the middle age 
group (18-64) as compared to the older age group (65-90).  
 The relationship of AI score and individual biomarkers with 
concurrent depressive symptoms was unchanged using HADS-D as 
a continuous outcome variable in linear regression models.  
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Table 5-8 Multivariable Linear Regression Models with HADS-D as continuous outcome variable.  
N=35,537. Missing values and exclusions=10,690. Available N= 25,401. Biomarkers used for AI score calculation: Systolic Blood Pressure, 
Diastolic Blood Pressure, Body Mass Index, Total Cholesterol. HADS-D as outcome variable after square root transformation. 
Confounders- age, sex, socio-economic status and number of co-morbid conditions. * For HbA1c subset of patients with Diabetes was 
used (N=18,457, missing values and exclusions=7824).  
 AI score – Method 
4- z score 
method N=24,847 
Systolic Blood 
Pressure N=24,847 
Diastolic Blood 
Pressure 
N=24,847 
Body Mass Index 
N=24,847 
Total Cholesterol 
N=24,847 
HbA1c* 
N=10,629 
Standardized 
regression 
coefficient with 
95% Confidence 
Intervals (CI); p-
value 
0.051 (0.043-
0.059; p<0.001 
-1.72 (-2.36 to -
1.08); p<0.001 
-1.98 (-3.12 to -
0.008); p<0.001 
-0.072 (-0.087 to 
-0.05); p<0.001 
-0.09 (-0.15 to -
0.027); p=0.005 
-0.08 (-0.15 to -
0.007); p=0.03 
Standardized 
regression 
coefficient for 
quadratic term 
with 95% CI; p-
value 
Not applicable 5.99 (3.68 to 
8.30); p<0.001 
1.32 (0.0002 to 
5.83); p<0.001 
0.0012 (0.0010 to 
0.0014); p<0.001 
0.012 (0.006 to 
0.189); p<0.001 
1.006 (1.001-
1.010); p=0.004 
Adjusted R2 0.040 0.037 0.036 0.041 0.038 0.040 
Akaike Information 
Criteria 
66417 66540 66557 66443 66528 28773 
Nadir Not applicable 143 75 36.2 3.59 6.65 
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5.3.4 Individual Biomarkers vs. Multiple Biomarkers 
5.3.4.1 Impact of Biomarker Values outside 1 Standard Deviation (Individual 
versus Multiple Biomarkers) 
The range for mean +/- 1 SD was 116 to 150 for SBP, 64 to 84 for DBP, 23.2 to 
34.4 for BMI and 3.3 to 5.3 for total cholesterol. Table 5-9 shows a steady 
incremental rise in percentage of patients with raised HADS-D across the eight 
categories. These categories were: patients with no biomarker values outside 1 
SD, four categories of having only one biomarker value outside 1 SD, patients 
with two, three and four biomarkers values outside 1 SD.  Interestingly, the rise 
in percentage was proportionately smaller for patients with 2 biomarkers outside 
1 SD as compared to those with only 1 biomarker value outside 1 SD of mean. On 
the other hand, the rise in percentage was much higher for patients with all four 
biomarkers outside 1 SD as compared to those with 3 biomarkers values outside 1 
SD of sample mean.  
The absolute count of patients across the eight categories of patients can be 
compared in Figure 5-9. The figure shows that the highest number (30.9%) of 
patients was those with all four biomarkers within 1 SD of sample mean and 
lowest number (1.1%) of patients had all four biomarkers outside 1 SD. There 
were proportionately a large number of patients (22.5%) with two biomarkers 
outside 1 SD of sample mean. Overall, patients with all four biomarker values 
outside 1 SD had much higher percentage of patients with raised HADS-D.
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Table 5-9 Percentage of raised HADS-D (≥8) for DepChron patients with biomarker values outside 1 standard deviation of sample mean.   
Patient Categories based on 4 biomarker values (Systolic Blood Pressure-SBP, Diastolic Blood Pressure-DBP, Body Mass Index-BMI and Total Cholesterol) N=25,375 
(after exclusions and missing values) 
 No biomarkers 
n=7850 
Only SBP 
n=1905 
Only DBP 
n=2260 
Only BMI 
n=2858 
Only Total 
Cholesterol 
n=2528 
2 Biomarkers 
n=5710 
3 Biomarkers 
n=1959 
4 Biomarkers 
n=303 
Percentage 
with raised 
HADS-D 
16.4% 18.6% 17.6% 22.2% 20.0% 22.6% 24.1% 30.6% 
Figure 5-9 Bar Chart for DepChron patients with biomarker values outside 1 standard deviation and frequency of raised HADS-D. 
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5.3.4.2 Impact of Biomarker Values outside 2 Standard Deviations 
(Individual versus Multiple Biomarkers) 
The range for mean +/- 2 SD was 99 to 167 for SBP, 54 to 94 for DBP, 17.6 to 
40.0 for BMI and 2.3 to 6.3 for total cholesterol. The results for analysis with 2 
SD biomarker values were very different to that of 1 SD. Table 5-10 shows that 
the variation in percentage of patients with raised HADS-D was very high and not 
incremental.  
There were very few patients with two or more biomarker values outside 2 SD of 
the sample mean. Hence, it is difficult to compare the frequency of raised HADS-
D across different patient categories in this analysis (see Figure 5-10). The most 
relevant part of this analysis was that the majority of patients had biomarker 
values within 2 SD of the sample mean. 
 
 
 
 
 
 
 
 
 
Key Findings (Individual biomarkers vs. multiple biomarkers):  
 Patients observed to have multiple biomarker values outside the 
mean +/- 1 SD range were incrementally more likely to have a 
raised HADS-D as compared to patients with no or only one 
biomarker value within the specified range.   
 There were relatively fewer patients with biomarker values outside 
the mean +/- 2 SD range and hence it was not possible to make the 
comparison between individual and multiple biomarkers 
effectively.  
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Table 5-10 Percentage of raised HADS-D (≥8) for DepChron patients with biomarker values outside 2 standard deviations of sample mean.  
Patient Categories based on 4 biomarker values (Systolic Blood Pressure-SBP, Diastolic Blood Pressure-DBP, Body Mass Index-BMI and 
Total Cholesterol) N=25,375 (after exclusions and missing values) 
 No biomarkers 
n=21218 
Only SBP 
n=825 
Only DBP 
n=774 
Only BMI 
n=1006 
Only Total 
Cholesterol 
n=946 
2 
Biomarkers 
n=527 
3 Biomarkers  
n=75 
4 Biomarkers  
n=4 
Percentage 
with raised 
HADS-D 
18.6% 22.9% 21.5% 29.3% 26.8% 28.8% 24% 100% 
Figure 5-10 Bar Chart for DepChron patients with biomarker values outside 2 standard deviations and frequency of raised HADS-D.  
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5.4 Discussion 
5.4.1 Summary of Findings 
AI score had a statistically significant association with concurrent depressive 
symptoms measured by raised HADS-D (≥8) in patients with existing 
cardiometabolic disease. This relationship was linear in nature. The regression 
model using AI score calculated by method 4 (z-score method) had better model 
parameters as compared to the models using the other three AI score calculation 
methods, but the differences between the regression models using different AI 
score methods were small. All individual biomarkers used in AI score calculation, 
SBP, DBP, total cholesterol, BMI and HbA1c (in diabetes subset), were found to 
have a non-linear relationship with concurrent depressive symptoms. The non-
linear relationships were “J-shaped” and “U-shaped”. Method 1 of AI score 
calculation (clinical cut-off method) was unable to utilize the strengths of 
relationships as method 1 was one tailed. These relationships remained 
significant after adjusting for potential confounders such as age, sex, socio-
economic status and number of co-morbid conditions. Although there were non-
linear relationships, in general the risk of concurrent depressive symptoms was 
higher with very high biomarker values than very low biomarker values with SBP 
being a notable exception.  
The strength of association between AI score and depressive symptoms was very 
similar to the observed associations between individual constituent biomarkers 
and depressive symptoms. Thus, AI score as a construct did not offer any 
additional benefits over using individual biomarkers for this population and these 
biomarkers. An important caveat of this finding is that the biomarkers used for 
AI score in this analysis were secondary biomarkers (only those which were 
clinically available) and there were no inflammatory or neuroendocrine 
biomarkers available. AI score had a significant interaction with age; patients in 
the younger age group (18-64) have more quickly increasing risk of concurrent 
depressive symptoms with increasing AI score as compared to the older age 
group (65-90).  
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The trends in results were unchanged after repeating the analyses with linear 
regression models using HADS-D as a continuous outcome variable. The group 
with multiple biomarker values outside 1 SD of the sample mean had a greater 
number of patients with raised HADS-D as compared to those with either none or 
a single biomarker value outside 1 SD; with an incremental rise in percentage of 
raised HADS-D seen with each increase in the number of biomarkers outside 1 SD 
range.  
5.4.2 Strengths 
There are certain key strengths of these analyses. They are:  
1. The DepChron dataset has a large sample size with a good distribution of 
demographic factors.  
2. The data was collected in routine clinical practice and not in a simulated 
environment.  
3. Depression screening was conducted in individuals with cardiometabolic 
disease using a standardized and validated screening tool in HADS-D (152).  
4. These findings have clinical applicability as the biomarkers used for AI 
score calculation are those which are used in routine clinical practice. 
5.4.3 Limitations 
There are several limitations of these analyses. They are discussed in detail 
below along with their possible implications for the interpretation of the 
observed results where applicable.  
1. A majority of patients with cardiometabolic disease in DepChron were not 
screened for depression. There are several potential explanations for this. 
The observed uptake for depression screening was much lower when 
compared with the uptake for depression screening in the Quality and 
Outcomes Framework (QOF) programme in Scotland (90.5%) for the year 
2008-09 (249). However, the QOF programme had target driven 
incentivisation where practices were only paid if they achieved 90% 
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coverage in depression screening. In comparison, the incentivisation for 
the LES programme used in this study depended on achieving a proportion 
of clinical indicators across the health assessment protocol so there were 
no direct monetary benefits of performing depression screening. 
Secondly, the screening tool used for the QOF programme consisted of 
two stem questions which are much quicker to administer when compared 
to the HADS-D questionnaire which consists of 7 items (149). 
In addition the other influencing factors for the observed poor uptake of 
depression screening could be previously reported barriers to discussing 
depression (or mental health) in patients with chronic disease in primary 
care, such as stigma associated around the ‘label’ and physicians’ 
preconception of normalizing depression in patients with chronic disease 
(250,251).  
2. The observed association between allostatic load biomarkers (composite 
score and individual biomarkers) and depressive symptoms could be due 
to reverse causality. The extreme values of individual biomarkers could be 
a sign of the severity of the underlying cardiometabolic disease which 
may influence the prevalence of co-morbid depressive symptoms. 
3.  Moreover, the study only included those patients who were able to 
attend their GP practice for annual health assessment. Hence, 
housebound patients were excluded who may have more severe form of 
illness.  
4.  The results may not be truly due to depression screening. GPs or practice 
nurses may have reviewed a patient whom they consider to have 
depression and thus targeted depression screening in some way. 
5. Since only a minority of the patients were actually screened, depression 
status was unknown for a large number of patients, which remains an 
important limitation. There may be important differences between 
patients who underwent depression screening and those who did not, 
which are not clearly evident from their baseline demographic data. The 
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demographic characteristics between patients who were screened for 
depression and those who were not are compared in chapter 4.  
6. We did not have complete information on biobehavioural factors such as 
smoking status, alcohol intake and levels of physical activity which are 
likely to influence the values of cardiovascular risk factors considered and 
also the prevalence of depressive symptoms (252–255). 
7. We also did not have information on history of previous episodes of 
depression for patients in our study which may influence the prevalence 
levels for depressive symptoms. 
8. Finally, the overall accuracy of depression screening in our study was 
reliant on HADS-D which is a self-reported measure and it is reported to 
have moderate sensitivity and specificity in assessing depressive 
symptoms in patients with cardiometabolic disease in a primary care 
setting (114,256,257). 
5.4.4 Comparison of Findings with Existing Literature 
There have been five previous studies analysing the cross-sectional relationship 
between AI score and depressive symptoms (209,216–219) (Please see Table 4-3 
in Chapter 4). There are several important differences between the findings in 
DepChron and the existing literature. Firstly, AI score calculation in DepChron 
only used five secondary biomarkers of AL construct while other studies in this 
area have used more biomarkers (range: 7-17 biomarkers) and have included 
both primary and secondary AL biomarkers for AI score calculation. Secondly, 
participants in existing studies have been recruited from the general population 
while DepChron patients were recruited from primary care and all patients had 
an existing diagnosis of cardiometabolic disease. On the other hand, DepChron 
has a larger sample size. Out of the five previously published studies, two 
studies (209,216) used the Social Environment and Biomarkers of Ageing Study 
(SEBAS) cohort with a sample size of 820 participants; while the other 3 studies 
had a sample size of fewer than 150 participants (217–219). DepChron is also 
different from previous studies of AI score and depressive symptoms in the 
method of depression assessment with three studies using CES-D (Centre for 
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Epidemiological Studies- Depression Scale)(209,216,219); while GDS (Geriatric 
Depression Scale)(217) and BDI (Beck Depression Inventory)(218) were used by 
one study each. These scales are also self-reported depression symptom 
questionnaires and similar in sensitivity and specificity to HADS-D (257).  
Only four out of five studies analysed the cross-sectional association between 
depressive symptoms and AI score; while 1 study only looked at AI score at 
baseline and depressive symptoms at three years of follow-up (209). Selpaki et 
al did not report any regression estimates for cross-sectional association 
between a composite AI score and depressive symptoms (216); while the study 
by Juster et al reported no significant association between AI score and 
depressive symptoms assessed by BDI(218). A standardized regression coefficient 
of 0.44 was reported in multivariable linear regression for cross-sectional 
association between AI score and GDS(217); while a regression estimate of 1.44 
(standardized regression coefficient was not reported) was observed in 
multivariable linear regression for cross-sectional association between AI score 
and CES-D(219). The regression estimate for multivariable linear regression for 
AI score and HADS-D was 0.05 and standardized beta co-efficient was 0.07 in 
DepChron. None of the five studies used logistic regression models to study the 
association between AI score and depressive symptoms.  
The relationship between individual AI biomarkers used in DepChron and 
depressive symptoms has been previously studied, mainly in the general 
population. Barrett-Connor et al reported a non-linear relationship between DBP 
and depression with an observed nadir of 75 mm Hg DBP for concurrent 
depressive symptoms in a general population sample (258). In various cross-
sectional studies involving mainly elderly populations, depression has been 
observed to have a non-linear association with SBP (259–262) and DBP (258,263). 
Similarly, increased prevalence of depressive symptoms has been observed with 
extreme values of total cholesterol (264,265) and HbA1c in general population 
samples (266), in a non-linear trend. There is as yet no published literature to 
the best of my knowledge that examines the relationship between these 
biomarkers and depressive symptoms in those with cardiometabolic disease. A 
number of these population studies have found a significant cross-sectional 
association between cardiovascular biomarkers and depressive symptoms, even 
after adjusting for lifestyle factors (such as smoking, alcohol and physical 
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activity) (262,265,266). Non-linear relationships between extreme values of SBP, 
DBP, BMI and HbA1c and adverse clinical outcomes such as increased incidence 
of vascular events and deaths in patients with cardiometabolic conditions have 
been reported extensively (267–271).  
A previous meta-analysis has studied the nature of cross-sectional association 
between depressive symptoms and having abnormal levels of multiple 
biomarkers (central obesity, hyperglycaemia, elevated blood pressure, 
hypertriglyceridemia, and decreased HDL cholesterol) (272). However, direct 
comparison between the findings of this study and the meta-analysis is not 
feasible mainly because the cluster of biomarkers used in the meta-analysis are 
different from those used in DepChron (272). Secondly, the meta-analysis only 
investigated the relationship between depressive symptoms and cardiovascular 
biomarker values higher than clinical cut-offs and did not examine the possibility 
of non-linear relationship (272). This meta-analysis reported a cross-sectional 
association  between a cluster of cardiovascular biomarkers and depressive 
symptoms based on findings of 27 cross-sectional studies, with most of the 
primary studies adjusting for lifestyle factors such as smoking, alcohol and 
physical activity levels (272).  
5.4.5 Implications of Findings 
There are three potential implications of the findings. Firstly, for most of these 
cardiovascular biomarkers it is still better to have very low than very high 
values, as far as concurrent association of depressive symptoms is concerned.  
Secondly, if the association between extreme values of these biomarkers or 
cardiometabolic risk factors with depressive symptoms in those with 
cardiometabolic disease is supported by prospective studies, then this 
relationship could be used to identify those at “high risk” of depression. This 
would then offer a mechanism for targeting of depression screening in those 
with cardiometabolic disease. These results need to be replicated using other 
datasets and also prospectively to further explain the nature and direction of 
the observed association between depressive symptoms and cardiometabolic 
biomarkers.   Such further investigation is necessary in order to determine 
whether the lower values of these biomarkers is due to other disease processes 
154 
(for example, low total cholesterol levels associated with malnutrition, liver 
diseases and haematological diseases) (273–275) that may make patients more 
vulnerable to experiencing depressive symptoms.  
Finally, AI score did not offer any added clinical value in predicting concurrent 
depressive symptoms, over and above the use of individual constituent 
biomarkers on their own. This may be due to the selection of patients with 
existing cardiometabolic disease and use of only secondary cardiovascular 
biomarkers for AI score calculation.  
5.4.6 Conclusion 
In a large community dwelling sample of patients with existing cardiometabolic 
disease, dysregulation of allostatic biomarkers (mainly cardiometabolic) was 
found to have a non-linear association with increased probability of co-morbid 
depressive symptoms. A composite AI score constructed using four or five 
biomarkers did not lead to any improvement in the observed strength of the 
association.  Further investigation of the relationship between cardiometabolic 
biomarkers and depressive symptoms is needed, in order to determine whether 
they have potentially important implications for clinical practice in relation to 
risk stratification for secondary prevention in individuals with cardiometabolic 
disease and concurrent depressive symptoms. 
In the next chapter, the findings from the cross-sectional analysis in Psobid 
dataset are presented.
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Chapter 6 Cross-sectional Analysis in Psobid 
Dataset 
6.1 Chapter Summary 
In this chapter, the cross-sectional relationship between allostatic load 
biomarkers and depressive symptoms in the general population (using the 
psychological, social, and biological determinants of ill health (Psobid) cohort)  
is described. The objective of this analysis is to explore the eitiology of 
depressive symptoms in general population, without implying any causality. This 
addresses research questions 1 and 2 in Psobid dataset. These research questions 
are:  
Research Question 1 (RQ1):  
What is the association, if any, between a composite Allostatic Index (AI) score 
calculated using available allostatic load biomarkers and depressive symptoms in 
general population (Psobid cohort)?   
2. Research Question 2 (RQ2): 
What is the association, if any, between individual allostatic load biomarkers 
and depressive symptoms and how does it compare with the relationship 
between composite AI score and depressive symptoms in general population 
(Psobid cohort)? 
This chapter is divided into three  sections: the first explains the statistical 
methods  used; the second provides  the results of the analysis of the cross-
sectional relationship  between a composite allostatic index (AI) score and 
depressive symptoms as assessed by the 28 items General Health Questionnaire 
(GHQ-28)(231) and a comparison of the  association of individual allostatic 
biomarkers versus a composite score AI score with depressive symptoms; while 
the final section  discusses the strengths and limitations of the  analyses, how 
these findings fit with the existing literature and their potential implications.  
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6.2 Methods 
6.2.1 AI Score Calculation and Depression Screening in Psobid 
The 12 biomarkers used for AI score calculation are listed below with their 
respective allostatic load category. The four biomarkers with a * mark are those 
which were also used in the DepChron dataset for AI score calculation.  
1. Systolic Blood Pressure (SBP) (Cardiovascular) * 
2. Diastolic Blood Pressure (DBP) (Cardiovascular) * 
3. Body Mass Index (BMI) (Anthropometric) * 
4. Waist Hip Ratio (WHR) (Anthropometric) 
5. Total Cholesterol (Metabolic) * 
6. High Density Lipoprotein (HDL) Cholesterol (Metabolic) 
7. Triglycerides (Metabolic) 
8. Fasting glucose (Metabolic) 
9. Creatinine (Metabolic) 
10. Fibrinogen- (Inflammatory) 
11. Interleukin-6 (IL-6) (Inflammatory) 
12. Highly sensitive C - reactive protein (CRP) (Inflammatory) 
Psobid was a research study led by the Glasgow Centre for Population Health 
(GCPH) with 666 participants recruited in 2006-07. The methods for recruitment 
and data collection for Psobid have been described in detail in the published 
literature (228–230) and a summary has been presented in Chapter 4-section 4.3.   
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Four different methods for AI score calculation were used in Psobid, similar to 
the analysis with the DepChron dataset. A brief description of these four 
methods and reasons for choosing these methods for AI score calculation have 
been discussed in Chapter 4 while these methods are described in detail in 
Chapter 5.  
5. The clinical cut-off method- (Method 1) 
6. The sample distribution cut-offs (25th and 75th percentile) method- 
(Method 2) 
7. The sample distribution cut-offs (10th and 90th percentile) method – 
(Method 3) 
8. The z-score method-(Method 4) 
The inflammatory biomarkers in the Psobid study, highly sensitive CRP, IL-6 and 
fibrinogen, are not currently used in routine clinical practice and hence their 
clinical cut-offs are not very well defined. However, highly sensitive CRP has 
been recognised as an emerging cardiovascular risk factor and its use in 
cardiovascular risk assessment has been recommended in a recent guideline 
published by the American College of Cardiology (ACC) and American Heart 
Association (AHA) (276). Based on the recommendation of this guideline, a 
clinical cut-off score of highly sensitive CRP ≥ 2 was selected for use in this study 
(276). The approach of using the 75th percentile of a biomarker distribution as a 
cut-off for AI score calculation has been used by various other studies in the 
published allostatic load literature (28), when the biomarker in question does 
not have a widely accepted clinical cut-off. For IL-6 and fibrinogen, the 75th 
percentile value of the sample distribution was used as a cut off and values 
higher than the 75th percentile were labelled as abnormal.  
Participants were screened in the Psobid study for the presence of psychological 
symptoms using the General Health Questionnaire (GHQ-28) score. The GHQ-28 
consists of 4 sub-scales with 7 questions each: somatic symptoms, anxiety and 
insomnia, social dysfunction and severe depression(231). Each question is given a 
score of 0 or 1, giving a total score out of 28. A cut-off score of GHQ-28≥5 was 
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used, as recommended by the national guidelines for case identification of 
depressive symptoms in a community setting (20).  
6.2.2 Statistical Modelling-Logistic Regression 
A raised GHQ-28 (≥5) was used as the outcome variable for logistic regression 
models. For raised GHQ-28, the strength of its cross-sectional association with AI 
score (calculated by the 4 different methods) in univariable and multivariable 
analysis was assessed. For multivariable analysis, adjustments were made for 
age (as a continuous variable), sex, socio-economic status (affluent and 
deprived), number of existing cardiometabolic conditions (coronary heart 
disease/stroke, diabetes, and hypertension), with a range from 0-3. These 
potential confounders were the same as those used in the DepChron analysis 
apart from the number of existing cardiometabolic conditions since there was no 
control group in DepChron, i.e. all patients in DepChron had at least one of the 
three cardiometabolic conditions. In addition, stroke and CHD were categorized 
as one problem in the Psobid dataset at the time of data collection, so it was not 
possible to differentiate between those who had stroke and those who had CHD 
among Psobid participants.  Participant’s smoking status (current vs. former 
smoker vs. non-smoker) was also used as a confounding factor. This information 
on smoking status was not available in the DepChron dataset.  
In the next part of the analysis, the cross-sectional relationships between 
individual biomarkers and raised GHQ-28 was analysed using univariable logistic 
regression models. If individual biomarkers were found to have a significant 
association with raised GHQ-28, their respective quadratic terms were entered 
into the regression models to allow for a non-linear relationship. The turning 
point for each individual biomarker with a significant non-linear relationship was 
calculated using the formula (nadir/min = −b/2a or zenith/max=b/-2a) where 
“a” represents the coefficient of the quadratic term and “b” represents the 
coefficient of the linear term. The turning point will be a “nadir” in the event of 
a “U-shaped” non-linear relationship, while the turning point will be a “zenith” 
in the event of a “bell-shaped” non-linear relationship. The strengths of these 
relationships were evaluated in multivariable analyses adjusting for the 
potentially confounding factors- age, sex, socio-economic status, number of 
cardiometabolic conditions and smoking status as described above. If a 
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confounder was found to be a non-significant predictor, it was removed from the 
final multivariable models.  
The results of each regression model were presented as an odds ratio (OR) with 
95% confidence intervals (CI) and corresponding p-values, for AI scores and 
individual biomarkers. Different logistic regression models were compared by 
using the Hosmer and Lemeshow's R2 measure (247) and Akaike information 
criterion (AIC) (248). The model assumption for multicollinearity for a 
multivariable logistic regression model was checked for a selected few models- 
by checking for multicollinearity using the parameter variance inflation factor 
(VIF <10). Presence of multicollinearity implies that two or more predictor 
variables in a model are highly correlated to each other. A logistic regression 
model assumes that there is no multicollinearity among its predictor variables.   
To visualise the results of regression models, predicted probability charts were 
constructed for only those predictors - AI score or individual biomarkers which 
were found to have a statistically significant association with raised GHQ-28 in 
logistic regression. Predicted probability graphs were constructed for a raised 
GHQ-28 against corresponding values for significant predictors with the best fit 
in regression modelling. A new data set was constructed using all possible 
combinations of the following confounders (only included if a confounder had 
statistically significant association): age (35 to 65 in increments of 10), gender, 
socio-economic status (deprived and affluent), number of cardiometabolic 
conditions (0-3) and smoking status (current/former smoker and non-smoker). In 
the new data set, a predicted value was calculated for the probability of a 
raised GHQ-28 based on a range of values of significant predictors and the values 
of the potential confounders using their respective logistic regression modelling 
results. Finally, different predicted probability charts were created for the 
probability of raised GHQ-28 against each significant predictor using their 
respective new data set.  
6.2.3 Sensitivity Analysis 
For a sensitivity analysis, the interactions of significant predictors (AI score or 
individual biomarkers) with confounders-age, gender, number of cardiometabolic 
conditions, socio-economic status and smoking status were tested to check for a 
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potential effect modification. If any predictor was found to have a significant 
interaction with a confounder, the results of the interaction were visualised 
using the predicted probability charts.  
In a subsequent sensitivity analysis, multivariable linear regression models were 
constructed using GHQ-28 as a continuous variable. As GHQ-28 was not normally 
distributed, it was transformed using the square root transformation. The best AI 
score and the twelve individual biomarkers were used as predictor variables in 
13 different regression models. Age, sex, socio-economic status, number of 
cardiometabolic conditions and smoking status were added to all models as 
potential confounding factors. Only significant confounders were added to the 
final multivariable model. The quadratic terms for individual biomarker were 
added to regression models to allow for a non-linear relationship. The turning 
point was calculated for each of the predictors using the formula explained 
above in the event of a significant non-linear relationship. The results of linear 
regression were presented using standardized regression coefficients for 
predictors with 95% CI and p-values, adjusted R2 values and AIC values. For 
individual biomarkers, standardized regression coefficients for their respective 
quadratic terms with CI were also presented only in the event of a significant 
non-linear relationship.  
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6.3 Results 
6.3.1 Results of Depression Screening, Biomarker and AI score 
distribution in Psobid 
The results for GHQ-28 were recorded for 639/666 (95.9%) participants in the 
Psobid dataset. 183 participants (27.4%) had a raised GHQ-28 (≥5) which is 
consistent with having significant depressive symptoms.  
Table 6-1 describes the distribution of the 12 biomarkers, their range and 
missing values, and different cut-offs used for various AI score calculations. 
Blood glucose and the 3 inflammatory markers had a higher number of missing 
values than the other markers. All missing values were excluded from the entire 
analysis. IL-6, highly sensitive CRP and triglycerides had high standard deviation 
values relative to their respective mean values. The value of the clinical cut-off 
was lower than the 75th percentile of sample distribution for SBP, WHR (for 
females), BMI, total cholesterol, HDL cholesterol and highly sensitive CRP. With 
the exception of fasting blood glucose and creatinine, the value of clinical cut-
off was lower than the 90th percentile of sample distribution for all biomarkers. 
The observed range for SBP, DBP, total cholesterol and BMI in the Psobid dataset 
was within the limits of the clinically plausible range defined for these 
biomarkers in the DepChron data.  These ranges were SBP: 90 to 240 mm Hg, 
DBP: 50 to 130 mm Hg, BMI: 15 to 55, and total cholesterol: 2-10. 
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Table 6-1 Distribution of Allostatic Biomarkers in Psobid (N=666).  
   Method 1 
AI 
Calculation  
Method 2 AI Calculation Method 3 AI Calculation Method 4 AI Calculation (Z-
score method) 
Biomarker 
 
Range Missing 
Values 
Clinical 
cut-offs 
25th 
percentile 
75th 
percentile 
10th 
percentile 
90th 
percentile 
Mean (Standard Deviation) 
Systolic Blood 
Pressure in mm Hg 
90 to 202 4 140 123.3 147 112 159 135.7 (18.8) 
Diastolic Blood 
Pressure in mm Hg 
52 to 119 4 90 74 88 68 95 81.2 (10.9) 
Waist Hip Ratio 0.64 to 
1.31 
7 0.9 F 0.95 
M 
0.84 0.94 0.78 0.99 0.89 (0.08) 
Body Mass Index in 
kg/m2 
16.3 to 
51.1 
4 30 24.1 30.4 21.4 35.1 27.7 (5.5) 
Total Cholesterol in 
mmol/l 
2.4 to 8.6 21 5.0 4.4 5.8 3.8 6.4 5.1 (1.0) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
0.4 to 3.0 21 1.2 1.1 1.6 0.9 1.8 1.3 (0.3) 
 Triglycerides in 
mmol/l 
0.3 to 
10.8 
21 2.0 0.9 1.7 0.3 2.6 1.5 (1.0) 
Fasting Blood 
Glucose in mmol/l 
3.2 to 
19.8 
54 6.0 4.8 5.4 4.5 5.9 5.2 (1.4) 
Creatinine in umol/l 55.2 to 
159.6 
28 110 F 120 
M 
74.2 89.6 68.2 97.3 82.4 (12.1) 
Highly sensitive C-
reactive protein in 
mg/l 
0.6 to 
18.9 
30 1 0.6 3.3 0.3 6.8 2.7 (3.4) 
Interleukin 6 in 
pg/ml 
0.2 to 
11.8 
37 NA 1.0 2.75 0.6 4.0 2.1 (1.5) 
Fibrinogen in g/l 1.1 to 6.4 33 NA 2.8 3.7 2.5 4.2 2.8 (0.7) 
M=Male; F=Female; NA=Not applicable. 
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Table 6-2 compares the AI scores calculated with methods 1-4 in the Psobid 
study population N=666 using 12 biomarkers (SBP, DBP, BMI, WHR, total 
cholesterol, HDL cholesterol, triglycerides, creatinine, fasting Glucose, highly 
sensitive CRP, IL-6 and fibrinogen). The AI scores calculated by methods 1 and 4 
had large standard deviations values relative to their respective mean value. The 
range of AI score for method 1 was from 0 to 10. This implies that there were 
some participants who had all of the 12 biomarker values less than the 
respective clinical cut-off values, which is appropriate as participants were 
recruited from the general population (as opposed to a setting) and likely to be 
healthier. The range of AI score was the widest for the method 4 AI score. In 
addition, the values of mean and median were very different for the method 4 AI 
score. The AI score calculated by method 3 had the narrowest total and 
interquartile range. Observations with missing values for AI scores were excluded 
from regression analysis.  
Table 6-2 Distribution of AI score in the Psobid dataset (N=666) with four different statistical 
methods. 
N=666. Missing values and exclusions=96.Available N=570. Biomarkers used for AI 
score calculation: Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass 
Index, Waist Hip Ratio, Total Cholesterol, High Density Lipoprotein Cholesterol, 
Triglycerides, Fasting Glucose, Creatinine, Highly sensitive C-reactive Protein, 
Interluekin-6 and Fibrinogen.  
 AI score- 
Method 1-
clinical cut-
off method    
Range=0-10 
AI score-
Method 2- 
25th/75th 
percentile 
method 
Range=1-12 
AI score-
Method 3- 
10th/90th 
percentile 
Range=1-9 
AI score – 
Method 4- z 
score method 
Range=3.7-
22.3  
Mean 3.3 5.7 3.0 8.5 
Standard 
Deviation 
2.1 2.0 1.5 8.0 
Median 3.0 6.0 3.0 2.7 
25%- 75% 2.0-5.0 4.0-7.0 2.0 – 4.0 6.6-9.9 
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6.3.2 AI score as a predictor variable 
6.3.2.1 Univariable Analysis 
In the univariable analysis in the Psobid dataset, AI score did not have a 
statistically significant association with depressive symptoms (defined by raised 
GHQ-28≥5). In logistic models with raised GHQ-28 (≥5) as the outcome variable, 
all four AI scores calculated with the four different statistical methods were 
found to have a statistically non-significant p-value (see Table 6-3). The ranges 
and distribution of the four AI scores were different and hence their odds ratios 
were not directly comparable. However, the values of odds ratios for the 4 AI 
scores were close to 1 which suggests that effect sizes were very small. The 
Hosmer and Lemeshow’s measure R2 value was small for all of the 4 models 
which imply that these models were a poor fit to the data.  
6.3.2.2 Multivariable Analysis 
The association between the AI scores and raised GHQ-28 remained statistically 
insignificant after adding various confounding factors (see Table 6-3). The odds 
ratios for the respective AI scores were close to 1 which suggests that the 
respective effect sizes were unchanged after adding confounders to these 
models. The Hosmer and Lemeshow’s measure R2 values improved after adding 
confounders. Among the confounders, sex (OR for male 0.62, 95% CI 0.43-0.90) 
socio-economic status (OR for deprived group 1.58, 95% CI 1.06-2.36) and 
smoking status (OR for smoker 1.51, 95% CI 1.02-2.25) were found to have a 
significant association with raised GHQ-28. Age and cardiometabolic co-
morbidity were again not significant predictors of depressive symptoms and 
hence they were removed from the final model. The model assumptions were 
checked for the multivariable model using the method 4 AI score. The model 
assumptions for logistic regression model- multicollinearity using the parameter 
variance inflation factor (VIF <10) was satisfactory for the multivariable logistic 
regression model using the method 4 AI score as the predictor variable. This 
implies that the predictor variables used in the model were not highly 
correlated.  
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Key Findings (AI score as Predictor Variable):  
 AI score (calculated by 4 different methods) did not have a 
significant cross-sectional association with the presence of 
depressive symptoms (as assessed by raised GHQ-28) in 
univariable or multivariable logistic regression analyses. 
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Table 6-3 Logistic Regression with AI score as a predictor and depressive symptoms (GHQ-28≥5) as outcome variable. 
N=666. Missing values and exclusions=97. Available N=570. 
Biomarkers used for AI score calculation: Systolic Blood Pressure, Diastolic Blood Pressure, Body Mass Index, Waist Hip Ratio, Total Cholesterol, High 
Density Lipoprotein Cholesterol, Triglycerides, Fasting Glucose, Creatinine, Highly sensitive C-reactive Protein, Interluekin-6 and Fibrinogen. 
Univariable Analysis 
 AI score- Method 1-clinical 
cut-off method    N=570 
Range=0-10 
AI score-Method 2- 25th/75th 
percentile method N=570 
Range=1-12 
AI score-Method 3- 
10th/90th percentile 
N=570 
Range=1-9 
AI score – Method 4- z score 
method N=570  
         Range=3.7-22.3  
AI score-Odds Ratio 1.06 1.04 0.98 1.01 
Odds Ratio-95% Confidence 
Intervals; p-value 
0.97-1.16;    p=0.15 0.95-1.14;      p=0.36 0.87-1.11; p=0.85 0.95-1.08;      p=0.61 
Hosmer and Lemeshow’s 
measure R2 
0.003 0.001 <0.001 <0.001 
Akaike Information Criteria 650 651 652 652 
Multivariable Analysis. Adjusted for confounders: age, sex, socio-economic status, number of cardiometabolic conditions, smoking 
status.  
AI score- Odds Ratio 1.00 1.00 0.92 0.97 
Odds Ratio-95% Confidence 
Intervals; p-value 
0.91-1.10; p=0.91 0.90-1.10; p=0.99 0.80-1.05;    p=0.25 0.90-1.05;      p=0.56 
Hosmer and Lemeshow’s 
measure R2 
0.043 0.043 0.045 0.043 
Akaike Information Criteria 634 634 633 634 
Only sex, socio-economic status and smoking status included in the final analysis as the other confounders were not statistically significant. 
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6.3.3 Individual Biomarkers as Predictor Variables 
6.3.3.1 Univariable Analysis 
The univariable modelling results for GHQ-28≥5 as the outcome variable and 
each of the 12 biomarkers as predictors are presented in Table 6-4. Six 
individual biomarkers were found to have a statistically significant association 
with raised GHQ-28 in the Psobid dataset. These biomarkers were SBP, BMI, 
triglycerides, creatinine, highly sensitive CRP and fibrinogen. The odds ratio for 
SBP and creatinine were less than 1 in value which suggests that these two 
biomarkers had an inverse association with the probability of having a raised 
GHQ-28.  
A quadratic term was added for these six biomarkers to allow for a non-linear 
relationship. The quadratic term was found to have a significant association with 
raised GHQ-28 for only highly sensitive CRP. The other five biomarkers with 
significant association were found to have a linear relationship. The odds ratios 
with univariable analysis for the linear and the quadratic terms for highly 
sensitive CRP were 1.27 (95% CI 1.10-1.47) and 0.98 (95% CI 0.97-0.99) 
respectively. The odds ratio of quadratic term was less than 1 in value which 
implies that highly sensitive CRP had a “bell shaped” non-linear association with 
the odds of raised GHQ-28. The zenith of the “bell” for highly sensitive CRP was 
calculated with the formula –b/2a and found to be at 9.4 mg/l. The possibility of 
having raised GHQ-28 concurrently was highest for CRP value of 9.4 and the 
possibility of raised GHQ-28 was lower with CRP values above and below 9.4 
mg/l. 
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Table 6-4 Univariable Logistic Regression using individual biomarkers as predictors and depressive symptoms (GHQ-28≥5) as outcome variable.  
N=666. Available N=639 GHQ-28=General Health Questionnaire 
Biomarker 
 
Missing 
Values 
Range Odds 
Ratio 
95% Confidence 
Intervals 
p-value Akaike 
Information 
Criteria 
Hosmer and 
Lemeshow’s measure 
R2 
Systolic Blood Pressure 
in mm Hg 
4 90 to 202 0.99 0.98-0.99 0.04 760 0.005 
Diastolic Blood 
Pressure in mm Hg 
4 52 to 119 0.09 0.98-1.01 0.73 764 <0.001 
Waist Hip Ratio 7 0.64 to 1.31 1.44 0.77-11.62 0.72 757 0.001 
Body Mass Index in 
kg/m2 
4 16.3 to 51.1 1.04 1.01-1.07 <0.01 757 0.009 
Total Cholesterol in 
mmol/l 
21 2.4 to 8.6 0.86 0.73-1.02 0.09 737 0.003 
High Density 
Lipoprotein Cholesterol 
in mmol/l 
21 0.4 to 3.0 0.79 0.50-1.26 0.34 739 0.001 
Triglycerides in mmol/l 21 0.3 to 10.8 1.18 1.00-1.39 0.03 732 0.005 
Fasting Blood Glucose 
in mmol/l 
54 3.2 to 19.8 0.97 0.83-1.10 0.69 707 <0.001 
Creatinine in umol/l 28 55.2 to 159.6 0.98 0.96-0.99 0.02 729 0.007 
Highly sensitive C-
reactive protein) in 
mg/l 
30 0.6 to 18.9 1.06 1.01-1.12 0.01 720 0.008 
Interleukin 6 in pg/ml 37 0.2 to 11.8 1.09 0.98-1.22 0.09 718 0.003 
Fibrinogen in g/l 33 1.1 to 6.4 1.32 1.03-1.70 0.02 722 0.006 
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6.3.3.2 Multivariable Analysis 
The association between the six (SBP, BMI, triglyceride, creatinine, highly 
sensitive CRP and fibrinogen) individual biomarkers which were significant in 
univariable analysis and raised GHQ-28 were checked in six different 
multivariable models after adding various confounding factors (see Table 6-5). 
Among the confounders, sex, socio-economic status and smoking status only 
were added to the multivariable model. The other confounders, age and 
cardiometabolic co-morbidity were not significant predictors of depressive 
symptoms and hence they were removed from the final model. Only BMI was 
found to have a significant association with raised GHQ-28 in multivariable 
analysis. All the other five biomarkers had statistically non-significant 
associations. BMI was found to have a significant linear relationship with raised 
GHQ-28 in multivariable analysis. The effect size for BMI suggested that with 
each unit increase in BMI, there was a 4% (95% CI: 1% to 7%) increase in the 
probability of raised GHQ-28; this was consistent with the effect size observed in 
the univariable model for BMI.  Model assumptions of multicollinearity were 
checked for the multivariable model using the parameter variance inflation 
factor (VIF <10) and it was satisfactory. This implies that the predictor variables 
used in the model were not highly correlated. 
Table 6-5 Multivariable Logistic Regression using individual biomarkers as predictors and 
depressive symptoms (GHQ-28≥5) as outcome variable  
N=666. Available N=639.  GHQ-28=General Health Questionnaire.  Confounders: 
sex, socio-economic status and smoking status 
Biomarker 
 
Missing 
Values 
Range Odds 
Ratio 
95% 
Confidence 
Intervals 
p-value Akaike 
Information 
Criteria 
Hosmer and 
Lemeshow’s 
measure R2 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 0.99 0.98-1.00 0.16 702 0.037 
Body Mass 
Index in kg/m2 
4 16.3 to 
51.1 
1.04 1.01-1.07 <0.01 696      0.044 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
1.16 0.97-1.38 <0.08 683 0.038 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
0.99 0.98-1.01 0.89 681 0.032 
Highly 
sensitive C-
reactive 
protein) in 
mg/l 
30 0.6 to 
18.9 
1.03 0.98-1.09 0.14 669 0.039 
Fibrinogen in 
g/l 
33 1.1 to 
6.4 
1.22 0.94-1.58 0.12 672 0.035 
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Key Findings (Individual Biomarkers as Predictor Variables):  
 Six individual biomarkers (SBP, BMI, triglycerides, creatinine, 
highly sensitive CRP and fibrinogen were found to have a 
significant cross-sectional association with the presence of 
depressive symptoms (as assessed by raised GHQ-28) in 
univariable logistic regression analyses.  
 BMI  (OR 1.04) was the only peripheral biomarker found to 
have a significant cross-sectional association with the presence 
of depressive symptoms in multivariable logistic regression 
analysis, after adjusting for the effect of statistically significant 
confounders.  
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6.3.3.3 Predicted Probability Charts 
A predicted probability chart was created for BMI against raised GHQ-28. This 
was based on the multivariable model for raised GHQ-28, with BMI as predictor, 
and sex, smoking status and socio-economic status as confounders.  The 
probability of raised GHQ-28 ranged from 18% to 52% for different BMI values 
(see Figure 6-1).  
Figure 6-1 Predicted Probability Chart of raised GHQ-28(≥5) against BMI in Psobid dataset.   
 
Legend: Adjusted for sex, smoking status and socio-economic status. 
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6.3.4 Sensitivity Analysis 
6.3.4.1 Interaction Analysis between depressive symptoms, BMI and 
confounders 
In the multivariable models showing a significant association between depressive 
symptoms (as assessed by raised GHQ-28) and BMI, the interactions between 
individual biomarkers and respective significant confounders were checked. For 
the multivariable model with raised GHQ-28 as the outcome, there was no 
interaction of BMI with sex (p=0.34), smoking status (p=0.07) and socio-economic 
status (p=0.07).  
6.3.4.2 Linear Regression with GHQ-28 as continuous measure 
Multiple multivariable linear regression models were performed with continuous 
GHQ-28 as the outcome variable. The GHQ-28 was square root transformed as 
the original score was not normally distributed. Among the confounders, sex, 
socio-economic status and smoking status were found to have a significant 
association with a continuous measure of GHQ-28. Age and number of 
cardiovascular co-morbidities were not significant predictors and hence removed 
from the models. Table 6-6 shows the results of separate multivariable linear 
regression models with AI score and 12 individual biomarkers as predictors 
respectively. AI score was not found to have a statistically significant association 
which is consistent with the findings from the logistic regression modelling. In 
the linear multivariable regression modelling, four individual biomarkers were 
found to have a significant association with GHQ-28: BMI, triglycerides, HDL 
cholesterol and highly sensitive CRP. The standardized regression coefficient was 
less than 0 in value for HDL cholesterol implying that lower HDL cholesterol 
values were associated with higher GHQ-28 scores.
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Table 6-6 Multivariable Linear Regression with continuous GHQ-28 (square root transformed) as outcome variable and AI score and the 12 individual 
biomarkers as predictor variables.  
N=666, Available N=639. Confounders- sex, socio-economic status and smoking status. 
Biomarker 
 
Missing 
Values 
Range Standardize
d 
Regression 
Coefficients 
95% Confidence 
Intervals 
p-value Akaike 
Information 
Criteria 
Hosmer and 
Lemeshow’s measure 
Adjusted R2 
AI score (z-score method) 96 3.7 to 22.3 0.005 -0.03 to 0.04 0.99 1809 0.069 
Systolic Blood Pressure in 
mm Hg 
4 90 to 202 -0.06 -0.01 to 0.001 0.15 2087 0.072 
Diastolic Blood Pressure 
in mm Hg 
4 52 to 119 0.006 -0.008 to 0.01 0.68 2089 0.069 
Waist Hip Ratio 7 0.64 to 1.31 0.024 -1.13 to 1.99 0.51 2074 0.071 
Body Mass Index in kg/m2 4 16.3 to 51.1 0.09 0.004 to 0.044 0.01 2080 0.081 
Total Cholesterol in 
mmol/l 
21 2.4 to 8.6 -0.03 -0.15 to 0.05 0.31 2046 0.069 
High Density Lipoprotein 
Cholesterol in mmol/l 
21 0.4 to 3.0 -0.084 -0.61 to -0.011 <0.01 2040 0.078 
Triglycerides in mmol/l 21 0.3 to 10.8 0.08 0.001 to 0.21 0.04 2043 0.074 
Fasting Blood Glucose in 
mmol/l 
54 3.2 to 19.8 -0.04 -0.11 to 0.03 0.53 1949 0.073 
Creatinine in umol/l 28 55.2 to 159.6 -0.02 -0.01 to 0.007 0.81 2025 0.065 
Highly sensitive C-
reactive protein) in mg/l 
30 0.6 to 18.9 0.099 0.008 to 0.074 0.01 2012 0.079 
Interleukin 6 in pg/ml 37 0.2 to 11.8 0.05 -0.02 to 0.12 0.15 1993 0.068 
Fibrinogen in g/l 33 1.1 to 6.4 0.05 -0.04 to 0.26 0.16 2003 0.069 
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The possibility of a non-linear relationship for the 4 biomarkers that were found 
to have a significant association in multivariable linear regression models- BMI, 
triglycerides, HDL cholesterol and highly sensitive CRP was checked by adding 
their respective quadratic terms to each of the individual models. The p-values 
for quadratic terms were not significant for BMI, triglycerides and HDL 
cholesterol and highly sensitive CRP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Key Findings (Sensitivity Analysis):  
 No significant statistical interaction observed between 
BMI and any of the significant confounders in 
multivariable logistic regression with raised GHQ-28 as 
the outcome variable.  
 In the multivariable linear regression using the 
continuous measure of GHQ-28 as the outcome 
variable, AI score was not found to have a significant 
cross-sectional association.  
 Four peripheral biomarkers were found to have a 
significant cross-sectional association with GHQ-28 in 
multivariable linear regression. They were: BMI, 
triglycerides, HDL cholesterol and highly sensitive CRP, 
with HDL cholesterol observed to have an inverse 
linear relationship with continuous GHQ-28.   
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6.4 Discussion 
6.4.1 Summary of Findings 
The prevalence estimate for depressive symptoms in participants recruited from 
the general population in Psobid data was 27.4% (based on raised GHQ-28≥5). AI 
score did not have a significant cross-sectional association with depressive 
symptoms as assessed by GHQ-28 in either logistic regression (using raised GHQ-
28) or in linear regression (continuous GHQ-28).  
Six individual biomarkers were found to have a significant cross-sectional 
association with raised GHQ-28 in univariable analysis: SBP, BMI, triglycerides, 
creatinine, highly sensitive CRP and fibrinogen. Highly sensitive CRP was found 
to have a non-linear bell shaped relationship with a peak at the value of 9.4 
mg/l for the highest probability of raised GHQ-28. In the multivariable analysis 
with raised GHQ-28 as the outcome variable, only BMI was found to have a 
significant linear relationship after adjusting for statistically significant 
confounders (sex, smoking status and socio-economic status). The effect size of 
the association implied that with increase in BMI by 5 units, there was 20% 
higher chances of having associated raised GHQ-28.   
Four individual biomarkers (BMI, triglycerides, HDL cholesterol and highly 
sensitive CRP) had a significant cross-sectional association with the continuous 
measure of GHQ-28 in multivariable linear regression models. HDL-cholesterol 
had an inverse linear relationship with continuous GHQ-28; while BMI, 
triglycerides and highly sensitive CRP were found to have a direct linear 
relationship. The results were adjusted for the effects of the statistically 
significant confounders- sex, smoking status and socio-economic status. 
Individual biomarkers did not have a statistically significant interaction with any 
confounding factors in predicting co-existing depressive symptoms. 
Interestingly, BMI was the only peripheral biomarker which had a significant 
cross-sectional association with depressive symptoms (assessed with both 
versions of GHQ-28- clinical cut-off and continuous scale), after adjusting for 
confounders.  
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6.4.2 Strengths 
1. The rate of data completion was very good (>90% participants) for GHQ-
28.  
2. The study participants were well characterized with detailed information 
available on demographics and availability of both primary and secondary 
allostatic load biomarkers.  
6.4.3 Limitations 
1. The participants were chosen from the most deprived and the least 
deprived areas to highlight the impact of socio-economic status. However, 
socio-economic status is a continuum and hence the results of this study 
cannot be generalized to the whole population.   
2. Secondly, the response rate for study participation was 25%. Hence there 
is a possibility of response bias.  
3. In this analysis, GHQ-28 was used for estimating prevalence of depressive 
symptoms. GHQ-28 was originally designed to screen for minor 
psychological distress (not restricted to depressive symptoms) (231). 
However, it has been validated for screening of depressive symptoms in 
the general population (reported sensitivity 79.2% and specificity 79.6% 
against a composite international diagnostic instrument for DSM-IV criteria 
for major depressive disorder) (277) and for assessing depressive 
symptoms in patients with chronic physical health problems in primary 
care with good diagnostic accuracy (reported sensitivity 90%, reported 
specificity 80%) (257).  
6.4.4 Comparison of findings with the existing literature and with 
DepChron 
The prevalence estimate for depressive symptoms was 27.4% (based on GHQ-
28≥5) in Psobid participants, which is higher than those reported in the general 
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population based on recent global estimates of <6%, even after taking dysthymia 
into account (8). This prevalence levels observed in Psobid is even higher than 
the prevalence levels observed in DepChron (19.9%). DepChron had patients with 
existing cardiometabolic disease who would be expected to be more likely to 
have co-existing depressive symptoms than the general population 
(106,107,278). There was no significant cross-sectional association between 
depressive symptoms and AI score in Psobid participants, either with logistic or 
linear regression modelling. As discussed previously in Chapters 4 and 5, 3 out of 
4 studies have reported a significant cross-sectional association between AI score 
and depressive symptoms (216,217,219). None of the previously published 
studies have used GHQ-28 for estimating prevalence of depressive symptoms, 
however as previously suggested GHQ-28 has been validated for assessing 
depressive symptoms in the general population and primary care. The findings 
from Psobid are in contrast to those of DepChron, which showed a significant 
relationship between AI score and depressive symptoms; the important caveat 
being that the AI score constituents were very different for the two datasets.  
In Psobid participants, a cross-sectional association was observed between 
individual biomarkers such as SBP, BMI triglycerides, HDL cholesterol, creatinine 
and the two inflammatory markers: highly sensitive CRP and fibrinogen) and 
depressive symptoms. However, the majority of these relationships, apart from 
the one between BMI and depressive symptoms, were no longer significant after 
adjusting for potential confounders. In DepChron, depressive symptoms had a 
significant non-linear relationship with SBP, DBP, BMI and total cholesterol, after 
adjusting for confounders. BMI has also been found to have a non-linear cross-
sectional association (U-shaped) with depressive symptoms in the general 
population, in a large study published previously (279). In contrast, BMI had a 
positive linear relationship (with raised GHQ-28) in Psobid participants. 
Similarly, in various cross-sectional studies involving mainly elderly populations, 
depression has been observed to have a non-linear association with  SBP (259–
262), which was contradictory to the non-significant relationship observed in the 
Psobid participants. Also, DBP and total cholesterol did not have a significant 
association with depressive symptoms in Psobid, which is different to the 
findings of DepChron.  
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Finally, based on the results of a meta-analysis of 51 cross-sectional studies, 
raised highly sensitive CRP and IL-6  have been found to have a positive linear 
association with depressive symptoms (280). In Psobid, there was a significant 
cross-sectional association between depressive symptoms and highly sensitive 
CRP, but not with IL-6. 
6.4.5 Implications of Findings 
There are two potential implications of the observed relationships between AI 
score and peripheral biomarkers with depressive symptoms in Psobid 
participants. Previous evidence supporting a significant cross-sectional 
association between a composite AI score and depressive symptoms has mainly 
come from studies involving older populations (>65 years). The association may 
not be statistically significant in middle aged populations such as the Psobid 
participants. Further research should focus on investigating relationship between 
AI score and depressive symptoms in different age groups.  
A significant cross-sectional association was observed between certain individual 
cardiometabolic (BMI) and inflammatory (highly sensitive CRP) biomarkers and 
concurrent depressive symptoms in Psobid participants, which resonates with the  
existing literature (281,282)(283). These relationships are cross-sectional in 
nature and hence it is not possible to infer causality based on these 
relationships. Previously reported meta-analyses have found a bi-directional 
relationship of depressive symptoms with raised inflammatory markers (281,282) 
and with obesity (283). In other words,  studies have shown that obesity and 
raised inflammatory markers at baseline could be predictors of onset of 
depressive symptoms in future in someone who has not got depressive symptoms 
(281,282)(283).  But the added risk of adverse clinical outcomes to the people 
who are obese or who have raised inflammatory markers and also concurrent 
depressive symptoms remains unclear. The hypothesis of this study is that these 
people with depressive symptoms and abnormal biomarkers are at higher risk of 
suffering from adverse physical outcomes which have been associated with 
depressive symptoms, such as death and cardiovascular events. This research 
question will be answered through longitudinal analysis of outcomes in Psobid 
participants in Chapter 8.  
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6.4.6 Conclusion 
In a community dwelling sample of participants selected from the most affluent 
and deprived socio-economic sections of the general population, certain 
individual cardiometabolic and inflammatory biomarkers (such as BMI and CRP) 
were found to have a significant cross-sectional association with depressive 
symptoms. A composite AI score constructed using 12 biomarkers did not show a 
significant association with depressive symptoms. Future research should be 
directed towards longitudinal studies that examine clinical outcomes and the 
role of peripheral biomarkers in predicting clinical outcomes in patients with 
depressive symptoms.  
In the next two chapters- Chapters 7 and 8, the findings from longitudinal 
analysis of the DepChron and Psobid datasets are presented respectively.
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Chapter 7: Longitudinal Analysis in DepChron 
Dataset 
7.1 Chapter Summary 
In this chapter, the relationship between depressive symptoms, peripheral 
biomarkers and general and cardiovascular clinical outcomes is examined in 
patients with existing cardiometabolic disease, using the DepChron data. The 
objective of this analysis is to study the prognosis of depressive symptoms co-
morbid with cardiometabolic disease. This addresses research questions 3 and 4 
in the DepChron dataset. These research questions are:  
Research Question 3 (RQ3):  
What is the association, if any, between a composite AI score at baseline 
and the risk of future adverse health outcomes such as vascular events, 
hospitalisation and mortality in patients with depressive symptoms co-
morbid with cardiometabolic disease (DepChron cohort)?  
Research Question 4 (RQ4):  
What is the association, if any, between individual allostatic load 
biomarkers at baseline and the risk of future adverse health outcomes, 
such as vascular events, hospitalisation and mortality in patients with 
depressive symptoms co-morbid with cardiometabolic disease and how does 
it compare with the relationship between composite AI score at baseline 
and risk of adverse outcomes? 
The three sections in this chapter address: a)the methods for data collection of 
clinical outcomes and statistical analysis;  b) the association of AL biomarkers 
(composite AI score and individual biomarkers) and depressive symptoms with 
the risk of adverse clinical outcomes (general and cardiovascular) at 4 years as 
well as the statistical analyses of the interaction of depressive symptoms with 
allostatic load biomarkers (composite AI score and individual biomarkers) in risk 
prediction of these outcomes; and c) a discussion of how the findings compare 
with the existing literature and  strengths, limitations and possible implications.  
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7.2 Methods 
7.2.1 Data Collection- Adverse Clinical Outcomes 
Clinical outcomes were studied via electronic data linkage performed by the 
Information Services Division (ISD), Scotland data linkage services. The follow-up 
period was 4 years between April 2009 and March 2013. The process of 
electronic data linkage was completely anonymised and there was no access to 
any patient identifiable information at any point. Firstly, the list of the patients 
on the DepChron dataset was transferred to ISD with their dummy study 
numbers. The Keep Well Enhanced Services Data Group (data guardian for the 
DepChron dataset) transferred the list of original community health index (CHI) 
numbers along with their dummy study numbers to ISD. The ISD used patient CHI 
numbers to link the DepChron dataset with the general hospitalization and death 
registries. After extracting the information on clinical outcomes for DepChron 
patients, the CHI numbers were removed from the data by ISD and the data was 
forwarded to Glasgow University for analysis. This method of electronic data 
linkage has been shown to provide robust data on health care outcomes and has 
been used for a wide range of high profile epidemiological studies and large 
scale randomised controlled trials such as the West of Scotland Coronary 
Prevention Study and Heart Failure and Optimal Outcomes from Pharmacy 
Trial(284–286). The general and cardiovascular health outcomes, defined using 
the International System of Disease Classification- 10th Edition (ICD-10), were 
those studied (287). Only the first cause of death and the first cause of 
hospitalization were taken into account to improve accuracy, in line with the 
approach adopted by previously published studies using data linkage (284–286).  
The general Health Outcomes studied were:  
1. All-cause Death 
2. All-cause Hospitalization 
The cardiovascular health outcomes with respective ICD-20 codes are as follows:  
1. Admission due to myocardial Infarction (MI)- I21 
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2. Admission due to stroke – I61-I64 
3. Admission due to heart failure (HF): I50 
4. Death due to cardiovascular causes: I00- I99.  
Major adverse cardiovascular outcome (MACE) was used as the composite 
outcome variable, which included cardiovascular mortality or admission due to 
MI/stroke/HF. Patients were censored if they died due to reasons other than 
cardiovascular causes. 
7.2.2 Clinical Variables 
Depressive symptoms assessed by HADS-D were entered as a binary variable 
(present/absent) with HADS-D≥8 used as the threshold for presence of 
depressive symptoms, as per previous analyses.  
The values for individual biomarkers were restricted to clinically plausible 
ranges based on both clinical judgement and the findings of general population 
studies as before. SBP measurements were restricted to a range between 90 to 
240 mm Hg and DBP to a range between 50 to 130 mm Hg (236,237). Similarly, 
BMI was restricted to a range between 15 to 55 (238), total cholesterol to 2-10 
(239) and HbA1C to 3-18% (240). 
The AI score was calculated using the four different methods which have been 
described in detail in Chapter 5. These methods were: 1. Method 1- Clinical cut-
off 2. Method 2- Sample distribution cut-offs (25th and 75th percentile) 3. Method 
3- Sample distribution cut-offs (10th and 75th percentile). 4. Method 4- z-score.  
The 5 individual biomarkers (HbA1c was only available in the subset of patients 
with diabetes) were used both as continuous and categorical measures. BMI was 
classified into 4 categories: healthy 18.5-25, underweight 15-18.5, overweight 
25-30, obese 30-55 (245)  and total cholesterol levels into two categories (not 
raised vs. raised: >5 mmol/l (244)), based on published clinical guidelines.  
There is no consensus among various guidelines published internationally for 
optimal BP targets in patients with existing cardiometabolic disease (241–244). 
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Therefore, BP was classified into five different categories based on clinical 
judgement to improve the interpretability of results. SBP was classified into five 
categories:  very high (160-240), high (140-159), reference (130-139), tightly 
controlled (120-129), and low (80-119). Diastolic blood pressure (DBP) was also 
classified in to: very high (100-130), high (90-99), reference (85-89), tightly 
controlled (80-84) and low (40-79). 
7.2.3 Statistical Analysis-AI score 
Time to event analysis was used to study the association of the two predictors: 
a) AI score (4 different methods) and b) presence of depressive symptoms; with 
the risk of the two general health outcomes and the composite major adverse 
cardiovascular outcome in DepChron patients. A quadratic term of the AI score 
was added to check for a non-linear association between AI score and the 3 
clinical outcomes.  
If AI score or depressive symptoms were found to have a statistically significant 
relationship with a clinical outcome in multivariable analysis, a Kaplan-Meier 
plot was used to visualise the results of this relationship. 
Multivariable analysis was performed adjusting for the following confounders:  
age (continuous), sex (male and female), socio-economic status (deprived: SIMD 
deciles 1-5 vs. affluent: SIMD deciles 6-10), initiation of antidepressants within 6 
months of depression screening (yes/no), number of conditions (range 1-3, 
representing a combination of one or more of the three cardiometabolic diseases 
under investigation: CHD, stroke or diabetes. The results are presented as 
hazard ratios (HR) with 95% confidence intervals (CI) and Harrell’s Concordance 
statistics (with standard errors) using the “survival” package from R (288). The 
final adjusted Cox proportional hazard models were fitted for each of the 3 
adverse clinical outcomes with both AI score and depressive symptoms added 
together as predictors in all models, and in addition to the five potential 
confounders in the adjusted models.  
To understand the relationship between AI score and depressive symptoms in risk 
prediction of clinical outcomes, if any, an analysis of variance (ANOVA) test was 
undertaken to check for interaction between the AI score and presence of 
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depressive symptoms. The results were presented as p-values with a p-value less 
than 0.05 regarded as statistically significant. In the event of a significant 
interaction, a sub-group analysis was also conducted to further study the nature 
of the interaction.  
7.2.4 Statistical Analysis-Individual Biomarkers 
Time to event analysis was used to study the association between the 4 
individual biomarkers (SBP, DBP, BMI and total cholesterol, both as continuous 
and categorical measures based on categories described above) and the risk of 
general and cardiovascular adverse outcomes in DepChron patients. Cox 
proportional hazards regression analysis was performed and the results 
presented with hazard ratios and 95% confidence intervals.  
If a peripheral biomarker was found to have a statistically significant 
relationship with any of the clinical outcome, a Kaplan-Meier plot was 
constructed to visualise the results of this relationship.  
Three multivariable cox proportional models were constructed, with the 4 
individual peripheral biomarkers and depressive symptoms as predictors, 
adjusting for the same confounders:  age (continuous), sex (male and female), 
socio-economic status (deprived: SIMD deciles 1-5 vs. affluent: SIMD deciles 6-
10), initiation of antidepressants (yes/no) within six months of depression 
screening, number of conditions (range 1-3, representing a combination of one 
or more of the three cardiometabolic disease under investigations: CHD, stroke 
or diabetes. The results of these models were presented with HR with 95% CI and 
C-statistics (with standard errors). 
To understand the relationship between individual biomarkers and depressive 
symptoms in risk prediction of clinical outcomes, if any, an ANOVA test was 
undertaken to check for interaction between the individual biomarkers and the 
presence of depressive symptoms. The results were presented as p-values with a 
p-value less than 0.05 regarded as statistically significant. In the event of a 
significant interaction, sub-group analysis was performed to further study the 
nature of the interaction. In the sub-group analysis, the study sample was 
divided on the basis of individual biomarker categories. In each sub-group, a Cox 
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proportional hazards regression analysis was performed to study the risk of 
clinical outcomes with the presence of depressive symptoms at baseline, 
adjusting for potential confounders. The results of the interaction were 
visualised with the help of a forest plot for HRs with 95% CI. 
7.2.5 Sensitivity Analysis in Diabetes Subset 
For sensitivity analysis, the analyses for risk prediction of general and 
cardiovascular health outcomes were repeated in patients with diabetes. In 
these patients, Cox’s regression modelling was performed as described above, 
firstly for AI score using HbA1c as one of the biomarkers for AI calculation. Final 
multivariable models were then constructed for the three clinical outcomes 
under study using AI score, depressive symptoms and the five potential 
confounders described previously for the diabetic subgroup. Testing for a 
potential interaction between AI score and depressive symptoms in the risk 
prediction of these outcomes was also performed.  
In the next part, the analyses were repeated with individual biomarkers. The 
HbA1c was categorized, based on national guidelines (246), into reference: 6.5-
7.4 DCCT, low 3-6.4 DCCT, and high 7.5-18 DCCT. Similarly, final multivariable 
models were constructed for the three clinical outcomes using depressive 
symptoms, five biomarkers (as categorical variables based on national 
guidelines) and five confounders in subset of patients with diabetes. Finally, a 
potential interaction between HbA1c and depressive symptoms were explored 
using the ANOVA test. In the event of a significant interaction, the results were 
further analysed using forest plots and sub-group analysis as described 
previously.  
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7.3 Results 
7.3.1 Clinical Outcomes 
Electronic data linkage between primary care disease registers and hospital 
discharge and mortality records was successful for 99.4% (124414/125143) of 
patients. Among the patients who had recorded results of depression screening, 
19.9% (7080/35537) were identified as screen positives based on HADS-D ≥8. New 
antidepressants were initiated for 2.4% (696/28457) of patients with HADS-D 
negative and 8.1% (572/7080) of patients with HADS-D positive within six months 
of depression screening, while the overall rate of new antidepressant prescribing 
was 3.5% (1268/35537) of screened patients. 6.3% (4989/78936) of the 
unscreened population were started on new antidepressants during the 
observation period (with no clear explanation recorded) (see Figure 7-1).   
Figure 7-1 Results of Depression Screening and Antidepressant Initiation in DepChron(226) 
 
Table 7-1 shows that patients who were screened were more likely to be female, 
deprived, younger and less likely to have cardiometabolic multi-morbidity. The 
recording of biomarker values in the unscreened population was very poor across 
the 4 biomarkers with, for example, 59.5% missing values for BMI recordings.
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Table 7-1 Comparison between screened and unscreened patients in DepChron  
 Categories Depression Screened 
N= 35537 
Unscreened 
N=78936 
p-value 
Age(years) - mean (SD)  69.0 (11.9) 67.0 (14.3) <0.001 
White ethnicity (%)  30693 (92.4) 53343 (90.3) <0.001 
Male sex (%)  20658 (58.2) 42727 (54.2) <0.001 
Deprived socio-economic status SIMD deciles<=5 (%)  22726 (65.3) 51686 (67.4) <0.001 
Number of cardiometabolic conditions- (%) 
 
One 
Two 
Three 
          27356 (77.0) 
7410 (20.9) 
771 (2.2) 
           65417 (82.9) 
12265 (15.5) 
1254 (1.6) 
 
 
<0.001 
Antidepressant initiation (%)  1268 (3.5) 4989 (6.3) <0.001 
Systolic Blood Pressure-(%) 
 
130-139 mm Hg Reference 
120-129 mm Hg 
80-119 mm Hg 
140-159 mm Hg 
160-240 mm Hg 
Not Available (NA) 
8389 (23.6) 
6864 (19.3) 
5711 (16.0) 
8624 (24.2) 
2514 (7.0) 
3435 (9.6) 
13315 (16.8) 
10818 (13.7) 
9258 (11.7) 
15969 (20.2) 
5778 (7.3) 
23802 (30.1) 
 
<0.001 
Diastolic Blood Pressure- (%) 
 
85-89 mm Hg Reference 
80-84 mm Hg 
40-79 mm Hg 
90-99 mm Hg 
100-130 mm Hg 
NA 
            1909 (5.3) 
7070 (19.8) 
20585 (57.9) 
1981 (5.5) 
562 (1.5) 
3430 (9.6) 
4219 (5.3) 
13088 (16.5) 
31724 (40.1) 
4450 (5.6) 
1649 (2.0) 
23806 (30.1) 
 
<0.001 
Body Mass Index (%) 
 
18.5-25 kg/m2 Reference 
15-18.5 kg/m2 
25-30 kg/m2 
30-55 kg/m2 
NA 
           7349 (20.6) 
340 (0.9) 
11379 (32.0) 
10974 (30.8) 
5495 (15.4) 
7904 (10.1) 
627 (0.8) 
11505 (14.5) 
11882 (15.0) 
47018 (59.5) 
 
<0.001 
Total Cholesterol in mmol/l (%) 
 
2-5 mmol/l Reference 
5-10 mmol/l 
NA 
25134 (70.7) 
6093 (17.1) 
4310 (12.1) 
34027 (43.1) 
12264 (15.5) 
32645 (41.3) 
 
<0.001 
Composite major adverse cardiac outcome (MACE) (%)  3939 (11) 10990 (13.9) <0.001 
All-cause mortality (%)  5021 (14.1) 13569 (17.2) <0.001 
All-cause hospital admissions (%)  23717 (66.7) 52089 (66.0) 0.01 
SIMD=Scottish Index of Multiple Deprivation. SD= Standard Deviation. MI=Myocardial Infarction. MACE=Cardiovascular death or admission due to MI/stroke/heart failure. NA=Not available 
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The unscreened group of patients were more likely to die of any cause and more 
likely to have experienced the composite adverse cardiovascular outcome. 
Although the rate of all-cause first hospital admission was statistically different, 
clinically the difference in rate was negligible between the screened and 
unscreened groups of patients. As shown in Table 7-1, the number of patients 
within the screened group who suffered from adverse clinical outcomes during 4 
year follow-up were as follows: 5021 (14.1%) all-cause mortality, 23717 (66.7%) 
all-cause general hospital admission, and 3939 (11%) composite major adverse 
cardiovascular outcome-(cardiovascular death/ admission due to 
MI/stroke/heart failure). 
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7.3.2 Statistical Analysis- AI Score 
7.3.2.1 Univariable Analysis with AI score and depressive symptoms 
Table 7-2 shows that all 4 AI scores and the presence of depressive symptoms 
had a significant association with the 3 clinical outcomes in univariable analysis. 
The estimated elevated risk of all-cause death was 36% higher, all-cause hospital 
admission was 29% higher and MACE was 23% higher at 4 years with the presence 
of depressive symptoms (HADS-D≥8), when compared to patients with no 
depressive symptoms at baseline.  
The AI score calculated from 4 different statistical methods were observed to 
have different types of associations with the 3 clinical outcomes, in their 
respective univariable models. The method 1 AI scores (clinical cut-off method) 
had an inverse linear association with the 3 clinical outcomes, while the other 3 
AI scores had a direct linear association with the clinical outcomes. DepChron 
patients had a 19% lower risk of death at 4 years with each unit increase in the 
AI score calculated from method 1- clinical cut off method (mean 0.85, median 
1.0) at baseline. Similarly, the risk of all-cause hospital admission and composite 
major cardiovascular outcome was lower with increasing AI score (method 1) at 
baseline. On the contrary, the risk of the 3 clinical outcomes was associated 
with increases in AI scores calculated from the other 3 methods (methods 2-4) at 
baseline. The effect sizes were largest for method 3 (10th/90th percentile cut-
off method) with 18% higher risk of death, 3% higher risk of all-cause hospital 
admission and 12% higher risk of composite major adverse cardiovascular 
outcome with each unit increase in AI score. The confidence intervals were the 
narrowest for method 4 AI score- the z-score method. The effect sizes in the 
first 3 methods were not directly comparable to method 4 as the distribution of 
AI score was different for method 4; the range for methods 2 and 3 AI scores was 
0 to 4, while the range of method 4 AI was 0.2 to 12.4. In general, the effects 
sizes observed for AI scores were lower than that of depressive symptoms (see 
Table 7-2).   
Finally, comparing the concordance statistics (C-statistics) for the 4 AI scores, 
the z-score method had the best C-statistic values. However, the differences 
between the C-statistic values of the 4 AI score methods were very small and 
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unlikely to be statistically significant based on the values of corresponding 
standard errors.  
Next, the possibility of a non-linear association between AI score and the 3 
clinical outcomes was checked by entering a quadratic term for AI score in the 
respective regression models. There was no significant non-linear relationship 
between the 4 AI scores and the 3 clinical outcomes in their respective Cox 
regression models. The results in detail were as follows: The quadratic term for 
AI score (method 1) did not have a significant association with the risk of all-
cause death (p-value = 0.26), all-cause general hospital admission (p-value = 
0.67) or composite major adverse cardiovascular outcome (p-value = 0.31). The 
quadratic term for AI score (method 2) did not have a significant association 
with the risk of all-cause death (p-value = 0.99), all-cause general hospital 
admission (p-value = 0.35) or composite major adverse cardiovascular outcome 
(p-value = 0.54). The quadratic term for AI score (method 3) did not have a 
significant association with the risk of all-cause death (p-value = 0.99), all-cause 
general hospital admission (p-value = 0.79) or composite major adverse 
cardiovascular outcome (p-value = 0.23). The quadratic term for AI score 
(method 4) did not have a significant association with the risk of all-cause death 
(p-value = 0.21), all-cause general hospital admission (p-value = 0.19) or 
composite major adverse cardiovascular outcome (p-value = 0.98). 
 
 
 
 
 
 
Key Findings (AI score-Univariable Analysis):  
 Method 1 AI score had an inverse linear association with the risk of 
3 clinical outcomes. 
 Methods 2-4 AI score had direct linear association with the risk of 
3 clinical outcomes (HR for method 4 AI score=1.08). 
 Presence of depressive symptoms was associated with a higher 
risk of 3 adverse clinical outcomes. 
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Table 7-2 Univariable Cox's proportional hazards for the three clinical outcomes with AI score and presence of depressive symptoms as predictors. 
Clinical Outcomes  AI score- 
Method 1-
clinical cut-off 
(Range 0-4) 
Available 
N=25375 
 
AI score-Method 
2- 25th/75th 
percentile 
(Range 0-4) 
Available 
N=25375 
AI score-Method 
3- 10th/90th 
percentile 
(Range 0-4) 
Available 
N=25375 
AI score – 
Method 4- z 
score method 
(Range 0.2-
12.4) 
Available 
N=25375 
Presence of 
depressive 
symptoms 
(HADS-D≥8) 
(Yes against No) 
All-cause death      
 
HR 0.81 1.12 1.18 1.08 1.36 
95% CI 0.78 to 0.85 1.09 to 1.16 1.13 to 1.22 1.06 to 1.11 1.27 to 1.45 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 
C statistics- (SE) 0.543 (0.004) 0.536 (0.005) 0.537 (0.004) 0.543 (0.005) 0.527 (0.003) 
All-cause hospital 
admission  
HR 0.95 1.02 1.03 1.02 1.29 
95% CI 0.93 to 0.96 1.01 to 1.04 1.01 to 1.05 1.01 to 1.03 1.25 to 1.33 
p-value <0.001 <0.001 <0.001 <0.001 <0.001 
C-statistics (SE) 0.512 (0.002) 0.509 (0.002) 0.510 (0.002) 0.513 (0.002) 0.523 (0.002) 
Composite major 
adverse cardiovascular 
outcome (MACE) 
 
HR 0.95 1.08 1.12 1.07 1.23 
95% CI 0.91 to 0.99 1.05 to 1.12 1.07 to 1.17 1.04 to 1.10 1.14 to 1.32 
p-value 0.01 <0.001 <0.001 <0.001 <0.001 
C-statistics (SE) 0.511 (0.005) 0.526 (0.005) 0.527 (0.005) 0.534 (0.005) 0.518 (0.004) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to 
MI/stroke/heart failure. 
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7.3.2.2 Kaplan-Meier plots for AI score, depressive symptoms and clinical 
outcomes 
The absolute event rate for all-cause mortality (p-value <0.001) and major 
adverse cardiovascular event (cardiovascular death or admission due to 
MI/stroke/HF) (p-value <0.001) was significantly higher for participants with 
raised AI score- the z-score method (defined as >3.85; 75th percentile value) at 
baseline as compared to participants without raised AI score (p-value < 0.001). 
Figure 7-2 shows that nearly 17% of patients with raised AI score at baseline 
were dead and 14% had experienced at least one major adverse cardiovascular 
event at 4 years as compared to approximately 13% and 12% event rates 
observed for patients without a raised AI score at baseline respectively. 
Figure 7-2 Kaplan-Meier plot comparing clinical outcomes for different AI scores. 
 
Legend: Raised AI score= defined as >3.85 (75th percentile value). AI score calculated by the z-score 
method.  
Figure 7-3 shows a similar relationship between the presence of depressive 
symptoms and clinical outcomes, with a higher rate of adverse clinical outcomes 
observed for patients with the presence of depressive symptoms at baseline (p-
value <0.001 for both outcomes). 
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Figure 7-3 Kaplan-Meier plot comparing clinical outcomes for presence and absence of 
depressive symptoms. 
 
Legend: Depressive symptoms defined as HADS-D≥8 
7.3.2.3 The final Model for three clinical outcomes using AI score and 
depressive symptoms 
The z-score method AI score was chosen for the final models of risk prediction 
for the three clinical outcomes based on its marginally better C-statistics values 
and narrower confidence intervals. The final model consisted of both AI score 
and presence of depressive symptoms as predictors, along with all the other 
potential confounding factors added together (see Table 7-3). Patients with 
depressive symptoms at baseline were 46% more likely to die at the end of 4 
years, while one unit increase in AI score (equals to 1 SD higher or lower 
biomarker value than the sample mean) was associated with 12% higher risk of 
all-cause death. Increase in age by one year was associated with 8% higher risk 
of death. The risk of death was higher for patients with multiple cardiovascular 
co-morbidities and lower for female sex, affluent socio-economic class and those 
who were initiated on antidepressants within 6 months of depression screening. 
In the risk prediction of all-cause hospital admission, the effect sizes of AI score 
and depressive symptoms were comparatively smaller. Sex was no longer a 
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significant predictor for hospital admission and patients who were initiated on 
antidepressants were more likely to get admitted during four years follow-up, 
which was contrary to the results observed for all-cause death.  
Finally, in the risk prediction of major adverse cardiovascular outcomes, the 
presence of depressive symptoms was associated with a 21% higher risk while 
one unit in AI score was associated with a 10% higher risk of the event at 4 years. 
Notably, the presence of two cardiovascular co-morbidities was associated with 
89% higher risk while presence of all three cardiovascular co-morbidities was 
associated with approximately three times higher risk of an event, compared to 
having only one of the three cardiometabolic diseases at baseline. Initiation of 
antidepressants within six months of depression screening did not have a 
significant impact on the event rate of major adverse cardiovascular outcome at 
four years. The C-statistic was highest in value for all-cause death which 
suggests the best predictability of the model out of the three clinical outcomes 
under study.   
 
 
Key Findings (AI score-Multivariable Analysis):  
 Method 4 AI score had a direct linear association 
with the risk of 3 adverse clinical outcomes. 
 Presence of depressive symptoms was associated 
with higher risk of the 3 adverse clinical outcomes. 
 Results were adjusted for the effect of 5 potential 
confounders and the trends were unchanged. 
 
195 
 
Table 7-3 Final multivariable Cox's proportional hazards for the three clinical outcomes with AI score and presence of depressive symptoms as predictors. 
Available N=25375.  
 All-cause Death 
HR with 95% CI 
All-cause Hospital Admissions 
HR with 95% CI 
Composite major adverse 
cardiovascular outcome (MACE) 
HR with 95% CI 
AI score (z-score method) 1.12 (1.10 to 1.15) 1.03 (1.02 to 1.04) 1.10 (1.07 to 1.13) 
Presence of depressive 
symptoms    (HADS-D≥8) 
1.46 (1.35 to 1.58) 1.28 (1.23 to 1.32) 1.21 (1.11 to 1.33) 
Age 1.08 (1.076 to 1.085) 1.025 (1.023 to 1.026) 1.054 (1.050 to 1.058) 
Sex-female 0.71 (0.67 to 0.77) 1.00 (0.97 to 1.03) 0.83 (0.77 to 0.89) 
Socio-economic status-affluent 
group 
0.73 (0.68 to 0.78) 0.90 (0.87 to 0.93) 0.80 (0.74 to 0.87) 
Number of cardiovascular co-
morbidities 
2 vs. 1 
 
 
1.32 (1.23 to 1.42) 
 
 
1.25 (1.20 to 1.29) 
 
 
1.89 (1.75 to 2.04) 
3 vs. 1 1.95 (1.68 to 2.26) 1.56 (1.43 to 1.70) 3.06 (2.63 to 3.57) 
Initiation of anti-depressants- 
treated vs. non-treated 
0.76 (0.62 to 0.93) 1.35 (1.25 to 1.46) 0.84 (0.68 to 1.04) 
Concordance (SE) 0.720 (0.005) 0.595 (0.002) 0.692 (0.005) 
Confounders: Age, Sex, Socio-economic status, Number of cardiovascular co-morbidity, Initiation of anti-depressants within 6 months of depression screening. 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to MI/stroke/heart failure. 
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7.3.2.4 Interaction analysis- AI score and depressive symptoms 
Table 7-4 shows that there was no statistically significant interaction between 
the AI scores and depressive symptoms (HADS-D≥8) in risk prediction of the 3 
clinical outcomes under study. The results are presented as p-values for 
interaction analysis based on ANOVA and none of the p-values were statistically 
significant.   
Table 7-4 Interaction Analysis for three clinical outcomes with AI score and presence of 
depressive symptoms as predictors in DepChron.  
 AI score- Method 
1-clinical cut-off 
(Range 0-4) 
AI score-Method 
2- 25th/75th 
percentile 
(Range 0-4) 
AI score-Method 
3- 10th/90th 
percentile 
(Range 0-4) 
AI score – 
Method 4- z 
score method 
(Range 0.2-12.4) 
All-cause death p-value = 0.11 p-value = 0.89 p-value = 0.86 p-value = 0.21 
All-cause hospital 
admission 
p-value = 0.24 p-value = 0.07 p-value = 0.23 p-value = 0.26 
Composite major 
adverse 
cardiovascular 
outcome  
p-value = 0.18 p-value = 0.93 p-value = 0.76 p-value = 0.82 
Confounders: Age, Sex, Socio-economic status, Number of cardiovascular co-morbidity, Initiation of anti-
depressants within 6 months of depression screening. 
 
 
 
 
 
 
 
 
 
 
Key Findings (AI score-Interaction Analysis):  
 No significant statistical interaction between 
AI score (all 4 methods) and depressive 
symptoms in risk prediction of the 3 adverse 
clinical outcomes.  
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7.3.3 Statistical Analysis – Individual Biomarkers 
7.3.3.1 Individual Biomarkers as continuous measures (univariable analysis) 
Table 7-5 shows the results of univariable survival analyses with the individual 
biomarkers as predictors for the 3 adverse clinical outcomes. DBP, BMI and total 
cholesterol had a significant association with all of the three clinical outcomes 
with the respective HR values of less than 1.0 suggesting that lower values of 
these biomarkers was associated with higher risk of adverse clinical outcomes. In 
other words, these biomarkers had an inverse linear association with the risk of 
adverse clinical outcomes. The exception was the association between SBP and 
MACE. The HR for MACE was higher than 1.0 for SBP suggesting lower risk of 
MACE with lower SBP values. The continuous measure of SBP did not have a 
significant association with all-cause death and all-cause hospital admissions.   
7.3.3.2 Individual Biomarkers as categorical measures (univariable analysis) 
The association between the clinical outcomes and individual biomarkers was 
further analysed using clinical categories, as described in the methods (see 
Table 7-6).  DBP, BMI and total cholesterol were found to have an inverse linear 
association with the risk of 3 adverse clinical outcomes. For DBP and BMI, the 
highest risk for the 3 clinical outcomes at 4 years was observed with patients 
with the lowest values of DBP and BMI at baseline. Similarly, the risk of the 3 
adverse clinical outcomes was significantly lower in patients with high total 
cholesterol (5-10) values at baseline. SBP had a significant non-linear association 
with all 3 adverse clinical outcomes with a higher risk in patients with the two 
extremes of SBP at baseline- 80-119 and 160-240. Thus, the nature of the 
observed relationship between the individual peripheral biomarkers and adverse 
clinical outcomes was different. 
 
 
 
 
Key Findings (Individual Biomarkers-Univariable Analysis):  
 DBP, BMI and total cholesterol had an inverse linear relationship 
with the risk of the 3 adverse clinical outcomes.  
 SBP had a non-linear relationship with the risk of the 3 adverse 
clinical outcomes, with the risk higher in the two extremes (very 
high and low) of SBP categories.  
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Table 7-5 Univariable Cox's proportional hazards for the three clinical outcomes with the four individual biomarkers (continuous) as predictors. 
Clinical Outcomes  SBP Range: 90 to 240 DBP Range: 50 to 
130 
Total Cholesterol                
Range: 15 to 55 
BMI Range: 2 to 
10 
All-cause death     Number of 
events = 3628 
 
HR 1.001 0.975 0.939 0.860 
95% CI 0.999 to 1.003 0.972 to 0.979 0.932 to 0.945 0.831 to 0.890 
p-value 0.29 <0.001 <0.001 <0.001 
C statistics- 
(SE) 
0.503 (0.005) 0.565 (0.005) 0.594 (0.005) 0.546 (0.005) 
All-cause hospital admission 
Number of events = 17261 
HR 1.00 0.990 0.985 0.971 
95% CI 0.99 to 1.01 0.988 to 0.991 0.983 to 0.988 0.956 to 0.985 
p-value 0.66 <0.001 <0.001 <0.001 
C-statistics (SE) 0.497 (0.002) 0.529 (0.002) 0.525 (0.002) 0.512 (0.002) 
Composite major adverse 
cardiovascular outcome 
Number of events = 2939 
HR 1.004 0.984 0.971 0.960 
95% CI 1.002 to 1.006 0.981 to 0.988 0.964 to 0.977 0.926 to 0.995 
p-value <0.001 <0.001 <0.001 0.027 
C-statistics (SE) 0.515 (0.005) 0.543 (0.005) 0.545 (0.005) 0.518 (0.005) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to 
MI/stroke/heart failure. 
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Table 7-6 Univariable Cox's proportional hazards for the three clinical outcomes with the four individual biomarkers (categorical) as predictors. 
 
  All-cause Death  
Number of events = 
3628 
HR with 95% CI 
All-cause Hospital 
Admissions               
Number of events = 17261 
HR with 95% CI 
Composite major adverse 
cardiovascular outcome Number 
of events = 2939 
HR with 95% CI 
Systolic Blood Pressure in 
mm Hg 
 
80-119 1.21 (1.11 to 1.32) 1.10 (1.06 to 1.15) 1.15 (1.04 to 1.27) 
120-129 1.01 (0.92 to 1.10) 1.04 (1.00 to 1.08) 0.99 (0.90 to 1.09) 
130-139 1 1 1 
140-159 1.09 (1.00 to 1.18) 1.04 (1.01 to 1.08) 1.10 (1.00 to 1.20) 
160-240 1.30 (1.16 to 1.46) 1.12 (1.06 to 1.18) 1.43  (1.26 to 1.61) 
Diastolic Blood Pressure in 
mm Hg 
 
40-79 1.45 (1.26 to 1.67) 1.22 (1.15 to 1.30) 1.24 (1.07 to 1.44) 
80-84 1.10 (0.94 to 1.27) 1.08 (1.02 to 1.16) 1.05 (0.89 to 1.23) 
85-89 1 1 1 
90-99 0.80 (0.66 to 0.98) 0.95 (0.87 to 1.03) 0.83 (0.67 to 1.02) 
100-130 0.86 (0.64 to 1.16) 1.01 (0.89 to 1.14) 1.03 (0.77 to 1.39) 
BMI in kg/m2 15-18.5 2.13 (1.78 to 2.55) 1.30 (1.15 to 1.47) 1.37 (1.05 to 1.79) 
18.5-25 1 1 1 
25-30 0.63 (0.58 to 0.67) 0.87 (0.84 to 0.90) 0.78 (0.72 to 0.85) 
30-55 0.48 (0.44 to 0.52) 0.81 (0.78 to 0.83) 0.68 (0.62 to 0.74) 
Total Cholesterol in mmol/l 2-5 1 1 1 
5-10 0.79 (0.73 to 0.86) 0.96 (0.93 to 0.99) 0.98 (0.90 to 1.06) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to 
MI/stroke/heart failure. 
Significant results in bold. 
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7.3.3.3 Kaplan Meier Plots for peripheral biomarkers and clinical outcomes 
Kaplan-Meier plots were constructed for SBP, BMI and total cholesterol 
categories for two clinical outcomes- all-cause mortality and MACE 
(cardiovascular death or admission due to MI/stroke/HF).  
On comparing the event rate for the five SBP categories, patients with a raised 
SBP (160-240) at baseline had the highest event rate for both adverse clinical 
outcomes (p-value <0.001). The elevated event rate observed for patients with 
high SBP was more pronounced for major adverse cardiovascular event than for 
all-cause death (see Figure 7-4). 
Figure 7-4 Kaplan-Meier plot comparing clinical outcomes based on SBP values at baseline. 
 
Figure 7-5 shows a significant inverse linear relationship between BMI values at 
baseline and risk of all-cause death and major adverse cardiovascular event at 4 
years in DepChron patients (p-value <0.001). Notably, patients with low BMI (15 
to 18.5) had a substantially higher rate of mortality (approximately 40%).  
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Figure 7-5 Kaplan-Meier plot comparing clinical outcomes based on BMI values at baseline. 
 
Finally, Figure 7-6 shows the effects of raised total cholesterol at baseline on 
the two clinical outcomes. DepChron patients with low total cholesterol (< 5.0 
mmol/l) were more likely to die at the end of 4 years (p-value < 0.001). 
However, there was no significant difference in the two cholesterol categories as 
for major adverse cardiovascular event rate (p-value = 0.83).  
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Figure 7-6 Kaplan-Meier plot comparing clinical outcomes based on total cholesterol at 
baseline. 
 
 
 
 
7.3.3.4 Final model of risk prediction for three clinical outcomes using 
individual biomarkers and depressive symptoms 
Table 7-7 shows the results from multivariable analyses after adding four 
biomarkers, depressive symptoms and five potential confounders. The five 
confounders were: age, sex, socio-economic status, number of cardiovascular 
co-morbidities and initiation of antidepressants-within 6 months of depression 
screening. The non-linear association of SBP categories with MACE and with all-
cause hospital admissions was significant, after adjusting for the confounders. 
The association of the DBP categories with the 3 adverse clinical outcomes was 
no longer statistically significant, after adjusting for confounders. The BMI 
categories were observed to have an inverse linear association with the 3 
adverse clinical outcomes, in multivariable analyses.  
On the contrary, the association between total cholesterol at baseline and the 
three adverse clinical outcomes at four years was completely changed in 
multivariable analysis. High cholesterol was associated with significantly higher 
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risk of major adverse cardiovascular outcome and all-cause hospital admission in 
multivariable analysis. This was changed from the lower risk of all-cause hospital 
admission and non-significant association with major adverse cardiovascular 
outcome observed in univariable analysis. 
 
 
Key Findings (Individual Biomarkers- Multivariable Analysis):  
 SBP categories had a linear association with the risk of MACE (HR 
1.28) and all-cause hospital admissions (HR 1.07), while the risk 
of all-cause death was significantly lower in the low SBP 
category.  
 DBP categories did not have a significant association with any of 
the 3 adverse clinical outcomes.   
 BMI had an inverse linear association with the 3 adverse clinical 
outcomes, with higher observed risk in low BMI categories.   
 Total cholesterol was found to have a higher risk of MACE and 
all-cause hospital admissions in the high category as compare to 
low total cholesterol.   
 These results were adjusted for 5 confounders and for the 
presence of depressive symptoms and the trends were 
unchanged.    
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Table 7-7 Final multivariable Cox's proportional hazards for the three clinical outcomes with four peripheral biomarkers as predictors. Available N=25375 
  All-cause Death    
3594 events 
HR with 95% CI 
All-cause Hospital Admissions                  
17041 events 
HR with 95% CI  
Composite major adverse 
cardiovascular outcome (MACE) 2920 
events HR with 95% CI 
Systolic Blood Pressure in mm Hg 80-119 1.18 (1.06 to 1.30) 1.11 (1.06 to 1.16) 1.15 (1.03 to 1.29) 
120-129 1.00 (0.90 to 1.10) 1.05 (1.01 to 1.10) 1.00 (0.90 to 1.12) 
130-139 1 1 1 
140-159 1.05 (0.96 to 1.15) 1.04 (0.99 to 1.08) 1.07 (0.96 to 1.18) 
160-240 1.12 (0.97 to 1.28) 1.07 (1.00 to 1.14) 1.28 (1.11 to 1.49) 
Diastolic Blood Pressure in mm Hg 40-79 0.95 (0.80 to 1.12) 1.00 (0.93 to 1.07) 0.94 (0.78-1.12) 
80-84 0.93 (0.78 to 1.10) 0.99 (0.92 to 1.06) 0.93 (0.77-1.12) 
85-89 1 1 1 
90-99 0.83 (0.66 to 1.05) 0.93 (0.84 to 1.02) 0.90 (0.71-1.14) 
100-130 1.21 (0.86 to 1.68) 1.01 (0.87 to 1.16) 1.15 (0.82-1.62) 
BMI in kg/m2 15-18.5 1.99 (1.63 to 2.42) 1.21 (1.06 to 1.39) 1.36 (1.02 to 1.82) 
18.5-25 1 1 1 
25-30 0.71 (0.65 to 0.76) 0.92 (0.88 to 0.96) 0.83 (0.76 to 0.91) 
30-55 0.69 (0.63 to 0.75) 0.92 (0.88 to 0.96) 0.83 (0.75 to 0.92) 
Total Cholesterol in mmol/l 2-5 1 1 1 
5-10 1.01 (0.92 to 1.11) 1.05 (1.01 to 1.09) 1.21 (1.10 to 1.33) 
Presence of depressive symptoms (HADS-D≥8)  1.45 (1.34 to 1.57) 1.28 (1.23 to 1.32) 1.22 (1.11 to 1.33) 
Age  1.07 (1.07 to 1.07) 1.02 (1.02 to 1.02) 1.05 (1.04 to 1.05) 
Sex-female  0.72 (0.67 to 0.77) 1.00 (0.97 to 1.03) 0.81 (0.75 to 0.88) 
Socio-economic status-affluent group  0.71 (0.66 to 0.76) 0.90 (0.87 to 0.93) 0.79 (0.73 to 0.86) 
Number of cardiovascular co-morbidities (vs. 1) 
 
2 1.38 (1.29 to 1.49) 1.26 (1.22 to 1.31) 1.95 (1.81 to 2.11) 
3 2.13 (1.83 to 2.48) 1.60 (1.47 to 1.75) 3.22 (2.76 to 3.76) 
Initiation of anti-depressants- treated vs. non-treated  0.75 (0.61 to 0.92) 1.35 (1.25 to 1.45) 0.84 (0.68 to 1.04) 
Concordance (SE)  0.724 (0.005) 0.596 (0.002) 0.692 (0.005) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to MI/stroke/heart failure.  
Significant results in bold. 
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7.3.3.5 Interaction analysis- individual biomarkers and depressive 
symptoms 
In the final phase of analysis of individual biomarkers, the presence of a 
statistical interaction between depressive symptoms (HADS-D≥8) and 3 
biomarkers found to have a significant association with clinical outcomes in 
multivariable analysis (SBP, BMI and total cholesterol) was checked. The results 
are presented in Table 7-8 as p-values for a statistically significant interaction 
tested using the ANOVA test.  
Table 7-8 Interaction Analysis for three clinical outcomes with individual biomarkers and 
presence of depressive symptoms as predictors. 
 SBP Categories BMI Categories Total Cholesterol 
Categories 
All-cause death p-value = 0.11 p-value = 0.70 p-value = 0.05 
All-cause hospital 
admission 
p-value = 0.07 p-value = 0.35 p-value = 0.51 
Composite major 
adverse 
cardiovascular 
outcome (MACE) 
p-value = 0.03 p-value = 0.06 p-value = 0.97 
 
In the risk prediction of major adverse cardiovascular outcome, the interaction 
between SBP categories and the presence of depressive symptoms was 
statistically significant (p-value=0.03).  The observed statistical interaction 
between SBP categories and depressive symptoms was further analysed in 
greater detail. Patients were sub-divided based on various combinations of the 
two extremes of SBP categories and the presence or absence of depressive 
symptoms at baseline. Patients with low SBP (80-119) only, with very high SBP 
(160-240) only and depressive symptoms only at baseline had 10%, 19% and 17% 
higher risk respectively of a major adverse cardiovascular event as compared to 
those without extremes of SBP and no depressive symptoms. In comparison, 
patients with both low SBP and depressive symptoms at baseline had 36% higher 
risk while patients with both very high SBP and depressive symptoms had the 
highest increased risk of 83% as compared to those in the reference SBP group 
without depressive symptoms (see Figure 7-7).  
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Figure 7-7 Forest plot showing interaction between depressive symptoms and extremes of 
systolic blood pressure with the risk of first major adverse cardiovascular event (289).  
 
In the multivariable sub-group analysis of the five SBP categories, a non-linear 
trend was observed in the association between presence of depressive symptoms 
and risk prediction of a major adverse cardiovascular outcome at four years (see 
Table 7-9).    There was no evidence of an association between the presence of 
depressive symptoms and adjusted risk of major adverse cardiovascular outcome 
for the sub-group of patients with reference SBP (130-139) at baseline. The 
presence of depressive symptoms was associated with significantly higher risk of 
major adverse cardiovascular outcome for patients in all other baseline SBP 
categories. Patients with very high SBP and concurrent depressive symptoms had 
the highest event rate of 17.7%; moreover the change in the adjusted risk with 
the addition of depressive symptoms was highest for the sub-group of patients 
with very high SBP at 55% (see Table 7-9). 
 
 
 
 
 
Key Findings (Individual biomarkers-Interaction Analysis):  
 SBP and the presence of depressive symptoms were found to 
have a statistical significant interaction in risk prediction of 
MACE.  
 Presence of depressive symptoms compounded the risk of 
MACE, especially in patients with very high SBP (160-240).  
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Table 7-9 Presence of depressive symptoms and the risk of first major adverse 
cardiovascular outcome (MACE) based on SBP categories.  
 Systolic Blood Pressure Categories 
 Low 
80-119 
n=5711 
Tightly 
controlled 
120-129 
n=6864 
Reference 
130-139 
n=8389 
High 
140-159 
n=8624 
Very High 
160-240 
n=2514 
Not Depressed  
Event Rate 
492/4376  
(11.2%) 
555/5464 
(10.1%) 
730/6806 
(10.7%) 
776/7028 
(11.0%) 
278/2001 
(13.8%) 
Depressed   
(HADS-D≥8) 
Event Rate 
192/1335 
(14.3%) 
171/1400 
(12.2%) 
161/1583 
(10.1%) 
226/1596 
(14.1%) 
91/513 
(17.7%) 
HR with 95% CI 
Depressed vs.  
Not Depressed 
(*adjusted)  
1.23 
(1.01 to 
1.49) 
1.34 
(1.10 to 
1.63) 
0.94 
(0.77 to 
1.14) 
1.29 
(1.08 to 
1.53) 
1.55 
(1.18 to 
2.03) 
p-value <0.001 <0.001 0.54 <0.001 <0.001 
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7.3.4 Sensitivity Analysis for subset of patients with diabetes 
7.3.4.1 Analysis with AI score for subset of patients with diabetes 
Sensitivity analysis was performed for the subset of patients with diabetes 
(N=18,453). In patients with diabetes, there were 2412 patients who died 
(13.0%), 11,745 patients (63.6%) had at least 1 hospital admission and 1808 
patients (9.7%) suffered from a major adverse cardiovascular outcome 
(cardiovascular death/ admission due to MI/stroke/heart failure). 3580 (19.4%) 
were found to have depressive symptoms at baseline, based on HADS-D≥8. The z-
score method of calculating AI score was used for sensitivity analysis. The range 
of AI score (z-score method) was 0.5 to 12.93; while the mean was 3.85 and 
median was 3.59.  
Table 7-10 shows that AI score had a significant association with all of the 3 
adverse clinical outcomes in the subset of patients with diabetes, after adjusting 
for depressive symptoms and the 5 other previously described potential 
confounders. The effect sizes observed for AI score in the final survival models 
for the diabetes subset were very similar to the ones observed for the entire 
sample. The effect sizes for depressive symptoms were comparatively smaller in 
the diabetes sample to those observed in the whole sample.  
The AI score did not have a significant interaction with presence of depressive 
symptoms in risk prediction of all-cause mortality (p-value = 0.82), all-cause 
hospital admission (p-value = 0.68) or composite major adverse cardiovascular 
outcome (p-value = 0.31), using the ANOVA test for interaction analysis. 
Key Findings (AI score analysis-Diabetes Subset):  
 AI score had a significant association with the 3 adverse clinical 
outcomes in the diabetes subset, with similar effects sizes to 
the ones observed in the total sample.  
 No statistically significant interaction observed between AI 
score and depressive symptoms in the risk prediction of any of 
the 3 adverse clinical outcomes, in the diabetes subset.  
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Table 7-10 Final multivariable Cox’s proportional hazards for the three clinical outcomes in diabetes subset with AI score and depressive symptoms as 
predictors.  
 All-cause Death  number of 
events=1498   
HR with 95% CI 
All-cause Hospital Admissions    
number of events=6996 
HR with 95% CI 
Composite major adverse 
cardiovascular outcome (MACE) 
number of events=1184 
HR with 95% CI 
AI score (z-score method) 1.12 (1.08 to 1.15) 1.04 (1.02 to 1.05) 1.12 (1.08 to 1.16) 
Presence of depressive 
symptoms    (HADS-D≥8) 
1.38 (1.22 to 1.56) 1.22 (1.15 to 1.30) 1.18 (1.03 to 1.36) 
Age 1.07 (1.06 to 1.07) 1.02 (1.02 to 1.02) 1.04 (1.03 to 1.05) 
Sex-female 0.77 (0.69 to 0.85) 0.99 (0.95 to 1.04) 0.87 (0.77 to 0.98) 
Socio-economic status-affluent 
group 
0.72 (0.64 to 0.80) 0.88 (0.84 to 0.93) 0.77 (0.68 to 0.88) 
Number of cardiovascular co-
morbidities 
2 vs. 1 
 
 
1.37 (1.22 to 1.53) 
 
 
1.39 (1.32 to 1.47) 
 
 
2.79 (2.43 to 3.20) 
3 vs. 1 2.07 (1.74 to 2.46) 1.79 (1.62 to 1.97) 4.72 (3.90 to 5.72) 
Initiation of anti-depressants- 
treated vs. non-treated 
0.88 (0.66 to 1.18) 1.36 (1.21 to 1.52) 0.83 (0.59 to 1.16) 
Concordance (SE) 0.726 (0.007) 0.613 (0.004) 0.732 (0.008) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to 
MI/stroke/heart failure.  
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7.3.4.2 Sensitivity Analysis with Individual Biomarkers (HbA1c) for subset of 
patients with diabetes 
The final multivariable Cox regression models for the 3 adverse clinical outcomes 
were also analysed using the five individual biomarkers, depressive symptoms 
and the five confounders as described before (see Table 7-11). High HbA1c (7.5 
to 18 DCCT) values at baseline were associated with a 33% higher risk of 
mortality, 9% higher risk of hospital admission and 53% higher risk of composite 
major adverse cardiovascular outcome over 4 years,  as compared to reference 
HbA1c (6.5 to 7.4 DCCT) in the subset of patients with diabetes. There was no 
statistically significant difference observed in the risk of the 3 adverse clinical 
outcomes between the reference HbA1c category and low HbA1c (3 to 6.4 
DCCT).
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Table 7-11 Multivariable Cox's proportional hazards for the three clinical outcomes with individual peripheral biomarkers (categorical) and depressive 
symptoms as predictors in diabetes subset.  
 
  All-cause Death 1512 
events HR with 95% CI 
All-cause Hospital Admissions                    
7040 events HR with 95% CI  
Composite major adverse cardiovascular 
outcome (MACE) 1199 events HR with 
95% CI 
Systolic Blood Pressure in mm Hg 80-119 1.13 (0.96 to 1.33) 1.09 (1.01 to 1.18) 1.20 (1.00 to 1.44) 
120-129 1.03 (0.88 to 1.20) 1.06 (0.99 to 1.14) 1.01 (0.85 to 1.20) 
130-139 1 1 1 
140-159 1.12 (0.98 to 1.29) 1.05 (0.98 to 1.12) 1.15 (0.98 to 1.35) 
160-240 1.14 (0.93 to 1.40) 1.10 (1.00 to 1.21) 1.42 (1.14 to 1.77) 
Diastolic Blood Pressure in mm Hg 40-79 0.97 (0.76 to 1.25) 1.01 (0.91 to 1.12) 0.97 (0.74 to 1.29) 
80-84 0.84 (0.64 to 1.09) 0.99 (0.89 to 1.11) 0.87 (0.65 to 1.17) 
85-89 1 1 1 
90-99 0.71 (0.50 to 1.02) 0.89 (0.78 to 1.03) 0.71 (0.49 to 1.05) 
100-130 1.28 (0.81 to 2.04) 1.02 (0.83 to 1.25) 1.23 (1.75 to 2.01) 
BMI in kg/m2 15-18.5 1.99 (1.14 to 3.47) 1.17 (0.78 to 1.76) 1.29 (0.53 to 3.15) 
18.5-25 1 1 1 
25-30 0.74 (0.65 to 0.85) 0.86 (0.80 to 0.93) 0.92 (0.78 to 1.08) 
30-55 0.73 (0.63 to 0.83) 0.90 (0.84 to 0.97) 0.94 (0.79 to 1.10) 
Total Cholesterol in mmol/l 2-5 1 1 1 
5-10 0.97 (0.83 to 1.12) 1.01 (0.95 to 1.08) 1.17 (1.00 to 1.37) 
HbA1c in DCCT 3-6.4 1.13 (0.99 to 1.29) 0.99 (0.93 to 1.06) 1.12 (0.96 to 1.30) 
6.5-7.4 1 1 1 
7.5-18 1.33 (1.18 to 1.51) 1.09 (1.03 to 1.15) 1.53 (1.33 to 1.76) 
Presence of depressive symptoms (HADS-D≥8)  1.39 (1.23 to 1.57) 1.23 (1.16 to 1.30) 1.21 (1.05 to 1.38) 
Age  1.06 (1.06 to 1.07) 1.02 (1.02 to 1.02) 1.04 (1.03 to 1.05) 
Sex-female  0.78 (0.70 to 0.87) 0.99 (0.95  to 1.04) 0.85 (0.76 to 0.96) 
Socio-economic status-affluent group  0.69 (0.61 to 0.78) 0.87 (0.83 to 0.92) 0.76 (0.67 to 0.86) 
Number of cardiovascular co-morbidities (vs. 1) 
 
2 1.38 (1.23 to 1.54) 1.39 (1.32 to 1.47) 2.80 (2.44 to 3.22) 
3 2.11 (1.77 to 2.51) 1.79 (1.62 to 1.97) 4.71 (3.89 to 5.71) 
Initiation of anti-depressants- treated vs. non-treated  0.88 (0.65 to 1.18) 1.35 (1.22 to 1.52) 0.81 (0.58 to 1.13) 
Concordance Statistics (Standard Error)  0.727 (0.007) 0.613 (0.004) 0.736 (0.008) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to MI/stroke/heart failure. Significant results in bold. 
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HbA1c categories did not have a significant interaction with the presence of 
depressive symptoms (HADS-D≥8) in risk prediction of all-cause hospital 
admission (0.08) and MACE (p-value = 0.08), however the interaction was 
statistically significant in risk prediction of all-cause death (p-value =0.04). The 
statistically significant interaction between HbA1c categories and depressive 
symptoms in risk prediction of all-cause death was analysed in further detail.  
Patients with diabetes were further sub-divided based on different combinations 
of the three HbA1c categories and presence or absence of depressive symptoms 
at baseline. Patients with low HbA1c (3 to 6.4) only, with high HbA1c ( 7.5 to 18) 
only and depressive symptoms only at baseline had 18%, 27% and 37% higher risk 
respectively of all-cause death as compared to those with reference HbA1c (6.5 
to 7.4) and no depressive symptoms. In comparison, patients with both low 
HbA1c and depressive symptoms at baseline had 34% higher risk (see Figure 7-8) 
of all-cause death while patients with both high HbA1c and depressive symptoms 
had the most elevated risk of all-cause death at 108% as compared to those in 
the reference HbA1c group without depressive symptoms.  
 
 
 
 
 
 
 
 
 
 
 
Key Findings (HbA1c Analysis in Diabetes Subset):  
 High HbA1c was associated with a higher risk of the 3 adverse 
clinical outcomes in the diabetes subset, after adjusting for 
potential confounders and other biomarkers in multivariable 
analysis.  
 Statistically significant interaction was observed between 
HbA1c and the presence of depressive symptoms in the risk 
prediction of all-cause death, in the diabetes subset.  
 Presence of depressive symptoms compounded the risk of 
all-cause mortality in patients with high HbA1c (7.5-18) 
category, in the diabetes subset.  
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Figure 7-8 Forest plot showing interaction between depressive symptoms and HbA1c at 
baseline with the risk of all-cause mortality in patients with diabetes. 
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7.4 Discussion 
7.4.1 Summary of Findings 
In DepChron patients, the presence of depressive symptoms (HADS-D≥8) was 
associated with an increased risk of all 3 adverse clinical outcomes – all-cause 
death, all-cause hospital admission and composite major adverse cardiovascular 
outcome (cardiovascular death or admission due to MI/stroke/HF) at 4 years in 
patients with existing cardiometabolic disease (CHD or stroke or diabetes). A 
composite AI score calculated using mainly peripheral cardiometabolic 
biomarkers was also found to have a significant association (direct linear) with 
the 3 adverse clinical outcomes described above. These results were adjusted 
for the effects of 5 potential confounding factors namely, age, sex, socio-
economic status, number of cardiovascular comorbidities and initiation of 
antidepressants within six months. 
Among the individual biomarkers, different types of non-linear association was 
observed between SBP values at baseline and the risk of all-cause hospital 
admission and major adverse cardiovascular outcome at four years. Patients with 
very high and low SBP at baseline were observed to have a significantly higher 
adjusted risk of a major adverse cardiovascular outcome than those with SBP in 
the reference range. On the contrary, DBP was not a significant predictor in the 
multivariable analysis for any of the 3 adverse clinical outcomes. Among the 
metabolic biomarkers, an inverse linear relationship was observed between BMI 
at baseline and the risk of 3 adverse clinical outcomes. High BMI (overweight and 
obese categories) was associated with low risk while low BMI was associated with 
higher risk of all 3 adverse clinical outcomes, when compared to the reference 
BMI categories. In the subset of patients with diabetes, high HbA1c was 
associated with higher risk of all 3 adverse clinical outcomes as compared to 
reference HbA1c at baseline. These results were adjusted for the effects of 5 
potential confounding factors, as described above.  
AI score did not have a significant interaction with the presence of depressive 
symptoms in risk prediction of any of the three clinical outcomes. There was a 
statistically significant interaction noted between SBP and depressive symptoms 
in risk prediction of MACE. The presence of depressive symptoms compounded 
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the risk of MACE at four years in all SBP categories higher and lower than the 
reference category, especially in patients with very high SBP (160-240). In the 
diabetes subset, HbA1c had a statistically significant interaction with depressive 
symptoms in risk prediction of all-cause mortality. In patients with high HbA1c 
(7.5-18) at baseline, presence of concurrent depressive symptoms at baseline 
compounded the risk of all-cause mortality at 4 years.  
Notably, cardiovascular comorbidities had comparatively larger effect sizes with 
significantly higher risk of all three adverse clinical outcomes with each increase 
in the number of co-morbid conditions among CHD, stroke and diabetes.  
7.4.2 Strengths 
This study has some key strengths:  
1. The data came from a large, community based sample reflecting real life 
clinical practice.  
2. Electronic data linkage enabled successful follow-up for the vast majority 
of patients in the cohort.  
3. The follow-up duration of four years was sufficient to study the clinical 
outcomes under investigation.  
7.4.3 Limitations 
There are several limitations with this study.  
1. Only a minority of the patients in the sample had depression screening 
recorded despite incentivisation.  Consequently, there may be important 
differences between patients with known depression status and those 
whose depression status was unknown that were not recorded in our data.  
2. Complete information on biobehavioural factors such as smoking status 
and levels of physical activity was not available, and this is likely to 
influence the prevalence of depressive symptoms and the clinical 
outcomes considered (252,253).  
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3. Information on cardiac related medications was not available for these 
patients.  
4. Only single assessments of biomarker values and depressive symptoms 
were available for the start of the study. The biomarker values and 
depressive symptoms may have changed over the course of the 4 year 
follow-up duration but this information was not available.  
5. The information on how depressive symptoms were managed was 
incomplete. The dataset only had information on which patients were 
initiated on antidepressants. However, it was not known how many 
patients were referred for other forms of depression treatment, such as 
psychological therapies.  
6. Finally, the overall accuracy of depression screening in this study was 
reliant on HADS-D which is a self-reported measure and has accuracy 
related drawbacks when used for assessing depressive symptoms in 
patients with cardiometabolic disease in a primary care setting 
(114,256,257). This has been discussed previously in Chapter 5.  
 
7.4.4 Comparison of Findings with Existing Literature 
In DepChron patients, the presence of depressive symptoms at baseline was 
associated with higher risk of all 3 adverse clinical outcomes- all-cause death, 
all-cause hospital admissions and MACE. The association between presence of 
depressive symptoms and higher risk of adverse clinical outcomes in patients 
with pre-existing cardiometabolic disease has been reported previously in the 
literature (108,110,139). Similarly, the relationship of higher AI score with 
higher all-cause mortality and higher cardiovascular events has been reported in 
older and ageing populations (28,233). However, DepChron is different from 
these studies, as only a few cardiometabolic biomarkers were used for AI score 
calculation, while other studies in this area have used a much wider selection of 
biomarkers (28,233). The selection of available biomarkers for AI score 
calculation was limited in DepChron as it was a routinely collected data. This is 
also one of the key differences between DepChron and other AI score studies 
where the analyses was based on research datasets (28,233).  
 
A SBP J curve was observed in this study in risk prediction of major adverse 
cardiac events which has also been reported extensively in various other studies 
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(290–294). With regards to DBP, our study did not find the evidence of a J- 
shaped curve; furthermore DBP at baseline was not a significant predictor of 
adverse cardiovascular outcomes.  Our study findings are contrary to the results 
observed in the SPRINT trial but there are important differences such as the 
study design and setting, and also the SPRINT trial excluded patients with 
diabetes and previous stroke which were included in our study (295). There are  
other studies which have reported similar findings of better predictive power of 
SBP over DBP in predicting cardiovascular outcomes (296,297). An inverse-linear 
relationship was observed in DepChron patients between BMI categories at 
baseline and risk of adverse clinical outcomes. The existence of a similar 
“obesity paradox” has been extensively discussed in the literature for patients 
with cardiometabolic conditions (270,298,299).  
 
In DepChron, a statistically significant interaction was observed between 
depressive symptoms and systolic blood pressure in risk prediction of 
cardiovascular events. There is evidence supporting the view that depression 
may be an independent risk factor for hypertension (300). Similarly, prospective 
studies of patients with hypertension have found that hypertension is an 
independent predictor of new-onset depression (301).   Depression is associated 
with aberrant inflammatory responses (302)  and inflammation plays a key role 
in the pathophysiology of hypertension (303). So, there is a possibility that 
aberrant inflammatory mechanisms might link the two apparently separate 
classes of disorder (namely, depression and hypertension).    
 
There is also evidence to suggest that the presence of depressive symptoms may 
lower the BP (304) and also lower BP is associated with poor mental health in 
these patients (305).  However, this is the first study, to our knowledge, which 
investigates the interacting relationship between depressive symptoms and BP 
values in the risk prediction of adverse clinical outcomes in patients with pre-
existing cardiometabolic disease.  
 
7.4.5 Potential Implications 
There are two potential implications of the findings from our study. Firstly, 
secondary prevention in cardiometabolic disease management could be targeted 
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at patients with depressive symptoms and extremes of SBP as they tend to have 
a “compounded” risk of adverse outcomes. These findings need to be replicated 
in other datasets and prospectively before making this recommendation. 
Secondly, the relationship between depressive symptoms and BP need to be 
studied in greater detail, particularly for patients with cardiometabolic disease 
who are likely to be on medications which will lower their BP. Similarly, further 
research is also needed to study the relationship between depressive symptoms 
and the extremes of HbA1c values for patients with diabetes. These 
relationships, if proven in other studies, may have two potential implications for 
clinical practice in secondary prevention of patients with cardiometabolic 
disease. Firstly, patients with extremes of SBP and HbA1c could be targeted for 
depression screening, as we know that presence of depressive symptoms can 
compound their risk of adverse clinical outcomes. Secondly, the management of 
patients with cardiometabolic disease and co-morbid depression should have “a 
greater focus” on SBP and HbA1c control, in order to reduce the risk of adverse 
clinical outcomes.  
7.4.6 Conclusion 
A composite AI score (calculated using only secondary cardiometabolic 
biomarkers) and depressive symptoms at baseline were independent predictors 
of all-cause mortality, all-cause hospital admission and major adverse 
cardiovascular event (cardiovascular death or admission due to MI/stroke/HF) at 
4 years in patients with existing cardiometabolic disease.  There was no 
significant interaction between AI score and depressive symptoms in risk 
prediction of these clinical outcomes, so AI score may not have a role in risk 
stratification of patients presenting with depressive symptoms with pre-existing 
cardiometabolic disease.  
SBP at baseline showed a J-shaped curve with a higher risk of adverse clinical 
outcomes in patients with very high and low SBP; DBP at baseline did not have a 
significant effect in risk prediction of any of the 3 adverse clinical outcomes. 
There was a statistically significant interaction between depressive symptoms 
and SBP in the risk prediction of MACE. The presence of depressive symptoms 
compounded the risk of a MACE event in patients with SBP lower or higher than 
the reference category at baseline. In patients with diabetes, presence of 
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depressive symptoms compounded the risk of all-cause death for patients with 
high HbA1c values. These relationships between depressive symptoms and 
cardiometabolic markers may have a potential role in secondary prevention of 
cardiometabolic disease patients, but further research is needed in this area.  
In the next chapter, the findings from longitudinal analysis in the Psobid dataset 
are presented.  
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Chapter 8 Longitudinal Analysis in Psobid dataset 
8.1 Chapter Summary 
This chapter presents results from the longitudinal analysis of clinical outcomes 
in Psobid patients. General and cardiovascular clinical outcomes for depressive 
symptoms in general population (Psobid cohort) for a follow-up period of 7 years 
are described. The objective of this analysis is to study the prognosis of 
depressive symptoms in general population, in relation to physical health 
outcomes. This addresses research questions 3 and 4 in Psobid dataset. These 
research questions are:  
Research Question 3 (RQ3):  
What is the association, if any, between a composite AI score at baseline 
and the risk of future adverse health outcomes such as vascular events, 
hospitalisation and mortality in participants with depressive symptoms 
recruited from general population (Psobid cohort)?  
Research Question 4 (RQ4):  
What is the association, if any, between individual allostatic load 
biomarkers at baseline and the risk of future adverse health outcomes, 
such as vascular events, hospitalisation and mortality in participants with 
depressive symptoms recruited from general population (Psobid cohort) and 
how does it compare with the relationship between composite AI score at 
baseline and risk of adverse outcomes? 
The following sections describe: the methods for data collection of clinical 
outcomes and statistical analysis; the association of AL biomarkers (composite AI 
score and individual biomarkers) and depressive symptoms with the risk of 
adverse clinical outcomes (general and cardiovascular) at 7 years; the statistical 
analyses of the interaction of depressive symptoms with allostatic load 
biomarkers (composite AI score and individual biomarkers) in risk prediction of 
these outcomes; and how the results compare with the existing literature as well 
as strengths, limitations and possible implications of the findings.  
221 
8.2 Methods 
8.2.1 Data Collection for Clinical Outcomes 
Electronic data linkage using the Information Services Division (ISD), Scotland 
data linkage services was used to study the clinical outcomes. The follow-up 
period was approximately 7 years between 31st May 2007 and 31st March 2014. 
The process of electronic data linkage was completely anonymised and no 
patient identifiable information was accessible at any stage. The process of data 
linkage has been already described in detail in Chapter 7. The ISD used patient 
CHI numbers to link the Psobid dataset with the general hospitalization, cancer 
and death registries. After extracting the information on clinical outcomes for 
Psobid patients, the CHI numbers were removed from the data by ISD and the 
data was forwarded for analysis. General and cardiovascular health outcomes 
were studied using the International System of Disease Classification- 10th 
Edition (ICD-10) (15).  
General Health Outcomes:  
1. All-cause Death 
2. All-cause Hospitalization 
3.  Any new incidence of cancer 
Cardiovascular Health Outcomes with respective ICD-20 codes are as follows:  
1. Admission due to myocardial Infarction (MI) - I21 
2. Admission due to stroke – I61-I64 
3. Admission due to heart failure (HF): I50 
4. Death due to cardiovascular causes: I00- I99.  
Major adverse cardiovascular outcome (MACE) was used as the composite 
outcome variable, and similar to the analysis in DepChron it included events 
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such as cardiovascular mortality or admission due to MI/stroke/HF. Patients 
were censored if they died due to reasons other than cardiovascular causes. Only 
the first cause of death and the first cause of hospitalization were taken into 
account to improve accuracy, in line with the approach adopted by previously 
published studies using data linkage (284–286). 
8.2.2 Clinical Variables 
Two different criteria for detecting presence of depressive symptoms were used, 
as assessed by continuous and cut-off scale of GHQ-28. A cut-off score of GHQ-
28≥5 was used, as recommended by the national guidelines for case 
identification of depressive symptoms in a community setting (20).  
The AI score was calculated using with the four different methods, which have 
been described in detail in Chapter 4. These methods were: 1. Method 1- Clinical 
cut-off 2. Method 2- Sample distribution cut-offs (25th and 75th percentile) 3. 
Method 3- Sample distribution cut-offs (10th and 75th percentile). 4. Method 4- 
z-score.  
8.2.3 Statistical Analysis-AI score as predictor variable 
Time to event analysis was used to study the association of the 2 predictors: a) 
AI score (4 different methods) and b) presence of depressive symptoms (GHQ-28 
≥5); with the risk of general health outcomes and composite major adverse 
cardiovascular outcome in Psobid patients. Various Cox proportional hazards 
regression analyses were performed for the four clinical outcomes under 
consideration. The four clinical outcomes were: all-cause mortality; all-cause 
hospital admission; MACE (cardiovascular death or admission due to 
MI/stroke/HF); and incidence of new cancer. The results are presented as 
hazard ratios (HR) with 95% confidence intervals (CI) and Harrell’s Concordance 
statistics (with standard errors) using the “survival” package from R (288). 
Multivariable analysis was undertaken adjusting for the following confounders: 
age (as a continuous variable), sex, socio-economic status (affluent and 
deprived), participant’s smoking status (current vs. former smoker vs. non-
smoker), and number of existing cardiometabolic conditions (coronary heart 
disease/stroke, diabetes, and hypertension) with a range from 0-3. The majority 
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of potential confounders were the same as those used in the DepChron analysis 
apart from few differences. Differences included that there was no control 
group in DepChron as far as cardiometabolic conditions were concerned, i.e. all 
patients in DepChron had at least one of the three cardiometabolic conditions. 
In addition, stroke and CHD were categorized as one problem in the Psobid 
dataset at the time of data collection so it was not possible to differentiate who 
had stroke and who had CHD among Psobid participants.  Also, information on 
initiation of antidepressants was not available in Psobid, which was available in 
DepChron. On the other hand, information on the participant’s smoking status 
was available in Psobid, which was not available in DepChron.    
Cox regression models were fitted to each of the four clinical outcomes with 
both AI score and depressive symptoms added together as predictors, along with 
the potential confounders. Confounders that were not statistically significant 
were excluded from the final multivariable analysis. The results of these models 
were presented with HR with 95% CI and Harrell’s Concordance statistics (with 
standard errors).  
If AI score or depressive symptoms were found to have a statistically significant 
relationship with a clinical outcome in multivariable analysis, a Kaplan-Meier 
plot was constructed to visualise the results of this relationship.  
To understand the relationship between AI score and depressive symptoms in risk 
prediction of clinical outcomes, if any, an analysis of variance (ANOVA) test to 
check for interaction between the AI score and presence of depressive symptoms 
was undertaken. The results were presented as p-values with a p-value less than 
0.05 regarded as statistically significant. In the event of a significant 
interaction, a sub-group analysis was also performed to further study the nature 
of the interaction.  
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8.2.4 Statistical Analysis-Individual Biomarkers 
Time to event analysis was used to study the association between the 12 
individual biomarkers (SBP, DBP, BMI, total cholesterol, HDL cholesterol, 
triglycerides, creatinine, glucose, highly sensitive CRP, IL-6 and fibrinogen) as 
continuous measures and the risk of general and cardiovascular adverse 
outcomes in Psobid patients. WHR was categorised into raised WHR (>0.9 for 
females, 0.95 for males) and non-raised WHR. Cox proportional hazards 
regression analysis, unadjusted and adjusted for potential confounding factors, 
was performed and the results are presented with hazard ratios and 95% 
confidence intervals and Harrell’s Concordance (C-statistics) with standard 
errors.  
Multivariable analysis adjusting for the same confounders: age (as continuous 
variable), sex, socio-economic status (affluent and deprived), number of existing 
cardiometabolic conditions (coronary heart disease/stroke, diabetes, and 
hypertension) with a range from 0-3, and smoking status (current or former 
smoker vs. non-smoker) was performed. Cox regression models were fitted to 
each of the four clinical outcomes with peripheral biomarkers found to have a 
significant effect in univariable analysis and potential confounders with 
significant results. The results of these models are presented with HR with 95% 
CI and C-statistics (with standard errors). 
In the event of a significant association between peripheral biomarkers (as 
continuous variables) and clinical outcome in multivariable analysis, the analysis 
was repeated using clinically relevant categories for respective biomarkers, 
where applicable. SBP was divided into five categories:  very high (160-240), 
high (140-159), reference (130-139), tightly controlled (120-129), and low (80-
119). I also used 5 categories for DBP: very high (100-130), high (90-99), 
reference (85-89), tightly controlled (80-84) and low (40-79). BMI was classified 
into 4 categories: normal: 18.5-25, underweight 15-18.5, overweight 25-30, 
obese 30-55 (245). Total cholesterol levels was divided into two categories (not 
raised vs. raised: >5 mmol/l (244)). HDL cholesterol was divided into two 
categories, low HDL cholesterol (<1.2 mmol/l) and not low HDL cholesterol. For 
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triglycerides and fasting glucose, the cut-offs for raised values were 2 and 6 
mmol/l respectively. For raised creatinine, the cut-off values selected were 
>120 umol/l for males and >110 umol/l for females.  
If a peripheral biomarker was found to have a statistically significant 
relationship with any of the adverse clinical outcomes in multivariable analysis, 
a Kaplan-Meier plot was constructed to visualise the results of this relationship.  
To understand the relationship between individual biomarkers and depressive 
symptoms in risk prediction of clinical outcomes, if any, an ANOVA test was 
constructed to check for interaction between the individual biomarkers and 
presence of depressive symptoms. The results were presented as p-values with a 
p-value less than 0.05 regarded as statistically significant. In the event of a 
significant interaction, a sub-group analysis was undertaken to further study the 
nature of interaction. In the sub-group analysis, the study sample was divided on 
the basis of individual biomarker categories. In each sub-group, a Cox 
proportional hazards regression analysis was performed to study the risk of 
clinical outcomes with presence of depressive symptoms at baseline, adjusting 
for potential confounders. The results of the interaction were visualised with the 
help of a forest plot for HRs with 95%. 
8.2.5 Comparing predictive power of AI score against individual 
peripheral biomarkers 
The strength of the associations observed between 4 AI scores and adverse 
clinical outcomes were compared with that of the peripheral biomarkers and 
adverse clinical outcomes, for those results which were statistically significant in 
multivariable analysis. Only those confounders which were found to have a 
statistically significant result were used. Harrell’s Concordance statistics (with 
standard errors) was used to compare different multivariable models with AI 
scores and peripheral biomarkers.  
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8.3 Results 
8.3.1 Clinical Outcomes 
Electronic data linkage between the Psobid dataset and hospital discharge, 
cancer registry and mortality records was successful for all 666 participants. The 
results for GHQ-28 were recorded for 639/666 (95.9%) participants in the Psobid 
dataset. 183 participants (27.4%) had depressive symptoms based on the criteria 
of a raised GHQ-28 (≥5).  
Among Psobid participants (n=666), 30 participants (4.5%) were dead at the end 
of the seven year follow-up period. 418 participants (62.7%) had experienced at 
least one all-cause hospital admission, while 52 participants (7.8%) had been 
diagnosed with at least one new cancer. Finally, 31 participants (4.6%) had 
experienced at least one major adverse cardiovascular event at the end of 7 
years.  
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8.3.2 Statistical Analysis- AI Score as Predictor 
Table 8-1 shows the results of univariable analysis for the association between AI 
score (four different methods), presence of depressive symptoms (as assessed by 
GHQ-28≥5) and four different clinical outcomes. Presence of depressive 
symptoms did not have a significant association with any of the four clinical 
outcomes studied in the Psobid participants.  
There was no significant association between the risk of all-cause death over 
seven years and any of the AI scores in Psobid participants. The risk of a 
composite major adverse cardiovascular event (cardiovascular death/admission 
due to MI/HF/stroke) and risk of all-cause hospital admissions in Psobid 
participants was significantly higher with higher AI score at baseline (all 4 
methods). Finally, none of the AI scores had any significant association with the 
risk of incidence of new cancer over seven years in the Psobid participants.  
Overall, AI score was found to have a significant association with only two 
clinical outcomes (MACE and all-cause hospital admission), while depressive 
symptoms did not have a significant association for any clinical outcomes. The 
effect sizes for AI score were not comparable to each other as the range for the 
4 AI scores were different. Multivariable analysis was conducted for only two 
clinical outcomes- all cause hospital admission and MACE. For the final 
multivariable analysis, the clinical cut-offs and the z-score method AI scores 
were chosen on the basis of their better C-statistics values. 
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Table 8-1Univariable Cox proportional hazards for four clinical outcomes with AI score and depressive symptoms (GHQ-28≥5) as predictors.  
Clinical Outcomes  AI score- Method 1-
clinical cut-off                          
(Range 0 to 10) 
Available N = 570 
 
AI score-Method 2- 
25th/75th percentile 
(Range 1 to 12)    
Available N=570 
AI score-Method 3- 
10th/90th percentile 
(Range 1 to 9)     
Available N=570 
AI score – Method 
4- z score method 
(Range 3.7 to 
22.3)  Available 
N=570 
Presence of 
depressive 
symptoms (GHQ-
28≥5) 
(Yes against No) 
Available N=639 
All-cause death   Number 
of events = 30   
 
Hazard Ratio 
(HR) 
1.18 1.20 1.21 1.14 2.02 
95% Confidence 
Intervals (CI) 
0.98 to 1.42 0.97 to 1.47 0.94 to 1.57 0.99 to 1.31 0.94 to 4.32 
p-value 0.07 0.07 0.12 0.06 0.06 
C statistics- (SE) 0.639 (0.062) 0.604 (0.062) 0.608 (0.062) 0.626 (0.065) 0.581 (0.043) 
All-cause hospital 
admission        Number of 
events = 418 
HR 1.06 1.05 1.06 1.05 1.12 
95% CI 1.01 to 1.11 1.00 to 1.10 0.99 to 1.14 1.01 to 1.09 0.90 to 1.38 
p-value 0.01 0.04 0.05 0.007 0.29 
C-statistics (SE) 0.532 (0.016) 0.527 (0.016) 0.537 (0.016) 0.553 (0.016) 0.509 (0.012) 
Composite major adverse 
cardiovascular outcome 
(MACE) 
Number of events = 31 
 
HR 1.49 1.24 1.47 1.25 0.79  
95% CI 1.25 to 1.77 1.02 to 1.49 1.18 to 1.82 1.13 to 1.39 0.33 to 1.85 
p-value <0.001 0.02 <0.001 <0.001 0.59 
C-statistics (SE) 0.755 (0.057) 0.634 (0.057) 0.702 (0.057) 0.722 (0.06) 0.522 (0.042) 
Incidence of new cancer            
Number of events = 52 
HR 0.99 0.93  0.87 0.97 1.53 
95% CI 0.85 to 1.15 0.79 to 1.10 0.69 to 1.10 0.84 to 1.11 0.86 to 2.72 
p-value 0.91 0.43 0.26 0.68 0.14 
C-statistics (SE) 0.507 (0.048) 0.529 (0.048) 0.55 (0.047) 0.515 (0.049) 0.546 (0.032) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; MACE=Cardiovascular death or admission due to MI/stroke/heart failure. 
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8.3.2.1 The influence of Confounders 
The potential effects of five confounders were considered on the adverse clinical 
outcomes. They were: age (as a continuous variable), sex, socio-economic status 
(affluent and deprived), number of existing cardiometabolic conditions (coronary 
heart disease/stroke, diabetes, and hypertension) with a range from 0-3, and 
smoking status (current or former smoker vs. non-smoker). In the next part of 
analysis, the statistical significance of the impact of five confounders on each of 
the two adverse clinical outcomes considered for multivariable analysis was 
checked. For all-cause hospital admissions, sex (p-value=0.52) and smoking 
status (p-value=0.65) were not significant predictors and hence removed from 
the final analysis. For composite major adverse cardiovascular event, statistical 
association with age (p-value=0.15), smoking status (p-value=0.15) and socio-
economic status (p-value=0.54) was not significant.  
8.3.2.2 Multivariable Analysis 
Table 8-2 shows that for risk prediction of all-cause hospital admission over 
seven years, age, socio-economic status and cardiovascular co-morbidity (1 
against 0 and 2 against 0) had a significant association in multivariable analysis. 
In other words, if the participants had any one or two of the three conditions- 
MI/previous stroke or diabetes or hypertension at baseline, they were 35% and 
66% respectively more likely to experience a hospital admission during 7 years as 
compared to those participants without these conditions. Participants selected 
from a socio-economically deprived background were 26% more likely to 
experience a hospital admission over seven years, as compared to those from an 
affluent background. AI score did not have a significant association with these 
outcomes. 
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Table 8-2 Multivariable Cox’s proportional hazards for all-cause hospital admissions 
Available N = 565, available number of events =341.  
C-Statistics = 0.607 (SE = 0.016) for AI score (clinical cut-off method).  
C-Statistics = 0.613 (SE = 0.016) for AI score (z-score method). 
 HR 95% CI p-value 
Age 1.03 1.01 to 1.04 <0.001 
Socio-economic status-
deprived group 
1.26 1.00 to 1.58 0.04 
Cardiovascular co-
morbidity 1 (vs.0)  
2 (vs. 0) 
3 (vs. 0) 
1.35 
 
1.03 to 1.78 0.02 
1.66 1.05 to 2.61 0.02 
1.36 0.57 to 3.24 0.47 
The 2 AI scores (clinical cut-off and z-score method), were added individually and not together 
to the multivariable analysis.  
AI score (clinical-cut 
off method) 
0.99 0.94 to 1.06 0.95 
AI score (z-score 
method) 
1.02 0.93 to 1.70 0.18 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; Only significant 
confounders included in the final analysis. 
 
Male sex and cardiovascular co-morbidity (2 and 3 against 0) were found to have 
a significant association with the risk of major adverse cardiovascular event over 
seven years in Psobid participants, in the multivariable analysis (see Table 8-3). 
The risk of a composite cardiovascular event was observed to be very high (up to 
approximately 5 and 16 times higher) among participants with cardiovascular co-
morbidity. The association of AI score was found to be to be statistically 
significant for the clinical cut-off method (p-value = 0.015), but the association 
was not significant with the z-score method (p-value = 0.066). One unit increase 
in AI score (clinical cut-off method) at baseline was associated with 
approximately 30% higher risk of experiencing a major adverse cardiovascular 
event (cardiovascular death or admission due to MI/stroke/HF) over seven years.   
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Table 8-3 Multivariable Cox’s proportional hazards for major adverse cardiovascular event 
(cardiovascular death/admission due to HF/stroke/MI)  
Available N = 565, available number of events = 25.  
C-Statistics = 0.795 (SE = 0.058) for AI score (clinical cut-off method).  
C-Statistics= 0.783 (SE = 0.058) for AI score (z-score method). 
 Hazard Ratio 95% Confidence 
Intervals 
p-value 
Sex-male 2.69 1.12 to 6.48 0.02 
Cardiovascular co-
morbidity 1 (vs.0) 
2 (vs. 0) 
3 (vs. 0) 
1.88 
 
0.66 to 5.29 0.22 
5.18 1.63 to 16.41 0.005 
16.92 3.76 to 75.98 <0.001 
The 2 AI scores (clinical cut-off and z-score method), were added individually and not together 
to the multivariable analysis. 
AI score (clinical-cut 
off method) 
1.31 1.05 to 1.64 0.015 
AI score (z-score 
method) 
1.12 0.99 to 1.27 0.066 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error; Only significant 
confounders included in the final analysis. 
 
In summary, AI score (using the clinical cut-off method) at baseline was found to 
have a significant association with only one outcome - major adverse 
cardiovascular event over seven years in Psobid participants, in multivariable 
analysis. The z-score method AI score did not have a significant association with 
any clinical outcomes, in multivariable analysis.  With the exception of all-cause 
hospital admissions, the available event rate was very low for the other 3 
outcomes analysed.  
8.3.2.3 Kaplan-Meier plots for AI score and clinical outcomes 
The absolute event rate for major adverse cardiovascular event (cardiovascular 
death or admission due to MI/stroke/HF) was significantly higher for participants 
with raised AI score- the clinical cut-off method (defined as >5; 75th percentile 
value) at baseline as compared to participants with non-raised AI score (p-value 
= 0.005). Figure 8-1 shows that nearly 10% of participants with raised AI score at 
baseline had experienced at least one major adverse cardiovascular event over 7 
years as compared to approximately 4% of participants without raised AI score at 
baseline.  
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Figure 8-1 Kaplan-Meier plot comparing the rate of major adverse cardiovascular event and 
AI scores at baseline 
Legend: Raised AI score= defined as >5; 75
th
 percentile value; AI score calculated with clinical cut-off 
method 
8.3.2.4 Interaction between AI score and depressive symptoms  
Considering the low event rate, an interaction analysis was performed between 
AI score and depressive symptoms using ANOVA, but without using the 
confounders for the individual events. There was no significant interaction 
between AI score (clinical cut-off method) and depressive symptoms (GHQ-28≥5) 
in risk prediction of any of the four clinical outcomes. The corresponding p-
values were as follows: all-cause death (p-value = 0.47), all-cause hospital 
admission (p-value = 0.62), major adverse cardiovascular outcome (p-value = 
0.30) and incidence of new cancer (p-value = 0.65).  
The results were unchanged with no significant interaction found between AI 
score (z-score method) and depressive symptoms (GHQ-28≥5) in risk prediction 
of any of the four clinical outcomes. The corresponding p-values were as follows: 
all-cause death (p-value = 0.61), all-cause hospital admission (p-value = 0.75), 
major adverse cardiovascular outcome (p-value = 0.42) and incidence of new 
cancer (p-value = 0.66). 
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Key Findings (AI score and depressive symptoms as predictor variables):  
 Presence of depressive symptoms did not have a significant association 
with any of the four adverse clinical outcomes considered.   
 AI score (clinical cut-off method) HR 1.31 had a significant impact on risk 
prediction of major adverse cardiovascular event (cardiovascular death or 
admission due to MI/HF/stroke) over seven years. This result remained 
significant after adjusting for statistically significant potential confounders.   
 AI score did have a statistically significant association with the risk of all-
cause hospital admission, but the relationship was no longer significant 
after adjusting for confounders.  
 Finally, there was no significant interaction between AI score and 
depressive symptoms in risk prediction of any of the clinical outcomes in 
Psobid participants.  
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8.3.3 Statistical Analysis- Individual Biomarkers as Predictors 
8.3.3.1 All-cause death as an outcome variable 
Table 8-4 shows six out of 12 biomarkers had a significant association with the 
risk of all-cause death over seven years. They were: raised WHR, total 
cholesterol, HDL cholesterol, fasting glucose, creatinine and IL-6. 
Table 8-4 Univariable Cox’s Proportional for all-cause death with individual biomarkers as 
predictors.  
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-value C statistics-
Concordance 
(SE= standard 
error) 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 1.01 0.99 to 1.03 0.07 0.596 (0.053) 
Diastolic Blood 
Pressure in mm 
Hg 
4 52 to 119 1.01 0.98 to 1.04 0.31 0.554 (0.053) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
2.70 1.31 to 5.56 0.007 0.62 (0.043) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.05 0.99 to 1.11 0.07 0.6 (0.053) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.43 0.29 to 0.64 <0.001 0.733 (0.055) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.23 0.07 to 0.74 0.01 0.641 (0.055) 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
0.94 0.63 to 1.40 0.78 0.475 (0.055) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.17 1.03 to 1.33 0.01 0.57 (0.06) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
1.02 1.00 to 1.05 0.049 0.611 (0.055) 
Highly sensitive 
C-reactive 
protein) in mg/l 
30 0.6 to 
18.9 
1.06 0.98 to 1.16 0.11 0.612 (0.056) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.31 1.13 to 1.51 <0.001 0.704 (0.056) 
Fibrinogen in g/l 33 1.1 to 6.4 1.42 0.87 to 2.31 0.15 0.587 (0.055) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 31. Significant results in Bold. 
 
For multivariable analysis, the six biomarkers with a statistically significant 
result in univariable analysis were included. As seen with the results in the 
previous section, only age and sex (male vs. female) were included as 
confounders as other confounders did not have a statistically significant result. 
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Only total cholesterol and IL-6 had statistically significant effects of prediction 
of all-cause death in multivariable analysis (see Table 8-5).  
Table 8-5 Multivariable Cox’s Proportional Hazards for all-cause death with individual 
biomarkers as predictors  
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-value C statistics- 
(SE) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
1.90 0.91 to 3.98 0.084 0.774 (0.053) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.51 0.35 to 0.74 <0.001 0.819 (0.055) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.45 0.14 to 1.47 0.19 0.779 (0.055) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.13 0.98 to 1.30 0.08 0.77 (0.06) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
0.99 0.95 to 1.02 0.67 0.772 (0.055) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.19 1.02 to 1.39 0.02 0.791 (0.056) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 31. Significant results in Bold. Confounders= Age and Sex. 
 
To further understand the relationship between the two biomarkers (total 
cholesterol and IL-6 with significant results in multivariable analysis) and all-
cause mortality, the possibility for a non-linear association was checked by 
adding a quadratic term to the multivariable analysis as described above. The 
quadratic terms for the two biomarkers did not have a significant association 
with the risk of all-cause death: total cholesterol (p-value = 0.67) and IL-6 (p-
value = 0.08).  
The multivariable analysis was repeated using clinical categories for total 
cholesterol i.e. raised total cholesterol (defined as >5.0 mmol/l). Psobid 
participants with raised total cholesterol at baseline had an 88% (HR 0.12, 95% CI 
0.03 to 0.40, p-value = <0.001) lower risk of all-cause mortality over 7 years, as 
compared to participants with total cholesterol <5 at baseline.  
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8.3.3.2 All-cause hospital admission as an outcome variable 
In univariable analysis with all-cause hospital admissions as an outcome variable, 
five individual biomarkers were found to have a significant effect on risk 
prediction among Psobid participants: BMI, fasting glucose, highly sensitive CRP, 
IL-6 and fibrinogen (Table 8-6). Notably, all 3 inflammatory markers were found 
to have a statistically significant result.  
Table 8-6 Univariable Cox’s Proportional Hazards for all-cause hospital admissions with 
individual biomarkers as predictors 
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-
value 
C statistics- (SE) 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 1.00 0.99 to 1.00 0.34 0.513 (0.015) 
Diastolic Blood 
Pressure in mm 
Hg 
4 52 to 119 0.99 0.98 to 1.00 0.75  0.499 (0.015) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
1.19 0.97 to 1.45 0.087 0.515 (0.012) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.02 1.00 to 1.04 0.01 0.521 (0.015) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.93 0.84 to 1.02 0.14 0.510 (0.015) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.84 0.64 to 1.11 0.23 0.524 (0.015) 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
1.05 0.96 to 1.14 0.22 0.531 (0.015) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.11 1.05 to 1.18 <0.001 0.508 (0.015) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
1.00 0.99 to 1.01 0.81 0.490 (0.015) 
Highly sensitive 
C-reactive 
protein) in mg/l 
30 0.6 to 
18.9 
1.02 1.00 to 1.05 0.048 0.534 (0.015) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.13 1.07 to 1.19 <0.001 0.575 (0.015) 
Fibrinogen in g/l 33 1.1 to 6.4 1.15 1.00 to 1.32 0.049 0.525 (0.015) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 418. Significant results in Bold. 
 
For multivariable analysis, three potential confounders with a statistically 
significant result: age, socio-economic status (deprived vs. affluent) and number 
of cardiovascular co-morbidity (0-3) were included. Table 8-7 shows only fasting 
glucose and IL-6 were found to have a statistically significant association in 
multivariable analysis.  
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Table 8-7 Multivariable Cox’s Proportional Hazards for all-cause hospital admissions with 
individual biomarkers as predictors 
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-value C statistics- 
(SE) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.00 0.98 to 1.02 0.56 0.607 (0.015) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.08 1.00 to 1.17 0.03 0.603 (0.015) 
Highly sensitive 
C-reactive 
protein) in mg/l 
30 0.6 to 
18.9 
0.99 0.96 to 1.02 0.91 0.606 (0.015) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.06 1.00 to 1.13 0.02 0.610 (0.015) 
Fibrinogen in g/l 33 1.1 to 6.4 0.97 0.83 to 1.12 0.71 0.608 (0.015) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 418. Significant results in Bold.  
Confounders = age, socio-economic status, number of cardiometabolic conditions (0-3). 
 
The quadratic term for fasting glucose (p-value = 0.21) and IL-6 (p-value = 0.06) 
did not have a statistically significant in multivariable analysis, implying that 
both of these biomarkers did not have a non-linear relationship with the risk of 
all-cause hospital admission.  
Clinical relevant categories were used for fasting glucose (raised = >6 mmol/l vs. 
not raised) and added to the multivariable analysis. The hazard ratio for raised 
fasting glucose was 1.40 (95% CI 0.97 to 2.02) and the p-value was 0.06. Thus, 
for the multivariable risk prediction of all-cause hospital admission over 7 years, 
only IL-6 was found to have a statistically significant association in Psobid 
participants. The result for glucose was not statistically significant after using 
clinically relevant categories.  
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8.3.3.3 MACE (cardiovascular death or admission due to MI/stroke/HF) as an 
outcome variable 
In univariable analysis for major adverse cardiovascular event, only two 
individual biomarkers- highly sensitive CRP and DBP had a non-significant 
association. The other ten biomarkers had a significant result (see Table 8-8).  
Table 8-8 Univariable Cox’s Proportional Hazards for major adverse cardiovascular event 
with individual biomarkers as predictors  
Biomarker 
 
Missing 
Values 
Range Hazard 
Ratio 
95% 
Confidence 
Intervals 
p-value C statistics-
Concordance 
(SE= standard 
error) 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 1.01 1.00 to 1.03 0.02 0.608 (0.052) 
Diastolic Blood 
Pressure in mm 
Hg 
4 52 to 119 1.00 0.97 to 1.03 0.79 0.510 (0.052) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
9.18 3.76 to 22.4 <0.001 0.749 (0.042) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.05 1.00 to 1.11 0.040 0.628 (0.052) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.59 0.40 to 0.87 0.008 0.622 (0.055) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.11 0.03 to 0.38 <0.001 0.682 (0.055) 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
1.34 1.11 to 1.63 0.002 0.703 (0.055) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.23 1.11 to 1.36 <0.001 0.696 (0.058) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
1.03 1.00 to 1.05 0.01 0.607 (0.055) 
Highly sensitive 
C-reactive 
protein) in mg/l 
30 0.6 to 
18.9 
1.05 0.96 to 1.14 0.22 0.627 (0.055) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.34 1.16 to 1.53 <0.001 0.746 (0.055) 
Fibrinogen in g/l 33 1.1 to 6.4 1.73  1.09 to 2.75 0.02 0.640 (0.055) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 31. Significant results in Bold. 
 
For multivariable analysis, only sex and number of cardiometabolic conditions 
were included as confounders, as they had a significant result. Table 8-9 shows 
only raised WHR and IL-6 were found to have a statistically significant 
association with the risk of a major adverse cardiovascular event in 
multivariable analysis. IL-6 had a linear association with the risk of MACE as the 
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quadratic term for IL-6 was found to have a non-significant result in the 
multivariable analysis (p-value = 0.054).  
Table 8-9 Multivariable Cox’s Proportional Hazards for major adverse cardiovascular event 
with individual biomarkers as predictors  
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-value C statistics- 
(SE) 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 1.00 0.99 to 1.02 0.35 0.760 (0.052) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
5.51 2.14 to 
14.15 
<0.001 0.839 (0.051) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.01 0.94 to 1.08 0.63 0.750 (0.052) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.95 0.63 to 1.43 0.83 0.749 (0.055) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.36 0.10 to 1.28 0.11 0.788 (0.055) 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
1.23 0.94 to 1.61 0.12 0.800 (0.055) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
1.03 0.89 to 1.19 0.67 0.779 (0.058) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
1.01 0.98 to 1.04 0.36 0.758 (0.055) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.22 1.03 to 1.44 0.02 0.802 (0.055) 
Fibrinogen in g/l 33 1.1 to 6.4 1.36 0.82 to 2.25 0.22 0.778 (0.055) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 31. Significant results in Bold.  
Confounders= Sex and Number of cardiometabolic conditions (0-3). 
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8.3.3.4 Incidence of new cancer as outcome variable 
Table 8-10 shows that none of the individual biomarkers had a statistically 
significant association with incidence of new cancer over 7 years among Psobid 
participants. Considering the negative results in univariable analysis, 
multivariable analysis was not undertaken for any of the biomarkers.  
Table 8-10 Univariable Cox’s Proportional Hazards for incidence of new cancer with 
individual biomarkers as predictors  
Biomarker 
 
Missing 
Values 
Range HR 95% CI p-value C statistics 
(SE) 
Systolic Blood 
Pressure in mm 
Hg 
4 90 to 202 1.01 0.99 to 1.02 0.12 0.561 (0.04) 
Diastolic Blood 
Pressure in mm 
Hg 
4 52 to 119 1.01 0.99 to 1.04 0.15 0.560 (0.04) 
Waist Hip Ratio 
(raised vs. not 
raised) 
7 0.64 to 
1.31 
1.00 0.56 to 1.80 0.98 0.50 (0.033) 
Body Mass Index 
in kg/m2 
4 16.3 to 
51.1 
1.00 0.95 to 1.05 0.78 0.524 (0.04) 
Total Cholesterol 
in mmol/l 
21 2.4 to 8.6 0.76 0.58 to 1.00 0.054 0.576 (0.041) 
High Density 
Lipoprotein 
Cholesterol in 
mmol/l 
21 0.4 to 3.0 0.86 0.41 to 1.81 0.70 0.527 (0.041) 
Triglycerides in 
mmol/l 
21 0.3 to 
10.8 
1.01 0.77 to 1.32 0.92 0.516 (0.041) 
Fasting Blood 
Glucose in 
mmol/l 
54 3.2 to 
19.8 
0.93 0.69 to 1.24 0.62 0.476 (0.044) 
Creatinine in 
umol/l 
28 55.2 to 
159.6 
1.01 0.99 to 1.03 0.21 0.566 (0.042) 
Highly sensitive 
C-reactive 
protein) in mg/l 
30 0.6 to 
18.9 
0.99 0.91 to 1.08 0.93  0.501 (0.041) 
Interleukin 6 in 
pg/ml 
37 0.2 to 
11.8 
1.04 0.87 to 1.23 0.64 0.544 (0.043) 
Fibrinogen in g/l 33 1.1 to 6.4 1.07 0.73 to 1.56 0.72 0.526 (0.041) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 52. Significant results in Bold.  
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8.3.3.5 Kaplan Meier Plots for peripheral biomarkers and clinical outcomes 
Figure 8-2 shows the higher mortality rate among participants with raised IL-6 
(defined as higher than 75th percentile value i.e. IL-6 >2.75 pg/ml) at baseline 
than the rest of the Psobid participants (p-value <0.001). Approximately 10% of 
participants with raised IL-6 at baseline were dead at the end of seven years.  
Figure 8-2 Kaplan Meier plot showing all-cause mortality against IL-6 values at baseline 
 
 
Legend: raised IL-6=defined as higher than 75
th
 percentile value >2.75 pg/ml 
In contrast, an inverse linear association was observed between total cholesterol 
and all-cause death. Figure 8-3 shows that Psobid participants with raised total 
cholesterol (>5.0 mmol/l) at baseline were less likely to die than the rest of the 
Psobid participants (p-value <0.001). The mortality rate over seven years was 
approximately 7% among participants with cholesterol less than 5.0 as compared 
to approximately 2% rate observed among those with cholesterol higher than 
5.0.  
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Figure 8-3 Kaplan Meier plot showing all-cause mortality with raised total cholesterol (> 5.0) 
at baseline  
Participants with raised IL-6 at baseline had higher chances (p-value <0.001) of 
experiencing an all-cause hospital admission during 7 years (Figure 8-4). 
Participants with raised IL-6 experienced an absolute event rate of roughly 75% 
over 7 years as compared to approximately 55% event rate observed among 
those without raised IL-6. 
Figure 8-4 Kaplan Meier plot showing all-cause hospital admissions against IL-6 values at 
baseline 
 
Legend: raised IL-6=defined as higher than 75
th
 percentile value >2.75 pg/ml 
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Statistically significant higher risk of experiencing at least one major adverse 
cardiovascular event (cardiovascular death or admission due to MI/stroke/HF) 
was observed among Psobid participants with raised IL-6 (p-value < 0.001) and 
raised WHR (p-value <0.001) at baseline. The absolute event rates observed for 
participants with raised IL-6 and those with raised WHR (>0.85 in females, >1.0 
in males) at baseline were approximately 10% and 12% respectively (Figure 8-5 
and Figure 8-6).  
Figure 8-5 Kaplan Meier plot showing major adverse cardiovascular event against IL-6 
values at baseline 
 
 
Legend: raised IL-6=defined as higher than 75
th
 percentile value >2.75 pg/ml 
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Figure 8-6 Kaplan Meier plot showing major adverse cardiovascular event against raised 
WHR (>0.90 in females, 0.95 in males) at baseline 
 
 
8.3.3.6 Interaction analysis between peripheral biomarkers and depressive 
symptoms 
A statistical interaction analysis between the presence of depressive symptoms 
and only those peripheral biomarkers which had a significant result in 
multivariable analysis for any of the 4 clinical outcomes under consideration was 
performed. Again, as with the analysis with AI score, confounders were not 
added to the interaction analysis due to the low event rate. These peripheral 
biomarkers were: IL-6 and total cholesterol (all-cause death), IL-6 (all-cause 
hospital admission) and IL-6 and WHR (major adverse cardiovascular event). No 
interaction analysis was undertaken for incidence of new cancer as none of the 
peripheral biomarkers had a significant association with that outcome.  
In summary, there was no significant interaction between the peripheral 
biomarkers and depressive symptoms for any of the four clinical outcomes under 
consideration.  
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Key Findings (Individual Biomarkers as Predictor):  
 IL-6 (continuous) and raised total cholesterol >5.0 (vs.  not raised total 
cholesterol) were found to have a direct linear association with an 
increased probability of all-cause death at seven years, after adjusting for 
the effects of potential confounders.  
 IL-6 (continuous) was also found to have a linear association with increased 
probability of all-cause hospital admission at seven years, after adjusting 
for the effects of potential confounders.  
 IL-6 (continuous) and raised WHR >0.85 in females, >1.0 in males (vs. not 
raised WHR) were found to have a direct linear association with increased 
probability of MACE at seven years, after adjusting for the effects of 
potential confounders. 
 None of the available peripheral biomarkers had any statistically significant 
association with incidence of new cancer at seven years among the Psobid 
participants.  
 There was no significant statistical interaction between the presence of 
depressive symptoms and peripheral biomarkers in the risk prediction of 
any clinical outcomes under consideration among the Psobid participants.  
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8.3.4 Comparing predictive power of AI score against individual 
peripheral biomarkers 
The strength of the associations observed between AI scores and clinical 
outcomes was compared with that of the peripheral biomarkers and adverse 
clinical outcomes, for those results which were statistically significant in 
multivariable analysis. AI score had a significant association with the risk of only 
one clinical outcome in multivariable analysis- MACE (cardiovascular death or 
admission due to MI/stroke/HF). On the other hand, IL-6 and WHR were observed 
to have a statistically significant impact in predicting major adverse 
cardiovascular event in multivariable analysis. Sex and number of 
cardiometabolic conditions (0-3) were used in the multivariable analysis, as they 
were the significant confounders. Table 8-11 shows that the model containing 
WHR had the best C-statistics value, suggesting best fit to the data.  
Table 8-11 Comparison of AI scores and peripheral biomarkers as predictors in 
multivariable Cox’s proportional for major adverse cardiovascular event (cardiovascular 
death/admission due to HF/stroke/MI)  
 
 HR 95% CI p-value C-statistics (SE) 
AI score- Method 
1-clinical cut-off                         
(Range 0 to 10) 
1.31 1.05 to 1.64 0.015 0.795 (0.058) 
AI score – Method 
4- z score method 
(Range 3.7 to 
22.3) 
1.12 0.99 to 1.27 0.066 0.783 (0.058) 
IL-6        (Range 
0.2 to 11.8) 
1.22 1.03 to 1.44 0.021 0.802 (0.055) 
Raised WHR (vs. 
not raised WHR)       
(>0.85 in females; 
1.0 in males) 
5.51 2.14 to 14.15 <0.001 0.839 (0.051) 
HR=Hazard Ratio; CI=Confidence Intervals; C-statistics=Concordance; SE=Standard Error.  
Number of events = 31. Significant results in Bold.  
Confounders= Sex and Number of cardiometabolic conditions (0-3). 
 
Based on these results, a composite AI score did not offer any better predictive 
value for major adverse cardiovascular event over seven years, when compared 
to individual peripheral biomarkers such as WHR.  
Finally, the combined predictive power of raised WHR and IL-6 was checked by 
adding both of these biomarkers together along with sex and number of 
cardiometabolic conditions in a multivariable Cox’ proportional hazards, with 
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MACE as the outcome variable. In this model, IL-6 did not have a statistically 
significant relationship (HR 1.13, 95% CI 0.95-1.35, p-value=0.15) while raised 
WHR was still found to have a statistically significant relationship (HR 5.13, 95% 
CI 1.83-14.38, p-value<0.01) with the risk of having a MACE event over seven 
years. The C-statistics (Concordance=0.865, se=0.055) of the model using WHR 
and IL-6 together (along with confounders) was marginally better than the one 
used for only WHR with confounders, implying that this model has marginally 
better predictive power for a MACE event over seven years. 
 
 
 
 
 
 
 
 
 
 
 
 
Key Findings (Comparing Predictive Power for a MACE event):  
 Individual biomarkers such as WHR and IL-6 had a better 
predictive power for a MACE event over seven years than a 
composite AI score in a multivariable Cox Regression, after 
adjusting the effects of potential confounders.  
 Using WHR and IL-6 together marginally improved the predictive 
power of the model for a MACE event over seven years; 
however the association of IL-6 with MACE was no longer 
statistically significant when used together with WHR.  
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8.4 Discussion 
8.4.1 Summary of Findings 
The observed event rate among Psobid participants for the 4 adverse clinical 
outcomes under study were as follows: 30 participants (4.5%) were dead, 418 
participants (62.7%) had experienced at least one all-cause hospital admission, 
52 participants (7.8%) had been diagnosed with at least one new cancer and 31 
participants (4.6%) had experienced at least one major adverse cardiovascular 
event at the end of seven years. Major adverse cardiovascular event was defined 
as a combination of cardiovascular death and admission to hospital due to MI or 
stroke or HF. Presence of depressive symptoms identified by GHQ-28 at baseline 
did not have a significant association with any clinical outcomes over 7 years 
among Psobid participants.  
A composite AI score (all 4 methods) at baseline had a significant association 
with the risk of major adverse cardiovascular event (cardiovascular death or 
admission due to MI/stroke/HF) and all-cause hospital admissions over 7 years. 
However, only the association of AI score (clinical cut-off) with major adverse 
cardiovascular event remained significant in multivariable analysis.  
A continuous measure of IL-6 observed at baseline had a significant association 
with the risk of 3 clinical outcomes- all-cause mortality, all-cause hospital 
admissions and major adverse cardiovascular event. These associations remained 
significant after adjusting for potential confounders.  
Psobid participants with raised total cholesterol (values >5.0 mmol/l) had lower 
risk of all-cause death over 7 years as compared to those with non-raised total 
cholesterol values at baseline. This result remained statistically significant in 
multivariable analysis.  
Presence of raised WHR (defined as >0.85 in females and >1.0 in males) at 
baseline was associated with higher risk of major adverse cardiovascular event 
over seven years among Psobid participants. These results were adjusted for 
potential confounders in a multivariable analysis.  
249 
There was no significant interaction between presence of depressive symptoms 
and AI score (all 4 methods) in risk prediction of any of the 4 adverse clinical 
outcomes under consideration. There was no significant interaction between 
presence of depressive symptoms and the 12 peripheral biomarkers in risk 
prediction of any of the adverse clinical outcomes under consideration.  
A model containing a composite AI score did not offer any better predictive 
power for MACE, when compared to a model containing individual peripheral 
biomarker such as raised WHR. These results were adjusted for 5 potential 
confounders: age, sex, socio-economic status (deprived vs. affluent), number of 
cardiometabolic conditions (0-3) and smoking status (current or former smoker 
vs. never smoked). However, only significant confounders were included in the 
multivariable analysis owing to low event rates.   
8.4.2 Strengths 
1. The rate of data completion in Psobid was very good (>90% participants) 
for GHQ-28.  
2. The study participants were well characterized with detailed information 
available on demographics and availability of both primary and secondary 
allostatic load biomarkers.  
3. A 100% electronic data linkage was achieved for Psobid participants using 
ISD services.  
8.4.3 Limitations 
1. The participants were chosen from the most deprived and the least 
deprived areas to highlight the impact of socio-economic status, which is 
also a strength of the study as well as a limitation. Socio-economic status 
is a continuum and hence the results of this study cannot be generalized 
to the whole population.   
2. The response rate for study participation was 25%. Hence there is a 
possibility of a response bias.   
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3. GHQ-28 was used for estimating the prevalence of depressive symptoms. 
GHQ-28 was originally designed to screen for minor psychological distress 
(not restricted to depressive symptoms) (231). However, GHQ-28 has been 
validated for screening of depressive symptoms in the general population 
against MDD; GHQ-28 has been reported to have a sensitivity of 79.2% and 
specificity of 79.6% against a composite international diagnostic 
instrument for DSM-IV criteria for major depressive disorder (277). 
4. A major limitation of this analysis is the low number of adverse clinical 
outcomes or event rate observed which limited the power of the analysis.   
5. There were only single assessments available for biomarker values and 
depressive symptoms at the start of the study for Psobid participants. The 
biomarker values and depressive symptoms may have changed over the 
course of the seven year follow-up duration but this information was not 
available.  
6. In this analysis, IL-6 values at baseline were found to be a significant 
predictor of three adverse clinical outcomes. IL-6 is not used in routine 
clinical practice. Hence, there are unlikely to be any clinical implications 
from these results at the present time.  
8.4.4 Comparison of Findings with Existing Literature 
The relationship between AI score and all-cause mortality and cardiovascular 
events has been extensively studied in older and ageing populations, but it has 
not been studied in detail in middle-aged populations like the Psobid 
participants (28,233). The third national health and nutritional examination 
survey (NHANES III) in the U.S. studied the relationship between AI score and all-
cause mortality in more than 13,000 adults older than 25 years (306). The study 
used single measurements of 9 peripheral biomarkers (albumin, CRP, total 
cholesterol, HDL cholesterol, HbA1c, WHR, SBP, DBP and heart rate) and a single 
cut-off method to calculate a composite AI score. The study showed that 
participants with high AI score (>2 and >3) were more likely to die at follow-up 
(median follow-up 8.7 years) as compared to those with AI score ≤ 1 at baseline 
(306). These findings are contrary to those observed in our study, although there 
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are some key differences between the NHANES III study and Psobid. The 
biomarkers used by that NHANES II were different to those used in Psobid and 
also the participants were relatively older in Psobid with lower observed event 
rates (306).  
Seeman et al. showed an association between higher AI score (calculated using 
the single cut-off method) at baseline and incident CVD (defined as MI or stroke 
or a new diagnosis of hypertension or diabetes) at 2.5 years in 736 elderly 
participants (age 70-79) from the New England region of U.S. (208). Psobid is one 
of the first studies to show an association between AI score and cardiovascular 
events in a middle-aged population.  
Psychological distress measured by the General Health Questionnaire (GHQ) has 
been linked with an increased risk of all-cause mortality in various studies 
before. Data from the health survey for England using more than 60,000 
participants showed a dose-response relationship between psychological distress 
measured by GHQ-30 and all-cause mortality with a mean follow-up of 8.2 years 
(307). Similarly, other studies have also shown an association between higher 
risk of all-cause mortality with higher GHQ-30 at baseline (308,309). All of these 
three studies have been sampled from the general population and they have all 
used GHQ-30. Interestingly, the other studies have also shown a strong 
association of GHQ-30 with cardiovascular deaths (308,309), while in Psobid 
participants there was no significant association observed between depressive 
symptoms and the risk of all-cause death and MACE (caveat being the low event 
rate in Psobid which could be a contributory factor for the observed results).  
In Psobid participants, IL-6 was associated with an increased risk of all-cause 
mortality. There have been three studies investigating the relationship between 
IL-6 and all-cause mortality (310). Two out of these three studies have shown a 
positive association (311,312), while one study did not report a significant 
relationship (313). Overall, the results from meta-analysis of these studies did 
not report a significant association between IL-6 and all-cause mortality (310). 
This is contrary to the results observed in Psobid. Notably, the participants in 
these three studies were comparatively older than the Psobid participants (310). 
The relationship between IL-6 and cardiovascular events (cardiovascular death or 
MI) has been studied more extensively in 17 different population studies (314). 
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Based on the results of meta-analysis of 17 studies, an increase in IL-6 values by 
1 standard deviation was associated with 61% higher risk of cardiovascular events 
(adjusted odds ratio 1.61, 95% 1.42  to 1.83) (314). In comparison, with each 
unit increase in IL-6, the risk of cardiovascular event increased by 22% in Psobid 
participants (adjusted HR 1.22, 95% CI 1.03 to 1.44). The standard deviation for 
IL-6 was 1.5 in Psobid participants.  
Carriere and colleagues observed that low total cholesterol (<4.95 mmol/l in 
males and <5.23 mmol/l in females) values were associated with higher risk of 
all-cause mortality at 5 years, when compared to the reference total cholesterol 
values (4.95 to 6.18 mmol/l in males and 5.23 to 6.61 mmol/l in females) in 
more than 1400 French residents >60 years of age (315). However, this 
association was no longer significant with longer follow-up, i.e. 5 to 9 years. In 
contrast, a statistically significant relationship was observed in Psobid 
participants between low total cholesterol (<5 mmol/l) and higher risk of all-
cause mortality over 7 years.  
In Psobid participants, a strong association was observed between baseline WHR 
and risk of major adverse cardiovascular event over 7 years. A meta-analysis of 
15 studies and 258,114 participants showed that a 0.10 increase in WHR was 
associated with 50% adjusted higher risk of cardiovascular event (316). The 
observed effect size was much larger in Psobid, with approximately 25 times 
higher risk of cardiovascular event with every 0.10 increase in WHR values. The 
meta-analysis did not perform a regression using categorical values of WHR.  
8.4.5 Potential Implications 
There are three potential implications for future research. Firstly, a composite 
AI score did not offer any better accuracy in predicting cardiovascular events, 
when compared with individual biomarkers such as WHR, especially in this 
middle aged population. Secondly, in spite of strong evidence of a relationship 
between IL-6 and adverse clinical outcomes, the clinical applicability of IL-6 
remains uncertain. The focus of future research should be the possibility of 
identifying a clinically relevant cut-off for IL-6, which may aid its clinical use. 
Similarly, WHR measurement is time consuming and it may be difficult to 
implement in an average 10 minute GP consultation. Finally, there was no 
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significant interaction observed between depressive symptoms and peripheral 
biomarkers (individual or composite) in predicting clinical outcomes in Psobid. 
This is contrary to the results of significant interaction of depressive symptoms 
and cardiovascular biomarkers observed in the DepChron dataset. The 
differences in the observed results could be due to differences in the two 
datasets, such as, study setting, age-group, and prevalence of underlying health 
conditions.  
8.4.6 Conclusion 
Presence of depressive symptoms was not associated with any of the measured 
clinical outcomes at seven years follow-up in Psobid participants. A composite AI 
score was shown to have an association with the risk of major adverse 
cardiovascular events in middle aged participants sampled from the general 
population. However, the strength of this association was not any stronger than 
the relationship observed between WHR and cardiovascular events. IL-6 was 
found to have a statistically significant relationship with the risk of adverse 
health outcomes such as all-cause mortality and all-cause hospital admissions, as 
well as risk of major adverse cardiovascular events.  
The longitudinal analysis in Psobid has suggested that the hypothesis of 
usefulness of peripheral biomarkers in risk prediction of clinical outcomes in 
patients with depressive symptoms may not be applicable to middle aged 
participants selected from the general population. In the next chapter, the 
results of developing a risk scoring system for predicting clinical outcomes in 
patients with depressive symptoms using demographics and peripheral biomarker 
values are presented. 
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Chapter 9: Development of a Risk Scoring System 
for Adverse Clinical Outcomes in Patients with 
Depressive Symptoms 
9.1 Chapter Summary 
In this chapter, the development of a scoring system based on the risk of adverse 
clinical outcomes in patients with depressive symptoms is presented. The 
objective of this analysis is to study the role of peripheral biomarkers in 
prognosis of depressive symptoms in relation to physical adverse health 
outcomes. This addresses the research question 5 in DepChron and Psobid 
datasets.  
Research Question 5 (RQ5):  
What is the accuracy of a risk scoring system developed using patient 
demographics, allostatic load biomarker values and severity of depressive 
symptoms, in predicting adverse health outcomes in patients with 
depressive symptoms?    
DepChron 
DepChron patients had existing cardiometabolic disease, hence major adverse 
cardiovascular event (cardiovascular death or admission due to MI/stroke/HF) 
was chosen as the outcome of interest.  
The purpose of this analysis was to develop a risk prediction model for secondary 
cardiovascular events using demographic factors, peripheral biomarker values 
and depressive screening results in patients with existing cardiometabolic 
disease. The sample was the subset of patients in DepChron who underwent 
depression screening (n=35537).  
Psobid 
In Psobid, it was not possible to perform this analysis as the observed event rate 
for different clinical outcomes was low (all-cause death: 30, major adverse 
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cardiovascular event: 31 and incidence of new cancer: 52). As a rough guide, 10 
events are required for every predictor variable in a model (317). Incidence of 
new cancer possibly had a sufficient number of events, but neither depressive 
symptoms nor any of the allostatic load biomarkers was found to have a 
significant association with that outcome (see Chapter 8). Hence, this analysis 
was not undertaken in the Psobid population. Incidence of hospital admissions 
also had a sufficient number of events, however information on other factors 
such as polypharmacy and information on previous admission was missing in 
Psobid cohort, which are likely to influence rate of hospital admissions and thus 
this analysis was not performed.  
In the following section, the methods and results for developing a risk scoring 
system in the DepChron dataset are described. Finally, the strengths and 
limitations of the findings are discussed and compared with existing literature.  
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9.2 Methods 
9.2.1 Developing a Risk Prediction Model 
In the development of a risk prediction model, the statistical methods described 
by Streyerberg in his book “Clinical Prediction Models” were adopted 
(318)(319,320). MACE (cardiovascular death and admission due to MI/Stroke/HF) 
was used as the outcome variable. This was a development and validation study 
using resampling with bootstrapping, Type 1B based on TRIPOD statement 
classification of risk prediction studies (30) 
The series of seven steps used in creating a risk prediction model have been 
summarized here.  
The first step involved managing the observations with missing values. 
Considering the relatively big sample size in DepChron, the observations with 
missing values were excluded. The DepChron patients with missing depression 
scores were observed to a have a higher rate of MACE events- see Table 7.1 in 
Chapter 7. Excluding patients with missing values means that patients at higher 
risk of MACE for unknown reasons were excluded. The second step involved 
coding the predictor variables appropriately. The predictor variables considered 
were: age (categorized into 3 groups: 18-44, 45-64 and 65-90), gender, socio-
economic status (affluent based on SIMD1-5 vs. deprived based on SIMD 6-10), 
number of co-morbid cardiometabolic conditions (1-3 of diabetes, stroke and 
CHD), SBP at baseline (very high=160-240, high=140-159, reference=130-139, 
tightly controlled=120-129, and low=80-119), DBP at baseline (very high=100-
130, high=90-99, reference=85-89, tightly controlled=80-84 and low=40-79), BMI 
at baseline (reference=18.5-25, underweight=15-18.5, overweight=25-30, 
obese=30-55), and total cholesterol at baseline (reference<5.0, raised=>5.0). 
HADS-D at baseline was categorized into no depressive symptoms (0-7) and 
presence of depressive symptoms (≥8)(152).  
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Thus, there were nine potential predictors in the scoring system. These included 
four cardiovascular biomarkers  and they were all categorized based on relevant 
clinical guidelines (245)(244)). There is no consensus among various guidelines 
published internationally for optimal BP targets in patients with existing 
cardiometabolic disease (241–244). BP was divided into five different categories 
based on clinical judgement to improve the interpretability of results. The 
values for individual biomarkers were restricted to a clinically plausible range 
based on both clinical judgement and the findings of general population studies, 
as in the analysis in previous Chapters. SBP measurements were restricted to a 
range between 90 to 240 mm Hg and DBP to a range between 50 to 130 mm Hg 
(236,237). Similarly, BMI was restricted to a range between 15 to 55 (238), total 
cholesterol to 2-10 (239).  
The third step was called model specification, which involved examination of 
clinical relevance of the selected outcome and predictor variables. DepChron 
patients had existing cardiometabolic conditions; hence the outcome variable 
selected was clinically relevant for this population. The nine predictors selected 
were also clinically relevant however there were some notable absences. The 
information on smoking status, disease severity and cardiovascular medication 
was not available and this is discussed further in the limitations.  
The fourth step was called model estimation, which involved selecting the 
predictors which have a significant impact on the outcome under consideration. 
A backward stepwise regression analysis was used for choosing the predictors for 
the final prediction model. This method employs Akaike Information Criterion 
(AIC), which uses Chi-square value should be less than twice the value of degree 
of freedom (DF), as a requirement for selection of a predictor (321).   
The fifth step was called model performance. In this step, the discriminatory 
power of the final prediction model was visualised using a cumulative incidence 
plot. The sample was divided into four risk quartiles based on the predictor 
values selected in the final model.  
The sixth step was called model validation or stability using bootstrapping 
techniques. The idea behind bootstrap is to use the data of a sample study at 
hand as a “surrogate population”, for the purpose of approximating the sampling 
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distribution of a statistic; i.e. to resample (with replacement) from the sample 
data at hand and create a large number of “phantom samples” known as 
bootstrap samples (322). In step four which has been described above, selection 
of predictors (out of the nine predictors in total) for the final model was based 
on backward stepwise regression using the original sample data. In step six 
bootstrapping, backward stepwise regression was repeated on 200 “phantom 
samples” using bootstrapping. The choice of the predictors selected from the 
200 boot strapping samples was compared with that of the choice of predictors 
from the original sample selected from step four.  
The final step was called model presentation. In this step, the final prediction 
model was presented using a “nomogram” (a graphical representation of a 
scale). Each predictor in the final model was given a score based on its strength 
of influence on the outcome under consideration. The individual points assigned 
to a variable category were based on the strength of the association between 
that category and the outcome of interest. Additionally, the event free survival 
rates for sample patients with different scores were presented against different 
time intervals during follow-up, in a tabular format.  
The “rms” package in R, published by Frank Harrell, was used for the entire 
analysis described above (323).  
9.2.2 Area Under Curve for Risk Prediction Model 
The performance of the final prediction model in predicting a major adverse 
cardiovascular event was evaluated using “Area Under Curve (AUC)” graphs. An 
AUC value of more than 50% suggests that the predictive power of a particular 
predictor or a group of predictors is better than chance. The AUC values were 
presented along with 95% confidence intervals, which were calculated using 200 
boot strapping samples. The performance of the final model was compared to 
that of the individual predictors selected in the final model alone using AUC 
values with 95% CI.    
The “pROC” package in R was used for this part of the analysis(324).  
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9.3 Results 
9.3.1 Risk prediction model in DepChron patients who underwent 
depression screening (n=35537) 
3939 patients (11%) of the 35537 DepChron patients who underwent depression 
screening at baseline had suffered a major adverse cardiovascular event 
(cardiovascular death or admission due to MI/stroke/HF) by the end of 4 years of 
follow-up. Of the 35537 who were screened, 24829 patients (69.8%) were 
included for the final model prediction and the rest of the patients were 
excluded either due to extreme values of one of the peripheral biomarkers or 
due to missing values. In the final selected sample, 2886 patients (11.6%) had 
experienced an event by the end of 4 years follow-up. 
The nine predictor variables with their respective categories and distribution are 
described in Table 9-1.   
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Table 9-1 Distribution of predictors considered for MACE risk prediction model in DepChron 
patients  
Predictors considered for the final model development 
and their distribution 
Sample used for model 
development  
N=24829 
Age Group 
18-44 
45-64 
65-90 
 
565 (2.2%) 
6799 (27.4%) 
17465 (70.4%) 
Male sex (%) 14527 (58.5%) 
Deprived socio-economic status SIMD deciles<=5 (%) 16078 (64.8%) 
Number of cardiometabolic conditions- (%) 
One 
Two 
Three 
 
18215 (73.4%) 
5965 (24.0%) 
649 (2.6%) 
Systolic Blood Pressure-(%) 
130-139 mm Hg Reference 
120-129 mm Hg 
80-119 mm Hg 
140-159 mm Hg 
160-240 mm Hg 
 
6566 (26.4%) 
5332 (21.5%) 
4444 (17.9%) 
6565 (26.4%) 
1922 (7.8%) 
Diastolic Blood Pressure- (%) 
85-89 mm Hg Reference 
80-84 mm Hg 
40-79 mm Hg 
90-99 mm Hg 
100-130 mm Hg 
 
1424 (5.7%) 
5418 (21.8%) 
16105 (64.8%) 
1467 (5.9%) 
415 (1.8%) 
Body Mass Index (%) 
18.5-25 kg/m2 Reference 
15-18.5 kg/m2 
25-30 kg/m2 
30-55 kg/m2 
 
6091 (24.5%) 
278 (1.1%) 
9483 (38.2%) 
8977 (36.2%) 
Total Cholesterol in mmol/l (%) 
5-10 mmol/l 
 
4709 (19.0%) 
HADS-D Categories 
No Depression 
Presence of Depressive symptoms (≥8) 
 
 
19908 (75.3%) 
4921 (24.7%) 
 
MACE=Major adverse cardiovascular event (Cardiovascular death or admission due to MI/stroke/heart 
failure) 
 
Using the backward stepwise regression analysis, 8 out of 9 predictors were 
chosen for the final risk prediction model. Only DBP (p-value=0.48, DF=4) was 
eliminated from the final model as it did not make a significant impact on 
predicting the outcome. The final model consisted of 8 predictor variables: SBP, 
BMI, total cholesterol, age group, gender, socio-economic status, HADS-D 
screening result and number of cardiometabolic conditions (see Table 9-2).  
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Table 9-2 Final multivariable cox’s regression analysis-final model used for risk prediction 
model specification 
 
 
 
Figure 9-1 shows the performance of the eight selected predictors together in 
predicting a major adverse cardiovascular event using a cumulative incidence 
curve. Patients in the risk quartile four (based on the highest risk values of the 8 
predictors) had the highest event rate over four years. Patients in risk quartile 
four had an approximately 22% event rate at the end of four years as compared 
to an event rate of approximately 4% observed in patients in risk quartile one 
(lowest risk values of the 8 predictors). 
  Composite major adverse 
cardiovascular outcome (MACE) 
2920 events HR with 95% CI 
Systolic Blood Pressure in mm Hg 80-119 1.15 (1.03 to 1.29) 
120-129 1.00 (0.90 to 1.12) 
130-139 1 
140-159 1.07 (0.96 to 1.18) 
160-240 1.28 (1.11 to 1.49) 
BMI in kg/m2 15-18.5 1.36 (1.02 to 1.82) 
18.5-25 1 
25-30 0.83 (0.76 to 0.91) 
30-55 0.83 (0.75 to 0.92) 
Total Cholesterol in mmol/l 2-5 1 
5-10 1.21 (1.10 to 1.33) 
Presence of depressive symptoms (HADS-
D≥8) 
 1.22 (1.11 to 1.33) 
Age  1.05 (1.04 to 1.05) 
Sex-female  0.81 (0.75 to 0.88) 
Socio-economic status-affluent group  0.79 (0.73 to 0.86) 
Number of cardiovascular co-morbidities 
(vs. 1) 
 
2 1.95 (1.81 to 2.11) 
3 3.22 (2.76 to 3.76) 
Initiation of anti-depressants- treated vs. 
non-treated 
 0.84 (0.68 to 1.04) 
Concordance (SE)  0.692 (0.005) 
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Figure 9-1 Four risk quartiles based risk prediction model and cumulative incidence of 
MACE  
 
Legend:  Risk prediction model= eight predictors-SBP, BMI, total cholesterol, age group, gender, socio-
economic status, HADS-D screening result and number of cardiometabolic conditions; MACE=Major adverse 
cardiovascular event (Cardiovascular death or admission due to MI/stroke/heart failure) 
In bootstrapping analysis, backward stepwise regression was repeated on 200 re-
samples or “phantom samples”. Five out of eight predictors were chosen in the 
final prediction model for all of the 200 boot strap samples: age, SBP, BMI, 
socio-economic status and number of cardiometabolic conditions. Gender was 
chosen in 181 samples, total cholesterol in 184 and HADS-D screening result in 
188 samples. In total, all eight predictors were chosen in the final risk prediction 
model in 177 re-samples (88.5%) out of 200. Thus, the boot strapping analysis 
validated the choice of variables selected in the final risk prediction model for a 
major adverse cardiovascular event, based on this dataset.  
Table 9-3 shows the details of a risk prediction score (range 0-29) based on these 
8 predictor values at baseline. The age categories had the highest difference in 
points between  categories (10 points for age group 65-90 against 0 points for 
age group 18-44), closely followed by number of cardiometabolic conditions (8 
points for having all three cardiometabolic conditions, 4 points for having two 
cardiometabolic conditions and 0 points for having only one cardiometabolic 
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condition). The lowest differences were observed for socio-economic status, 
gender, HADS-D screening result and total cholesterol values (1 point each for 
deprived, male, positive result on depression screening and raised cholesterol 
categories against 0 for their respective low risk category). 
Table 9-3 Risk scoring system for prediction of MACE in DepChron 
Predictors  Points Predictors Points 
SBP 130-139 reference 0 Socio-economic status-deprived 1 
SBP 120-129 tightly 
controlled 
0 Socio-economic status-affluent 0 
SBP 80-119 low 1 Age group 18-44 0 
SBP 140-159 high 1 Age group 45-64 5 
SBP 160-240 very high 2 Age group 65-90 10 
BMI 18.5-25 reference 2 Gender Female 0 
BMI 15-18.5 low 5 Gender Male 1 
BMI 25-30 Overweight 1 HADS-D 0-7 No depressive 
symptoms 
0 
BMI 30-55 Obese 0 HADS-D 8-21 Presence of depressive 
symptoms 
1 
Number of 
cardiometabolic 
conditions-1 
0 Total cholesterol 2-5 0 
Number of 
cardiometabolic 
conditions-2 
4 Total cholesterol 5-10 1 
Number of 
cardiometabolic 
conditions-3 
8 Maximum Score=29 
Minimum Score=0 
1 
Legend:  Risk prediction model= eight predictors-SBP, BMI, total cholesterol, age group, gender, socio-
economic status, HADS-D screening result and number of cardiometabolic conditions; MACE=Major adverse 
cardiovascular event (Cardiovascular death or admission due to MI/stroke/heart failure) 
 
Figure 9-2 shows a “nomogram” or graphical representation of the points in the 
scoring system based on variable categories and also the event free survival rate 
based on corresponding scores on the scoring system. The figure shows that an 
increase in the score on the scale was associated with lower chances of being 
event free at 1, 2 and 4 years of follow-up. 
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Figure 9-2 Nomogram of risk scoring system for prediction of MACE in DepChron 
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Difference in event free survival rates observed with the different scores on the 
scoring system is also illustrated in Table 9-4. A higher score implies higher risk 
of subsequent MACE events. The table shows that with increase in follow-up 
duration, the event free survival rates reduce significantly for those with very 
high scores (and higher risk) on the scale. For example, the difference in event 
free survival at one year was 18% between those with the highest and lowest 
risk. However, the difference in event free survival at four years increased to 
62% between those with the highest and lowest risk.  
Table 9-4 Scoring system and event (MACE) free survival rate for the risk prediction model 
Points 1 year event 
free survival 
2 year event 
free survival 
4 year event free 
survival 
29 72% 50% 30% 
28 74% 55% 32% 
27 76% 60% 36% 
26 80% 65% 40% 
25 82% 70% 45% 
24 86% 75% 50% 
22 88% 80% 50% 
21 90% 82% 65% 
20 92% 85% 70% 
18 94% 90% 79% 
15 96% 92% 84% 
11 98% 95% 92% 
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Key Findings (Risk Prediction Model):  
 A risk scoring system with a range from 0-29 (consisting of eight 
predictor variables: age, gender, socio-economic status, SBP, BMI, 
HADS-D screening result, total cholesterol and number of 
cardiometabolic conditions) for predicting a MACE (cardiovascular 
death or admission due to MI/stroke/HF) over four years was 
constructed for DepChron patients who underwent depression 
screening (n=35537).  
 These results for the choice of predictor variables were validated for 
200 “phantom samples” or re-samples using bootstrapping 
 Higher scores on the scoring system were associated with higher risk of 
experiencing a MACE over four years. . 
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9.3.2 Area Under Curve for the risk prediction model for 
DepChron patients who underwent depression screening 
(n=35537) 
Figure 9-3 shows the AUC graph for the risk prediction model (eight predictors: 
SBP, BMI, total cholesterol, age group, gender, socio-economic status, HADS-D 
screening result and number of cardiometabolic conditions) with 95% confidence 
intervals, with MACE as the outcome. The AUC value of 56.7% suggests that the 
model had limited accuracy with reduction in specificity as sensitivity increased. 
Figure 9-3 AUC for risk prediction model for MACE at four years 
 Legend:  Risk prediction model= eight predictors-SBP, BMI, total cholesterol, age group, gender, socio-
economic status, HADS-D screening result and number of cardiometabolic conditions; MACE=Major adverse 
cardiovascular event (Cardiovascular death or admission due to MI/stroke/heart failure) 
Finally, the AUC value from the final model was compared to that of the AUC 
value for each of the eight predictors in the risk scoring system-HADS-D 
screening result, SBP, BMI, total cholesterol, age, gender, socio-economic status 
and number of cardiometabolic conditions (see Figure 9-4 to Figure 9-11). Age 
had the best individual AUC value among the eight predictors at 53.4% (see 
Figure 9-8) while number of cardiometabolic conditions was second best at 50.9% 
(see Figure 9-11). Among the peripheral biomarkers, BMI had the best AUC value 
at 50.4% (see Figure 9-6). All of the individual AUC values apart from age were 
less than 51%, which suggests that the individual predictors were not 
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substantially better at predicting the outcome than chance. Thus, using these 
eight predictors together in a risk scoring system did improve the AUC value as 
compared to using them individually, though the improvement was modest. 
Figure 9-4 AUC for HADS-D screening result for MACE at four years 
 
Figure 9-5 AUC for SBP for MACE at four years  
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Figure 9-6 AUC for BMI for MACE at four years  
 
Figure 9-7 AUC for total cholesterol for MACE at four years  
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Figure 9-8 AUC for age for MACE at four years 
 
Figure 9-9 AUC for gender for MACE at four years 
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Figure 9-10 AUC for socio-economic status for MACE at four years 
 
Figure 9-11 AUC for number of cardiometabolic conditions for MACE at four years 
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Key Findings (AUC analysis):  
 A model using eight predictors (SBP, BMI, total cholesterol, age 
group, gender, socio-economic status, HADS-D screening result 
and number of cardiometabolic conditions) was found to have a 
modest AUC value (56.7%, 95% CI 55.6%-57.5%) in risk prediction 
of MACE at four years. 
 The AUC value of the combined model was better than AUC 
values of the eight individual predictors, in risk prediction of 
MACE at four years.  
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9.4 Discussion 
9.4.1 Summary of Findings 
A risk scoring system (range=0-29) for predicting a major adverse cardiovascular 
event (cardiovascular death or admission due to MI/stroke/HF) over 4 years was 
constructed for DepChron patients who underwent depression screening 
(n=35537). The risk scoring system consisted of eight predictor variables (age, 
gender, socio-economic status, SBP, BMI, HADS-D screening result, total 
cholesterol and number of cardiometabolic conditions). DBP was considered but 
excluded from the final model due to having a statistically non-significant 
association with the outcome. Four out of the eight predictors selected were 
potentially modifiable: SBP, BMI, HADS-D screening result and total cholesterol.  
A higher score on the scoring system at baseline was associated with higher risk 
of major adverse cardiovascular event at 1, 2 and 4 year intervals. The AUC 
value of the scoring system was 56.7%, which implied poor  predictive ability. 
The AUC value of the scoring system using eight predictors together was better 
than that of the eight predictors used individually.  
9.4.2 Comparison of Findings with Existing Literature 
There are very few studies investigating the predictors of long term prognosis for 
patients who have experienced a myocardial infarction or stroke. The PREDICT 
score was devised to calculate the risk of six year all-cause mortality in patients 
hospitalized with a myocardial infarction (325). The variables included in the 
PREDICT score were age, kidney function, ECG findings, history of heart failure, 
admission day and history of shock at the time of hospitalization. In another 
study, the predictors for one year all-cause mortality in elderly patients 
hospitalized with acute myocardial infarction were investigated (326). The 
factors with the strongest association with mortality were older age, urinary 
incontinence, assisted mobility, presence of heart failure or cardiomegaly any 
time before discharge, presence of peripheral vascular disease, body mass index 
<20 kg/m2, renal dysfunction (defined as creatinine >2.5 mg/dl or blood urea 
nitrogen >40 mg/dl) and left ventricular dysfunction (left ventricular ejection 
fraction <40%). A systematic review found only one risk score for long term 
prediction of cardiovascular and general health outcomes in patients with 
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existing CHD (327). The GRACE risk score based on nine factors independently 
predicted death and the combined end point of death or myocardial infarction in 
the period from admission to six months after discharge: age, development (or 
history) of heart failure, peripheral vascular disease, systolic blood pressure, 
Killip class, initial serum creatinine concentration, elevated initial cardiac 
markers, cardiac arrest on admission, and ST segment deviation. The reported C-
statistics was 0.73 for death or myocardial infarction from admission to six 
months after discharge, which is higher than that of the model proposed in this 
analysis (328).  Finally, the data from the Heart and Soul study proposed a model 
consisting of N‐terminal pro‐type brain natriuretic peptide, high‐sensitivity 
cardiac troponin T, urinary albumin: creatinine ratio, and current smoking for 5‐
year secondary CV event and reported a C‐index  of 0.65 (329). 
A systematic review found a few studies investigating the use of prediction 
models for calculating the long term risk of recurrent stroke but these studies 
mainly used data at the time of acute presentation with stroke or transient 
ischaemic attack (TIA) (330). The majority of the scoring systems included in this 
systematic review were either of shorter duration or calculated for patients 
presenting with a TIA and hence not comparable to DepChron findings (330). The 
Oxford TIA score predicted five year risk of a cardiovascular event (combined 
risk of myocardial infarction or stroke) with a AUC value of 65% (95% CI 62% to 
68%) in patients presenting with acute stroke or TIA using eight clinical factors at 
the time of presentation: age, sex, affected region (amaurosis fugax as well as 
carotid and vertebrobasilar), frequency of TIA, residual neurological deficits, 
peripheral vascular disease, and left ventricular hypertrophy (331). The Essen 
Stroke Risk Score (ESRS) was derived from the CAPRIE (clopidogrel vs aspirin in 
patients at risk of ischemic events) trial in patients with vascular disease with a 
mean follow-up of 1.9 years (332). The study used eight clinical predictors to 
calculate the risk of recurrent stroke: age, hypertension, diabetes mellitus, 
myocardial infarction, other cardiovascular disease, peripheral artery disease, 
smoking status, and history of TIA or stroke; and the reported AUC value was 61% 
(95% CI 54% to 69%). (332). 
This is the first study to my knowledge which involved calculating a risk scoring 
system for predicting a major adverse cardiovascular event for patients with 
existing cardiometabolic disease in a community setting. 
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9.4.3 Strengths of Findings 
1. The method used for developing the scoring system was robust and has been 
validated in the published literature (318,320,333–336).  
2. The clinical outcome and the various predictors considered for developing the 
risk prediction models were relevant for the sample under study.  
3. The data was collected from a community setting as a part of routine practice 
hence likely to reflect real life clinical practice and had a large sample size. The 
event per variable ratio was appropriate after excluding missing values.  
9.4.4 Limitations of Findings 
There are various limitations of this dataset which have been highlighted 
previously in chapters 5 and 7. The limitations of this particular analysis were: 
1. There was no external validation of the findings. The accuracy of risk scoring 
systems has to be investigated in different patient samples. In addition, the 
overall AUC value of the risk prediction model was poor.  
2. Information on smoking status at the time of the start of study was missing 
from this data. Smoking status is likely to influence the outcome considered i.e. 
major adverse cardiovascular event and could be an important component of a 
risk scoring system for predicting secondary cardiovascular events in patients 
with existing cardiometabolic disease (332). In addition, information on disease 
severity and duration, polypharmacy and presence of chronic kidney disease was 
missing, which may have influenced the outcome considered.  
3. Information on other relevant co-morbid conditions such as heart failure and 
peripheral vascular disease was missing. These are likely to be important 
predictors of the outcome considered (325,326,331,332). 
9.4.5 Potential Implications 
There are various national guidelines recommending lifestyle and 
pharmacological interventions in patients with existing cardiometabolic disease 
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for secondary prevention (244,246,337). However, adherence to pharmacological 
and lifestyle measures remains sub-optimal (338,339). Moreover, evidence has 
suggested that better adherence may lead to better outcomes in this population 
(340).  
Improving treatment adherence for patients with cardiometabolic disease is a 
huge challenge for health care resources considering the increase in survival 
rates post MI and stroke (341). Better risk stratification based on prognosis may 
potentially lead to better resource allocation by increasing monitoring for 
patients with the highest risk of secondary events (334,336). This in turn, may 
lead to improvement in clinical outcomes; however further research is needed in 
this area. For example, currently in  UK primary care, a comprehensive annual 
health assessment is offered to all patients with cardiometabolic disease, based 
on QOF incentives (342,343). This disease management programme does not take 
account of a patient’s risk of having secondary cardiovascular outcomes when 
offering monitoring (342,343). In other words, this is a “one size fits all” 
approach. Further research is warranted to explore the benefits, if any, of 
modifying the level of monitoring offered on the basis of a patient’s individual 
risk of suffering adverse clinical outcomes.  
9.4.6 Conclusion 
In a cohort of patients with existing cardiometabolic disease (CHD, previous 
stroke or diabetes), it was possible to construct a scoring system based on 
baseline demographic and clinical variables collected in the community to 
predict the risk of a secondary cardiovascular event (cardiovascular death or 
admission due to MI/stroke/HF). The risk scores constructed had limited 
accuracy. The risk score needs further external validation in other patient 
groups and may need modification by including other relevant predictors missing 
from this data to improve accuracy. Risk stratification based on prognosis may 
have the potential to improve resource allocation to the highest risk patients, 
and this in turn may lead to better clinical outcomes.  
In the final chapter of this thesis, the overall findings are summarized and key 
strengths and limitations as well as potential implications for future research are 
discussed. 
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Chapter 10 Discussion: Key Findings, Implications, 
Summary of Strengths and Limitations, and 
Conclusion 
10.1 Chapter Summary 
In this chapter, the main findings of this thesis and its potential clinical and 
research implications are discussed. A summary of key strengths and limitations 
of the whole body of work is followed by reflections on development of personal 
skills and learning during the course of writing this thesis and an overall 
conclusion. 
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10.2 Key Findings and Comparison with Literature 
Literature Review Findings 
The reviews showed that blood based peripheral biomarkers were statistically 
significant in predicting six different clinical outcomes in participants with 
depressive symptoms. Outcomes related to both mental health (depressive 
symptoms) and physical health were statistically associated with pre-treatment 
levels of peripheral biomarkers; however only two studies investigated outcomes 
related to physical health. Twelve different biomarkers related to five different 
biological systems were found to have a statistically significant association with 
clinical outcomes in patients with depressive symptoms, while 24 biomarkers 
were found to have no statistical association with clinical outcomes studied. 
Despite extensive research on the relationship of biomarkers and depressive 
symptoms, the research was of generally limited quality and clinical utility. 
Depression and cardiometabolic disease                                                     
DepChron patients had a high prevalence of depressive symptoms (19.9%). In 
addition, DepChron patients with co-morbid depressive symptoms were more 
likely to suffer from all-cause mortality, all-cause hospital admissions and major 
adverse cardiovascular events over four years as compared to those without 
depressive symptoms, after adjusting for potential confounders (see Chapter 7). 
This resonates with findings from the published literature which suggests that 
patients with cardiometabolic disease are more likely to have co-existing 
depressive symptoms than the general population  (105–107) and that patients 
with cardiometabolic disease and depressive symptoms are more likely to have 
adverse clinical outcomes as compared to those without depressive 
symptoms(127,128,278,344).  
Role of peripheral biomarkers in depression risk assessment 
Analysis of the DepChron dataset suggested that SBP and HbA1c may have a 
potential role in risk stratification of patients with cardiometabolic disease and 
co-morbid depressive symptoms (see Chapter 7). There was a statistically 
significant interaction noted between SBP and depressive symptoms in risk 
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prediction of major adverse cardiovascular outcome (p-value=0.03). Patients 
with low SBP only, with very high SBP only and depressive symptoms only at 
baseline had 10%, 19% and 17% higher risk respectively of a MACE as compared to 
those without extremes of SBP and no depressive symptoms. In comparison, 
patients with both low SBP and depressive symptoms at baseline had 36% higher 
risk while patients with both very high SBP and depressive symptoms had the 
highest increased risk of 83%. There was also a statistically significant 
interaction between HbA1c and depressive symptoms in risk prediction of all-
cause mortality for patients with diabetes (p-value=0.04). Patients with low 
HbA1c (3 to 6.4) only, with high HbA1c ( 7.5 to 18) only and depressive 
symptoms only at baseline had 18%, 27% and 37% higher risk respectively of all-
cause death as compared to those with reference HbA1c (6.5 to 7.4) and no 
depressive symptoms. In comparison, patients with both low HbA1c and 
depressive symptoms at baseline had 34% higher risk while patients with both 
high HbA1c and depressive symptoms had the most elevated risk of 108% as 
compared to those in the reference HbA1c group without depressive symptoms. 
This is the first study, to my knowledge, which investigates the interacting 
relationship between depressive symptoms and BP and HbA1c values in the risk 
prediction of adverse clinical outcomes in patients with pre-existing 
cardiometabolic disease. 
AI score, depression and clinical outcomes 
Among DepChron patients (majority of older age group >65 and with existing 
cardiometabolic conditions), there was a cross-sectional association between AI 
score calculated with primarily cardiometabolic biomarkers and depressive 
symptoms (see Chapter 5). Among Psobid participants (aged 35-65 and chosen 
from general population), a cross-sectional association was not observed 
between AI score and depressive symptoms (see Chapter 6). In DepChron and 
Psobid, AI score using multiple biomarkers did not have a stronger association 
with depressive symptoms than its individual biomarkers (see Chapter 5 and 6). 
In various cross-sectional studies involving mainly elderly populations, depression 
has been observed to have a significant association with AI score (216,217,219), 
which was contradictory to the non-significant relationship observed in the 
Psobid participants.  In addition, AI score did not have any statistical interaction 
in predicting adverse physical outcomes in patients presenting with depressive 
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symptoms in the DepChron and Psobid cohorts (see Chapter 7 and 8).On the basis 
of the analysis in this thesis, using an algorithm of multiple biomarkers (such as 
AI score), instead of using single peripheral biomarkers, did not offer any added 
utility in predicting adverse physical health outcomes in patients with depressive 
symptoms. Again, this is in contrast with some of the previously published 
studies reporting an association between AI score with various adverse physical 
adverse health outcomes (233)(28). 
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10.3 Discussion - Implications of Findings 
The findings of this programme of work have potential implications for: 
1. The studies of relationship between depressive symptoms and peripheral 
biomarkers and depressive symptoms   
2. The management of patients presenting with depressive symptoms and 
co-morbid cardiometabolic disease.  
10.3.1 Relationship between depressive symptoms and 
peripheral biomarkers 
General practitioners are faced everyday with the challenge of differentiating 
“normal distress” caused by difficult life circumstances from a “pathological” 
depressed state, for patients presenting with depressive symptoms, in clinical 
practice. Risk stratification for depressive symptoms is important because it is 
likely to guide management recommendations for the patient. We now have 
evidence to suggest that merely counting depressive symptoms reported by the 
patient may not be good enough to formulate management plans, due to a lack 
of accuracy and heterogeneity in presentation (33,345). So this leads to the 
question: What are the possible alternatives for assessing patients presenting 
with depressive symptoms? 
An alternative strategy could be to stratify patients presenting with depressive 
symptoms based on their risk of adverse clinical outcomes, and such a strategy 
has been used widely in other areas of medicine (320,335,336).  In future, more 
work is needed in the area of outcomes based risk stratification of depressive 
symptoms, particularly investigating the role of peripheral biomarkers. In this 
thesis, only physical health outcomes were assessed in the two cohorts. Future 
research needs to investigate the role of peripheral biomarkers in risk 
stratification of depressive symptoms with a focus on mental health outcomes 
such as recovery or remission of depressive symptoms. Secondly, the findings 
from this thesis need to be replicated in different patient populations, ideally in 
prospective studies where more information on potential confounders such as 
disease severity and duration and lifestyle factors (such as smoking status) are 
known, to validate the observed association between peripheral biomarkers and 
adverse physical outcomes noted in the DepChron data.  Future research in this 
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area could potentially lead to the use of peripheral biomarkers in defining the 
risk of both physical and mental adverse health outcomes in patients presenting 
with depressive symptoms, which in turn might improve their risk stratification 
in clinical practice. The important caveat being that the findings of DepChron 
and Psobid are based on depressions screening rather than a clinical diagnosis of 
MDD.  
The reasons for the observed findings of this thesis between AI score, depressive 
symptoms and adverse clinical outcomes remain unclear and needs further 
research. Future research on the usefulness of AI score in clinical practice should 
focus on its relationship with depressive symptoms in a middle aged population, 
as this has not been studied extensively (216,217,219). Secondly, in both 
cohorts, some of the individual biomarkers were found to have a stronger 
association with adverse clinical outcomes than AI score. The clinical utility for 
AI score may depend on its predictive power for adverse clinical outcomes, over 
and above individual biomarkers. Further research is needed to compare the 
predictive power of AI score for adverse clinical outcomes against that of 
individual biomarkers to determine whether there really is added value from 
using AI score as has been previously (233)(28).   
10.3.2 Management of depressive symptoms in patients with 
cardiometabolic disease 
There are two important implications for research and practice, based on the 
findings from this programme of work. Firstly, findings from DepChron have 
suggested or raised the possibility that there may be practical means of 
identifying those cardiometabolic disease patients who are more likely to have 
co-existing depressive symptoms, who might benefit from “targeted” depression 
screening. Depression screening has been recommended for patients with 
cardiometabolic disease, in view of  the high prevalence of depression,  by the 
American Heart Association (112); however there is no evidence to date that 
routine depression screening for patients with cardiometabolic disease leads to 
any improvement in depressive symptoms or cardiovascular outcomes (114,115). 
In contrast to the findings of this thesis, there is some evidence to suggest that 
blanket depression screening for all cardiometabolic disease patients has been 
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found to have a “low yield” of positive results (346), and in turn may not be cost 
effective. The UK Quality and Outcomes Framework (QOF), an annual reward 
and incentive programme for primary care, offered financial incentives to 
primary care practitioners for routine depression screening for all patients with 
coronary heart disease and diabetes, between 2006/07 and 2013/14 (149); these 
financial incentives have subsequently been withdrawn since 2013/14 (150). 
NICE (National Institute for Health and Care Excellence) recommends that 
depression screening or ‘case finding’ in patients with chronic disease should 
only be targeted towards those who are believed to be ‘high risk’ (148).  
Findings form analysis of the DepChron dataset (see Chapter 5); suggest that 
cardiometabolic disease patients with abnormal biomarker values (such as SBP 
and HbA1c) are at ‘high risk’ of having co-morbid depressive symptoms. Further 
research is needed in this area, to validate these findings in other patient 
populations, before making any clinical recommendations but clearly this is an 
important area for further investigation. If these findings are validated in other 
cohorts, the next step for research in this area would be developing and testing 
an intervention which would target those identified through depression 
screening as ‘high risk’ (based on their biomarker values) cardiometabolic 
disease patients.  
Secondly, it was possible to construct a scoring system based on baseline 
demographic and clinical variables collected in the community to predict the 
risk of a secondary cardiovascular event (cardiovascular death or admission due 
to MI/stroke/HF) in the DepChron cohort, although with limited accuracy (see 
Chapter 9). The analysis of the DepChron data suggested that patients with 
multiple cardiometabolic conditions, who also had a combination of high SBP and 
depressive symptoms were at the highest risk of having a secondary 
cardiovascular event (see Chapter 9). Currently in the UK, patients with existing 
cardiometabolic disease are usually offered a yearly review appointment with 
the practice nurse in their GP surgery (149), not taking into account their risk of 
secondary cardiovascular events. Cardiometabolic disease patients who are at 
higher risk of secondary cardiovascular events may benefit from increased 
monitoring of some of their modifiable risk factors such as SBP or more intensive 
efforts at engagement if they do not attend or adhere to therapies.  It will be 
important to try to replicate the analyses undertaken using the DepChron 
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dataset in other datasets where potential confounders are better characterised 
and missing data is less of a problem. For example, these findings could be 
replicated in other large datasets such as UK Biobank 
(http://www.ukbiobank.ac.uk/about-biobank-uk/) or Generation Scotland 
(http://www.generationscotland.org ). Again, it is not possible to make any 
clinical recommendations based solely on the findings from DepChron but this 
work does indicate that further research is needed in this area.  
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10.4 Summary of Key Strengths and Limitations 
This programme of work has a number of key strengths which are summarized 
here. The analyses were performed in two different patient cohorts with 
different demographic profiles and characteristics. The DepChron dataset had a 
very large sample size and provided us with data collected from routine care, 
reflecting clinical practice. The second dataset, Psobid, provided access to a 
wide range of peripheral biomarkers, allowing a comprehensive calculation of AI 
score. Electronic data linkage was successful for the majority of the sample for 
both datasets. Two validated but different instruments were used for depression 
assessment in the two datasets; this latter issue can be viewed as strength but 
also a limitation.  
Important limitations have been described in detail within each section but some 
overarching limitations were as follows.  For both datasets, there was only a 
single measurement of the peripheral biomarkers and depression status available 
for both patient cohorts.   These factors could have changed over the course of 
follow-up and it would have been preferable to have information on these data 
available at multiple time points.  In general practice clinical setting, usually an 
approach consisting of multiple assessments over a period of time is used in 
making diagnostic and prognostic assessments of patients presenting with 
depressive symptoms. An important limitation in DepChron was the large number 
of patients with missing values which limited the scope of the analyses. 
Importantly, information about potential confounders such as smoking status, 
disease duration and severity, use of psychological therapies and cardiovascular 
medications were missing from DepChron participants.  
In addition, although the Psobid dataset had a broader range of biomarkers to 
study, the number of clinical outcomes observed among Psobid participants over 
the follow-up duration was low, which limited the intended statistical analysis. 
Finally, neuroendocrine biomarkers frequently used in AI score calculation were 
not available in either dataset.  
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10.5 Skills Development and Learning 
This project has enabled me to develop an understanding of some key statistical 
skills. I have learned to use logistic and linear regression modelling and 
presenting for studying cross-sectional association. I have also developed an 
understanding of using survival analysis methods such as cox regression analysis 
for cohort studies. Finally, I have learned the statistical techniques of 
developing a risk prediction model and checking its accuracy using methods such 
as Area under Curve. I have developed an understanding of using ‘R’, which is an 
open source statistical software. These statistical methods are likely to be very 
useful to me in future while pursuing a career in academic medicine.  
In addition to learning valuable statistical skills, I have acquired an 
understanding of the principles of conducting an epidemiological study. For 
example, sample size and the quality of data are important factors to be 
considered while selecting a dataset to answer a research question. DepChron 
was a large dataset with poor data completion rate, which is often the case for 
data collected as a part of routine clinical practice. Psobid was a smaller dataset 
with good data completion rate, which is more likely in a research project 
dataset. This thesis involved secondary data analysis which meant huge savings 
in the cost and the time involved for the project. However, there was a need to 
compromise on the number and the type of biomarkers used for AI score 
calculation, as it was a secondary data analysis. Importantly, external validation 
of findings is an important step for any epidemiological study, which I was 
unable to do with the resources available during the course of this fellowship. 
However, I am planning to repeat these analyses using other datasets in the near 
future.  
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10.6 Future Research Implications 
Further research should focus on studying the interaction of peripheral 
biomarkers with depressive symptoms in predicting clinical outcomes, and risk 
stratification of patients with cardiometabolic disease and co-morbid 
depression. Potential future research studies would include:  
• Replicating the findings of DepChron in different datasets, preferably in 
datasets which do not have some of the key limitations that have been described 
concerning the DepChron dataset. Importantly, re-examination in a dataset with 
good quality data on potential confounders such as lifestyle factors (e.g. 
smoking status), disease severity and cardiovascular medications would be 
useful.  
• The potential datasets could be large existing cohort studies, for 
example, UK Biobank cohort UK Biobank cohort 
(http://www.ukbiobank.ac.uk/about-biobank-uk/) and Generation Scotland 
(http://www.generationscotland.org ), or it could be secondary data analysis of 
trial datasets available from NIH (National Institute of Health) data repository 
(e.g. ENRICHD https://biolincc.nhlbi.nih.gov/studies/enrichd/) or elsewhere. 
If the results found in DepChron were replicable in other datasets then 
consideration could be given to intervention development such as:   
• Developing an intervention for targeting depression screening for those 
patients with cardiometabolic disease who are noted to have either extremes of 
cardiovascular biomarker values (for e.g. blood pressure, BMI and HbA1c), as 
they are at higher risk of having concurrent depressive symptoms.  
• Testing a disease management programme for patients with 
cardiometabolic disease where the level of monitoring offered to a patient is 
determined by their individual risk of suffering from adverse cardiovascular 
outcomes and exploring cost effectiveness of this intervention.   
• Developing an intervention for patients with cardiometabolic disease and 
co-morbid depressive symptoms where the management approach focuses 
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equally on cardiovascular risk reduction and improvement in depressive 
symptoms. The majority of intervention studies in this area have focussed on 
managing depressive symptoms and have failed to show any benefit in reducing 
cardiovascular outcomes. A management approach which focuses on 
cardiovascular risk reduction as well may lead to an improvement in 
cardiovascular outcomes in patients with cardiometabolic disease and co-morbid 
depressive symptoms.  
Clearly any of the above type of intervention studies would necessitate 
extensive user involvement to examine views of the acceptability and feasibility 
of such approaches and to aid intervention development. 
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10.7 Conclusion 
Depressive symptoms were found to have a cross-sectional association with 
individual peripheral biomarkers both in patients with cardiometabolic disease 
and middle-aged participants recruited from the general population.  Depressive 
symptoms were also associated with a higher risk of adverse clinical outcomes in 
patients with cardiometabolic disease. AI score calculated with different 
statistical formulations did not add any additional usefulness in predicting 
concurrent depressive symptoms or clinical outcomes at follow-up, over and 
above its individual constituent biomarkers, in either of the patient cohorts. 
 
SBP had a significant interaction with depressive symptoms in predicting 
cardiovascular events in patients with cardiometabolic disease; HbA1c had a 
significant interaction with depressive symptoms in predicting all-cause 
mortality in patients with diabetes. Peripheral biomarkers may have a role in 
predicting clinical outcomes in patients with depressive symptoms, especially for 
those with existing cardiometabolic disease. The scoring system for predicting a 
major adverse cardiovascular event in patients with depression and 
cardiometabolic disease showed limited predictive ability.  
 
 
The findings from this thesis have improved the understanding of the 
relationship between cardiovascular biomarkers, depressive symptoms and 
adverse clinical outcomes in patients with cardiometabolic disease. This has the 
potential to lead to further research in this sphere with the potential to change 
clinical practice by improving our understanding of the risk stratification of 
patients with depressive symptoms, especially in patients with existing 
cardiometabolic disease, which may in turn influence future management. 
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Depression is one of the major global health challenges and a leading contributor of
health related disability and costs. Depression is a heterogeneous disorder and current
methods for assessing its severity in clinical practice rely on symptom count, however this
approach is unreliable and inconsistent. The clinical evaluation of depressive symptoms is
particularly challenging in primary care, where the majority of patients with depression are
managed, due to the presence of co-morbidities. Current methods for risk assessment
of depression do not accurately predict treatment response or clinical outcomes. Several
biological pathways have been implicated in the pathophysiology of depression; however,
accurate and predictive biomarkers remain elusive. We conducted a systematic review of
the published evidence supporting the use of peripheral biomarkers to predict outcomes in
depression, using Medline and Embase. Peripheral biomarkers in depression were found
to be statistically significant predictors of mental health outcomes such as treatment
response, poor outcome and symptom remission; and physical health outcomes such as
increased incidence of cardiovascular events and deaths, and all-cause mortality. However,
the available evidence has multiple methodological limitations which must be overcome
to make any real clinical progress. Despite extensive research on the relationship of
depression with peripheral biomarkers, its translational application in practice remains
uncertain. In future, peripheral biomarkers identified with novel techniques and combining
multiple biomarkers may have a potential role in depression risk assessment but further
research is needed in this area.
Keywords: peripheral biomarkers, depression, treatment response, risk assessment, outcomes
INTRODUCTION
HETEROGENEITY IN DEPRESSIVE SYMPTOMS
Depression is a heterogeneous disorder with a spectrum ranging
from minor/sub threshold to major depressive disorder (MDD)
(Rodriguez et al., 2012). According to the latest global disease bur-
den study, depressive disorders (MDD and sub threshold/minor
depression) are the leading cause of disability and disease burden
globally (Ferrari et al., 2013). The methods currently available
for risk assessment and stratification of symptom severity for
patients presenting with depressive symptoms rely predominantly
on counting the absolute number of depressive symptoms present
but there is no universally accepted standardized definition. The
Diagnostics and Statistical Manual (DSM)-IV’s diagnosis of a
MDD requires the presence of at least 5 out of 9 symptoms of
depression with significant impairment or distress, while those
presenting with at least 2 but less than 5 symptoms and no
previous history of MDD are stratified as sub threshold or
minor depression (American Psychiatric Association, 2000). The
category of sub threshold depression has been removed from
recently published DSM-V (American Psychiatric Association,
2013). On the other hand, the International Classification of
Diseases (ICD-10) stratifies depressive symptoms on the basis
of the number of depressive symptoms present into mild (4 out
of 10), moderate (5 or 6 out of 10) and severe (7 or more out
of 10) depressive episode (WHO, 2010). However, this approach
has been questioned owing to lack of consensus (Wittchen et al.,
2001; Hegerl et al., 2012) and because it ignores the complexity
and diversity of depressive symptoms (Goldberg, 2011). The bulk
of patients reporting with depressive symptoms are managed in
primary care; however the rate of accurate stratification of depres-
sive symptoms in primary care was less than 50% based on a
meta-analysis involvingmore than 50,000 patients (Mitchell et al.,
2009). Minor or sub threshold depression has been associated
with severe deficits in psychological well-being and quality of life,
progression to major disorder and increased mortality (Cuijpers
and Smit, 2002; Lyness et al., 2006; Nierenberg et al., 2010),
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underlining the need for its early identification and appropriate
treatment.
MANAGEMENT OF DEPRESSION
The uncertainty in stratifying depression severity based on symp-
tom count affects subsequent management. A review of treat-
ment guidelines for depression across North America and Europe
revealed that “mild MDD and sub threshold depression has the
most variance in recommendations”; with suggested approaches
ranging from watchful waiting to active treatment with antide-
pressants (Davidson, 2010). In the last decade, three separate
meta-analyses reported that the efficacy of antidepressants is
related to the initial severity of depression and they may not be
effective in the treatment of mild depression (Khan et al., 2002;
Kirsch et al., 2008; Fournier et al., 2010). However, this view has
been challenged recently with emerging evidence suggesting that
the efficacy of antidepressants in depression may not be related
to its initial severity (Gibbons et al., 2012; Fountoulakis et al.,
2013). Psychological therapies have been found to be effective in
the management of mild depression but they have not been sub-
jected to the same level of scrutiny as pharmacological therapies as
yet (Cuijpers et al., 2007). The ambiguity surrounding stratifying
the severity of depression based on symptom count and its sub-
sequent management could partially explain why most patients
with depression do not receive adequate treatment and many
treated patients develop treatment resistance and relapse (Thase,
2006; Nemeroff, 2007). Therefore, different approaches for risk
assessment and severity stratification of patients presenting with
depressive symptoms are urgently required.
PATHOGENESIS OF DEPRESSION
The etiopathogenesis of depression has been extensively studied
over the last five decades with various explanatory mechanisms
involving different physiological systems, suggesting heterogene-
ity (Zunszain et al., 2011). The “monoamine hypothesis of
depression” was proposed in the 1960s with early work show-
ing increased levels of plasma tryptophan (serotonin precursor)
in patients with major depression (Coppen et al., 1973). Failure
to suppress cortisol in response to dexamethasone in patients
with depression was the initial finding which supported the role
of hypothalamic-pituitary-adrenal (HPA) axis hyperactivity in
the pathophysiology of depression (Carroll et al., 1981). The
“cytokine hypothesis” suggests that depression is triggered, in
part, via inflammatory processes in response to various internal
and external stressors, following some seminal work in the early
1990s (Maes et al., 1991). This hypothesis has been further devel-
oped to suggest that inflammatory, oxidative and nitrosative stress
are causally related to depression and increased translocation of
lipopolysaccharide from gram negative bacteria may aggravate
these pathways (Maes, 2008). The “neurogenesis hypothesis” of
depression proposes that depression is characterized by neurode-
generation and impaired neurogenesis in the brain, in particular
the hippocampus region (Sapolsky, 2004). The bi-directional
relationship between metabolic syndrome and depression and
their common pathophysiological pathways has been reported
extensively (McIntyre et al., 2009; Vancampfort et al., 2013). Of
course, several hypotheses may overlap or be relevant here.
BIOMARKERS OF DEPRESSION
A biomarker can be defined as a characteristic that is objec-
tively measured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention (Biomarkers Definitions Working
Group, 2001). The research into pathogenesis of depression has
led to a strong evidence base supporting a cross-sectional rela-
tionship between depressive symptoms and a number of differ-
ent biomarkers pertaining to some of the physiological systems
described above, but their role, if any, in predicting clinical out-
comes in depression remains unclear (Macaluso et al., 2012).
Peripheral biomarkers (blood based) are relatively non-invasive
(other than the need for a blood sample) and easier to measure;
hence they have a greater potential for translational application
into routine clinical practice, when compared to imaging, genetic
and CNS biomarkers. Peripheral biomarkers such as those related
to HPA axis, inflammatory and monoamine systems may have
a role in the diagnosis of depression by identifying a “biologi-
cal sub-type” of depression, and in prognostication of depression
by predicting treatment response, which in turn could help in its
severity stratification and management (Fisar and Raboch, 2008;
Leuchter et al., 2010; Schmidt et al., 2011). Various inflamma-
tory and oxidative stress biomarkers have been proposed to have
a potential role, not only in predicting antidepressant response,
but also in enhancing treatment matching and onset prediction in
patients with depression (Lopresti et al., 2014). For example, in a
study based on a multi-center trial involving depression patients,
showed an interaction between antidepressants and C-reactive
protein with patients with raised CRP more likely to respond to
nortripytline than escitalopram (Uher et al., 2014).
AIMS OF THE REVIEW
To attempt to address this issue, we examine the evidence base
exploring the potential role of peripheral biomarkers at base-
line in predicting future outcomes in patients with depression.
We discuss the potential role of peripheral biomarkers identi-
fied using novel and emerging techniques such as proteomics,
metabolomics, genetics, and epigenetics in risk assessment and
outcome prediction in patients with depressive symptoms. We
also review the relationship between depressive symptoms and
a composite index score derived using multiple peripheral
biomarkers such as allostatic index (AI) and discuss its possible
role in future, in management of depression.
METHODS
Two electronic databases (Ovid Medline and Embase) were
searched for studies published between 1946 and Jan 2013 using
the MESH terms “Biological markers” AND “Depression.” All
original and review studies using peripheral biomarkers at base-
line as a risk assessment tool for predicting future outcomes
in patients with depression were included. Clinical outcomes
pertaining to both mental health (e.g., depressive symptoms)
and physical health (e.g., cardiovascular event) were included.
Only studies published in English language were considered
for inclusion. Studies related to animal, imaging biomarkers,
cerebrospinal fluid biomarkers, and mood disorders other than
depression were excluded. Studies which investigated the role of
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depressive symptoms and peripheral biomarkers independently
in predicting adverse physical outcomes but did not examine
the interaction between depressive symptoms and peripheral
biomarkers, or in other words did not perform a sub-group
analysis in patients with depression, were excluded. Studies that
investigated changes in peripheral biomarker levels following
treatment for depression and which didn’t report any correla-
tion between baseline biomarker levels and depressive symptoms
were excluded as the aim of this review was to focus on the use of
peripheral biomarkers at baseline or pre-treatment as a predictive
tool of clinical outcome (both mental and physical), rather than
a change in biomarker level itself. The search strategy returned
1096 studies from two databases after excluding duplicates (see
Figure 1 for details).
Title, abstract and full text screening followed by reference and
citation searching and data extraction were carried out indepen-
dently by two researchers (Bhautesh D. Jani and Gary McLean).
The data extraction comprised of study sample size and country,
type of study and setting, details of how depression was diagnosed
and treated, follow-up duration, biomarkers assessed, clinical
outcomes studied and potential bias in the results. The descrip-
tion of methodology used by included studies for biomarker
measurement and the source of peripheral biomarker (i.e., serum
or plasma or whole blood) was also reviewed in data extraction.
RESULTS
INCLUDED STUDIES AND THEIR CHARACTERISTICS
There was extensive evidence (109 studies) exploring and sup-
porting the cross-sectional relationship between depression and
different peripheral biomarkers. However, only a minority of
studies (n = 14) explored the use of peripheral biomarkers to pre-
dict outcomes in patients with depression. Fifteen papers were
included for data extraction; which consisted of nine prospec-
tive cohort studies (Duval et al., 1996; Perez et al., 1998; Alvarez
et al., 1999; Johnston et al., 1999; Lanquillon et al., 2000; Ladwig
et al., 2005; Binder et al., 2009; Jokinen and Nordstrom, 2009;
Baune et al., 2012), three case-control studies (Arolt et al., 2003;
Baldwin et al., 2006; Jang et al., 2008), two randomized controlled
trials (Kin et al., 1997; Raison et al., 2013) and one meta-analysis
(Ribeiro et al., 1993). Full details of included studies are summa-
rized in Table 1.
Sample sizes ranged from 8 to 986 with sample sizes of less
than 50 participants in00206 studies (Duval et al., 1996; Alvarez
et al., 1999; Johnston et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003; Baldwin et al., 2006), while three studies had a sample
size of 25 or less (Alvarez et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003). Follow-up duration ranged from 4 weeks to 18 years
with the follow-up duration being less than 6 months in 9 stud-
ies(Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez
et al., 1999; Lanquillon et al., 2000; Arolt et al., 2003; Jang et al.,
2008; Binder et al., 2009; Raison et al., 2013) while only 5 stud-
ies followed their subjects for more than 12 months (Johnston
et al., 1999; Ladwig et al., 2005; Baldwin et al., 2006; Jokinen and
Nordstrom, 2009; Baune et al., 2012). Six studies used a diagnos-
tic interview technique (Duval et al., 1996; Johnston et al., 1999;
Lanquillon et al., 2000; Arolt et al., 2003; Baldwin et al., 2006; Jang
et al., 2008) and seven studies used a depression rating scale (Kin
et al., 1997; Perez et al., 1998; Alvarez et al., 1999; Ladwig et al.,
2005; Binder et al., 2009; Baune et al., 2012; Raison et al., 2013)
while diagnostic method was not specified in one of the included
FIGURE 1 | Flow chart for the systematic review on the role of peripheral biomarkers predicting outcomes in patients with depression.
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studies (Jokinen and Nordstrom, 2009). The nature of the treat-
ment was specified in nine studies(Duval et al., 1996; Kin et al.,
1997; Perez et al., 1998; Alvarez et al., 1999; Lanquillon et al., 2000;
Arolt et al., 2003; Jang et al., 2008; Binder et al., 2009; Raison et al.,
2013); the relationship between outcome and baseline depres-
sion severity was only taken into account in 5 studies (Duval
et al., 1996; Johnston et al., 1999; Lanquillon et al., 2000; Arolt
et al., 2003; Baldwin et al., 2006). The included meta-analysis
had a variable sample size and follow-up duration depending
on the different research questions considered by the study and
the diagnostic methods used were heterogeneous including var-
ious symptoms scores and interview techniques (Ribeiro et al.,
1993).
BIOMARKERS STUDIED AND METHOD OF COLLECTION
The included studies assessed 36 different peripheral biomarkers
at baseline as a predictor of clinical outcomes. These biomark-
ers were measured in serum or plasma and could be broadly
classified as pertaining to inflammatory (n = 14), neurotrans-
mitter metabolism (n = 9), neuroendocrine (n = 8), metabolic
(n = 4), and neurotrophic (n = 1) systems. All included stud-
ies assessed statistical significance based on the criteria of having
a p-value less than 0.05. Twelve biomarkers were found to be
statistically significant in predicting outcomes (summarized in
Figure 2). Inflammatory (Lanquillon et al., 2000; Ladwig et al.,
2005; Baldwin et al., 2006; Baune et al., 2012; Raison et al., 2013)
and neuroendocrine (Ribeiro et al., 1993; Duval et al., 1996; Kin
et al., 1997; Johnston et al., 1999; Jokinen and Nordstrom, 2009)
biomarkers were each assessed in five of the included studies, fol-
lowed by neurotransmitter (Perez et al., 1998; Alvarez et al., 1999;
Johnston et al., 1999) biomarkers in three studies, neurotrophic
(Arolt et al., 2003; Jang et al., 2008) biomarker in two studies,
while metabolic (Baldwin et al., 2006) biomarkers were assessed
in only one study.
The source of peripheral biomarker measurement was plasma
in half of the included studies (n = 7) (Duval et al., 1996; Kin
et al., 1997; Perez et al., 1998; Johnston et al., 1999; Arolt et al.,
2003; Jokinen and Nordstrom, 2009; Raison et al., 2013); serum
in three studies (Ladwig et al., 2005; Jang et al., 2008; Baune
et al., 2012); whole blood (Lanquillon et al., 2000) and mixed
(both serum and plasma) (Alvarez et al., 1999) in 1 study each;
and not reported in two of the included studies (Ribeiro et al.,
1993; Baldwin et al., 2006). Four of the included studies did not
describe the procedures of measuring peripheral biomarker in
detail (Ribeiro et al., 1993; Duval et al., 1996; Baldwin et al.,
2006; Jokinen and Nordstrom, 2009). Four of the included stud-
ies describe the anticoagulant used for collecting plasma samples
with ethylenediaminetetraacetic acid (EDTA) used by two studies
(Perez et al., 1998; Raison et al., 2013); and heparin (Arolt et al.,
2003) and sodium citrate (Alvarez et al., 1999) used by one study
each.
TYPES OF CLINICAL OUTCOMES STUDIED AND STATISTICAL METHODS
The majority of included studies (n = 12) (Ribeiro et al., 1993;
Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez et al.,
1999; Johnston et al., 1999; Lanquillon et al., 2000; Arolt et al.,
2003; Baldwin et al., 2006; Jang et al., 2008; Baune et al., 2012;
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FIGURE 2 | Different outcomes in depression and their significant
predictors. This Figure describes the various mental and physical health
outcomes considered by included studies in the review, the number of
studies which examined each outcome, the peripheral biomarkers which
were found to have a statistically significant impact in predicting each
outcome and the direction of the relationship. DST, Dexamethasone
Suppression Test; CRP, C Reactive Protein; IL, Interleukin; 5HT, 5
Hydroxytryptamine; TSH, Thyroid Stimulating Hormone; ↑: higher, ↓: lower.
∗The study did not specify the source of the biomarker studied (i.e., serum or
plasma).
Raison et al., 2013) examined outcomes pertaining to mental
health or depressive symptoms, with only two studies assess-
ing physical health outcomes (Ladwig et al., 2005; Jokinen and
Nordstrom, 2009). Author defined positive treatment response to
anti-depressants with improvement in depressive symptoms [e.g.,
50% reduction in depression rating scale Hamilton Depression
Rating Scale (HDRS) from baseline] was the commonest out-
come considered by nine included studies (Ribeiro et al., 1993;
Duval et al., 1996; Kin et al., 1997; Perez et al., 1998; Alvarez
et al., 1999; Lanquillon et al., 2000; Arolt et al., 2003; Jang et al.,
2008; Raison et al., 2013). This was followed by other men-
tal health outcomes such as author defined criteria for poor
outcome of depressive symptoms (n = 3) (Ribeiro et al., 1993;
Johnston et al., 1999; Baldwin et al., 2006) for e.g., Lee andMurray
operational criteria for outcome in depression; and remission of
depression symptoms (n = 3) (Duval et al., 1996; Baune et al.,
2012; Raison et al., 2013) for e.g., HDRS <8 at follow-up. The
physical health outcomes measured were cardiovascular deaths
(n = 2) (Ladwig et al., 2005; Jokinen and Nordstrom, 2009),
myocardial infarction (n = 1) (Ladwig et al., 2005) and death
due to natural causes (n = 1) (Jokinen and Nordstrom, 2009).
The usefulness of statistical models for physical outcomes was
not compared against routinely used and evidence backed risk
scores such as the Framingham score for cardiovascular events.
Biomarkers were shown to be statistically significant in predicting
all of the six outcomes considered, including mental and physi-
cal outcomes. Figure 2 summarizes the six different mental and
physical health outcomes studied, the number of studies which
examined each outcome, the 12 peripheral biomarkers which
were noted to be statistically significant in predicting each out-
come and the direction of the relationship between the biomarker
and the outcome.
The Area Under Curve (AUC) statistic was presented only
by 1 study, with AUC statistic for Dexamethasone suppression
test (DST) reported as 0.65 for predicting increased incidence
of cardiovascular deaths only for the male subset of their sam-
ple (Jokinen and Nordstrom, 2009). DST was found to have
a significant impact in predicting three different outcomes in
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two different studies; which included adverse outcomes such
as increased incidence of all-cause mortality and cardiovascular
deaths (Jokinen and Nordstrom, 2009), and favorable outcome
such as positive treatment response to anti-depressants (Kin et al.,
1997). In the included meta-analysis, DST failed to have a signif-
icant impact in predicting positive response to anti-depressants
but was significant in predicting positive response to placebo
(Ribeiro et al., 1993). Elevated levels of serum S100B was the
only biomarker which was found to have a statistically significant
role in predicting the same clinical outcome (positive treatment
response to anti-depressants) in more than one included studies
(Arolt et al., 2003; Jang et al., 2008).
PATIENT DEMOGRAPHICS AND ATTRITION RATE
Description of patient demographics, co-morbid conditions and
attrition at follow-up for included studies is provided in Table 2.
Details of the age of participants were not described by three stud-
ies (Ribeiro et al., 1993; Kin et al., 1997; Baune et al., 2012); while
information on gender distribution was missing from five studies
(Ribeiro et al., 1993; Kin et al., 1997; Arolt et al., 2003; Baldwin
et al., 2006; Baune et al., 2012). The socio-economic status of
participants was very poorly described with only two studies
(Ladwig et al., 2005; Raison et al., 2013) characterizing it and only
one study (Ladwig et al., 2005) including socio-economic sta-
tus in their statistical analysis. Patients with pre-existing chronic
disease were excluded by the majority of the included studies
(n = 8) (Duval et al., 1996; Perez et al., 1998; Johnston et al.,
1999; Lanquillon et al., 2000; Arolt et al., 2003; Ladwig et al.,
2005; Jang et al., 2008; Jokinen andNordstrom, 2009) and chronic
disease status was not considered or described by four of the
included studies (Ribeiro et al., 1993; Kin et al., 1997; Alvarez
et al., 1999; Baldwin et al., 2006). Of the two studies which
included patients with co-existing chronic disease (Baune et al.,
2012; Raison et al., 2013), only one study accounted for the num-
ber of co-morbidities in their statistical analysis (Raison et al.,
2013). The reported participant attrition rate at follow-up var-
ied from 0 to 44%; with two included studies (Ribeiro et al., 1993;
Baune et al., 2012) not specifying the details of attrition.
DISCUSSION
SUMMARY OF FINDINGS
Our review shows that blood based peripheral biomarkers were
statistically significant in predicting six different clinical out-
comes in participants with depression. Outcomes related to
both mental health (depressive symptoms) and physical health
were statistically associated with pre-treatment levels of periph-
eral biomarkers; however only two studies investigated out-
comes related to physical health. Twelve different biomarkers
related to five different biological systems (inflammatory, neu-
roendocrine, neurotransmitter metabolism, neurotrophic, and
metabolic) were found to have a potential role in predicting out-
comes of depression. Despite extensive research on the biomark-
ers of etiopathogenesis of depression, there is limited published
research exploring its translational application in clinical practice.
Furthermore, the research is of generally limited quality and lacks
clinical utility.
The included studies have several methodological problems.
The study sample size was small and follow-up duration was short
in the majority of included studies. The majority of included
studies used questionnaire scores using symptom count for diag-
nosing depression at baseline, while the gold standard interview
technique for depression diagnosis was used only by a minority.
Baseline severity of depressive symptoms assessed using symp-
tom count is associated with higher rate of relapse in patients
with depression (Ishak et al., 2013) but accounting for the base-
line severity of depressive symptoms was only undertaken by a
minority of studies. There is a strong evidence base suggesting
that depression is two to three time more prevalent in patients
with co-existing chronic disease as compared to the general pop-
ulation (Egede, 2007; Moussavi et al., 2007; Mitchell et al., 2013)
but the effect of co-morbidity on clinical outcomes was examined
by only two studies.
Importantly, the clinical implications of the observed statisti-
cal relationships in the included studies were not well explained.
The c-statistic or area under receiver operating characteristic
(ROC) curve (Cook, 2007), which is regarded as one of the stan-
dard methods for evaluating clinical discriminating power of a
statistical model, was reported by only one study. The useful-
ness of statistical models for physical outcomes in the included
study was not compared against robustly validated and routinely
used risk scores such as the Framingham score for cardiovascular
events (D’Agostino et al., 2008). Finally, some of the biomarkers
included in this review are complicated tomeasure and likely to be
expensive. The source and method of measurement for biomark-
ers in the included studies were heterogeneous and this may have
an influence on assay levels of the biomarkers measured (Tort
et al., 2003; Wong et al., 2008; Yu et al., 2011). The cost impli-
cations of doing these tests were not considered in detail in the
included studies and this is likely to be a relevant factor when
considering their potential use in routine clinical practice. There
is some evidence that peripheral biomarkers may have a role
in stratifying depression severity by means of predicting various
physical and mental health outcomes in depression but further
more robust research needs to be done in this area to address the
shortcomings of the available evidence.
OUTCOMES BASED APPROACH IN DEPRESSION SEVERITY
STRATIFICATION
The use of prediction rules and biomarkers to inform clinical
decision making is not a novel concept. It has been used in mak-
ing management decisions in a wide variety of clinical scenarios
such as patients presenting with high cholesterol, atrial fibril-
lation, chest pain, ankle injury, and intensive care (Reilly and
Evans, 2006). In psychiatry, it has been proposed to use this
principle for predicting inpatient violence (Abderhalden et al.,
2006). Depression contributes to disease burden not only owing
to reduction in quality of life and functional productivity, but
also due to the increased risk of adverse physical outcomes such
as hospitalization and mortality (Ferrari et al., 2013). There is
strong evidence showing an association of depression (MDD and
mild depression) with increased risk of adverse physical out-
comes such as all-cause mortality, cardiovascular disease, hyper-
tension, stroke, diabetes, alzeimer’s disease, obesity, and cancer
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Table 2 | Patient population and attrition rates in included studies.
Study Mean Age in years (Standard
Deviation, if available) and Sex
F, Females; M, Males
Socio-economic status Co-morbid medical conditions Participant numbers
Number of participants
at baseline (B) and
follow-up(FU); attrition
in percentage
Alvarez et al., 1999 45 (13.8)
6F, 2M
Not described Not described 10 B
8 FU 20% attrition
Arolt et al., 2003 46.4 (9.8)
Not described
Not described Patients with co-morbid
conditions excluded from study
25 B
25 FU No attrition
Baldwin et al., 2006 73.9
Not described
Not described Not described 50 B
28 FU 44% attrition
Baune et al., 2012 Not described Not described Presence/absence of a list of
medical conditions noted and
entered into statistical analysis
73 B
Sample size at follow-up
not specified
Duval et al., 1996 39.8 (12.9);
19M, 11F
Not described Patients with co-morbid
conditions excluded from study
30 B
30 FU No attrition
Jang et al., 2008 60.3;
43F, 16M
Not described Patients with co-morbid
conditions excluded from study
59 B
59 FU No attrition
Johnston et al., 1999 47;
24F, 10M
Not described Patients with co-morbid
conditions excluded from study
47 B
34 FU 27.6% attrition
Jokinen and
Nordstrom, 2009
52 (16.4);
256F, 126M
Not described Patients with co-morbid
conditions excluded from study
382 B
346 FU 9.4% attrition
Kin et al., 1997 Not described Not described Not described 95 B
70 FU 26.3% attrition
Ladwig et al., 2005 57.75 (7.8);
975M
Education status
described and entered
into statistical analysis
Patients with co-morbid
conditions excluded from study
986 B
975 FU 1.1% attrition
Lanquillon et al.,
2000
53.5;
15F, 9M
Not described Patients with co-morbid
conditions excluded from study
35 B
24 FU 30.5% attrition
Perez et al., 1998 M 45 (2.9), F 44.9 (2.0);
59F, 24M
Not described Patients with co-morbid
conditions excluded from study
89 B
83 FU 6.7% attrition
Raison et al., 2013 42.5(8.2) placebo group, 44.3
(9.4) intervention group;
40F, 20M
Education and
employment status
described but not
entered into statistical
analysis
Notable exclusions- previous
history of cancer, history of
unstable cardiovascular,
endocrinologic, hematologic,
hepatic, renal, or neurologic
disease (determined by
Physical examination and
laboratory testing).
Number of co-morbid medical
conditions noted and entered into
statistical analysis
60 B
60 FU No attrition
Ribeiro et al., 1993 Not described Not described Not described Not described
(Penninx et al., 2013). Physical adverse outcomes associated with
depression attribute to a significant amount of morbidity and
mortality (Ferrari et al., 2013; Penninx et al., 2013). Consequently,
it is imperative that the risk of adverse physical outcomes
associated with depression should be considered while taking
decisions regarding depression severity stratification and subse-
quent management. Crucially, the clinical utility of biomarkers
in predicting physical outcomes in depression, if any, should be
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compared and validated against some of the established and avail-
able risk scoring systems (e.g., Framingham, D’Agostino et al.,
2008) for physical outcomes.
ROLE OF PERIPHERAL BIOMARKERS IN IDENTIFYING DEPRESSION
SUBTYPES
The use of peripheral biomarkers in identifying different subtypes
of depression has been explored by other studies in the litera-
ture. A meta-analysis reviewing the association between HPA axis
hyperactivity (Dexamethasone non-suppression) and depression
suggested a dose-response relationship, with patients with mild
depression showing higher HPA hyperactivity compared to con-
trols but lower than that of patients with MDD (Stetler and
Miller, 2011). Peripheral inflammatory markers such as Tumor
necrotic factor (TNF)-α and IL (Interleukin)-6, serum neopterin
have been shown to have association with melancholic subtypes
of MDD (Maes et al., 2012; Dunjic-Kostic et al., 2013). A review
of metabolic and neuroendocrine biomarkers (Body mass index
BMI, waist-hip ratio, fasting glucose, serum adrenocorticotropic
hormone ACTH) in pre-menopausal women with MDD sup-
ported their role in identifying three different subtypes of MDD-
melancholic, atypical and undifferentiated (Cizza et al., 2012).
This suggests that peripheral biomarkers may have a useful role
in addressing some of the challenges posed by heterogeneity of
depression, with a particular biomarker likely to have a more use-
ful role in a specific subtype of depression. However, before any
decisions are made, much better high quality research is needed.
NOVEL BIOMARKERS IN DEPRESSION
In recent years, novel techniques in proteomics, metabolomics,
genetics, and epigenetics have led to several new biomarkers
being proposed in depression. Proteomic techniques have been
used to identify nine differentiating proteins belonging to lipid
metabolism and immune system from treatment naïve patients
with depression, when compared against healthy controls (Xu
et al., 2012). Similarly, metabolomic techniques such as nuclear
magnetic response (NMR) based analysis of both urine and
plasma have been utilized to identify differentiating proteins
related to lipid metabolism and neurotransmitter system with
good accuracy in treatment naïve patients with depression, when
compared to healthy controls (Zheng et al., 2012a,b). The role
of brain-derived neurotrophic gene polymorphisms, glucocorti-
coid receptor polymorphism and serotonin gene receptor have
been studied in diagnosis and prognostification of depression
with some encouraging results (Chi et al., 2010; Szczepankiewicz
et al., 2011; Uher et al., 2011). Although the findings from genome
wide association studies (GWAS) till date in depression have failed
to make a major breakthrough, they may have a potential role
in stratification of depression and further research is ongoing
(Wray et al., 2012; Flint and Kendler, 2014). Thus, these emerging
techniques and biomarkers may have a role in diagnosis, iden-
tifying specific subtypes of depression and prognostification in
depression (Schneider and Prvulovic, 2013).
MULTIPLE BIOMARKERS, ALLOSTATIC LOAD, AND DEPRESSION
The term allostasis refers to the adaptive physiological responses
organisms activate when homeostasis is disrupted during acute
stress, real or interpreted threats (McEwen and Stellar, 1993).
When chronically activated, allostatic mechanisms become phys-
iologically taxing—or an allostatic load (AL)—that consequently
increase one’s susceptibility to disease (McEwen, 1998). There is
some early evidence to suggest that an index comprising multiple
biomarkers or AI may exhibit a stronger relationship with depres-
sive symptoms, especially in elderly populations, when compared
with examination of individual biomarkers in isolation (Juster
et al., 2011). The role of multiple biomarkers in risk assessment
and predicting outcomes in patients with depression needs to be
explored and compared against the role of individual biomarkers.
LIMITATIONS
Our search strategy was limited to studies published in English
language. A variety of other biomarkers such as genetic, imaging
and CSF biomarkers may have a role in depression stratifica-
tion by predicting clinical outcomes (Schneider and Prvulovic,
2013). However, this review considered only peripheral or blood-
based biomarkers used in current clinical practice due to their
comparative non-invasive nature and ease of measurement. The
uncertainty surrounding management decisions in patients with
depression in current practice is a particular issue at the time
of initial presentation (Davidson, 2010). Hence, this review was
focussed on addressing the issue of the use of peripheral biomark-
ers at baseline or pre-treatment as a predictive tool of clinical out-
come (both mental and physical) and not on assessing changes in
a peripheral biomarker level following treatment for depression.
FUTURE RESEARCH
There is a need for further research in this area, involving large
scale studies with longer duration of follow-up, better charac-
terization of patient populations and inclusion of patients with
chronic diseases. An “ideal” scientific process for a biomarker
evaluation in clinical risk discrimination has been highlighted
in other fields such as cardiovascular disease, a similar approach
can be adopted for biomarkers of depression (Welsh et al., 2008).
Further epidemiological studies of greater quality which min-
imize potential bias and evaluate clinical utility are urgently
needed. Future studies also need to incorporate other physical
health outcomes such as rate of cardiovascular events, incidence
of cancer and all-cause mortality associated with depression and
compare validity against established benchmarks, along with
mental health outcomes related to depression symptoms.
CONCLUSION
Pre-treatment levels of 12 different blood based peripheral
biomarkers related to five different biological pathways were
found to have a statistically significant relationship with outcomes
in patients with depression. Six different outcomes in depres-
sion were predicted using these biomarkers, pertaining to both
physical and mental health, but the clinical implications remain
unclear. It appears likely that peripheral biomarkers may have an
important role in helping clinicians to stratify depression severity
and to predict clinical outcomes. However, the available evidence
has multiple methodological limitations which must be over-
come to make any real clinical headway; in particular, interaction
between these biomarkers, depressive symptoms and co-morbid
physical conditions needs to be explored further.
Frontiers in Human Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 18 | 11
Jani et al. Peripheral biomarkers and depression assessment
AUTHOR CONTRIBUTIONS
Literature search was carried out by Bhautesh D. Jani and Barbara
I. Nicholl. Title, abstract and full text screening followed by refer-
ence and citation searching and data extraction were carried out
by Bhautesh D. Jani and Gary McLean. All authors contributed to
the manuscript.
ACKNOWLEDGMENTS
The study was funded by Chief Scientist Office, Scotland
CAF/12/04. The funders had no role in study design, data col-
lection and analysis, decision to publish, or preparation of the
manuscript.
REFERENCES
Abderhalden, C., Needham, I., Dassen, T., Halfens, R., Haug, H. J., and Fischer, J.
(2006). Predicting inpatient violence using an extended version of the Broset-
Violence-Checklist: instrument development and clinical application. BMC
Psychiatry 6:17. doi: 10.1186/1471-244X-6-17
Alvarez, J.-C., Gluck, N., Fallet, A., Gregoire, A., Chevalier, J.-F., Advenier, C., et al.
(1999). Plasma serotonin level after 1 day of fluoxetine treatment: a biological
predictor for antidepressant response? Psychopharmacology (Berl.) 143, 1999.
doi: 10.1007/s002130050924
American Psychiatric Association. (2000). Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR). Washington, DC: American Psychiatric
Association.
American Psychiatric Association. (2013). Diagnostic and Statistical Manual
of Mental Disorders (DSM-V). Washington, DC: American Psychiatric
Association.
Arolt, V., Peters, M., Erfurth, A., Wiesmann, M., Missler, U., Rudolf, S., et al.
(2003). S100B and response to treatment in major depression: a pilot study.
Eur. Neuropsychopharmacol. 13, 235–239. doi: 10.1016/S0924-977X(03)00016-6
Baldwin, R. C., Gallagley, A., Gourlay, M., Jackson, A., and Burns, A. (2006).
Prognosis of late life depression: a three-year cohort study of outcome and
potential predictors. Int. J. Geriatr. Psychiatry 21, 57–63. doi: 10.1002/gps.1424
Baune, B. T., Smith, E., Reppermund, S., Air, T., Samaras, K., Lux, O.,
et al. (2012). Inflammatory biomarkers predict depressive, but not anxiety
symptoms during aging: the prospective Sydney memory and aging study.
Psychoneuroendocrinology 37, 1521–1530. doi: 10.1016/j.psyneuen.2012.02.006
Binder, E. B., Kunzel, H. E., Nickel, T., Kern, N., Pfennig, A., Majer, M., et al.
(2009). HPA-axis regulation at in-patient admission is associated with antide-
pressant therapy outcome in male but not in female depressed patients.
Psychoneuroendocrinology 34, 99–109. doi: 10.1016/j.psyneuen.2008.08.018
Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate end-
points: preferred definitions and conceptual framework. Clin. Pharmacol. Ther.
69, 89–95. doi: 10.1067/mcp.2001.113989
Carroll, B. J., Feinberg, M., Greden, J. F., Tarika, J., Albala, A. A., Haskett, R.
F., et al. (1981). A specific laboratory test for the diagnosis of melancholia.
Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 38, 15–22.
doi: 10.1001/archpsyc.1981.01780260017001
Chi, M. H., Chang, H. H., Lee, S.-Y., Lee, I. H., Gean, P.W., Yang, Y. K., et al. (2010).
Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-
term antidepressant response in major depressive disorder. J. Affect. Disord. 126,
430–435. doi: 10.1016/j.jad.2010.07.006
Cizza, G., Ronsaville, D. S., Kleitz, H., Eskandari, F., Mistry, S., Torvik, S., et al.
(2012). Clinical subtypes of depression are associated with specific metabolic
parameters and circadian endocrine profiles in women: the power study. PLoS
ONE 7:e28912. doi: 10.1371/journal.pone.0028912
Cook, N. R. (2007). Use and misuse of the receiver operating char-
acteristic curve in risk prediction. Circulation 115, 928–935. doi:
10.1161/CIRCULATIONAHA.106.672402
Coppen, A., Eccleston, E. G., and Peet, M. (1973). Total and free tryptophan
concentration in the plasma of depressive patients. Lancet 2, 60–63. doi:
10.1016/S0140-6736(73)93259-5
Cuijpers, P., and Smit, F. (2002). Excess mortality in depression: a meta-analysis
of community studies. J. Affect. Disord. 72, 227–236. doi: 10.1016/S0165-
0327(01)00413-X
Cuijpers, P., Smit, F., and van Straten, A. (2007). Psychological treatments of
subthreshold depression: a meta-analytic review. Acta Psychiatr. Scand. 115,
434–441. doi: 10.1111/j.1600-0447.2007.00998.x
D’Agostino, R. B. Sr., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro,
J. M., et al. (2008). General cardiovascular risk profile for use in primary care:
the Framingham Heart Study. Circulation 117, 743–753.
Davidson, J. R. (2010). Major depressive disorder treatment guidelines
in America and Europe. J. Clin. Psychiatry 71(Suppl. E1), e04. doi:
10.4088/JCP.9058se1c.04gry
Dunjic-Kostic, B., Ivkovic, M., Radonjic, N. V., Petronijevic, N. D.,
Pantovic, M., Damjanovic, A., et al. (2013). Melancholic and atypi-
cal major depression–connection between cytokines, psychopathology
and treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 43, 1–6. doi:
10.1016/j.pnpbp.2012.11.009
Duval, F., Mokrani, M. C., Crocq, M. A., Jautz, M., Bailey, P., Diep, T. S., et al.
(1996). Effect of antidepressant medication on morning and evening thyroid
function tests during a major depressive episode. Arch. Gen. Psychiatry 53,
833–840. doi: 10.1001/archpsyc.1996.01830090081012
Egede, L. E. (2007). Major depression in individuals with chronic medical disor-
ders: prevalence, correlates and association with health resource utilization, lost
productivity and functional disability. Gen. Hosp. Psychiatry 29, 409–416. doi:
10.1016/j.genhosppsych.2007.06.002
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C.
J. L., et al. (2013). Burden of depressive disorders by country, sex, age, and year:
findings from the global burden of disease study 2010. PLoS Med. 10:e1001547.
doi: 10.1371/journal.pmed.1001547
Fisar, Z., and Raboch, J. (2008). Depression, antidepressants, and peripheral blood
components. Neuro Endocrinol. Lett. 29, 17–28.
Flint, J., and Kendler, K. S. (2014). The genetics of major depression. Neuron 81,
484–503. doi: 10.1016/j.neuron.2014.01.027
Fountoulakis, K. N., Veroniki, A. A., Siamouli, M., andMoller, H. J. (2013). No role
for initial severity on the efficacy of antidepressants: results of a multi-meta-
analysis. Ann. Gen. Psychiatry 12:26. doi: 10.1186/1744-859X-12-26
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D.,
Shelton, R. C., et al. (2010). Antidepressant drug effects and depression severity:
a patient-level meta-analysis. JAMA 303, 47–53. doi: 10.1001/jama.2009.1943
Gibbons, R. D., Hur, K., Brown, C. H., Davis, J. M., and Mann, J. J. (2012). Benefits
from antidepressants: synthesis of 6-week patient-level outcomes from double-
blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch.
Gen. Psychiatry 69, 572–579. doi: 10.1001/archgenpsychiatry.2011.2044
Goldberg, D. (2011). The heterogeneity of major depression. World Psychiatry 10,
226–228.
Hegerl, U., Allgaier, A. K., Henkel, V., and Mergl, R. (2012). Can effects of antide-
pressants in patients withmild depression be considered as clinically significant?
J. Affect. Disord. 138, 183–191. doi: 10.1016/j.jad.2011.05.015
Ishak, W. W., Greenberg, J. M., and Cohen, R. M. (2013). Predicting relapse
in major depressive disorder using patient-reported outcomes of depressive
symptom severity, functioning, and quality of life in the individual burden
of illness index for depression (IBI-D). J. Affect. Disord. 151, 59–65. doi:
10.1016/j.jad.2013.05.048
Jang, B. S., Kim, H., Lim, S. W., Jang, K. W., and Kim, D. K. (2008). Serum S100B
Levels and major depressive disorder: its characteristics and role in antidepres-
sant response. Psychiatry Investig. 5, 193–198. doi: 10.4306/pi.2008.5.3.193
Johnston, T. G., Kelly, C. B., Stevenson, M. R., and Cooper, S. J. (1999). Plasma
norepinephrine and prediction of outcome in major depressive disorder. Biol.
Psychiatry 46, 1. doi: 10.1016/S0006-3223(99)00134-1
Jokinen, J., and Nordstrom, P. (2009). HPA axis hyperactivity and cardiovascu-
lar mortality in mood disorder inpatients. J. Affect. Disord. 116, 88–92. doi:
10.1016/j.jad.2008.10.025
Juster, R. P., Marin, M. F., Sindi, S., Nair, N. P., Ng, Y. K., Pruessner, J. C., et al.
(2011). Allostatic load associations to acute, 3-year and 6-year prospective
depressive symptoms in healthy older adults. Physiol. Behav. 104, 360–364. doi:
10.1016/j.physbeh.2011.02.027
Khan, A., Leventhal, R. M., Khan, S. R., and Brown, W. A. (2002). Severity of
depression and response to antidepressants and placebo: an analysis of the food
and drug administration database. J. Clin. Psychopharmacol. 22, 40–45. doi:
10.1097/00004714-200202000-00007
Kin, N. M., Nair, N. P., Amin, M., Schwartz, G., Ahmed, S. K., Holm, P.,
et al. (1997). The dexamethasone suppression test and treatment outcome in
Frontiers in Human Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 18 | 12
Jani et al. Peripheral biomarkers and depression assessment
elderly depressed patients participating in a placebo-controlled multicenter trial
involving moclobemide and nortriptyline. Biol. Psychiatry 42, 925–931. doi:
10.1016/S0006-3223(97)00158-3
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., and
Johnson, B. T. (2008). Initial severity and antidepressant benefits: a meta-
analysis of data submitted to the Food and Drug Administration. PLoS Med
5:e45. doi: 10.1371/journal.pmed.0050045
Ladwig, K. H., Marten-Mittag, B., Lowel, H., Doring, A., and Koenig, W. (2005). C-
reactive protein, depressed mood, and the prediction of coronary heart disease
in initially healthy men: results from the MONICA-KORA Augsburg Cohort
Study 1984-1998. Eur. Heart J. 26, 2537–2542. doi: 10.1093/eurheartj/ehi456
Lanquillon, S., Krieg, J. C., Bening-Abu-Shach, U., and Vedder, H. (2000).
Cytokine production and treatment response in major depressive disorder.
Neuropsychopharmacology 22, 370–379. doi: 10.1016/S0893-133X(99)00134-7
Leuchter, A. F., Cook, I. A., Hamilton, S. P., Narr, K. L., Toga, A., Hunter, A.M., et al.
(2010). Biomarkers to predict antidepressant response. Curr. Psychiatry Rep. 12,
553–562. doi: 10.1007/s11920-010-0160-4
Lopresti, A. L., Maker, G. L., Hood, S. D., and Drummond, P. D. (2014). A review
of peripheral biomarkers in major depression: the potential of inflammatory
and oxidative stress biomarkers. Prog. Neuropsychopharmacol. Biol. Psychiatry
48, 102–111. doi: 10.1016/j.pnpbp.2013.09.017
Lyness, J. M., Heo, M., Datto, C. J., Ten Have, T. R., Katz, I. R., Drayer,
R., et al. (2006). Outcomes of minor and subsyndromal depression among
elderly patients in primary care settings. Ann. Intern. Med. 144, 496–504. doi:
10.7326/0003-4819-144-7-200604040-00008
Macaluso, M., Drevets, W. C., and Preskorn, S. H. (2012). How biomark-
ers will change psychiatry. Part II: biomarker selection and potential
inflammatory markers of depression. J. Psychiatr. Pract. 18, 281–286. doi:
10.1097/01.pra.0000416018.83709.3e
Maes, M. (2008). The cytokine hypothesis of depression: inflammation, oxida-
tive & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive
treatments in depression. Neuro Endocrinol. Lett. 29, 287–91.
Maes, M., Bosmans, E., Suy, E., Vandervorst, C., DeJonckheere, C., and Raus,
J. (1991). Depression-related disturbances in mitogen-induced lymphocyte
responses and interleukin-1 beta and soluble interleukin-2 receptor production.
Acta Psychiatr. Scand. 84, 379–386. doi: 10.1111/j.1600-0447.1991.tb03163.x
Maes, M., Mihaylova, I., Kubera, M., and Ringel, K. (2012). Activation of cell-
mediated immunity in depression: association with inflammation, melan-
cholia, clinical staging and the fatigue and somatic symptom cluster of
depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 36, 169–175. doi:
10.1016/j.pnpbp.2011.09.006
McEwen, B. S. (1998). Stress, adaptation, and disease. Allostasis and allostatic load.
Ann. N. Y. Acad. Sci. 840, 33–44. doi: 10.1111/j.1749-6632.1998.tb09546.x
McEwen, B. S., and Stellar, E. (1993). Stress and the individual. Mechanisms
leading to disease. Arch. Intern. Med. 153, 2093–101. doi: 10.1001/arch-
inte.1993.00410180039004
McIntyre, R. S., Rasgon, N. L., Kemp, D. E., Nguyen, H. T., Law, C. W. Y.,
Taylor, V. H., et al. (2009). Metabolic syndrome and major depressive disor-
der: co-occurrence and pathophysiologic overlap. Curr. Diab. Rep. 9, 51–9. doi:
10.1007/s11892-009-0010-0
Mitchell, A. J., Ferguson, D.W., Gill, J., Paul, J., and Symonds, P. (2013). Depression
and anxiety in long-term cancer survivors compared with spouses and healthy
controls: a systematic review and meta-analysis. Lancet Oncol. 14, 721–732. doi:
10.1016/S1470-2045(13)70244-4
Mitchell, A. J., Vaze, A., and Rao, S. (2009). Clinical diagnosis of depression
in primary care: a meta-analysis. Lancet 374, 609–619. doi: 10.1016/S0140-
6736(09)60879-5
Moussavi, S., Chatterji, S., Verdes, E., Tandon, A., Patel, V., and Ustun, B.
(2007). Depression, chronic diseases, and decrements in health: results from
the World Health Surveys. Lancet 370, 851–858. doi: 10.1016/S0140-6736(07)
61415-9
Nemeroff, C. B. (2007). Prevalence andmanagement of treatment-resistant depres-
sion. J. Clin. Psychiatry 68(Suppl. 8), 17–25.
Nierenberg, A. A., Rapaport, M. H., Schettler, P. J., Howland, R. H., Smith, J. A.,
Edwards, D., et al. (2010). Deficits in psychological well-being and quality-
of-life in minor depression: implications for DSM-V. CNS Neurosci. Ther. 16,
208–216. doi: 10.1111/j.1755-5949.2009.00108.x
Penninx, B. W., Milaneschi, Y., Lamers, F., and Vogelzangs, N. (2013).
Understanding the somatic consequences of depression: biological mechanisms
and the role of depression symptom profile. BMC Med. 11:129. doi:
10.1186/1741-7015-11-129
Perez, V., Bel, N., Celada, P., Ortiz, J., Alvarez, E., and Artigas, F. (1998).
Relationship between blood serotonergic variables, melancholic traits, and
response to antidepressant treatments. J. Clin. Psychopharmacol. 18, 222–230.
doi: 10.1097/00004714-199806000-00007
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F.,
et al. (2013). A randomized controlled trial of the tumor necrosis factor antag-
onist infliximab for treatment-resistant depression: the role of baseline inflam-
matory biomarkers. JAMA Psychiatry 70, 31–41. doi: 10.1001/2013.jamapsychi-
atry.4
Reilly, B. M., and Evans, A. T. (2006). Translating clinical research into clinical prac-
tice: impact of using prediction rules to make decisions. Ann. Intern. Med. 144,
201–209. doi: 10.7326/0003-4819-144-3-200602070-00009
Ribeiro, S. C., Tandon, R., Grunhaus, L., and Greden, J. F. (1993). The DST as
a predictor of outcome in depression: a meta-analysis. Am. J. Psychiatry 150,
1618–1629. doi: 10.1176/ajp.150.11.1618
Rodriguez, M. R., Nuevo, R., Chatterji, S., and Ayuso-Mateos, J. L. (2012).
Definitions and factors associated with subthreshold depressive conditions: a
systematic review. BMC Psychiatry 12:181. doi: 10.1186/1471-244X-12-181
Sapolsky, R. M. (2004). Is impaired neurogenesis relevant to the affective symptoms
of depression? Biol. Psychiatry 56, 137–139. doi: 10.1016/j.biopsych.2004.04.012
Schmidt, H. D., Shelton, R. C., and Duman, R. S. (2011). Functional
biomarkers of depression: diagnosis, treatment, and pathophysiology.
Neuropsychopharmacology 36, 2375–2394. doi: 10.1038/npp.2011.151
Schneider, B., and Prvulovic, D. (2013). Novel biomarkers in major depression.
Curr. Opin. Psychiatry 26, 47–53. doi: 10.1097/YCO.0b013e32835a5947
Stetler, C., and Miller, G. E. (2011). Depression and hypothalamic-pituitary-
adrenal activation: a quantitative summary of four decades of research.
Psychosom. Med. 73, 114–126. doi: 10.1097/PSY.0b013e31820ad12b
Szczepankiewicz, A., Leszczynska-Rodziewicz, A., Pawlak, J., Rajewska-Rager, A.,
Dmitrzak-Weglarz, M., Wilkosc, M., et al. (2011). Glucocorticoid receptor poly-
morphism is associated with major depression and predominance of depres-
sion in the course of bipolar disorder. J. Affect. Disord. 134, 138–144. doi:
10.1016/j.jad.2011.06.020
Thase, M. E. (2006). Preventing relapse and recurrence of depression: a brief review
of therapeutic options. CNS Spectr. 11, 12–21.
Tort, A. B. L., Dietrich, M. O., Goncalves, C. A., Souza, D. O., and Portela, L. V.
C. (2003). Influence of anticoagulants on the measurement of S100B protein in
blood. Clin. Biochem. 36, 629–632. doi: 10.1016/S0009-9120(03)00107-3
Uher, R., Caspi, A., Houts, R., Sugden, K., Williams, B., Poulton, R., et al.
(2011). Serotonin transporter gene moderates childhood maltreatment’s effects
on persistent but not single-episode depression: replications and implica-
tions for resolving inconsistent results. J. Affect. Disord. 135, 56–65. doi:
10.1016/j.jad.2011.03.010
Uher, R., Tansey, K. E., Dew, T., Maier, W., Mors, O., Hauser, J., et al. (2014).
An inflammatory biomarker as a differential predictor of outcome of depres-
sion treatment with escitalopram and nortriptyline. Am. J. Psychiatry 171,
1278–1286. doi: 10.1176/appi.ajp.2014.14010094
Vancampfort, D., Correll, C. U.,Wampers,M., Sienaert, P., Mitchell, A. J., DeHerdt,
A., et al. (2013). Metabolic syndrome and metabolic abnormalities in patients
with major depressive disorder: a meta-analysis of prevalences and moderating
variables. Psychol. Med. 1–12. doi: 10.1017/S0033291713002778
Welsh, P., Packard, C. J., and Sattar, N. (2008). Novel antecedent plasma
biomarkers of cardiovascular disease: improved evaluation methods and com-
parator benchmarks raise the bar. Curr. Opin. Lipidol. 19, 563–571. doi:
10.1097/MOL.0b013e32831551e0
WHO (2010). International Statistical Classification of Diseases and Related
Health Problems (International Classification of Diseases) (ICD) 10th Revision
- Version:2010. Available online at: http://apps.who.int/classifications/icd10/
browse/2010/en.
Wittchen, H. U., Hofler, M., and Meister, W. (2001). Prevalence and recognition
of depressive syndromes in German primary care settings: poorly recognized
and treated? Int. Clin. Psychopharmacol. 16, 121–135. doi: 10.1097/00004850-
200105000-00001
Wong, H.-L., Pfeiffer, R. M., Fears, T. R., Vermeulen, R., Ji, S., and Rabkin,
C. S. (2008). Reproducibility and correlations of multiplex cytokine levels in
asymptomatic persons. Cancer Epidemiol. Biomarkers Prev. 17, 3450–3456. doi:
10.1158/1055-9965.EPI-08-0311
Frontiers in Human Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 18 | 13
Jani et al. Peripheral biomarkers and depression assessment
Wray, N. R., Pergadia, M. L., Blackwood, D. H. R., Penninx, B. W. J. H., Gordon, S.
D., Nyholt, D. R., et al. (2012). Genome-wide association study of major depres-
sive disorder: new results, meta-analysis, and lessons learned.Mol. Psychiatry 17,
36–48. doi: 10.1038/mp.2010.109
Xu, H.-B., Zhang, R.-F., Luo, D., Zhou, Y., Wang, Y., Fang, L., et al.
(2012). Comparative proteomic analysis of plasma from major depres-
sive patients: identification of proteins associated with lipid metabolism
and immunoregulation. Int. J. Neuropsychopharmacol. 15, 1413–1425. doi:
10.1017/S1461145712000302
Yu, Z., Kastenmuller, G., He, Y., Belcredi, P., Moller, G., Prehn, C., et al. (2011).
Differences between human plasma and serum metabolite profiles. PLoS ONE
6:e21230. doi: 10.1371/journal.pone.0021230
Zheng, P., Gao, H. C., Li, Q., Shao, W. H., Zhang, M. L., Cheng, K., et al. (2012a).
Plasma metabonomics as a novel diagnostic approach for major depressive
disorder. J. Proteome Res. 11, 1741–1748. doi: 10.1021/pr2010082
Zheng, P., Wang, Y., Chen, L., Yang, D., Meng, H., Zhou, D., et al.
(2012b). Identification and validation of urinary metabolite biomarkers
for major depressive disorder. Mol. Cell Proteomics 12, 207–214. doi:
10.1074/mcp.M112.021816
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., and Pariante,
C. M. (2011). Glucocorticoids, cytokines and brain abnormalities in
depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 722–729.
doi: 10.1016/j.pnpbp.2010.04.011
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 16 October 2014; accepted: 09 January 2015; published online: 02 February
2015.
Citation: Jani BD, McLean G, Nicholl BI, Barry SJE, Sattar N, Mair FS and Cavanagh
J (2015) Risk assessment and predicting outcomes in patients with depressive symp-
toms: a review of potential role of peripheral blood based biomarkers. Front. Hum.
Neurosci. 9:18. doi: 10.3389/fnhum.2015.00018
This article was submitted to the journal Frontiers in Human Neuroscience.
Copyright © 2015 Jani, McLean, Nicholl, Barry, Sattar, Mair and Cavanagh. This
is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the orig-
inal publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Human Neuroscience www.frontiersin.org February 2015 | Volume 9 | Article 18 | 14
323 
 
Appendix 2 
RESEARCH ARTICLE Open Access
Revisiting the J shaped curve, exploring the
association between cardiovascular risk factors
and concurrent depressive symptoms in patients
with cardiometabolic disease: Findings from a
large cross-sectional study
Bhautesh Dinesh Jani1, Jonathan Cavanagh2, Sarah JE Barry3, Geoff Der4, Naveed Sattar5 and Frances S Mair6*
Abstract
Background: Depression is common in patients with cardiometabolic diseases but little is known about the
relationship, if any, between cardiovascular risk factor values and depressive symptoms in patients with these
conditions. The objective of this paper is to study the association between cardiovascular risk factors and
concurrent depressive symptoms in patients with three common cardiometabolic conditions: coronary heart
disease (CHD), stroke and diabetes.
Methods: We retrospectively reviewed primary care data for N = 35537 with 1 of the above 3 conditions who
underwent depression screening using the depressive subscale of hospital anxiety and depression score (HADS-D). We
reviewed 4 cardiometabolic risk factors (Systolic Blood Pressure [SBP], Diastolic Blood Pressure [DBP], BMI and total
cholesterol) recorded concurrently in all patients and HbA1c in patients with diabetes (n = 18453). We analysed the
association between individual risk factor value and a positive HADS-D screening result (>7) using logistic regression.
Results: SBP and BMI were noted to have a non-linear “J-shaped” relationship with the probability of having a positive
HADS-D and observed nadirs (levels with the lowest probability) of 148 mm Hg and 30.70 kg/m2, respectively. Total
cholesterol and DBP found to have a weaker curvilinear association with concurrent depression symptoms and nadirs
of 3.60 mmol/l and 74 mmHg. Among patients with Diabetes, HbA1c was also found to have a “J-shaped” relationship
with probability of having a positive HADS-D with an observed nadir of 7.06% DCCT. The above relationships remain
significant after adjusting for age, sex, socio-economic status and number of co-morbid conditions.
Conclusion: In patients with cardiometabolic disease, cardiovascular risk factor values at both extremes were
associated with higher positive depression screening after adjusting for confounders. These findings have potentially
important implications for clinical practice in relation to both risk stratification for depression and approaches to
secondary prevention in individuals with cardiometabolic disease and merit further investigation to determine the
nature and direction of the observed association.
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Background
Patients with chronic disease are two to three times
more likely to suffer from depression when compared to
the general population [1,2]. It is estimated that depression
prevalence is 15-25% in patients with cardio-metabolic
diseases such as coronary heart disease (CHD), diabetes
and stroke [3-5]. Those with cardiometabolic disease who
have suffered from depression have been reported to ex-
perience increased adverse clinical outcomes and mortal-
ity, and poorer functional abilities [4,6-8].
In 2008, the American Heart Association Science Ad-
visory recommended routine depression screening for all
patients with CHD [9]. However, there is no evidence to
date that routine depression screening for patients with
cardiometabolic disease leads to any improvement in de-
pression or cardiac outcomes [10,11]. Moreover, there is
some evidence in the UK and US to suggest that routine
depression screening for all patients with cardiometa-
bolic disease may struggle to achieve universal coverage
[12-14]. In the UK, NICE(National Institute for Health
and Care Excellence) recommends that depression screen-
ing or ‘case finding’ in patients with chronic disease should
be targeted towards those who are believed to be ‘high
risk’ [15]; but further research is needed to define who is
at ‘high risk’.
The relationship between depression and traditional
cardiometabolic disease risk factors such as obesity, hyper-
tension, hyperlipidaemia and raised HbA1c have been
studied extensively in the general population. Depression
is noted to have a significant positive association with
obesity in the general population, with a stronger associ-
ation noted in females [16,17]. In addition, evidence from
longitudinal studies show that depression may have a bi-
directional relationship with obesity [18]. Results from a
meta-analysis of prospective cohort studies shows that de-
pression increases the risk of hypertension incidence in
the community [19]. A contradictory relationship has been
observed between depression and hyperlipidaemia in eld-
erly men and women in the community; with increased
prevalence of depressive symptoms observed with low
levels of high density lipoprotein cholesterol (higher
atherogenic risk) in women and with low levels of low
density lipoprotein cholesterol (lower atherogenic risk) in
men [20]. In a prospective study of older adults in the gen-
eral population, the probability of depression increased
with raised HbA1c [21]. However, most of the evidence in
this area has come from general population studies and
there is a paucity of research in those with known cardio-
metabolic diseases who are likely to be subjected to treat-
ment to reduce these risk factors.
Little is known about the relationship between cardio-
vascular risk factors and depressive symptoms in those
with cardiometabolic disease. The aim of this project is
to address this gap by studying the relationship, if any,
between a range of cardiovascular risk factors (specific-
ally SBP, DBP, total cholesterol, HbA1c and BMI) and
depressive symptoms in those with three cardiometa-
bolic conditions, namely, stroke, diabetes and CHD.
Methods
Ethics statement
We received approval from the West of Scotland re-
search ethics committee to undertake this work. The
work involved retrospective analysis of a large routinely
collected dataset which was completely annonymised
and the research team did not have access to patient
identifiers, hence individual patient consent was not ob-
tained. NHS Greater Glasgow and Clyde Enhanced Ser-
vices data group, which was the authorised “guardian” of
this data set, granted the permission to analyse the data.
Study design and setting
The data reported in this paper comes from the West of
Scotland, with a population of circa 1.8 million served
by two different health boards. The local health boards
oversee a programme of incentivised depression screen-
ing in chronic disease as part of a wider chronic disease
management programme of ‘Local Enhanced Services’
(LES). These are contractual arrangements at a local
health board level with family practices where incentivi-
sation is offered to primary care practitioners on certain
indicators of chronic disease management. However,
there are no penalties for non-adherence. In the areas
under investigation in our study, family practices were
paid under the LES scheme to carry out a comprehensive
annual health assessment, which included depression
screening, for patients with three common cardiometa-
bolic conditions, CHD, diabetes and stroke. The annual
health assessment was usually carried out by a practice
nurse and lasted approximately one hour. The protocol
for health assessment was specific for each of the three
diseases but included monitoring of blood pressure (BP),
total cholesterol, body mass index (BMI) and in those with
diabetes, HbA1c. The assessment included detailed history
taking, various physical examinations and blood tests.
Participants
We restricted our analysis to adults aged from 18 to 90
and health assessments recorded between 01/04/2008 to
31/03/2009. A total of 125,143 patients were listed as
having CHD, diabetes or stroke in the year 2008–09, the
“DepChron” dataset [14], described in a previous publi-
cation. Of the total sample, 10,670 (8.5%) patients were
under treatment for depression and were thus exempt
from screening. The remaining 114,473 (91.5% of total
sample size) patients were eligible for depression screen-
ing. However, the uptake of depression screening was
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poor and only undertaken in 35,537 (31.1% of those eli-
gible) and 78,936 (68.9%) were not screened.
Measurement of clinical risk factors and outcome variable
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) measurements were recorded in mm Hg and
BMI in kg/m2 determined from height and weight mea-
surements. A blood sample was collected by the practice
nurse at the time of assessment; the result for total chol-
esterol was reported in mmol/l and HbA1c was reported
in Diabetes Control and Complications Trial (DCCT)
units.
We restricted the values for cardiovascular risk factors
to a clinically plausible range based on both our clinical
judgement and the findings of general population stud-
ies. SBP measurements were restricted to a range be-
tween 90 to 240 mm Hg and DBP to a range between 50
to 130 mm Hg [22,23]. Similarly, BMI was restricted to a
range between 15 to55 [24], total cholesterol to 2–10
[25] and HbA1C to 3-18% [26]. Observations in the data
which were outside these range were excluded from the
analysis. The depression subscale of HADS (HADS-D)
gives a total score of 0 to 21, and a threshold of >7 was
used to define the presence of depressive symptoms, as
endorsed by national guidelines [27]. The area based
Scottish Index of Multiple Deprivations (SIMD) was
used as a measure of socioeconomic status [28].
Statistical analysis
We used multiple logistic regression with the outcome
variable as the prevalence of a positive screening for de-
pression (defined as HADS-D >7). We used five separate
regression models to examine the impact of each indi-
vidual cardiovascular risk factor (SBP, DBP, total choles-
terol, BMI, HbA1c) on the odds of a raised HADS-D.
We entered quadratic terms for each clinical measure
into regression models to allow for a non-linear relation-
ship. We entered age (18–64 vs. 65–90), sex (male vs. fe-
male) and socio-economic status (deprived: SIMD deciles
1–5 vs. affluent: SIMD deciles 6–10) into all of the models
as binary variables. We also included the number of co-
morbid conditions (range 1–3, representing a combin-
ation of one or more of the three cardiometabolic disease
under investigations: CHD, stroke or diabetes) into all re-
gression models as a categorical variable. We present the
results as a graph of the predicted probability of a raised
HADS-D against corresponding values of the clinical risk
factor. We calculated the turning point for each risk fac-
tor using the formula min = −b/2a where “a” represents
coefficient of quadratic term and “b” represents coeffi-
cient of linear term.
We used the R statistical software, version 3.0.2 for
statistical analysis [29].
Supplementary and sensitivity analyses
The screened population was a subset of the whole data-
set and the majority of the patients eligible for depres-
sion screening did not have HADS-D recorded due to
poor uptake of depression screening. We compared the
demographic features and distribution of clinical risk
factors in both the screened population and the total
population. We tested for interactions of each clinical
risk factor with age, gender, number of comorbid condi-
tion and deprivation status for each of the corresponding
regression models to check for potential effect modifica-
tion. We also tested for cubic terms in each of the five
regression models for five clinical measures. Sensitivity
of the results to excluded values was assessed by repeat-
ing the analyses with all available patients.
We also performed multiple linear regression analysis
with HADS-D as a continuous scale. We used five separ-
ate regression models to examine the impact of each
individual cardiovascular risk factor (SBP, DBP, total
cholesterol, BMI, HbA1c) on HADS-D as a continuous
scale after excluding extreme values for each clinical
measure as defined above. Quadratic and cubic terms
for each clinical measure and other predictor variables,
such as age, sex, socio-economic status and number of
co-morbid conditions were added to the linear regres-
sion model as described above. The turning point or the
“nadir” was calculated using the same formula described
in the preceding section.
Results
Sample size and characteristics
N= 35,537 (32.5% of total population) patients with one of
the three chronic cardiometabolic diseases CHD, previous
stroke and diabetes had results of depression screening
with HADS-D recorded (see Figure 1). The demographic
characteristics and cardiovascular risk factor distribution
between the screened and total population were similar
(please see “Additional file 1-Additional Analysis”). The
HADS-D was positive (>7) for 7080 patients (19.9%). The
demographic characteristics of the study sample are de-
scribed in Table 1.
The distributions of the five cardiovascular risk factors
in the study sample such as sample mean, standard devi-
ation, missing values and the observations outside the
plausible range considered and observed nadirs are de-
scribed in Table 2.
Blood pressure, total cholesterol, body mass index
and depression
SBP was found to have a “J-shaped” relationship with
the probability of having a positive result with HADS-D
screening, based on a regression model using all of the
screened population with at least one of the three chronic
diseases. The nadir or the minimum level of SBP with the
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least probability of having a positive screening result with
HADS-D was found to be 148 mm Hg (see Figure 2). DBP
was found to have a “J-shaped” relationship with the prob-
ability of having a positive result with HADS-D screening,
based on a regression model using all of the screened
population with at least one of the three chronic diseases.
However, the shape of the J-curve was shallow for DBP
when compared with SBP. The nadir for DBP with the
least probability of having a positive screening result with
HADS-D was found to be 74 mm Hg. This observed rela-
tionship between SBP, DBP and depressive symptoms
remained significant after adjusting for age, sex, number
of comorbid conditions and socio-economic status.
BMI was found to have a non-linear relationship with
the probability of having a positive result with HADS-D
screening, based on a regression model using all of the
screened population with at least one of the three cardio-
metabolic conditions. The nadir or the minimum level for
BMI was found to be 30.70 kg/m2 (see Figure 2). Total
Cholesterol was found to have a non-linear relationship
with the probability of having a positive result with
HADS-D screening (HADS-D > 7), based on the same re-
gression model described above. However, the shape of
the curve was less pronounced with lower values of total
cholesterol and wider confidence intervals when com-
pared to SBP and BMI. The nadir or the minimum level
for total cholesterol was found to be 3.60 mmol/l (see
Figure 2). The relationship between BMI and total choles-
terol with probability of having HADS-D positive re-
mained significant after adjusting for age, sex, number of
comorbid conditions and socio-economic status.
HbA1C and depression
HbA1c was found to have a non-linear “J-shaped” re-
lationship with the probability of having a positive re-
sult with HADS-D screening (HADS-D > 7), based on
a regression model using only patients with diabetes
(n = 18,453, missing = 2775, excluded = 2). The shape of
the curve was more similar but the confidence intervals
were slightly wider, when compared to SBP, DBP and BMI.
The nadir or the minimum level for HbA1c was found to
7.06% DCCT (54 mmol/mol IFCC) (see Figure 3). This re-
lationship also remained significant after adjusting for age,
sex, number of comorbid conditions and socio-economic
status.
Supplementary and sensitivity analysis
There were no significant cubic terms for any of the car-
diovascular risk factors. There were significant interac-
tions between DBP and sex (p-value = 0.01) and BMI
and age (p-value = 0.009) (please see “Additional file 1-
Additional Analysis”). Hence, we calculated the nadirs
separately for these groups with significant interactions.
The nadirs for DBP were 78 mm Hg for males and
63 mm Hg for females respectively. The nadirs for BMI
were 32.12 kg/m2 for those aged18-64 years and
29.54 kg/m2 for those 65–90 years respectively. The
shape of the curve was unchanged for DBP and BMI
after doing sub-group analysis for sex and age respect-
ively (please see “Additional file 1-Additional Analysis”).
The results were unchanged after including extremes of
clinical values outside the clinically plausible range de-
scribed above (please see “Additional file 1-Additional
Analysis”).
The five cardiovascular risk factors had a non-linear
relationship in the respective linear regression models,
after adjusting for age, sex, socio-economic status and
number of co-morbid conditions. The observed nadirs
for SBP, DBP, total cholesterol and BMI were 145 mm
Hg, 78 mm Hg, 3.41 mmol/l and 30.25 kg/m2 respect-
ively. The observed nadir for HbA1c in patients with
diabetes was 6.21 DCCT (44.4 mmol/mol IFCC). The
value for HADS-D increased with increase in value of
these clinical measures above their respective nadirs but
Figure 1 Study sample size and recruitment.
Table 1 Patient demographics of the study sample
Demographics DepChron
(n=35,537)
Age group Missing 11
18-64 11553 (32.52%)
64-90 23973 (67.48%)
Gender Missing 18
Male 20658 (58.16%)
Female 14861 (41.84%)
Deprivation status Missing 732
Deprived 22726 (65.30%)
Affluent 12079 (34.70%)
Number of comorbid condition Missing 0
One 27356 (76.99%)
Two 7410 (20.85%)
Three 771 (2.16%)
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it increased with decrease in value below these observed
nadirs. There were no significant cubic terms. The re-
sults of each linear regression are presented in detail in
“Additional file 2- Linear Regression with HADS-D as
continuous measure”.
Discussion
In a large, community based sample of patients with
CHD, previous stroke, or diabetes depressive symptoms
assessed using depression screening were found to have
a nonlinear association with five routine cardiovascular
risk factors of disease management. The relationships
were ‘J-shaped’ with high levels of SBP and BMI associ-
ated with greater levels of concurrent depressive symp-
toms, but with the lowest levels also associated with
increased prevalence of depressive symptoms. DBP and
total Cholesterol had a similar but weaker relationship
with depression. In patients with diabetes, a “J-shaped”
relationship was again observed between HbA1c levels
and depressive symptoms. These associations remained
significant after adjusting for demographic factors such
as age, sex, number of comorbid conditions and socio-
economic status; including or excluding clinical obser-
vations with extreme values and using HADS-D as
continuous scale.
Previous evidence studying the relationship between
cardiovascular risk factor values and depressive symp-
toms has mainly come from general population studies.
Barrett-Connor et al. reported a non-linear relationship
between DBP and depression with a observed nadir of
75 mm Hg DBP for concurrent depressive symptoms in a
general population sample [30]. In various cross-sectional
studies involving mainly elderly population, depression
has been observed to have a non-linear association with
SBP [31-34] and DBP [30,35]. Similarly, increased preva-
lence of depressive symptoms has been observed with ex-
treme values of total cholesterol [36,37] and HbA1c in
general population samples [38], in a non-linear trend.
There is as yet no published literature that we know of
that examines the relationship between cardiovascular risk
factors and depressive symptoms in those with cardiomet-
abolic disease.
Table 2 Study sample (n = 35537) distribution for the five clinical risk factors, missing values, the number of extreme
observations outside the usually observed clinically plausible values, analyzed data and observed nadirs
Clinical measure (range included) Mean (SD) N missing Exclusions N analyzed Observed nadirs
Systolic BP (90–240) 133 (17.54) 3398 n <90 = 110 32029 148 mm Hg
n >240 = 0
Diastolic BP (50–130) 74 · 57 (10.32) 3398 n <50 = 165 31972 74 mm Hg
n >130 = 2
Body mass index (15–55) 28 · 95 (6.02) 5398 n <15 = 29 30042 30.70 kg/m2
n >55 = 68
Total cholesterol (2–10) 4 · 31 (1.05) 4226 n <2 = 50 31244 3.60 mmol/l
n >10 = 17
HbA1c (3–18) 7 · 52 (1.68) 2775 n <3 = 2 15676 7.06 DCCT
n >18 = 0
Legend: BP = Blood Pressure; n = 18453 for HbA1c.
Figure 2 Relationship of Systolic BP (SBP), Diastolic BP (DBP), Body Mass Index (BMI) and total cholesterol with probability of having a
positive HADS-D (>7) with 95% confidence intervals.
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Non-linear relationship between extreme values of
SBP, DBP, BMI and HbA1c and adverse clinical out-
comes such as increased incidence of vascular events
and deaths in patients with cardiometabolic conditions
has been reported extensively [39-43].
There are two potential implications of our findings.
Firstly, if the association between extreme values of
these risk factors with depressive symptoms in those
with cardiometabolic disease is supported by prospective
studies, then this relationship could be used to identify
those at “high risk” of depression. This would then offer
a mechanism for targeting of depression screening in
those with cardiometabolic disease. Secondly, these re-
sults need to be replicated using other datasets and also
prospectively to further explain the nature and direction
of the observed association between depressive symp-
toms and cardiovascular risk factors values. Such further
investigation is necessary in order to determine whether
the lower cardiovascular risk factors are merely markers
of other disease processes (for example, low total choles-
terol levels associated with malnutrition, liver diseases
and haematological diseases) [44-46] that may make pa-
tients more vulnerable to experiencing depressive symp-
toms or whether it could be attributed to a potential
side-effect of aggressive cardiovascular risk factor man-
agement [47-50].
This study has a number of key strengths. The data came
from a large, community based sample, and importantly
reflecting real life clinical practice. There are several
limitations. As the study was based on cross-sectional
analysis, it is not possible to make causal inferences
from the findings of this study. It is therefore unclear
whether the observed non-linear association of cardio-
vascular risk factors with prevalent depressive symptoms
is due to cause or effect.
Secondly, we did not have complete information on
biobehavioural factors such as smoking status, alcohol
intake and levels of physical activity which are likely
to influence the values of cardiovascular risk factors
considered and also the prevalence of depressive
symptoms [51-54].
Since only a minority of the patients were actually
screened, depression status was unknown for a large
number of patients, which remains an important limita-
tion. There may be important differences between pa-
tients with known depression status and those whose
depression status was unknown, which are not clearly
evident from their baseline demographic data. Practi-
tioners may intuitively screen those patients where they
are more likely to get a positive result, for instance pa-
tients with multimorbidity. Also, there is a possibility of
reverse causality with GPs reviewing a patient whom
they consider to have depression and offering screening
subsequently. Previously reported barriers to discussing
depression (or mental health) in patients with chronic
disease in primary care, such as stigma associated
around the ‘label’ and physicians’ preconception of nor-
malizing depression in patients with chronic disease,
could be influencing factors behind low uptake of de-
pression screening in our study [55,56].
Finally, the overall accuracy of depression screening in
our study was reliant on HADS-D which is a self-reported
measure and it is not a gold standard measure for asses-
sing depressive symptoms in patients with cardiometabolic
disease in a primary care setting [11,57,58]. We also did
not have information on history of previous episodes of
depression for patients in our study which may influence
the prevalence levels for depressive symptoms.
Conclusion
In a general practice sample of patients with CHD,
stroke, or diabetes, depressive symptoms were found to
have a strong curvilinear association with SBP, BMI, and
HbA1c; and a weaker curvilinear association with total
cholesterol and DBP. Further investigation of these rela-
tionships is urgently needed to clarify the nature of these
associations, in order to determine whether they have
potentially important implications for clinical practice in
relation to either risk stratification for depression or our
approach to secondary prevention in individuals with
cardiometabolic disease.
Figure 3 Relationship of HbA1C with probability of having a
positive HADS-D (>7) with 95% confidence intervals.
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Appendix 3 
Relationship Between Blood Pressure Values, Depressive Symptoms,
and Cardiovascular Outcomes in Patients With Cardiometabolic Disease
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The authors studied the joint effect of blood pressure (BP)
and depression on the risk of major adverse cardiovascular
outcome in patients with existing cardiometabolic disease.
A cohort of 35,537 patients with coronary heart disease,
diabetes, or stroke underwent depression screening and BP
measurement recorded concurrently. The authors used
Cox’s proportional hazards to calculate risk of major
adverse cardiovascular event (MACE; myocardial infarc-
tion/heart failure/stroke or cardiovascular death) over
4 years associated with baseline BP and depression. A
total of 11% (3939) had experienced a MACE within
4 years. Patients with very high systolic BP (160–240 mm
Hg; hazard ratio, 1.28) and depression (hazard ratio, 1.22) at
baseline had significantly higher adjusted risk. Depression
had a significant interaction with systolic BP in risk
prediction (P=.03). Patients with a combination of high
systolic BP and depression at baseline had 83% higher
adjusted risk of MACE, as compared with patients with
reference systolic BP without depression. Patients with
cardiometabolic disease and comorbid depression may
benefit from closer monitoring of systolic BP. J Clin
Hypertens (Greenwich). 2016;1–9. ª 2016 The Authors.
The Journal of Clinical Hypertension Published by Wiley
Periodicals, Inc.
Blood pressure (BP) reduction is recommended for all
patients diagnosed with hypertension by various guide-
line bodies, especially for patients with cardiometabolic
disease (coronary heart disease [CHD], diabetes, and
previous stroke), as it is associated with a reduction in
the risk of future adverse cardiovascular (CV) out-
comes.1–4 However, a “J-shaped phenomenon” has also
been reported in epidemiological and interventional
studies for both systolic BP (SBP) and diastolic BP
(DBP), whereby BP lower than 130/80 mm Hg has been
associated with higher risk of adverse health outcomes
including fatal and nonfatal myocardial infarction (MI)
and stroke.5–8 The optimal level of BP control in
patients with existing cardiometabolic disease remains
an area of ongoing debate.9,10 Results from the recently
published Systolic Blood Pressure Intervention Trial
(SPRINT)11 suggest that patients with CHD may have a
lower risk of CV events with intensive SBP lowering
(<120 mm Hg).11
Patients with existing cardiometabolic diseases such
as CHD, diabetes, and stroke are two to three times
more likely to experience depressive symptoms than the
general population.12–14 Moreover, comorbid depres-
sion in these patients with cardiometabolic disease is
associated with higher risk of subsequent vascular
events.15–17 Depression screening, as a standalone
intervention, in these patient groups has not shown
any meaningful benefits in reducing CV events,18,19 and
it has been recommended that screening should be
followed by further evaluation by a professional qual-
ified in the diagnosis and management of depression.20
Depression treatment with models such as collaborative
care in cardiometabolic disease patient groups has been
found to be beneficial in reducing depressive symptoms
and improving treatment adherence but not useful in
reducing CV events.21,22
The relationship between depressive symptoms and
BP has been investigated in several cross-sectional
epidemiological studies.23–27 These studies have shown
that depression has a nonlinear relationship to SBP and
DBP, with greater depressive symptoms at both low and
high BP values.23–27 One longitudinal study concluded
that persistent depression leads to lowering of both
systolic and diastolic BP.28
The mediating mechanism for the observed higher risk
of CV events in patients with cardiometabolic disease and
comorbid depression remains unclear, with factors such
as autonomic dysfunction and chronic inflammation
proposed as contributors to a causal pathway.29 We
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hypothesized that patients with depression in car-
diometabolic disease with poor BP control may represent
a “high-risk” subtype, as the abovemechanisms have also
been associated with poor BP control.30,31
To date, the joint associations of depression and BP
with the risk of CV disease has not been studied. In this
study, we use data from a large cohort of primary care
patients with cardiometabolic disease (CHD/diabetes/
stroke), followed up for 4 years, to examine the
associations of depression and BP with the risk of
subsequent CV events. In doing so, we allow for both
nonlinearity of their effects and of interactions between
them.
METHODS
Study Design and Setting
The patient sample in this study was recruited from
two health boards in the West of Scotland that serve a
population of approximately 1.8 million. We received
approvals from the National Research Ethics Service
and National Services Scotland (NHS) Privacy
Advisory Committee and NHS Greater Glasgow and
Clyde Enhanced Services data group, which was the
authorized “guardian” of this data set. We retrospec-
tively analysed a large routinely collected data set,
which was completely anonymous with no patient
identifiers, therefore individual patient consent was
not obtained.
The local health boards oversaw a program of
incentivized depression screening in chronic disease as
part of a wider chronic disease management program of
Local Enhanced Services (LESs). Family practices in the
health boards studied were paid under the LES scheme
to carry out a comprehensive annual health assessment,
which included depression screening, for all patients
with one of the three common cardiometabolic condi-
tions: CHD, diabetes, and stroke. However, there were
no penalties for nonadherence. The nurse in the family
practice usually carried out the annual health assess-
ment and it lasted for approximately 1 hour. Patients
recognized as being “under treatment” for depression at
the time of their health assessment were exempt from
depression screening. Patients with a positive result on
depression screening were offered treatment as per
routine care for management of depressive symptoms
based on national guidelines.
Participants
The analysis described here was restricted to adults who
had a health assessment recorded for at least one of the
three conditions between January 4, 2008, to March 31,
2009, and were aged between 18 and 90 years, who
underwent depression screening. The “DepChron” data
set consisted of a total of 125,143 patients who were in
a family practice disease register with a diagnosis of at
least one of CHD, diabetes, or stroke in 2008–2009; all
of these patients underwent a comprehensive health
assessment as part of LES.32,33 Patients were labeled as
under treatment for depression and exempt from
depression screening if they were noted to be on
antidepressants based on their prescription record at
the time of depression screening.
Measurement of Clinical Variables
The depression subscale of the Hospital Anxiety and
Depression Scale (HADS-D)34 has a range of total score
from 0 to 21. A threshold of >7 was used to define the
presence of depressive symptoms, as endorsed by
national guidelines.35 The area-based Scottish Index of
Multiple Deprivations (SIMD) was used as a measure of
socioeconomic status, with patients categorized into
deciles of deprivation relative to the Scottish popula-
tion.36 Patients who were identified to have depressive
symptoms as a result of depression screening were
offered “routine care,” as recommended for manage-
ment of depressive symptoms in national guidelines.35 A
new antidepressant prescription for a period up to
6 months after screening was labeled as “new treat-
ment” for the screened patients. We also analyzed
antidepressant prescriptions after excluding amitripty-
line as it is often used in the management of chronic
pain in primary care. No reliable information was
available on the number of patients who were referred
for psychological therapies following their depression
screening.
SBP and DBP measurements and body mass index
(BMI) were recorded determined from height and
weight measurements. These BP measurements were
performed by the primary care practice nurse during
routine clinical assessments. As the data were collected
during routine clinical practice, information on methods
used for recording the BP (manual or digital; single
reading or multiple readings) was not available. A blood
sample was collected by the practice nurse at the time of
assessment, and the result for total cholesterol was
reported in mmol/L and glycated hemoglobin (only
available for patients with diabetes) was reported in
Diabetes Control and Complications Trial units.
We restricted the values for CV risk factors to clinically
plausible ranges based on both our clinical judgement
and the findings of general population studies.
SBP measurements were restricted to a range between
90 mm Hg and 240 mm Hg and DBP to a range
between 50 mm Hg and 130 mm Hg.37 Similarly,
BMI was restricted to a range between 15 mg/dL
and 55 mg/dL,38 total cholesterol between 2 mg/dL and
10 mg/dL,39 and glycated hemoglobin between 3%
and 18%.40 Observations in the data, which
were outside these ranges, were excluded from the
analysis.
Measurement of Outcome Variables
We used electronic data linkage methods to measure the
outcome variables for the patient cohort recruited in our
study for a follow-up duration of 4 years from April
2009 to March 2013. We electronically linked the
health records for patients in primary care registers with
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the records held by the Information Services Division
Scotland for any occurrence of hospitalization or
mortality during the follow-up period. We studied four
different clinical outcomes for the patients in our study
using the International Classification of Diseases–10th
Revision (ICD-10).41 The outcomes studied and their
respective ICD-10 codes are as follows:
1 Admission due to MI: I21
2 Admission due to stroke: I61-I64
3 Admission due to heart failure (HF): I50
4 Death due to CV causes: I00-I99.
Major adverse CV outcome (CV mortality or admis-
sion due to MI/stroke/HF) was used as the composite
outcome variable. Patients were censored if they expe-
rienced a composite CV outcome as described above or
if they died of reasons other than CV causes.
BP Measurement
There is no consensus among various guidelines pub-
lished internationally for optimal BP targets in patients
with existing cardiometabolic disease.1–4 We classified
BP into five different categories based on clinical
judgement to improve interpretability of results. SBP
was classified into five categories: very high (160–240
mm Hg), high (140–159 mm Hg), reference (130–139
mm Hg), tightly controlled (120–129 mm Hg), and low
(80–119 mm Hg). DBP was also classified into: very
high (100–130 mm Hg), high (90–99 mm Hg), reference
(85–89 mm Hg), tightly controlled (80–84 mm Hg), and
low (40–79 mm Hg). SBP and DBP were also added as
continuous variables in the regression models as
described below.
Statistical Analysis
We used time-to-event analysis to study the association
between three predictors: (1) SBP categories, (2) DBP
categories, and (3) presence of depressive symptoms,
and the risk of major adverse CV outcome in the study
population. Cox’s proportional hazards regression anal-
ysis was performed, unadjusted and adjusted for poten-
tial confounding factors, and the results are presented in
terms of hazard ratios (HRs) and 95% confidence
intervals (CIs). We performed multivariable analysis
adjusting for the following confounders: age (continu-
ous), sex (male and female), socioeconomic status
(deprived: SIMD deciles 1–5 vs affluent: SIMD deciles
6–10), initiation of antidepressants (yes/no), number of
cardiometabolic comorbidities (range 1–3, representing
a combination of one or more of the three car-
diometabolic diseases under investigations: CHD,
stroke, or diabetes), BMI (normal: 18.5–25 mg/dL,
underweight 15–18.5 mg/dL, overweight 25–30 mg/
dL, obese 30–50 mg/dL42), and total cholesterol levels
(not raised vs raised: >5 mmol/L4).
To understand the relationship between BP and
depressive symptoms in risk prediction of major adverse
CV outcome, if any, we carried out an analysis of
variance test to check for interaction between the BP
categories and presence of depressive symptoms. In the
event of a significant interaction, we also carried out a
subgroup analysis to further study the nature of inter-
action. In the subgroup analysis, the study sample was
divided on the basis of BP categories as described above.
In each subgroup, a Cox’s proportional hazards
regression analysis was performed to study the risk of
outcome with the presence of depressive symptoms at
baseline, adjusting for potential confounders. Analysis
was carried out using the R statistical software, version
3.0.2 (The R Project for Statistical Computing).
Sensitivity Analysis
We performed four different sensitivity analyses in the
following patients: those with diabetes, those with
affluent socioeconomic class, those with estimated
glomerular filtration rate results available at baseline,
and those with smoking and alcohol consumption
results available.
RESULTS
Patient Population and Clinical Outcomes
A total of 125,143 patients with at least one of the
following underwent a comprehensive health assess-
ment in 2008–2009: diabetes (62,275 patients), CHD
(62,990 patients), or previous stroke (26,060 patients).
A total of 10,670 (8.5%) patients were exempt from
depression screening as they were noted to be under
treatment for depression and excluded from analysis,
while the remaining 114,473 (91.5% of total sample
size) were eligible for depression screening. The uptake
of depression screening was low and HADS-D was
recorded in 35,537 (31.1% of those eligible) of those
undergoing the annual health assessment (Figure 1), and
it is the data from this subset that we focus on in this
paper. A total of 7080 of 35,537 patients had positive
HADS-D results (>7) at baseline. Electronic data linkage
between primary care disease registers and hospital
discharge and mortality records, based on Community
Health Index number was successful for 99.4% of
patients.
Among the patients who were screened (n=35,537),
12,485 (35.1%) had diabetes only, 11,716 (32.9%) had
CHD only, 3558 (10%) had previous stroke only, 7410
(20.8%) had two of these conditions, and 771 (2.1%)
had all of the three conditions. Table I compares the
demographic features, observed BP values, and the
absolute number of adverse CV outcomes for the
screened and unscreened population. In the study
population of patients with depression screening results
(n=35,537), 11% (3939) experienced at least one major
adverse cardiovascular event (MACE) within 4 years. In
the study population, the observed mean SBP at baseline
was 133 mm Hg in the reference SBP group (130–139
mm Hg), 123 mm Hg in the tightly controlled SBP
group (120–129 mm Hg), 109 mm Hg in the low SBP
group (80–119 mm Hg), 145 mm Hg in the high SBP
group (140–159 mm Hg), and 170 mm Hg in the very
high SBP group (160–240 mm Hg).
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BP, Depressive Symptoms, and Risk of a MACE at
4 Years
In the adjusted multivariable analyses for SBP cate-
gories, patients with very high SBP (160–240 mm Hg)
and low SBP (80–119 mm Hg) at baseline had a
significantly higher risk of a MACE at 4 years compared
with patients with reference SBP (130–139 mm Hg) at
baseline (Table II). There was no statistical difference in
the risk between patients with reference SBP, tightly
controlled SBP (120–129 mm Hg), and high SBP (140–
159 mm Hg) at baseline. The adjusted risk was 15%
higher for patients with low SBP and 28% higher for
patients with very high SBP compared with patients
with reference SBP at baseline. The presence of depres-
sive symptoms (HADS-D >7) at baseline was associated
with a 22% higher adjusted risk of a major CV event
compared with those without depressive symptoms
(Table II). Figure 2 shows that patients with high SBP
had a significantly higher cumulative incidence rate
compared with patients in the other SBP categories;
similarly, patients with depressive symptoms had
a higher cumulative incidence than those without
depression.
In the adjusted analysis for DBP categories, none of
the DBP categories at baseline had any statistically
significant difference in the risk prediction of MACE,
compared with the reference (Table II). The results were
adjusted for age, sex, socioeconomic status, number of
CV comorbidities, BMI, and total cholesterol values at
baseline and initiation of antidepressants within
6 months of depression screening. Interestingly, initia-
tion of antidepressants after depression screening did
not have any significant impact on the risk of MACE
(HR, 0.84; 95% CI, 0.68–1.04; P=.11). SBP as a
continuous variable was found to have a significant
nonlinear relationship with risk prediction of a MACE
while DBP was not a significant predictor as a contin-
uous variable in the multivariable analysis (results not
shown). We also repeated the analysis by adjusting for
different disease categories and combinations among the
three cardiometabolic diseases, and there was no
difference in the results (not shown).
Interaction Between SBP and Depressive Symptoms
in Risk Prediction of Major CV Event at 4 Years
In the risk prediction of major CV event, the interaction
between SBP categories and presence of depressive
symptoms was statistically significant (P=.03). Patients
with low SBP (80–119 mm Hg) only, with very high SBP
(160–240 mm Hg) only, and depressive symptoms only
at baseline had 10%, 19%, and 17% adjusted higher
risks of a major CV event, respectively, compared with
those without extremes of SBP and no depressive
symptoms (Figure 3). In comparison, patients with both
low SBP and depressive symptoms at baseline had a
36% (95% CI, 15%–62%) higher risk while patients
with both very high SBP and depressive symptoms had
the highest increased risk of 83% (95% CI, 46%–
130%) compared with those in the reference SBP group
without depressive symptoms.
In the multivariable subgroup analysis of five SBP
categories, a nonlinear trend was observed in the
association between presence of depressive symptoms
and risk prediction of a major CV event at 4 years
(Table III). There was no evidence of an association
between the presence of depressive symptoms and
adjusted risk of major adverse event for the subgroup
of patients with reference SBP (130–139 mm Hg) at
baseline. Presence of depressive symptoms was associ-
ated with significantly higher risk of a major CV adverse
FIGURE 1. Study sample size and recruitment.33 CHD indicates coronary heart disease; HADS, Hospital Anxiety and Depression Score.
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event for patients in all other baseline SBP categories.
Patients with very high SBP and concurrent depressive
symptoms had the highest absolute event rate of 17.7%;
moreover, the change in the adjusted risk with addition
of depressive symptoms was highest for the subgroup of
patients with very high SBP at 55% (Table III).
Sensitivity Analysis
In all four sensitivity analyses, the subgroup of patients
with very high SBP and prevalent depressive symptoms
were observed to have the highest absolute event rate of
CV outcomes. In addition, in SBP subgroup analysis,
presence of depressive symptoms (against no depressive
symptoms) was observed to have the highest adjusted
effects size for MACE in the very high SBP subgroup for
all four sensitivity analyses. These results are presented
in detail in the supplementary information.
DISCUSSION
Summary of Findings
Patients with existing cardiometabolic disease and those
with very high and low SBP at baseline were observed to
have a significantly higher adjusted risk of a MACE than
those with SBP in the reference range. Presence of
depressive symptoms at baseline was also associated
with a significantly higher risk of a MACE, while DBP
was not a significant predictor in the multivariable
analysis in either pooled or subgroup analysis. Presence
of depressive symptoms compounded the risk of a
MACE in patients with very high SBP.
Strengths and Limitations
This study has a number of key strengths, in that the
data came from a large, community-based sample
reflecting real-life clinical practice, and electronic data
TABLE I. Comparison of the Depression Screened
and Unscreened Patient Groups in Existing
Cardiometabolic Disease
Depression
Screened
(n=35,537)
Depression
Unscreened
(n=78,936) P Value
Age, mean (SD), y 69.0 (11.9) 67.0 (14.3) <.001
White ethnicity, No. (%) 30,693 (92.4) 53,343 (90.3) <.001
Male sex, No. (%) 20,658 (58.2) 42,727 (54.2) <.001
Deprived socioeconomic
status SIMD deciles ≤5,
No. (%)
22,726 (65.3) 51,686 (67.4) <.001
Number of cardiometabolic conditions, No. (%)
One 27,356 (77.0) 65,417 (82.9) <.001
Two 7410 (20.9) 12,265 (15.5)
Three 771 (2.2) 1254 (1.6)
Antidepressant
initiation, No. (%)
1268 (3.5) 4989 (6.3) <.001
Systolic blood pressure, No. (%)
130–139 mm Hg
(reference)
8389 (23.6) 13,315 (16.8) <.001
120–129 mm Hg
(tightly controlled)
6864 (19.3) 10,818 (13.7)
80–119 mm Hg (low) 5711 (16.0) 9258 (11.7)
140–159 mm Hg (high) 8624 (24.2) 15,969 (20.2)
160–240 mm Hg
(very high)
2514 (7.0) 5778 (7.3)
Not available 3435 (9.6) 23,802 (30.1)
Diastolic blood pressure, No. (%)
85–89 mm Hg
(reference)
1909 (5.3) 4219 (5.3) <.001
80–84 mm Hg (tightly
controlled)
7070 (19.8) 13,088 (16.5)
40–79 mm Hg (low) 20,585 (57.9) 31,724 (40.1)
90–99 mm Hg (high) 1981 (5.5) 4450 (5.6)
100–130 mm Hg
(very high)
562 (1.5) 1649 (2.0)
Not available 3430 (9.6) 23,806 (30.1)
Major adverse
cardiovascular outcome
(cardiovascular death or
admission due to
MI/stroke/heart failure),
No. (%)
3939 (11) 10,990 (13.9) <.001
Abbreviations: MI, myocardial infarction; SD, standard deviation;
SIMD, Scottish Index of Multiple Deprivation.
TABLE II. SBP, DBP, and Presence of Depressive
Symptoms (HADS-D >7) at Baseline and Risk
Prediction of Major Adverse Cardiovascular Event
(Cardiovascular Death or Admission Due to MI/
Stroke/HF) in 35,537 Patients With Previous Stroke,
Coronary Heart Disease, or Diabetes at 4 Years of
Follow-Up
Predictors at
Baseline
Major Adverse Cardiovascular Event
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)a
SBP, mm Hg
80–119 1.15 (1.04–1.27) 1.15 (1.03–1.29)
120–129 0.99 (0.90–1.09) 1.00 (0.90–1.12)
130–139 1 1
140–159 1.10 (1.00–1.20) 1.07 (0.96–1.18)
160–240 1.43 (1.26–1.61) 1.28 (1.11–1.49)
DBP, mm Hg
40–79 1.24 (1.07–1.44) 0.94 (0.78–1.12)
80–84 1.05 (0.89–1.23) 0.93 (0.77–1.12)
85–89 1 1
90–99 0.83 (0.67–1.02) 0.90 (0.71–1.14)
100–130 1.03 (0.77–1.39) 1.15 (0.82–1.62)
HADS-D >7
Reference=HADS-D ≤7
1.23 (1.14–1.32) 1.22 (1.11–1.33)
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure;
HADS-D, Hospital Anxiety and Depression Score-depression sub-
scale; HF, heart failure; HR, hazard ratio; MI, myocardial infarction;
SBP, systolic blood pressure.
aAdjusted for confounders including body mass index, total choles-
terol, age, sex, socioeconomic status, number of comorbid condi-
tions, and initiation of antidepressants. Significant results are
indicated in bold.
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linkage enabled successful follow-up for the majority of
patients in the cohort. There are several limitations.
Only a minority of the patients in the sample had
depression screening recorded despite incentivization.
Consequently, there may be important differences
between patients with known depression status and
those whose depression status was unknown that were
not recorded in our data. In addition, we did not have
information on depression score or CV events for the
cohort of patients noted to be “under treatment” for
depression at the time of depression screening, which is
an important limitation.
The observed association between low SBP at baseline
and higher risk of major adverse CV outcomes could be
caused by reverse causality, where patients with low
SBP could be those with the most severe form of disease.
There was no available information on disease severity
for the study participants, which is an important
limitation. Morevoer, we had insufficient information
on biobehavioral factors such as smoking status, alcohol
consumption, and levels of physical activity and hence
we were unable to adjust the main results for these
factors. Biobehavioral factors are likely to influence the
prevalence of depressive symptoms in cardiometabolic
disease patients and, in turn, may affect the ability to
make positive health-related behavior changes and
influence outcomes.43–45 Information on cardiac-related
medications was not available for these patients. How-
ever, these patients had existing cardiometabolic disease
and were attending their primary care providers for
annual health assessment. Hence, the majority of them
were likely to be taking at least one medication that
could lower BP. In addition, we had information only
on initiation of antidepressants but did not have
information either on duration of antidepressants or
on the different class of antidepressants chosen.
FIGURE 2. Kaplan-Meier plots comparing unadjusted cumulative event rates for major adverse cardiovascular outcome based on systolic
blood pressure (SBP) values and presence of depressive symptoms at baseline in patients with existing cardiometabolic disease. A total of
35,537 patients with previous stroke, coronary heart disease, or diabetes. Major adverse cardiovascular event=cardiovascular death or
admission due to myocardial infarction/stroke/heart failure. Reference SBP=130–139 mm Hg, tightly controlled SBP=120–129 mm Hg, low
SBP=80–119 mm Hg, high SBP=140–159 mm Hg, very high SBP=160–240 mm Hg. Depressive symptoms (defined as Hospital Anxiety and
Depression Scale-depression subscale >7) at baseline.
FIGURE 3. Forest plot showing interaction between depressive
symptoms and extremes of systolic blood pressure (SBP) at
baseline with the risk of major adverse cardiovascular event at
4 years in patients with existing cardiometabolic disease. A total of
35,537 patients with previous stroke, coronary heart disease, or
diabetes. A forest plot for comparing cumulative hazard for major
adverse cardiovascular event (cardiovascular death or admission
due to myocardial infarction/stroke/heart failure) for patients with
very high (160–240 mm Hg) and low (80–119 mm Hg) SBP and
depressive symptoms (defined as Hospital Anxiety and Depression
Scale-depression subscale >7) at baseline.
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Moreover, there are other adverse clinical outcomes
of significance in this group of patients such as renal
failure, angina pectoris, and retinopathy.8,46 We did not
have information available for these outcomes in our
data. Finally, the overall accuracy of depression screen-
ing in our study was reliant on HADS-D, which is a self-
reported measure and has accuracy-related drawbacks
when used for assessing depressive symptoms in patients
with cardiometabolic disease in a primary care
setting.18,47
Comparison With Existing Literature
The association between presence of depressive symp-
toms and higher risk of adverse clinical outcomes in
patients with preexisting cardiometabolic disease has
been previously reported in the literature.15–17 SBP at
baseline was found to have a nonlinear relationship in
our study with the risk prediction of a MACE, which
has also been reported in various other studies.5,6,8 Our
study findings are contrary to the results observed in the
SPRINT trial, but there are important differences such
as the study design and setting. In addition, the SPRINT
trial excluded patients with diabetes and previous
stroke, who were included in our study.11 With regards
to DBP, our study found that DBP at baseline was not a
significant predictor of adverse CV outcomes, and there
are studies that have reported similar findings of better
predictive power of SBP over DBP in predicting CV
outcomes.48,49
This is the first study, to our knowledge, to investigate
the interacting relationship between depressive symp-
toms and BP in risk prediction of adverse clinical
outcomes in patients with preexisting cardiometabolic
disease.
CLINICAL IMPLICATIONS
Firstly, there may be potential benefits of depression
screening for patients with cardiometabolic disease who
have extremes of SBP. Secondly, cardiometabolic dis-
ease patients who are diagnosed with comorbid depres-
sive symptoms may benefit from closer monitoring of
their SBP for secondary prevention of CV events.
Further research is needed in this area before making
any clinical recommendations.
CONCLUSIONS
SBP and depressive symptoms at baseline were indepen-
dent predictors of a MACE at 4 years in patients with
existing cardiometabolic disease, while DBP at baseline
did not have a significant effect. Presence of depressive
symptoms compounded the risk of a MACE in SBP
categories both higher and lower than the reference SBP,
especially in patients with very high SBP. There may be
potential benefits from closer monitoring (over and
above routine care) of BP in patients with car-
diometabolic disease and comorbid depression. Further
research is needed to understand the relationship
between extremes of BP and depressive symptoms in
patients with existing cardiometabolic disease and the
underpinning biological mechanisms.
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AMSTAR Score for quality appraisal of systematic reviews included in Chapter 3 
In Chapter 3, the background chapter on depression in cardiometabolic disease, there 
were 3 tables (table 3.1, table 3.2 & table 3.3) describing the key characteristics and 
findings of 15 systematic review/meta-analysis on various topics. The performance of 
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5.  Park M, Katon WJ, Wolf FM. Depression and risk of mortality in individuals with diabetes: a meta-
analysis and systematic review. Gen Hosp Psychiatry. Jan;35(3):217–25.  
6.  Bartoli F, Lillia N, Lax A, Crocamo C, Mantero V, Carrà G, et al. Depression after stroke and risk of 
mortality: a systematic review and meta-analysis. Stroke Res Treat. 2013 Jan;2013:862978.  
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9.  Meader N, Moe-Byrne T, Llewellyn A, Mitchell AJ. Screening for poststroke major depression: a meta-
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10.  Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for depression in 
patients with coronary artery disease. Cochrane Database Syst Rev. 2011;9:CD008012.  
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systematic review and meta-analysis of randomised controlled trials. BMJ Open. 2015 Jan 
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13.  Atlantis E, Fahey P, Foster J. Collaborative care for comorbid depression and diabetes: a systematic 
review and meta-analysis. BMJ Open. 2014 Jan;4(4):e004706.  
14.  Mead GE, Hsieh C-F, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake 
inhibitors (SSRIs) for stroke recovery. Cochrane database Syst Rev. 2012 Jan;11:CD009286.  
15.  Eng JJ, Reime B. Exercise for depressive symptoms in stroke patients: a systematic review and meta-
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 Table: AMSTAR scores of the 15 key studies included in Chapter 3 
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lead author  
(publication 
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design 
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interest 
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Roy (2012)(2) 7 No No Yes Yes Yes Yes Yes Yes No No Yes 
Robinson 
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Meijer 
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Park 
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Atlantis 
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Mead 
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